APPROVED DRUG PRODUCTS
With Therapeutic Equivalence Evaluations

The "Orange Book"

FDA data supplied by DrugPatentWatch.com

CUMULATIVE SUPPLEMENT 8
AUGUST 2015



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Department of Health and Human Services
Food and Drug Administration
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Office of Generic Drugs

2015

Prepared By
Office of Generic Drugs
Office of Medical Products and Tobacco
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

Cumulative Supplement 8

August 2015

CONTENTS

PAGE

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

35th EDITION

CUMULATIVE SUPPLEMENT 8
August 2015

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month’s second work week (e.g., November’s supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.

- All product changes received and processed as of the date of publication.
  - o Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - o Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.

- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at orangebook@fda.hhs.gov. Send changes by FAX: 301-595-1446.

mail to: FDA/CDER Orange Book Staff
Office of Generic Drugs
7620 Standish Place
Rockville, MD 20855-2773

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AGILA SPECIALTIES PRIVATE LTD (AGILA SPECLTS)	MYLAN LABORORATORIES LTD (MYLAN LABS LTD)
EXCELLIUM PHARMACEUTICAL INC (EXCELLIUM)	LEADING PHARMA LLC (LEADING PHARMA LLC)
MYLAN PHARMACEUTICALS INC (MYLAN PHARMS INC)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
ONCO THERAPIES LTD (ONCO THERAPIES LTD)	MYLAN LABORATORIES LTD (MYLAN LABS LTD)
REDKITT BENCKISER PHARMACEUTICALS INC (RECKITT BENCKISER)	INDIVIOR INC (INDIVIOR INC)

1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752)tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levothroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent

number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, http://www.fda.gov/opacom/morechoices/fdaforms/default.html.

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST
COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2014	MAR 2015	JUN 2015	SEPT 2015	DEC 2015
DRUG PRODUCTS LISTED	16150	16352	16543		
SINGLE SOURCE	2572 (15.9%)	2608 (15.9%)	2586 (15.6%)		
MULTISOURCE	13578 (84.1%)	13744 (84.1%)	13957 (84.4%)		
THERAPEUTICALLY EQUIVALENT	13443 (83.2%)	13610 (83.2%)	13832 (83.6%)		
NOT THERAPEUTICALLY EQUIVALENT	135 (0.8%)	134 (0.8%)	125 (0.8%)		
EXCEPTIONS[1]	77 (0.5%)	75 (0.5%)	75 (0.5%)		
NEW MOLECULAR ENTITIES APPROVED	13	22	12		
NUMBER OF APPLICANTS	927	935	957		

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by “N” is a New Drug Application (NDA or innovator). The application number preceded by an “A” is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.

CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

		ACETAMINOPHEN; BUTALBITAL; CAFFEINE							
		TABLET;ORAL							
		FIORICET							
		@ ACTAVIS LABS UT INC	325MG;50MG;40MG	A088616	001	Nov 09, 1984	Feb CAHN		
		ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE							
		CAPSULE;ORAL							
		FIORICET W/ CODEINE							
	AB	+ ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N020232	001	Jul 30, 1992	Jan CAHN		
		ACETAMINOPHEN; CODEINE PHOSPHATE							
		TABLET;ORAL							
		ACETAMINOPHEN AND CODEINE PHOSPHATE							
	AA	SUN PHARM INDS LTD	300MG;30MG	A085868	001		Apr CAHN		
	AA		300MG;60MG	A087083	001		Apr CAHN		
		ACETAMINOPHEN; HYDROCODONE BITARTRATE							
		TABLET;ORAL							
		HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
	AA	+ MIKART	325MG;2.5MG	A040846	001	Jun 09, 2010	Feb CTEC		
		@ SUN PHARM INDS LTD	325MG;10MG	A040826	001	Aug 16, 2007	Apr CAHN		
		NORCO							
	AA	ACTAVIS LABS FL INC	325MG;2.5MG	A040148	004	Jul 07, 2014	Feb NEWA		
	AA		325MG;5MG	A040148	005	Jul 07, 2014	Feb NEWA		
		ACETAZOLAMIDE							
		CAPSULE, EXTENDED RELEASE;ORAL							
		DIAMOX							
	AB	+ TEVA BRANDED PHARM	500MG	N012945	001		Jun CAHN		
		ACETOHEXAMIDE							
		TABLET;ORAL							
		ACETOHEXAMIDE							
		@ ANI PHARMS INC	250MG	A070869	001	Feb 09, 1987	Jul CAHN		
		@	500MG	A070870	001	Feb 09, 1987	Jul CAHN		
		ACETYLCYSTEINE							
		INJECTABLE;INTRAVENOUS							
		ACETYLCYSTEINE							
	AP	AKORN INC	6GM/30ML (200MG/ML)	A203173	001	Mar 24, 2015	Mar NEWA		
	AP	MYLAN INSTITUTIONAL	6GM/30ML (200MG/ML)	A203624	001	Jun 19, 2015	Jun NEWA		
		ACITRETIN							
		CAPSULE;ORAL							
		ACITRETIN							
>A>	AB	MYLAN PHARMS INC	10MG	A202148	001	Sep 10, 2015	Aug NEWA		
>A>	AB		17.5MG	A203707	001	Sep 10, 2015	Aug NEWA		
>A>	AB		22.5MG	A203707	002	Sep 10, 2015	Aug NEWA		
>A>	AB		25MG	A202148	002	Sep 10, 2015	Aug NEWA		
	AB	SIGMAPHARM LABS LLC	10MG	A204633	001	May 22, 2015	May NEWA		
	AB		17.5MG	A204633	002	May 22, 2015	May NEWA		
	AB		22.5MG	A204633	003	May 22, 2015	May NEWA		
	AB		25MG	A204633	004	May 22, 2015	May NEWA		
		ACLIDINIUM BROMIDE							
		POWDER, METERED;INHALATION							
		TUDORZA PRESSAIR							
>D>		+ ASTRAZENECA PHARMS	0.375MG/INH	N202450	001	Jul 23, 2012	Aug CPOT		
		+	0.375MG/INH	N202450	001	Jul 23, 2012	Apr CAHN		
>A>		+	0.4MG/INH	N202450	001	Jul 23, 2012	Aug CPOT		
		ACYCLOVIR							
		TABLET;ORAL							
		ACYCLOVIR							
	AB	SUN PHARM INDS LTD	400MG	A074980	001	Sep 30, 1998	Apr CAHN		
	AB		800MG	A074980	002	Sep 30, 1998	Apr CAHN		

ADAPALENE; BENZOYL PEROXIDE

GEL;TOPICAL

EPIDUO FORTE

>A>	+	GALDERMA LABS	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug	CAHN
>D>	+	GALDERMA R AND D	0.3%;2.5%	N207917	001	Jul 15, 2015	Aug	CAHN
	+		0.3%;2.5%	N207917	001	Jul 15, 2015	Jul	NEWA

ADENOSINE

INJECTABLE;INJECTION

ADENOSINE

AP		EUROHLTH INTL SARL	3MG/ML	A076500	001	Jun 16, 2004	Jun	CAHN
	@	WOCKHARDT	3MG/ML	A090220	001	Jul 20, 2009	May	DISC

ALBENDAZOLE

TABLET, CHEWABLE;ORAL

ALBENZA

	+	AMEDRA PHARMS LLC	200MG	N207844	001	Jun 11, 2015	Jun	NEWA

ALBUTEROL SULFATE

POWDER, METERED;INHALATION

PROAIR RESPICLICK

	+	TEVA BRANDED PHARM	EQ 0.090MG BASE/INH	N205636	001	Mar 31, 2015	Mar	NEWA

SYRUP;ORAL

ALBUTEROL SULFATE

AA		G AND W LABS INC	EQ 2MG BASE/5ML	A074454	001	Sep 25, 1995	Apr	CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

AEROSOL, METERED;INHALATION

COMBIVENT

	@	BOEHRINGER INGELHEIM	EQ 0.09MG BASE/INH;0.018MG/INH	N020291	001	Oct 24, 1996	May	DISC

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

ALFUZOSIN HYDROCHLORIDE

	@	WOCKHARDT LTD	10MG	A090221	001	Aug 10, 2012	Feb	DISC

UROXATRAL

AB	+	CONCORDIA PHARMS INC	10MG	N021287	001	Jun 12, 2003	Jun	CAHN

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE

TABLET;ORAL

TEKAMLO

	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE	N022545	001	Aug 26, 2010	May	DISC
	@		EQ 150MG BASE;EQ 10MG BASE	N022545	002	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE	N022545	003	Aug 26, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE	N022545	004	Aug 26, 2010	May	DISC

ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

AMTURNIDE

	@	NOVARTIS	EQ 150MG BASE;EQ 5MG BASE;12.5MG	N200045	001	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE;12.5MG	N200045	002	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 5MG BASE;25MG	N200045	003	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE;12.5MG	N200045	004	Dec 21, 2010	May	DISC
	@		EQ 300MG BASE;EQ 10MG BASE;25MG	N200045	005	Dec 21, 2010	May	DISC

ALMOTRIPTAN MALATE

TABLET;ORAL

ALMOTRIPTAN MALATE

AB		TEVA PHARMS USA	EQ 6.25MG BASE	A078027	001	Jul 07, 2015	Jun	NEWA
AB			EQ 12.5MG BASE	A078027	002	Jul 07, 2015	Jun	NEWA

AXERT

AB		JANSSEN PHARMS	EQ 6.25MG BASE	N021001	001	May 07, 2001	Jun	CFTG
AB	+		EQ 12.5MG BASE	N021001	002	May 07, 2001	Jun	CFTG

ALOSETRON HYDROCHLORIDE

TABLET;ORAL

ALOSETRON HYDROCHLORIDE

AB		ROXANE	EQ 0.5MG BASE	A200652	001	May 04, 2015	Apr	NEWA
AB			EQ 1MG BASE	A200652	002	May 04, 2015	Apr	NEWA

	TABLET;ORAL						
	LOTRONEX						
AB	PROMETHEUS LABS	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Apr	CFTG
AB +		EQ 1MG BASE	N021107	001	Feb 09, 2000	Apr	CFTG
	ALPRAZOLAM						
	TABLET;ORAL						
	ALPRAZOLAM						
	@ ANI PHARMS INC	0.25MG	A074085	001	Feb 16, 1994	Jul	CAHN
	@	0.5MG	A074085	002	Feb 16, 1994	Jul	CAHN
	@	1MG	A074085	003	Feb 16, 1994	Jul	CAHN
	@	2MG	A074085	004	Feb 26, 1996	Jul	CAHN
AB	AUROBINDO PHARMA LTD	0.25MG	A203346	001	Jul 31, 2015	Jul	NEWA
AB		0.5MG	A203346	002	Jul 31, 2015	Jul	NEWA
AB		1MG	A203346	003	Jul 31, 2015	Jul	NEWA
AB		2MG	A203346	004	Jul 31, 2015	Jul	NEWA
AB	NATCO PHARMA LTD	0.25MG	A200739	001	Apr 15, 2015	Mar	NEWA
AB		0.5MG	A200739	002	Apr 15, 2015	Mar	NEWA
AB		1MG	A200739	003	Apr 15, 2015	Mar	NEWA
AB		2MG	A200739	004	Apr 15, 2015	Mar	NEWA
	AMANTADINE HYDROCHLORIDE						
	CAPSULE;ORAL						
	AMANTADINE HYDROCHLORIDE						
AB	BANNER LIFE SCIENCES	100MG	A078720	001	May 29, 2008	Jan	CAHN
	SYRUP;ORAL						
	AMANTADINE HYDROCHLORIDE						
	@ G AND W LABS INC	50MG/5ML	A072655	001	Oct 30, 1990	May	CAHN
	AMIKACIN SULFATE						
	INJECTABLE;INJECTION						
	AMIKACIN SULFATE						
	@ IGI LABS INC	EQ 50MG BASE/ML	A063167	001	Dec 14, 1995	Mar	CAHN
	@	EQ 250MG BASE/ML	A063169	001	Dec 14, 1995	Mar	CAHN
	AMILORIDE HYDROCHLORIDE						
	TABLET;ORAL						
	AMILORIDE HYDROCHLORIDE						
AB	ZYDUS PHARMS USA INC	5MG	A204180	001	Aug 07, 2015	Jul	NEWA
	AMINO ACIDS						
	INJECTABLE;INJECTION						
	BRANCHAMIN 4% IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	4% (4GM/100ML)	N018684	001	Sep 28, 1984	Feb	DISC
	AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE						
	INJECTABLE;INJECTION						
	TRAVASOL 3.5% SULFITE FREE W/ ELECTROLYTES IN PLASTIC CONTAINER						
	@ BAXTER HLTHCARE	3.5%;51MG/100ML;131MG/100ML;218MG/100ML;35MG/100ML	N020177	001	Oct 23, 1995	Feb	DISC
	AMINOCAPROIC ACID						
	SYRUP;ORAL						
	AMINOCAPROIC ACID						
AA	VERSAPHARM INC	1.25GM/5ML	A074759	001	Sep 02, 1998	May	CAHN
	TABLET;ORAL						
	AMINOCAPROIC						
AB	VERSAPHARM INC	500MG	A075602	001	May 24, 2001	May	CAHN
	AMITRIPTYLINE HYDROCHLORIDE						
	TABLET;ORAL						
	AMITRIPTYLINE HYDROCHLORIDE						
>A>	@ ANI PHARMS INC	10MG	A084910	003		Aug	CAHN
>A>	@	25MG	A085031	001		Aug	CAHN
>A>	@	50MG	A085032	001		Aug	CAHN
>A>	@	75MG	A085030	001		Aug	CAHN
>D>	@ TEVA	10MG	A084910	003		Aug	CAHN
>D>	@	25MG	A085031	001		Aug	CAHN
>D>	@	50MG	A085032	001		Aug	CAHN
>D>	@	75MG	A085030	001		Aug	CAHN

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

TABLET;ORAL

	LIMBITROL						
	@ HERITAGE PHARMS INC	EQ 12.5MG BASE;5MG	N016949	001			Jul CAHN
	LIMBITROL DS						
	@ HERITAGE PHARMS INC	EQ 25MG BASE;10MG	N016949	002			Jul CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

	AMLODIPINE BESYLATE						
AB	CHINA RESOURCES	EQ 5MG BASE	A090752	001	Apr 15, 2011		Mar CAHN
AB		EQ 10MG BASE	A090752	002	Apr 15, 2011		Mar CAHN
AB	SOVEREIGN PHARMS	EQ 2.5MG BASE	A204900	001	Jul 23, 2015		Jul NEWA
AB		EQ 5MG BASE	A204900	002	Jul 23, 2015		Jul NEWA
AB		EQ 10MG BASE	A204900	003	Jul 23, 2015		Jul NEWA
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A077974	001	Jul 09, 2007		Apr CAHN
AB		EQ 5MG BASE	A077974	002	Jul 09, 2007		Apr CAHN
AB		EQ 10MG BASE	A077974	003	Jul 09, 2007		Apr CAHN

AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET;ORAL

	AMLODIPINE BESYLATE, VALSARTAN AND HYDROCHLOROTHIAZIDE						
AB	LUPIN LTD	5MG;12.5MG;160MG	A200797	001	Jun 03, 2015		May NEWA
AB		5MG;25MG;160MG	A200797	002	Jun 03, 2015		May NEWA
AB		10MG;12.5MG;160MG	A200797	003	Jun 03, 2015		May NEWA
AB		10MG;25MG;160MG	A200797	004	Jun 03, 2015		May NEWA
AB		10MG;25MG;320MG	A200797	005	Jun 03, 2015		May NEWA
AB	PAR PHARM	5MG;12.5MG;160MG	A201087	001	Jun 01, 2015		May NEWA
AB		5MG;25MG;160MG	A201087	002	Jun 01, 2015		May NEWA
AB		10MG;12.5MG;160MG	A201087	003	Jun 01, 2015		May NEWA
AB		10MG;25MG;160MG	A201087	004	Jun 01, 2015		May NEWA
AB		10MG;25MG;320MG	A201087	005	Jun 01, 2015		May NEWA
AB	TEVA PHARMS	5MG;12.5MG;160MG	A200435	001	Sep 25, 2012		May CAIN
AB		5MG;25MG;160MG	A200435	002	Sep 25, 2012		May CAIN
AB		10MG;12.5MG;160MG	A200435	005	Sep 25, 2012		May CAIN
AB		10MG;25MG;160MG	A200435	003	Sep 25, 2012		May CAIN
AB		10MG;25MG;320MG	A200435	004	Sep 25, 2012		May CAIN
AB	TORRENT PHARMS LTD	5MG;12.5MG;160MG	A201593	001	Jun 04, 2015		May NEWA
AB		5MG;25MG;160MG	A201593	002	Jun 04, 2015		May NEWA
AB		10MG;12.5MG;160MG	A201593	003	Jun 04, 2015		May NEWA
AB		10MG;25MG;160MG	A201593	004	Jun 04, 2015		May NEWA
AB		10MG;25MG;320MG	A201593	005	Jun 04, 2015		May NEWA

AMLODIPINE BESYLATE; PERINDOPRIL ARGININE

TABLET;ORAL

	PRESTALIA						
	SYMPLMED PHARMS LLC	EQ 2.5MG BASE;3.5MG	N205003	001	Jan 21, 2015		Jan NEWA
		EQ 5MG BASE;7MG	N205003	002	Jan 21, 2015		Jan NEWA
+		EQ 10MG BASE;14MG	N205003	003	Jan 21, 2015		Jan NEWA

AMLODIPINE BESYLATE; VALSARTAN

TABLET;ORAL

	AMLODIPINE BESYLATE AND VALSARTAN						
AB	ALEMBIC PHARMS LTD	EQ 5MG BASE;160MG	A202713	001	Apr 03, 2015		Mar NEWA
AB		EQ 5MG BASE;320MG	A202713	003	Apr 03, 2015		Mar NEWA
AB		EQ 10MG BASE;160MG	A202713	002	Apr 03, 2015		Mar NEWA
AB		EQ 10MG BASE;320MG	A202713	004	Apr 03, 2015		Mar NEWA
AB	LUPIN	EQ 5MG BASE;160MG	A090245	001	Mar 30, 2015		Mar NEWA
AB		EQ 5MG BASE;320MG	A090245	003	Mar 30, 2015		Mar NEWA
AB		EQ 10MG BASE;160MG	A090245	002	Mar 30, 2015		Mar NEWA
AB		EQ 10MG BASE;320MG	A090245	004	Mar 30, 2015		Mar NEWA
AB	MATRIX LABS LTD	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015		Mar NEWA
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015		Mar NEWA
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015		Mar NEWA
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015		Mar NEWA
AB	MYLAN PHARMS INC	EQ 5MG BASE;160MG	A090483	001	Mar 30, 2015		Apr CAHN
AB		EQ 5MG BASE;320MG	A090483	003	Mar 30, 2015		Apr CAHN
AB		EQ 10MG BASE;160MG	A090483	002	Mar 30, 2015		Apr CAHN
AB		EQ 10MG BASE;320MG	A090483	004	Mar 30, 2015		Apr CAHN
AB	NOVEL LABS INC	EQ 5MG BASE;160MG	A202829	001	Mar 30, 2015		Mar NEWA
AB		EQ 5MG BASE;320MG	A202829	003	Mar 30, 2015		Mar NEWA
AB		EQ 10MG BASE;160MG	A202829	002	Mar 30, 2015		Mar NEWA

TABLET;ORAL
AMLODIPINE BESYLATE AND VALSARTAN

AB		EQ 10MG BASE;320MG	A202829	004	Mar 30, 2015	Mar	NEWA
AB	TEVA PHARMS USA	EQ 5MG BASE;160MG	A091235	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A091235	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A091235	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A091235	004	Mar 30, 2015	Mar	NEWA
AB	TORRENT PHARMS LTD	EQ 5MG BASE;160MG	A202377	001	Mar 30, 2015	Mar	NEWA
AB		EQ 5MG BASE;320MG	A202377	002	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;160MG	A202377	003	Mar 30, 2015	Mar	NEWA
AB		EQ 10MG BASE;320MG	A202377	004	Mar 30, 2015	Mar	NEWA

AMMONIA N-13

INJECTABLE;INTRAVENOUS
AMMONIA N 13

AP	BIOMEDCL RES FDN	48.75mCi-487.5mCi/13ML (3.75-37.5mCi/ML)	A204352	001	May 01, 2015	Apr	NEWA
	CENTRAL RADIOPHARM	3.75-260mCi/ML	A204539	001	Jun 23, 2015	Jun	NEWA
AP	IBA MOLECULAR N AM	18.8mCi-188mCi/5ML (3.75-37.5mCi/ML)	A204667	001	Apr 22, 2015	Apr	NEWA
	NCM USA BRONX LLC	3.75-260mCi/mL	A204515	001	Feb 04, 2015	Jan	NEWA
>A>	PRECISION NUCLEAR	3.75-260mCi/ML	A204547	001	Aug 14, 2015	Aug	NEWA
AP	SPECTRON MRC LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204455	001	Apr 23, 2015	Apr	NEWA

AMOXICILLIN

CAPSULE;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	250MG	A065016	001	Apr 08, 1999	Apr	CAHN
AB		500MG	A065016	002	Apr 08, 1999	Apr	CAHN

FOR SUSPENSION;ORAL
AMOXICILLIN

@	SUN PHARM INDS LTD	200MG/5ML	A065113	001	Nov 29, 2002	Apr	CAHN
@		400MG/5ML	A065113	002	Nov 29, 2002	Apr	CAHN

TABLET;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	500MG	A065059	001	Nov 24, 2000	Apr	CAHN
AB		875MG	A065059	002	Nov 24, 2000	Apr	CAHN

TABLET, CHEWABLE;ORAL
AMOXICILLIN

AB	SUN PHARM INDS LTD	125MG	A065021	001	Dec 23, 1999	Apr	CAHN
@		200MG	A065060	001	Nov 29, 2000	Apr	CAHN
AB		250MG	A065021	002	Dec 23, 1999	Apr	CAHN
@		400MG	A065060	002	Nov 29, 2000	Apr	CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

FOR SUSPENSION;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Apr	CAHN
AB		400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Apr	CAHN
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Apr	CAHN

TABLET;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

@	SUN PHARM INDS LTD	500MG;EQ 125MG BASE	A065109	001	Nov 04, 2002	Apr	CAHN
AB		875MG;EQ 125MG BASE	A065102	001	Sep 17, 2002	Apr	CAHN

TABLET, CHEWABLE;ORAL
AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Apr	CAHN
AB		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Apr	CAHN

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

TABLET;ORAL
DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	COREPHARMA	1.875MG;1.875MG;1.875MG;1.875MG	A040444	005	Nov 03, 2014	May	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A040444	006	Nov 03, 2014	May	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A040444	007	Nov 03, 2014	May	NEWA

AMPHETAMINE SULFATE

TABLET;ORAL
EVEKEO

	ARBOR PHARMS LLC	5MG	A200166	001	Aug 09, 2012	Mar	CTNA
+		10MG	A200166	002	Aug 09, 2012	Mar	CTNA

AMPICILLIN SODIUM

INJECTABLE;INJECTION

AMPICILLIN SODIUM

>A>	AP		HOSPIRA INC	EQ 250MG BASE/VIAL	A202864	001	Sep 04, 2015	Aug NEWA
>A>	AP			EQ 500MG BASE/VIAL	A202864	002	Sep 04, 2015	Aug NEWA
>A>	AP			EQ 1GM BASE/VIAL	A202864	003	Sep 04, 2015	Aug NEWA
>A>	AP			EQ 2GM BASE/VIAL	A202864	004	Sep 04, 2015	Aug NEWA
>A>	AP			EQ 10GM BASE/VIAL	A202865	001	Sep 04, 2015	Aug NEWA

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION;ORAL

PROBAMPACIN

			@ G AND W LABS INC	EQ 3.5GM BASE/BOT;1GM/BOT	A061741	001		Apr CAHN

ANASTROZOLE

TABLET;ORAL

ANASTROZOLE

			@ KREMERS URBAN PHARMS	1MG	A091331	001	Jan 05, 2011	Mar CAHN

ARGATROBAN

INJECTABLE;INJECTION

>D>			ACOVA					
>D>	AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Aug CTNA

ARGATROBAN

	AP		FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Apr CDFR
>A>	AP	+	PFIZER	250MG/2.5ML (100MG/ML)	N020883	001	Jun 30, 2000	Aug CTNA

INJECTABLE;IV (INFUSION)

ARGATROBAN

	AP		FRESENIUS KABI USA	250MG/2.5ML (100MG/ML)	N201811	001	Mar 23, 2015	Mar NEWA

ARIPIPRAZOLE

SOLUTION;ORAL

ARIPIPRAZOLE

>A>	AA		AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Aug NEWA
>A>	AA		SILARX PHARMS INC	1MG/ML	A204171	001	Aug 14, 2015	Aug NEWA

TABLET;ORAL

ABILIFY

	AB		OTSUKA	2MG	N021436	006	Nov 15, 2002	Apr CFTG
	AB	+		5MG	N021436	005	Nov 15, 2002	Apr CFTG
	AB	+		10MG	N021436	001	Nov 15, 2002	Apr CFTG
	AB			15MG	N021436	002	Nov 15, 2002	Apr CFTG
	AB			20MG	N021436	003	Nov 15, 2002	Apr CFTG
	AB			30MG	N021436	004	Nov 15, 2002	Apr CFTG

ARIPIPRAZOLE

	AB		ALEMBIC PHARMS LTD	2MG	A202101	001	Apr 28, 2015	Apr NEWA
	AB			5MG	A202101	002	Apr 28, 2015	Apr NEWA
	AB			10MG	A202101	003	Apr 28, 2015	Apr NEWA
	AB			15MG	A202101	004	Apr 28, 2015	Apr NEWA
	AB			20MG	A202101	005	Apr 28, 2015	Apr NEWA
	AB			30MG	A202101	006	Apr 28, 2015	Apr NEWA
	AB		APOTEX INC	2MG	A078583	001	Jul 24, 2015	Jul NEWA
	AB			5MG	A078583	002	Jul 24, 2015	Jul NEWA
	AB			10MG	A078583	003	Jul 24, 2015	Jul NEWA
	AB			15MG	A078583	004	Jul 24, 2015	Jul NEWA
	AB			20MG	A078583	005	Jul 24, 2015	Jul NEWA
	AB			30MG	A078583	006	Jul 24, 2015	Jul NEWA
	AB		HETERO LABS LTD V	2MG	A205064	001	Apr 28, 2015	Apr NEWA
	AB			5MG	A205064	002	Apr 28, 2015	Apr NEWA
	AB			10MG	A205064	003	Apr 28, 2015	Apr NEWA
	AB			15MG	A205064	004	Apr 28, 2015	Apr NEWA
	AB			20MG	A205064	005	Apr 28, 2015	Apr NEWA
	AB			30MG	A205064	006	Apr 28, 2015	Apr NEWA
	AB		TEVA PHARMS USA	2MG	A078607	001	Apr 28, 2015	Apr NEWA
	AB			5MG	A078607	002	Apr 28, 2015	Apr NEWA
	AB			10MG	A078608	001	Apr 28, 2015	Apr NEWA
	AB			15MG	A078708	001	Apr 28, 2015	Apr NEWA
	AB			20MG	A078708	002	Apr 28, 2015	Apr NEWA
	AB			30MG	A078708	003	Apr 28, 2015	Apr NEWA
	AB		TORRENT PHARMS LTD	2MG	A201519	001	Apr 28, 2015	Apr NEWA
	AB			10MG	A201519	003	Apr 28, 2015	Apr NEWA
	AB			5MG	A201519	002	Apr 28, 2015	Apr NEWA

TABLET;ORAL
ARIPIPRAZOLE

AB		15MG	A201519	004	Apr 28, 2015	Apr	NEWA
AB		20MG	A201519	005	Apr 28, 2015	Apr	NEWA
AB		30MG	A201519	006	Apr 28, 2015	Apr	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY

AB	+ OTSUKA	10MG	N021729	002	Jun 07, 2006	Apr	CFTG
AB		15MG	N021729	003	Jun 07, 2006	Apr	CFTG

ARIPIPRAZOLE

AB	ALEMBIC PHARMS LTD	10MG	A202102	001	Apr 28, 2015	Apr	NEWA
AB		15MG	A202102	002	Apr 28, 2015	Apr	NEWA

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

INJECTABLE;INJECTION
M.V.I.-12 LYOPHILIZED

	@ IGI LABS INC	100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL	N018933	002	Aug 08, 1985	Jun	CAHN

ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE

FOR SOLUTION;ORAL
>D> MOVIPREP

>D>	@ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Aug	CTNA

>A> PEG-3350, SODIUM SULFATE, SODIUM CHLORIDE, POTASSIUM CHLORIDE, SODIUM ASCORBATE AND ASCORBIC ACID

>A>	@ NOVEL LABS INC	4.7GM;100GM;1.015GM;5.9GM;2.691GM;7.5GM	A090145	001	Jan 25, 2012	Aug	CTNA

ASENAPINE MALEATE

TABLET;SUBLINGUAL
SAPHRIS

	FOREST LABS LLC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Jun	CAHN
+		EQ 10MG BASE	N022117	002	Aug 13, 2009	Jun	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL
FIORINAL

AA	+ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	005	Apr 16, 1986	Jan	CAHN

TABLET;ORAL
FIORINAL

	@ ACTAVIS LABS UT INC	325MG;50MG;40MG	N017534	003	Apr 16, 1986	Jan	CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL
FIORINAL W/CODEINE

AB	+ ACTAVIS LABS UT INC	325MG;50MG;40MG;30MG	N019429	003	Oct 26, 1990	Jan	CAHN

ASPIRIN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL
SYNALGOS-DC

>D>	+ CARACO	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983	Aug	CAHN
>A>	+ SUN PHARM INDS	356.4MG;30MG;16MG	N011483	004	Sep 06, 1983	Aug	CAHN

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET;ORAL
NORGESIC

	@ MEDICIS	385MG;30MG;25MG	N013416	003	Oct 27, 1982	Mar	DISC

NORGESIC FORTE

	@ MEDICIS	770MG;60MG;50MG	N013416	004	Oct 27, 1982	Mar	DISC

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

	SANDOZ	385MG;30MG;25MG	A074654	001	Dec 31, 1996	Mar	CTEC
+		770MG;60MG;50MG	A074654	002	Dec 31, 1996	Mar	CTEC

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET;ORAL

OXYCODONE AND ASPIRIN

AA	ACTAVIS LABS FL INC	325MG;4.8355MG	A090084	001	Mar 22, 2011	Mar	CAHN

ATAZANAVIR SULFATE; COBICISTAT

TABLET;ORAL

EVOTAZ

+	BRISTOL MYERS SQUIBB	EQ 300MG BASE;150MG	N206353	001	Jan 29, 2015	Jan	NEWA

ATENOLOL

TABLET;ORAL

ATENOLOL

AB	ALVOGEN IPCO SARL	25MG	A073646	001	Jul 31, 1992	Jul	CAHN
AB		50MG	A072303	001	Jul 15, 1988	Jul	CAHN
AB		100MG	A072304	001	Jul 15, 1988	Jul	CAHN
	@ DAVA PHARMS INC	25MG	A074099	001	Apr 28, 1992	Jun	DISC

TENORMIN

AB	ALVOGEN IPCO SARL	25MG	N018240	004	Apr 09, 1990	Feb	CAHN
AB		50MG	N018240	001		Feb	CAHN
AB +		100MG	N018240	002		Feb	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET;ORAL

ATENOLOL AND CHLORTHALIDONE

AB	ALVOGEN IPCO SARL	50MG;25MG	A072301	001	May 31, 1990	Jul	CAHN
AB		100MG;25MG	A072302	001	May 31, 1990	Jul	CAHN

TENORETIC 100

AB +	ALVOGEN IPCO SARL	100MG;25MG	N018760	001	Jun 08, 1984	Feb	CAHN

TENORETIC 50

AB	ALVOGEN IPCO SARL	50MG;25MG	N018760	002	Jun 08, 1984	Feb	CAHN

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	KREMERS URBAN PHARMS	EQ 10MG BASE	A091624	001	Apr 05, 2013	Mar	CAHN
AB		EQ 20MG BASE	A091624	002	Apr 05, 2013	Mar	CAHN
AB		EQ 40MG BASE	A091624	003	Apr 05, 2013	Mar	CAHN
AB		EQ 80MG BASE	A091624	004	Apr 05, 2013	Mar	CAHN
AB	SUN PHARM INDS LTD	EQ 10MG BASE	A076477	001	Nov 30, 2011	Apr	CAHN
AB		EQ 20MG BASE	A076477	002	Nov 30, 2011	Apr	CAHN
AB		EQ 40MG BASE	A076477	003	Nov 30, 2011	Apr	CAHN
AB		EQ 80MG BASE	A076477	004	Nov 30, 2011	Apr	CAHN

ATORVASTATIN CALCIUM; EZETIMIBE

TABLET;ORAL

LIPTRUZET

	@ MERCK SHARP DOHME	EQ 10MG BASE;10MG	N200153	001	May 03, 2013	May	DISC
	@	EQ 20MG BASE;10MG	N200153	002	May 03, 2013	May	DISC
	@	EQ 40MG BASE;10MG	N200153	003	May 03, 2013	May	DISC
	@	EQ 80MG BASE;10MG	N200153	004	May 03, 2013	May	DISC

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE

AB	GLENMARK GENERICS	62.5MG;25MG	A091211	002	Apr 06, 2015	Mar	NEWA

ATRACURIUM BESYLATE

INJECTABLE;INJECTION

ATRACURIUM BESYLATE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206011	001	Apr 08, 2015	Mar	NEWA

ATRACURIUM BESYLATE PRESERVATIVE FREE

AP	AUROBINDO PHARMA LTD	10MG/ML	A206010	001	Apr 08, 2015	Mar	NEWA

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

+	AKORN	1%	N206289	001	Jul 18, 2014	May	CRLD

ATROPINE SULFATE; DIFENOXIN HYDROCHLORIDE

TABLET;ORAL

MOTOFEN

	+	SEBELA IRELAND LTD	0.025MG;1MG	N017744	002		Feb CAHN

MOTOFEN HALF-STRENGTH

	@	SEBELA IRELAND LTD	0.025MG;0.5MG	N017744	001		Feb CAHN

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@	ANI PHARMS INC	0.025MG;2.5MG	A086727	001		Jul CAHN

AVIBACTAM SODIUM; CEFTAZIDIME

POWDER;IV (INFUSION)

AVYCAZ

	+	CEREXA INC	EQ 0.5GM BASE;2GM/VIAL	N206494	001	Feb 25, 2015	Feb NEWA

AZELAIC ACID

AEROSOL, FOAM;TOPICAL

FINACEA

	+	BAYER HLTHCARE	15%	N207071	001	Jul 29, 2015	Jul NEWA

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

AB		BRECKENRIDGE PHARMS	EQ 0.125MG BASE/SPRAY	A090176	001	Jul 28, 2015	Jul NEWA

AZITHROMYCIN

FOR SUSPENSION;ORAL

AZITHROMYCIN

AB		LUPIN LTD	EQ 100MG BASE/5ML	A065488	001	May 15, 2015	May NEWA
AB			EQ 200MG BASE/5ML	A065488	002	May 15, 2015	May NEWA

INJECTABLE;INJECTION

AZITHROMYCIN

AP		AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A203294	001	Jun 19, 2015	Jun NEWA

TABLET;ORAL

AZITHROMYCIN

AB		LUPIN LTD	EQ 250MG BASE	A065398	001	May 15, 2015	May NEWA
AB			EQ 500MG BASE	A065399	001	May 15, 2015	May NEWA
AB			EQ 600MG BASE	A065400	001	May 15, 2015	May NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

COLAZAL

AB	+	VALEANT PHARMS INTL	750MG	N020610	001	Jul 18, 2000	Jul CAHN

TABLET;ORAL

BALSALAZIDE DISODIUM

>A> AB		PAR PHARM INC	1.1GM	A206336	001	Sep 08, 2015	Aug NEWA

GIAZO

>D>	+	VALEANT PHARMS INTL	1.1GM	N022205	001	Feb 03, 2012	Aug CFTG
>A> AB	+		1.1GM	N022205	001	Feb 03, 2012	Aug CFTG
	+		1.1GM	N022205	001	Feb 03, 2012	Jul CAHN

BENAZEPRIL HYDROCHLORIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE

AB		AMNEAL PHARMS LLC	5MG	A076820	001	Feb 03, 2006	Jan CAHN
AB			10MG	A076820	002	Feb 03, 2006	Jan CAHN
AB			20MG	A076820	003	Feb 03, 2006	Jan CAHN
AB			40MG	A076820	004	Feb 03, 2006	Jan CAHN
AB		SUN PHARM INDS LTD	5MG	A076344	001	Feb 11, 2004	Apr CAHN
AB			10MG	A076344	002	Feb 11, 2004	Apr CAHN
AB			20MG	A076344	003	Feb 11, 2004	Apr CAHN
AB			40MG	A076344	004	Feb 11, 2004	Apr CAHN

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET;ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	AB		SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Apr CAHN
	AB			10MG;12.5MG	A077483	002	Sep 08, 2005	Apr CAHN
	AB			20MG;12.5MG	A077483	003	Sep 08, 2005	Apr CAHN
	AB			20MG;25MG	A077483	004	Sep 08, 2005	Apr CAHN

BENZONATATE

CAPSULE;ORAL

BENZONATATE

	AA		APOTEX INC	100MG	A091310	001	Jan 16, 2015	Jan NEWA
	AA			200MG	A091310	002	Jan 16, 2015	Jan NEWA
	AA		BANNER LIFE SCIENCES	100MG	A081297	001	Jan 29, 1993	Jan CAHN
	AA			200MG	A081297	002	Oct 30, 2007	Jan CAHN
	AA		CSPC NBP PHARM CO	200MG	A202765	001	Jul 31, 2015	Jul NEWA
>D>	AA		STRIDES ARCOLAB LTD	100MG	A091133	001	Jul 30, 2015	Aug CAHN
	AA			100MG	A091133	001	Jul 30, 2015	Jul NEWA
>D>	AA			200MG	A091133	002	Jul 30, 2015	Aug CAHN
	AA			200MG	A091133	002	Jul 30, 2015	Jul NEWA
>A>	AA		STRIDES PHARMA	100MG	A091133	001	Jul 30, 2015	Aug CAHN
>A>	AA			200MG	A091133	002	Jul 30, 2015	Aug CAHN

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

ACANYA

	AB	+	DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Jun CFTG

CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE

	AB		ACTAVIS LABS UT INC	2.5%;EQ 1.2% BASE	A205128	001	Jun 19, 2015	Jun NEWA

ONEXTON

		+	DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Jan CRLD

BENZPHETAMINE HYDROCHLORIDE

TABLET;ORAL

BENZPHETAMINE HYDROCHLORIDE

	AA	+	KVK TECH	50MG	A090968	001	Jul 20, 2010	Jun CRLD

DIDREX

		@	PHARMACIA AND UPJOHN	50MG	N012427	002		Jun DISC

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

	AA		NUVO PHARM INC	0.5MG	A204713	001	Apr 14, 2015	Mar NEWA
	AA			1MG	A204713	002	Apr 14, 2015	Mar NEWA
	AA			2MG	A204713	003	Apr 14, 2015	Mar NEWA

BETAMETHASONE DIPROPIONATE

LOTION;TOPICAL

BETAMETHASONE DIPROPIONATE

	AB		G AND W LABS INC	EQ 0.05% BASE	A071467	001	Aug 10, 1987	Apr CAHN
		@		EQ 0.05% BASE	A071882	001	Jun 06, 1988	Apr CAHN

BETAMETHASONE VALERATE

CREAM;TOPICAL

BETA-VAL

>A>	AB		G AND W LABS INC	EQ 0.1% BASE	N018642	001	Mar 24, 1983	Aug CAHN
>D>	AB		TEVA	EQ 0.1% BASE	N018642	001	Mar 24, 1983	Aug CAHN

LOTION;TOPICAL

BETA-VAL

	AB		G AND W LABS INC	EQ 0.1% BASE	A070072	001	Jun 27, 1985	Apr CAHN

BETHANECHOL CHLORIDE

TABLET;ORAL

BETHANECHOL CHLORIDE

	AA		HERITAGE PHARMA	5MG	A091256	001	May 04, 2010	Mar CAHN
	AA			10MG	A091256	002	May 04, 2010	Mar CAHN
	AA			25MG	A091256	003	May 04, 2010	Mar CAHN
	AA			50MG	A091256	004	May 04, 2010	Mar CAHN
	AA		LANNETT HOLDINGS INC	5MG	A040703	001	Mar 27, 2008	Feb CMFD
	AA			50MG	A040677	001	Mar 27, 2008	Feb CMFD

TABLET;ORAL
DUVOID

AA		WELLSPRING PHARM	10MG	A086262	001		Jan CMFD
AA			25MG	A086263	001		May CMFD
AA			50MG	A085882	003		May CMFD

BEXAROTENE
CAPSULE;ORAL
BEXAROTENE

AB		BANNER LIFE SCIENCES	75MG	A203174	001	Aug 12, 2014	Jun CMFD
	@		75MG	A203174	001	Aug 12, 2014	Jan CAHN

TARGRETIN

AB	+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Jun CTEC

BICALUTAMIDE
TABLET;ORAL
BICALUTAMIDE

AB		APOTEX INC	50MG	A200274	001	May 21, 2015	May NEWA
AB		STASON PHARMS	50MG	A091011	001	Jun 10, 2015	May NEWA

BIMATOPROST
SOLUTION/DROPS;OPHTHALMIC
BIMATOPROST

AT		ALCON RES LTD	0.03%	A202565	001	May 05, 2015	Apr NEWA
AT		APOTEX INC	0.03%	A090449	001	Jul 20, 2015	Jul NEWA
AT	+	LUPIN LTD	0.03%	A203991	001	Feb 20, 2015	Apr CTEC
	+		0.03%	A203991	001	Feb 20, 2015	Mar CTEC
AT	+		0.03%	A203991	001	Feb 20, 2015	Feb NEWA

>D> BIPERIDEN HYDROCHLORIDE
>D> TABLET;ORAL
>D> AKINETON

>D>	+	ABBVIE	2MG	N012003	001		Aug DISC
>A>	@		2MG	N012003	001		Aug DISC

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE
CAPSULE;ORAL
PYLERA

	+	FOREST LABS LLC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Jul CAHN

BIVALIRUDIN
INJECTABLE;INTRAVENOUS
BIVALIRUDIN

AP		HOSPIRA INC	250MG/VIAL	A090811	001	Jul 14, 2015	Jun NEWA
AP			250MG/VIAL	A090816	001	Jul 14, 2015	Jun NEWA

BOSUTINIB MONOHYDRATE
TABLET;ORAL
BOSULIF

	+	WYETH PHARMS INC	EQ 100MG BASE	N203341	001	Sep 04, 2012	Jun CRLD
			EQ 500MG BASE	N203341	002	Sep 04, 2012	Jun CRLD

BREXPIPRAZOLE
TABLET;ORAL
REXULTI

		OTSUKA PHARM CO LTD	0.25MG	N205422	001	Jul 10, 2015	Jul NEWA
			0.5MG	N205422	002	Jul 10, 2015	Jul NEWA
			1MG	N205422	003	Jul 10, 2015	Jul NEWA
			2MG	N205422	004	Jul 10, 2015	Jul NEWA
			3MG	N205422	005	Jul 10, 2015	Jul NEWA
	+		4MG	N205422	006	Jul 10, 2015	Jul NEWA

BROMFENAC SODIUM
SOLUTION/DROPS;OPHTHALMIC
BROMDAY

AT2	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	May CTEC

BROMFENAC SODIUM

AT2		APOTEX INC	EQ 0.09% ACID	A202620	001	Jun 23, 2014	May CTEC
AT1	+	COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	May CRLD
AT2		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	May CTEC
AT1		PADDOCK LLC	EQ 0.09% ACID	A201941	001	Feb 10, 2015	Jan NEWA

BUDESONIDE

AEROSOL, FOAM;RECTAL

UCERIS

	+ VALEANT PHARMS INTL	2MG/ACTUATION	N205613	001	Oct 07, 2014	Apr	CAHN

SPRAY, METERED;NASAL

BUDESONIDE

	APOTEX INC	0.032MG/INH	A078949	001	May 12, 2014	Mar	CTEC

TABLET, EXTENDED RELEASE;ORAL

UCERIS

>D>	+ SANTARUS INC	9MG	N203634	001	Jan 14, 2013	Aug	CAHN
>A>	+ VALEANT PHARMS INTL	9MG	N203634	001	Jan 14, 2013	Aug	CAHN

BUMETANIDE

INJECTABLE;INJECTION

BUMETANIDE

AP	EUROHLTH INTL SARL	0.25MG/ML	A079196	001	Apr 30, 2008	Jun	CAHN

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP	PAR STERILE PRODUCTS	EQ 0.3MG BASE/ML	A206586	001	Jul 28, 2015	Jul	NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	EQ 2MG BASE	A090819	001	Feb 19, 2015	Feb	NEWA
AB		EQ 8MG BASE	A090819	002	Feb 19, 2015	Feb	NEWA
AB	MYLAN PHARMS INC	EQ 2MG BASE	A201066	001	Mar 06, 2015	Feb	NEWA
AB		EQ 8MG BASE	A201066	002	Mar 06, 2015	Feb	NEWA
AB	SANDOZ INC	EQ 2MG BASE	A090279	001	Jun 10, 2015	May	NEWA
AB		EQ 8MG BASE	A090279	002	Jun 10, 2015	May	NEWA

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

TABLET;SUBLINGUAL

ZUBSOLV

	OREXO AB	EQ 2.9MG BASE;EQ 0.71MG BASE	N204242	005	Jun 04, 2015	Jun	NEWA

BUPROPION HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL

APLENZIN

	VALEANT PHARMS NORTH	174MG	N022108	001	Apr 23, 2008	Feb	CAHN
		348MG	N022108	002	Apr 23, 2008	Feb	CAHN
	+	522MG	N022108	003	Apr 23, 2008	Feb	CAHN

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1	PRINSTON INC	100MG	A202304	001	May 26, 2015	May	NEWA
AB1		150MG	A202304	002	May 26, 2015	May	NEWA
AB1		200MG	A202304	003	May 26, 2015	May	NEWA
AB2	SANDOZ INC	150MG	A077475	001	Mar 12, 2008	Mar	CAHN
	@ WOCKHARDT LTD	100MG	A201331	001	Aug 30, 2012	May	DISC
	@	150MG	A201331	002	Aug 30, 2012	May	DISC
	@	200MG	A201331	003	Aug 30, 2012	May	DISC

BUTABARBITAL SODIUM

ELIXIR;ORAL

BUTISOL SODIUM

	@ MEDA PHARMS	30MG/5ML	A085380	001		Jul	DISC

TABLET;ORAL

BUTISOL SODIUM

	@ MEDA PHARMS	50MG	N000793	003		May	DISC

BUTOCONAZOLE NITRATE

CREAM;VAGINAL

BUTOCONAZOLE NITRATE

	@ ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	May	CTNA

GYNAZOLE-1

	+ PERRIGO ISRAEL	2%	A200923	001	May 18, 2012	Jun	CTNA

CALCIPOTRIENE

CREAM;TOPICAL

CALCIPOTRIENE

AB		GLENMARK PHARMS LTD	0.005%	A205772	001	Jun 09, 2015	May	NEWA

CALCITONIN SALMON

INJECTABLE;INJECTION

CALCITONIN-SALMON

		@ IGI LABS INC	200 IU/ML	A073690	001	Apr 14, 1995	Mar	CAHN

MIACALCIN

>A>		@ MYLAN IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug	CAHN
>A>	+		200 IU/ML	N017808	002	Mar 29, 1991	Aug	CAHN
>D>		@ SEBELA IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Aug	CAHN
>D>	+		200 IU/ML	N017808	002	Mar 29, 1991	Aug	CAHN

SPRAY, METERED;NASAL

MIACALCIN

>A>	AB	+	MYLAN IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Aug	CAHN
>D>	AB	+	SEBELA IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Aug	CAHN

CALCITRIOL

CAPSULE;ORAL

CALCITRIOL

AB		BANNER LIFE SCIENCES	0.25MCG	A091174	001	May 24, 2013	Jan	CAHN
AB			0.5MCG	A091174	002	May 24, 2013	Jan	CAHN
AB		STRIDES PHARMA	0.25MCG	A091356	001	Dec 12, 2014	Jan	CAHN
AB			0.5MCG	A091356	002	Dec 12, 2014	Jan	CAHN

INJECTABLE;INJECTION

CALCIJEX

		@ ABBVIE	0.001MG/ML	N018874	001	Sep 25, 1986	Jun	DISC
		@	0.002MG/ML	N018874	002	Sep 25, 1986	Jun	DISC

CALCITRIOL

		@ AKORN	0.002MG/ML	A078066	002	Jan 29, 2008	Jun	DISC
		@ FRESENIUS KABI USA	0.001MG/ML	A075836	001	Dec 31, 2002	Jun	DISC
		@	0.002MG/ML	A075836	002	Dec 31, 2002	Jun	DISC
		@ FRESENIUS MEDCL	0.001MG/ML	A075766	001	Feb 20, 2003	Jun	DISC
		@	0.002MG/ML	A075766	002	Feb 20, 2003	Jun	DISC
		@ LUITPOLD	0.001MG/ML	A075746	001	Sep 26, 2003	Jun	DISC
		@	0.002MG/ML	A075746	002	Sep 26, 2003	Jun	DISC
		@ SAGENT PHARMS	0.001MG/ML	A077102	001	Feb 08, 2006	Jun	DISC

CALCIUM ACETATE

CAPSULE;ORAL

CALCIUM ACETATE

AB		LUPIN LTD	EQ 169MG CALCIUM	A202127	001	Jul 09, 2015	Jun	NEWA
AB		ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202315	001	Jun 29, 2015	Jun	NEWA

TABLET;ORAL

CALCIUM ACETATE

AB		ZYDUS PHARMS USA INC	EQ 169MG CALCIUM	A202885	001	Jan 22, 2015	Jan	NEWA

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PRISMASOL B22GK 2/0 IN PLASTIC CONTAINER

	+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	010	Oct 10, 2008	Jan	CPOT

PRISMASOL B22GK 2/2.5 IN PLASTIC CONTAINER

		@ GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.157GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	012	Oct 10, 2008	Jan	CPOT

PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER

	+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	011	Oct 10, 2008	Jan	CPOT

PRISMASOL B22GK 4/2.5 IN PLASTIC CONTAINER

	+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;7.07GM/1000ML (5000ML)	N021703	013	Oct 10, 2008	Jan	CPOT

INJECTABLE;INJECTION

PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	006	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 2/0 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	002	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.157GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	003	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	005	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;20GM/1000ML;5.4GM/1000ML;2.44GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	015	Oct 10, 2008	Jan CPOT

PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	3.68GM/1000ML;20GM/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	004	Oct 25, 2006	Jan CPOT

PRISMASOL BGK 4/3.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	5.15GM/1000ML;20GM/1000ML;5.4GM/1000ML;2.03GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	008	Oct 25, 2006	Jan CPOT

PRISMASOL BK 0/0 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	007	Oct 25, 2006	Jan CPOT

PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	N/A/1000ML;N/A/1000ML;5.4GM/1000ML;2.44GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	014	Oct 10, 2008	Jan CPOT

PRISMASOL BK 0/3.5 IN PLASTIC CONTAINER

+	GAMBRO RENAL PRODS	5.15GM/1000ML;N/A/1000ML;5.4GM/1000ML;2.03GM/1000ML;N/A/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	001	Oct 25, 2006	Jan CPOT

PRISMASOL BK 4/2.5 IN PLASTIC CONTAINER

@	GAMBRO RENAL PRODS	3.68GM/1000ML;N/A/1000ML;5.4GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.46GM/1000ML (5000ML)	N021703	009	Oct 25, 2006	Jan CPOT

CALCIUM CHLORIDE; DEXTROSE; LACTIC ACID; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	N/A/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N207026	002	Jan 13, 2015	Jan NEWA

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

+	GAMBRO LUNDIA	3.68GM/1000ML;N/A/1000ML;N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187GM/1000ML (5000ML)	N207026	001	Jan 13, 2015	Jan NEWA

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; OXIGLUTATIONE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION;IRRIGATION

NAVSTEL

@	ALCON PHARMS LTD	0.154MG/ML;0.92MG/ML;0.2MG/ML;0.184MG/ML;0.38MG/ML;2.1MG/ML;7.14MG/ML;0.42MG/ML	N022193	001	Jul 24, 2008	Jun DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE M AND DEXTROSE 5% IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	37MG/100ML;5GM/100ML;30MG/100ML;119MG/100ML;161MG/100ML;94MG/100ML;138MG/100ML	N	017390	001		Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE;INJECTION

PLASMA-LYTE R IN PLASTIC CONTAINER

	@	BAXTER HLTHCARE	36.8MG/100ML;30.5MG/100ML;74.6MG/100ML;640MG/100ML;496MG/100ML;89.6MG/100ML	N	017438	001		Mar DISC

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

INJECTABLE;INJECTION

PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER

	+	GAMBRO LUNDIA	N/A/1000ML;3.05GM/1000ML;0.314GM/1000ML;2.21GM/1000ML;6.95GM/1000ML;0.187GM/1000ML (5000ML)	N	207026	002	Jan 13, 2015	Feb CAIN

PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER

	+	GAMBRO LUNDIA	3.68GM/1000ML;3.05GM/1000ML;0.314GM/1000ML;3.09GM/1000ML;6.34GM/1000ML;0.187	N	207026	001	Jan 13, 2015	Feb CAIN

CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE

AB		MACLEODS PHARMS LTD	16MG;12.5MG	A	204100	001	Feb 27, 2015	Feb NEWA
AB			32MG;12.5MG	A	204100	002	Feb 27, 2015	Feb NEWA
AB			32MG;25MG	A	204100	003	Feb 27, 2015	Feb NEWA

CAPECITABINE

TABLET;ORAL

CAPECITABINE

AB		ACCORD HLTHCARE	150MG	A	202593	001	Apr 23, 2015	Apr NEWA
AB			500MG	A	202593	002	Apr 23, 2015	Apr NEWA

CAPTOPRIL

TABLET;ORAL

CAPOTEN

	@	PAR PHARM	12.5MG	N	018343	005	Jan 17, 1985	May DISC
	@		25MG	N	018343	002		May DISC
	@		50MG	N	018343	001		May DISC
	@		100MG	N	018343	003		May DISC

CAPTOPRIL

	@	G AND W LABS INC	12.5MG	A	074433	001	Feb 13, 1996	Jul CAHN
	@		12.5MG	A	074462	001	Feb 13, 1996	Apr CAHN
	@		12.5MG	A	074483	001	Feb 13, 1996	Jul CAHN
	@		12.5MG	A	074590	004	Aug 30, 1996	Apr CAHN
	@		25MG	A	074433	002	Feb 13, 1996	Jul CAHN
	@		25MG	A	074462	002	Feb 13, 1996	Apr CAHN
	@		25MG	A	074483	002	Feb 13, 1996	Jul CAHN
	@		25MG	A	074590	002	Aug 30, 1996	Apr CAHN
	@		50MG	A	074433	003	Feb 13, 1996	Jul CAHN
	@		50MG	A	074462	003	Feb 13, 1996	Apr CAHN
	@		50MG	A	074483	003	Feb 13, 1996	Jul CAHN
	@		50MG	A	074590	001	Aug 30, 1996	Apr CAHN
	@		100MG	A	074433	004	Feb 13, 1996	Jul CAHN
	@		100MG	A	074462	004	Feb 13, 1996	Apr CAHN
	@		100MG	A	074483	004	Feb 13, 1996	Jul CAHN
	@		100MG	A	074590	003	Aug 30, 1996	Apr CAHN
AB	+	MYLAN	100MG	A	074434	004	Feb 13, 1996	May CRLD

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL

CAPTOPRIL AND HYDROCHLOROTHIAZIDE

AB		G AND W LABS INC	25MG;15MG	A	074827	001	Dec 29, 1997	Apr CAHN
AB			25MG;25MG	A	074827	002	Dec 29, 1997	Apr CAHN
AB			50MG;15MG	A	074827	004	Dec 29, 1997	Apr CAHN

	TABLET;ORAL						
	CAPTOPRIL AND HYDROCHLOROTHIAZIDE						
AB		50MG;25MG	A074827	003	Dec 29, 1997	Apr	CAHN
	CARBAMAZEPINE						
	CAPSULE, EXTENDED RELEASE;ORAL						
	CARBAMAZEPINE						
AB	MYLAN PHARMS INC	100MG	A076697	001	May 20, 2011	May	CAHN
AB		200MG	A076697	002	May 20, 2011	May	CAHN
AB		300MG	A076697	003	May 20, 2011	May	CAHN
	CARBIDOPA; LEVODOPA						
	CAPSULE, EXTENDED RELEASE;ORAL						
	RYTARY						
	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	Jan	NEWA
		36.25MG;145MG	N203312	002	Jan 07, 2015	Jan	NEWA
		48.75MG;195MG	N203312	003	Jan 07, 2015	Jan	NEWA
+		61.25MG;245MG	N203312	004	Jan 07, 2015	Jan	NEWA
	SUSPENSION;ENTERAL						
	DUOPA						
+	ABBVIE INC	4.63MG/ML;20MG/ML	N203952	001	Jan 09, 2015	Jan	NEWA
	CARISOPRODOL						
	TABLET;ORAL						
	CARISOPRODOL						
AB	INDICUS PHARMA	250MG	A205126	001	Jul 08, 2015	Jun	NEWA
AA		350MG	A205126	002	Jul 08, 2015	Jun	NEWA
	SOMA						
AB +	MEDA PHARMS	250MG	N011792	004	Sep 13, 2007	Jun	CTEC
	CARVEDILOL						
	TABLET;ORAL						
	CARVEDILOL						
	@ HIKMA	3.125MG	A077887	001	Sep 07, 2007	Jun	DISC
	@	6.25MG	A077887	002	Sep 07, 2007	Jun	DISC
	@	12.5MG	A077887	003	Sep 07, 2007	Jun	DISC
	@	25MG	A077887	004	Sep 07, 2007	Jun	DISC
AB	SUN PHARM INDS LTD	3.125MG	A076989	001	Sep 05, 2007	Apr	CAHN
AB		6.25MG	A076989	002	Sep 05, 2007	Apr	CAHN
AB		12.5MG	A076989	003	Sep 05, 2007	Apr	CAHN
AB		25MG	A076989	004	Sep 05, 2007	Apr	CAHN
	CEFADROXIL/CEFADROXIL HEMIHYDRATE						
	FOR SUSPENSION;ORAL						
	CEFADROXIL						
	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Apr	CAHN
AB		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Apr	CAHN
AB		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Apr	CAHN
	CEFAZOLIN SODIUM						
	INJECTABLE;INJECTION						
	CEFAZOLIN SODIUM						
AP	FACTA FARMA	EQ 500MG BASE/VIAL	A063214	001	Dec 27, 1991	Jan	CAHN
AP		EQ 1GM BASE/VIAL	A063207	001	Dec 27, 1991	Jan	CAHN
AP		EQ 10GM BASE/VIAL	A063209	001	Dec 27, 1991	Jan	CAHN
AP +		EQ 20GM BASE/VIAL	A063209	002	Apr 30, 1999	Jan	CAHN
>A>	SOLUTION;INTRAVENOUS						
>A>	CEFAZOLIN IN PLASTIC CONTAINER						
>A>	CELERITY PHARMS	EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	Aug	NEWA
	CEFIXIME						
	FOR SUSPENSION;ORAL						
	CEFIXIME						
AB	AUROBINDO PHARMA LTD	100MG/5ML	A204835	001	Apr 14, 2015	Apr	NEWA
AB		200MG/5ML	A204835	002	Apr 14, 2015	Apr	NEWA
	SUPRAX						
AB	LUPIN PHARMS	100MG/5ML	A065129	001	Feb 23, 2004	Apr	CFTG
AB		200MG/5ML	A065355	001	Apr 10, 2007	Apr	CFTG

CEFOTETAN DISODIUM

INJECTABLE;INJECTION

CEFOTAN

	@	IGI LABS INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	May CAHN
	@		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Mar CAHN
	@		EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	May CAHN
	@		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Mar CAHN
	@		EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Mar CAHN

CEFOTAN IN PLASTIC CONTAINER

	@	IGI LABS INC	EQ 20MG BASE/ML	N050694	002	Jul 30, 1993	Mar CAHN
	@		EQ 40MG BASE/ML	N050694	001	Jul 30, 1993	Mar CAHN

CEFPODOXIME PROXETIL

FOR SUSPENSION;ORAL

CEFPODOXIME PROXETIL

AB		SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Apr CAHN
AB			EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Apr CAHN

TABLET;ORAL

CEFPODOXIME PROXETIL

AB		SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Apr CAHN
AB			EQ 200MG BASE	A065083	002	Aug 20, 2003	Apr CAHN

CEFTAZIDIME

INJECTABLE;INJECTION

FORTAZ

AP	+	CONCORDIA PHARMS INC	500MG/VIAL	N050578	001	Jul 19, 1985	Jun CAHN
AP	+		1GM/VIAL	N050578	002	Jul 19, 1985	Jun CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	Jun CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	Jun CAHN

CEFTAZIDIME SODIUM

INJECTABLE;INJECTION

FORTAZ IN PLASTIC CONTAINER

	@	CONCORDIA PHARMS INC	EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Jun CAHN
	+		EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Jun CAHN
	+		EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Jun CAHN

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

POWDER;IV (INFUSION)

ZERBAXA

>D>	+	CUBIST PHARMS	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug CAHN
>A>	+	CUBIST PHARMS LLC	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Aug CAHN

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION

CEFTRIAXONE

AP		FACTA FARMA	EQ 10GM BASE/VIAL	A065269	001	Feb 28, 2007	Jan CAHN

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS

CEFTRIAXONE

	@	FACTA FARMA	EQ 1GM BASE/VIAL	A065268	001	Feb 28, 2007	Jan CAHN
	@		EQ 2GM BASE/VIAL	A065268	002	Feb 28, 2007	Jan CAHN
	@	FRESENIUS KABI USA	EQ 250MG BASE/VIAL	A065245	001	Feb 15, 2006	Jul DISC

CEFUROXIME AXETIL

FOR SUSPENSION;ORAL

CEFUROXIME AXETIL

AB		SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Apr CAHN
AB			EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Apr CAHN

TABLET;ORAL

CEFUROXIME AXETIL

AB		ANI PHARMS INC	EQ 250MG BASE	A065190	001	Oct 18, 2004	Jul CAHN
AB			EQ 500MG BASE	A065190	002	Oct 18, 2004	Jul CAHN
AB		SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Apr CAHN
AB			EQ 250MG BASE	A065118	002	Apr 25, 2003	Apr CAHN
AB			EQ 500MG BASE	A065118	003	Apr 25, 2003	Apr CAHN

CEFUROXIME SODIUM

		INJECTABLE;INJECTION						
		CEFUROXIME SODIUM						
AP		FACTA FARMA	EQ 1.5GM BASE/VIAL	A064125	002	May 30, 1997	Jan CAHN
AP			EQ 7.5GM BASE/VIAL	A064124	001	May 30, 1997	Jan CAHN
		ZINACEF					
AP	+	CONCORDIA PHARMS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jun CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jun CAHN
		ZINACEF IN PLASTIC CONTAINER					
	@	CONCORDIA PHARMS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jun CAHN
	+		EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jun CAHN
		INJECTABLE;INTRAMUSCULAR, INTRAVENOUS					
		CEFUROXIME SODIUM					
AB		FACTA FARMA	EQ 750MG BASE/VIAL	A064125	001	May 30, 1997	Jan CAHN
		ZINACEF					
AB	+	CONCORDIA PHARMS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jun CAHN

CELECOXIB

		CAPSULE;ORAL						
		CELECOXIB						
>A>	AB	ALEMBIC PHARMS LTD	50MG	A204519	001	Aug 21, 2015	Aug NEWA
>A>	AB		100MG	A204519	002	Aug 21, 2015	Aug NEWA
>A>	AB		200MG	A204519	003	Aug 21, 2015	Aug NEWA
>A>	AB		400MG	A204519	004	Aug 21, 2015	Aug NEWA
	AB	APOTEX INC	50MG	A204197	001	Jun 02, 2015	May NEWA
	AB		100MG	A204197	002	Jun 02, 2015	May NEWA
	AB		200MG	A204197	003	Jun 02, 2015	May NEWA
	AB	LUPIN LTD	100MG	A202240	002	Jun 09, 2015	May NEWA
	AB		200MG	A202240	003	Jun 09, 2015	May NEWA
	AB		400MG	A202240	004	Jun 09, 2015	May NEWA
	AB	MYLAN PHARMS INC	100MG	A078857	002	Feb 11, 2015	Jan NEWA
	AB		200MG	A078857	003	Feb 11, 2015	Jan NEWA
	AB		400MG	A078857	004	Feb 11, 2015	Jan NEWA
	AB	WATSON LABS INC	50MG	A200562	001	Feb 11, 2015	Jan NEWA
	AB		100MG	A200562	002	Feb 11, 2015	Jan NEWA
	AB		200MG	A200562	003	Feb 11, 2015	Jan NEWA
	AB		400MG	A200562	004	Feb 11, 2015	Jan NEWA

CEPHALEXIN

		CAPSULE;ORAL						
		CEPHALEXIN						
AB		SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Apr CAHN
AB			EQ 500MG BASE	A065007	002	Sep 16, 1999	Apr CAHN
		FOR SUSPENSION;ORAL						
		CEPHALEXIN						
	@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Apr CAHN
	@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Apr CAHN

CETIRIZINE HYDROCHLORIDE

		SYRUP;ORAL						
		ZYRTEC						
>A>	AA	+ J AND J CONSUMER INC	5MG/5ML	N020346	001	Sep 27, 1996	Aug CAHN
>D>	AA	+ MCNEIL CONSUMER	5MG/5ML	N020346	001	Sep 27, 1996	Aug CAHN

CHLOROTHIAZIDE SODIUM

		INJECTABLE;INJECTION						
		CHLOROTHIAZIDE SODIUM						
AP		SAGENT PHARMS	EQ 500MG BASE/VIAL	A202462	001	May 29, 2015	May NEWA

CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

		TABLET, EXTENDED RELEASE;ORAL						
		CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE						
		SPRIASO LLC	8MG;54.3MG	N206323	001	Jun 22, 2015	Jun NEWA

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE

		SOLUTION;ORAL						
		HYDROCODONE BITARTRATE AND CHLORPHENIRAMINE MALEATE						
AA		TRIS PHARMA INC	4MG/5ML;5MG/5ML	A206438	001	Jan 27, 2015	Jan NEWA
		VITUZ						
AA	+	CYPRESS PHARM	4MG/5ML;5MG/5ML	N204307	001	Feb 20, 2013	Jan CFTG

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA		COASTAL PHARMS	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Jul	NEWA

CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX

SUSPENSION, EXTENDED RELEASE;ORAL

TUZISTRA XR

	+	TRIS PHARMA INC	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Apr	NEWA
	+	VERNALIS R AND D LTD	EQ 2.8MG BASE/5ML;EQ 14.7MG BASE/5ML	N207768	001	Apr 30, 2015	Jun	CAHN

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE;ORAL

CHLORPROMAZINE HYDROCHLORIDE INTENSOL

	@	CYCLE PHARMS LTD	30MG/ML	A088157	001	Apr 27, 1983	Jun	CAHN
	@		100MG/ML	A088158	001	Apr 27, 1983	Jun	CAHN

INJECTABLE;INJECTION

CHLORPROMAZINE HYDROCHLORIDE

	+	EUROHLTH INTL SARL	25MG/ML	A083329	001		Feb	CAHN

TABLET;ORAL

CHLORPROMAZINE HYDROCHLORIDE

	@	CYCLE PHARMS LTD	10MG	A085331	001		Jun	CAHN
	@		25MG	A085331	002		Jun	CAHN
	@		50MG	A085331	003		Jun	CAHN
	@		100MG	A085331	004		Jun	CAHN
	@		200MG	A085331	005		Jun	CAHN
	@	SANDOZ	10MG	A080439	001		May	DISC
	@		25MG	A080439	002		May	DISC
	@		50MG	A080439	003		May	DISC
	@		100MG	A080439	004		May	DISC
	@		200MG	A080439	005		May	DISC

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

	@	G AND W LABS INC	50MG	A088651	001	May 30, 1985	Apr	CAHN
AB		MUTUAL PHARM	50MG	A089286	001	Jul 21, 1986	Mar	CMFD
AB	+	MYLAN	50MG	A086831	001		Jun	CTEC

THALITONE

	@	CITRON PHARMA LLC	15MG	N019574	001	Dec 20, 1988	Jun	DISC

CHOLESTYRAMINE

POWDER;ORAL

CHOLESTYRAMINE

>A>	@	ANI PHARMS INC	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Aug	CAHN
>A>	@		EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Aug	CAHN
>D>	@	TEVA PHARMS	EQ 4GM RESIN/PACKET	A074554	001	Oct 02, 1996	Aug	CAHN
>D>	@		EQ 4GM RESIN/SCOOPFUL	A074554	002	Oct 02, 1996	Aug	CAHN

CHOLIC ACID

CAPSULE;ORAL

CHOLBAM

		ASKLEPION PHARMS LLC	50MG	N205750	001	Mar 17, 2015	Mar	NEWA
	+		250MG	N205750	002	Mar 17, 2015	Mar	NEWA
		RTRX	50MG	N205750	001	Mar 17, 2015	Apr	CAHN
	+		250MG	N205750	002	Mar 17, 2015	Apr	CAHN

CIDOFOVIR

INJECTABLE;INJECTION

CIDOFOVIR

AP	+	MYLAN INSTITUTIONAL	EQ 75MG BASE/ML	A201276	001	Jun 27, 2012	May	CRLD

VISTIDE

	@	GILEAD SCIENCES INC	EQ 75MG BASE/ML	N020638	001	Jun 26, 1996	May	DISC

CIMETIDINE HYDROCHLORIDE

SOLUTION;ORAL

CIMETIDINE HYDROCHLORIDE

	@	G AND W LABS INC	EQ 300MG BASE/5ML	A	074176	001	Jun 01, 1994	Apr CAHN

CIPROFLOXACIN

INJECTABLE;INJECTION

CIPROFLOXACIN

AP		CLARIS PHARMASERVICE	200MG/20ML (10MG/ML)	A	078062	001	Apr 29, 2008	Apr CAHN
AP			400MG/40ML (10MG/ML)	A	078062	002	Apr 29, 2008	Apr CAHN

CIPROFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		CLARIS PHARMASERVICE	200MG/100ML	A	078024	001	Mar 18, 2008	Apr CAHN
AP			400MG/200ML	A	078024	002	Mar 18, 2008	Apr CAHN

CIPROFLOXACIN HYDROCHLORIDE

TABLET;ORAL

CIPROFLOXACIN HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 250MG BASE	A	075747	001	Jun 09, 2004	Apr CAHN
AB			EQ 500MG BASE	A	075747	002	Jun 09, 2004	Apr CAHN
AB			EQ 750MG BASE	A	075747	003	Jun 09, 2004	Apr CAHN

CISATRACURIUM BESYLATE

INJECTABLE;INJECTION

CISATRACURIUM BESYLATE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A	203183	001	Feb 26, 2015	Feb NEWA

CISATRACURIUM BESYLATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	EQ 2MG BASE/ML	A	203182	001	Feb 26, 2015	Feb NEWA
AP			EQ 10MG BASE/ML	A	203182	002	Feb 26, 2015	Feb NEWA

CISPLATIN

INJECTABLE;INJECTION

CISPLATIN

>A> AP		ACCORD HLTHCARE	1MG/ML	A	206774	001	Aug 18, 2015	Aug NEWA

CITALOPRAM HYDROBROMIDE

TABLET;ORAL

CITALOPRAM HYDROBROMIDE

AB		G AND W LABS INC	EQ 10MG BASE	A	077048	001	Nov 16, 2004	Apr CAHN
AB			EQ 20MG BASE	A	077048	002	Nov 16, 2004	Apr CAHN
AB			EQ 40MG BASE	A	077048	003	Nov 16, 2004	Apr CAHN

CLARITHROMYCIN

FOR SUSPENSION;ORAL

CLARITHROMYCIN

AB		SUN PHARM INDS LTD	125MG/5ML	A	065382	001	Aug 30, 2007	Apr CAHN
AB			250MG/5ML	A	065382	002	Aug 30, 2007	Apr CAHN

TABLET;ORAL

CLARITHROMYCIN

AB		SUN PHARM INDS LTD	250MG	A	065174	001	Sep 24, 2004	Apr CAHN
AB			500MG	A	065174	002	Sep 24, 2004	Apr CAHN

TABLET, EXTENDED RELEASE;ORAL

CLARITHROMYCIN

>A> AB		LUPIN LTD	500MG	A	202532	001	Sep 15, 2015	Aug NEWA
AB	+	TEVA	500MG	A	065154	001	May 18, 2005	Jan CRLD

CLAVULANATE POTASSIUM; TICARCILLIN DISODIUM

INJECTABLE;INJECTION

TIMENTIN

	@	GLAXOSMITHKLINE	EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	A	062691	001	Dec 19, 1986	May DISC
	@		EQ 100MG BASE/VIAL;EQ 3GM BASE/VIAL	N	050590	001	Apr 01, 1985	May DISC
	@		EQ 200MG BASE/VIAL;EQ 3GM BASE/VIAL	N	050590	002	Apr 01, 1985	May DISC
	@		EQ 1GM BASE/VIAL;EQ 30GM BASE/VIAL	N	050590	003	Aug 18, 1987	May DISC

TIMENTIN IN PLASTIC CONTAINER

	@	GLAXOSMITHKLINE	EQ 100MG BASE/100ML;EQ 3GM BASE/100ML	N	050658	001	Dec 15, 1989	May DISC

CLEMASTINE FUMARATE

TABLET;ORAL

CLEMASTINE FUMARATE

	@ ANI PHARMS INC	1.34MG	A073282	001	Jan 31, 1992	Jul	CAHN

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

AB	G AND W LABS INC	EQ 150MG BASE	A063029	001	Sep 20, 1989	Apr	CAHN
AB		EQ 300MG BASE	A063029	002	Aug 05, 2005	Apr	CAHN
AB	SUN PHARM INDS LTD	EQ 150MG BASE	A065061	001	Feb 02, 2001	Apr	CAHN
AB		EQ 300MG BASE	A065061	002	Feb 02, 2001	Apr	CAHN

CLINDAMYCIN PHOSPHATE

INJECTABLE;INJECTION

CLINDAMYCIN PHOSPHATE

	@ IGI LABS INC	EQ 150MG BASE/ML	A062928	001	Feb 13, 1989	Mar	CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

	@ BOCA PHARMA LLC	EQ 1% BASE	A062944	001	Jan 11, 1989	Jan	CAHN
AT	VINTAGE PHARMS	EQ 1% BASE	A203343	001	May 29, 2015	May	NEWA

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE AND TRETINOIN

AB	ACTAVIS MID ATLANTIC	1.2%;0.025%	A202564	001	Jun 12, 2015	Jun	NEWA
	ZIANA						
AB	+ MEDICIS	1.2%;0.025%	N050802	001	Nov 07, 2006	Jun	CTEC

CLOBETASOL PROPIONATE

CREAM;TOPICAL

CLOBETASOL PROPIONATE (EMOLLIENT)

AB2	+ FOUGERA PHARMS	0.05%	A075430	001	May 26, 1999	May	CRLD
	CORMAX						
AB1	+ HI TECH PHARMA	0.05%	A074220	001	May 16, 1997	Jun	CRLD
	TEMOVATE						
	@ FOUGERA PHARMS	0.05%	N019322	001	Dec 27, 1985	Jun	DISC
	TEMOVATE E						
	@ FOUGERA PHARMS	0.05%	N020340	001	Jun 17, 1994	May	DISC

GEL;TOPICAL

CLOBETASOL PROPIONATE

AB	+ FOUGERA PHARMS	0.05%	A075368	001	Feb 15, 2000	May	CRLD
	TEMOVATE						
	@ FOUGERA PHARMS	0.05%	N020337	001	Apr 29, 1994	May	DISC

OINTMENT;TOPICAL

CLOBETASOL PROPIONATE

AB	G AND W LABS INC	0.05%	A074089	001	Feb 16, 1994	Feb	CAHN

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

AT	G AND W LABS INC	0.05%	A074331	001	Dec 15, 1995	Mar	CMFD

CLOMIPHENE CITRATE

TABLET;ORAL

SEROPHENE

	@ EMD SERONO	50MG	N018361	001	Mar 22, 1982	Jun	DISC

CLONIDINE

FILM, EXTENDED RELEASE;TRANSDERMAL

CLONIDINE

AB	ACTAVIS LABS UT INC	0.1MG/24HR	A090873	001	May 06, 2014	Mar	CAHN
AB		0.2MG/24HR	A090873	002	May 06, 2014	Mar	CAHN
AB		0.3MG/24HR	A090873	003	May 06, 2014	Mar	CAHN

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

	@ DAVA PHARMS INC	0.1MG	A071783	001	Apr 05, 1988	May	DISC
	@	0.2MG	A071784	001	Apr 05, 1988	May	DISC
	@	0.3MG	A071785	001	Apr 05, 1988	May	DISC

TABLET, EXTENDED RELEASE;ORAL
CLONIDINE HYDROCHLORIDE

	AB2		ACTAVIS ELIZABETH	0.1MG	A202792	001	May 15, 2015	May NEWA
	AB1			0.1MG	A203320	001	May 15, 2015	May NEWA
>D>	AB2			0.2MG	A202792	002	May 15, 2015	Aug DISC
>A>		@		0.2MG	A202792	002	May 15, 2015	Aug DISC
	AB2			0.2MG	A202792	002	May 15, 2015	May NEWA
>D>	AB1			0.2MG	A203320	002	May 15, 2015	Aug DISC
>A>		@		0.2MG	A203320	002	May 15, 2015	Aug DISC
	AB1			0.2MG	A203320	002	May 15, 2015	May NEWA
>D>	AB2		ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Aug DISC
>A>		@		0.1MG	A202983	001	Apr 02, 2014	Aug DISC
	AB2			0.1MG	A202983	001	Apr 02, 2014	May CTEC
>D>	AB2			0.2MG	A202983	002	Apr 02, 2014	Aug DISC
>A>		@		0.2MG	A202983	002	Apr 02, 2014	Aug DISC
	AB2			0.2MG	A202983	002	Apr 02, 2014	May CTEC

CLONIDINE HYDROCHLORIDE

	AB1		ANCHEN PHARMS	0.1MG	A202984	001	Sep 30, 2013	May CTEC
>D>	AB1			0.2MG	A202984	002	Sep 30, 2013	Aug DISC
>A>		@		0.2MG	A202984	002	Sep 30, 2013	Aug DISC
	AB1			0.2MG	A202984	002	Sep 30, 2013	May CTEC

KAPVAY

>D>	AB1		CONCORDIA PHARMS INC	0.1MG	N022331	003	Sep 28, 2010	Aug CRLD
>A>	AB1	+		0.1MG	N022331	003	Sep 28, 2010	Aug CRLD
	AB1			0.1MG	N022331	003	Sep 28, 2010	Jun CRLD
	AB1	+		0.1MG	N022331	003	Sep 28, 2010	May CTEC
>D>	AB1	+		0.2MG	N022331	004	Sep 28, 2010	Aug DISC
>A>		@		0.2MG	N022331	004	Sep 28, 2010	Aug DISC
	AB1	+		0.2MG	N022331	004	Sep 28, 2010	Jun CRLD
	AB1			0.2MG	N022331	004	Sep 28, 2010	May CTEC

CLORAZEPATE DIPOTASSIUM

TABLET;ORAL
CLORAZEPATE DIPOTASSIUM

	AB		SUN PHARM INDS LTD	3.75MG	A076911	001	Sep 29, 2004	Apr CAHN
	AB			7.5MG	A076911	002	Sep 29, 2004	Apr CAHN
	AB			15MG	A076911	003	Sep 29, 2004	Apr CAHN

CLOZAPINE

TABLET;ORAL
CLOZARIL

>A>	AB		HERITAGE LIFE	25MG	N019758	001	Sep 26, 1989	Aug CAHN
>A>	AB	+		100MG	N019758	002	Sep 26, 1989	Aug CAHN
>D>	AB		NOVARTIS	25MG	N019758	001	Sep 26, 1989	Aug CAHN
>D>	AB	+		100MG	N019758	002	Sep 26, 1989	Aug CAHN

TABLET, ORALLY DISINTEGRATING;ORAL

>A>			CLOZAPINE					
>A>	AB		MYLAN PHARMS INC	25MG	A201824	002	Sep 15, 2015	Aug NEWA
>A>	AB			100MG	A201824	003	Sep 15, 2015	Aug NEWA

FAZACLO ODT

>D>			JAZZ PHARMS III	25MG	N021590	001	Feb 10, 2004	Aug CFTG
>A>	AB			25MG	N021590	001	Feb 10, 2004	Aug CFTG
>D>		+		100MG	N021590	002	Feb 10, 2004	Aug CFTG
>A>	AB	+		100MG	N021590	002	Feb 10, 2004	Aug CFTG

COBICISTAT; DARUNAVIR ETHANOLATE

TABLET;ORAL
PREZCOBIX

		+	JANSSEN PRODS	150MG;EQ 800MG BASE	N205395	001	Jan 29, 2015	Jan NEWA

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL
PROMETHAZINE HYDROCHLORIDE,PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

>A>	AA		AMNEAL PHARMS	10MG/5ML;5MG/5ML;6.25MG/5ML	A200963	001	Aug 26, 2015	Aug NEWA

CODEINE SULFATE

SOLUTION;ORAL
CODEINE SULFATE

		@	ROXANE	30MG/5ML	N202245	001	Jun 30, 2011	Jan DISC

	COLCHICINE						
	CAPSULE;ORAL						
	MITIGARE						
	HIKMA INTL PHARMS	0.6MG	N204820	001	Sep 26, 2014	Jan CAHN
	COLCHICINE; PROBENECID						
	TABLET;ORAL						
	PROBENECID AND COLCHICINE						
>A>	@ ANI PHARMS INC	0.5MG;500MG	A083734	001		Aug CAHN
>D>	@ IVAX SUB TEVA PHARMS	0.5MG;500MG	A083734	001		Aug CAHN
	COLISTIMETHATE SODIUM						
	INJECTABLE;INJECTION						
	COLISTIMETHATE SODIUM						
AP	XELLIA PHARMS APS	EQ 150MG BASE/VIAL	A205356	001	May 29, 2015	May NEWA
	CORTICOTROPIN						
	INJECTABLE;INJECTION						
	H.P. ACTHAR GEL						
>A>	@ MALLINCKRODT ARD	40 UNITS/ML	N008372	006		Aug CAHN
>A>	+	80 UNITS/ML	N008372	008		Aug CAHN
>D>	@ QUESTCOR PHARMS	40 UNITS/ML	N008372	006		Aug CAHN
>D>	+	80 UNITS/ML	N008372	008		Aug CAHN
	CYANOCOBALAMIN						
	INJECTABLE;INJECTION						
	CYANOCOBALAMIN						
	@ EUROHLTH INTL SARL	1MG/ML	A080515	002		Feb CAHN
	CYCLOBENZAPRINE HYDROCHLORIDE						
	TABLET;ORAL						
	CYCLOBENZAPRINE HYDROCHLORIDE						
AB	ORIT LABS LLC	5MG	A078218	002	Jun 19, 2015	Jun NEWA
AB	SUN PHARM INDS LTD	5MG	A078722	001	May 12, 2008	Apr CAHN
AB		7.5MG	A078722	002	May 12, 2008	Apr CAHN
AB		10MG	A078722	003	May 12, 2008	Apr CAHN
	DABRAFENIB MESYLATE						
	CAPSULE;ORAL						
	TAFINLAR						
	NOVARTIS PHARMS CORP	EQ 50MG BASE	N202806	001	May 29, 2013	Mar CAHN
	+	EQ 75MG BASE	N202806	002	May 29, 2013	Mar CAHN
	DACLATASVIR DIHYDROCHLORIDE						
	TABLET;ORAL						
	DAKLINZA						
	BRISTOL-MYERS SQUIBB	EQ 30MG BASE	N206843	001	Jul 24, 2015	Jul NEWA
	+	EQ 60MG BASE	N206843	002	Jul 24, 2015	Jul NEWA
	DALTEPARIN SODIUM						
	INJECTABLE;INJECTION						
	FRAGMIN						
	@ PFIZER INC	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Jun CAHN
	@ PHARMACIA AND UPJOHN	7,500 IU/0.75ML	N020287	008	Apr 04, 2002	Apr CAHN
	INJECTABLE;SUBCUTANEOUS						
	FRAGMIN						
	PFIZER INC	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Jun CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Jun CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Jun CAHN
	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Jun CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Jun CAHN
		12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Jun CAHN
		15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Jun CAHN
		18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Jun CAHN
	+	95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Jun CAHN
	@	95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Jun CAHN
	PHARMACIA AND UPJOHN	2,500IU/0.2ML (12,500IU/ML)	N020287	001	Dec 22, 1994	Apr CAHN
		5,000IU/0.2ML (25,000IU/ML)	N020287	003	Mar 18, 1996	Apr CAHN
		7,500IU/0.3ML (25,000IU/ML)	N020287	005	Apr 04, 2002	Apr CAHN
	@	10,000IU/0.4ML (25,000IU/ML)	N020287	002	May 01, 2007	Apr CAHN
		10,000IU/ML (10,000IU/ML)	N020287	004	Jan 30, 1998	Apr CAHN

		INJECTABLE;SUBCUTANEOUS						
		FRAGMIN						
			12,500IU/0.5ML (25,000IU/ML)	N020287	009	May 01, 2007	Apr CAHN
			15,000IU/0.6ML (25,000IU/ML)	N020287	010	May 01, 2007	Apr CAHN
			18,000IU/0.72ML (25,000IU/ML)	N020287	011	May 01, 2007	Apr CAHN
	+		95,000IU/3.8ML (25,000IU/ML)	N020287	006	Apr 04, 2002	Apr CAHN
	@		95,000IU/9.5ML (10,000IU/ML)	N020287	007	Apr 04, 2002	Apr CAHN
		DANTROLENE SODIUM						
		CAPSULE;ORAL						
		DANTROLENE SODIUM						
AB		ELITE LABS INC	25MG	A076686	001	Oct 24, 2005	May CAHN
AB			50MG	A076686	002	Oct 24, 2005	May CAHN
AB			100MG	A076686	003	Oct 24, 2005	May CAHN
		DARIFENACIN HYDROBROMIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		DARIFENACIN HYDROBROMIDE						
AB		ANCHEN PHARMS	EQ 7.5MG BASE	A091190	001	Mar 13, 2015	Mar NEWA
AB			EQ 15MG BASE	A091190	002	Mar 13, 2015	Mar NEWA
		ENABLEX						
AB		WARNER CHILCOTT LLC	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Mar CFTG
AB	+		EQ 15MG BASE	N021513	002	Dec 22, 2004	Mar CFTG
		DECITABINE						
		INJECTABLE;INTRAVENOUS						
		DACOGEN						
AP	+	OTSUKA PHARM CO LTD	50MG/VIAL	N021790	001	May 02, 2006	Jan CAHN
		DEFERASIROX						
		TABLET;ORAL						
		JADENU						
		NOVARTIS PHARMS CORP	90MG	N206910	001	Mar 30, 2015	Mar NEWA
			180MG	N206910	002	Mar 30, 2015	Mar NEWA
	+		360MG	N206910	003	Mar 30, 2015	Mar NEWA
		DEMECLOCYCLINE HYDROCHLORIDE						
		TABLET;ORAL						
		DEMECLOCYCLINE HYDROCHLORIDE						
>A> AB		EPIC PHARMA LLC	150MG	A065447	001	Aug 18, 2015	Aug NEWA
>A> AB			300MG	A065447	002	Aug 18, 2015	Aug NEWA
		DEOXYCHOLIC ACID						
		SOLUTION;SUBCUTANEOUS						
		KYBELLA						
	+	KYTHERA BIOPHARMS	20MG/2ML (10MG/ML)	N206333	001	Apr 29, 2015	Apr NEWA
		DESIRUDIN RECOMBINANT						
		INJECTABLE;SUBCUTANEOUS						
		IPRIVASK						
	+	VALEANT PHARMS NORTH	15MG/VIAL	N021271	001	Apr 04, 2003	May CAHN
		DESLORATADINE						
		SOLUTION;ORAL						
		CLARINEX						
AA	+	MERCK SHARP DOHME	0.5MG/ML	N021300	001	Sep 01, 2004	Jun CFTG
		DESLORATADINE						
AA		TARO PHARM INDS	0.5MG/ML	A202592	001	Jun 30, 2015	Jun NEWA
		DESMOPRESSIN ACETATE						
		TABLET;ORAL						
		DDAVP						
AB		FERRING PHARMS INC	0.1MG	N019955	001	Sep 06, 1995	Jan CAHN
AB	+		0.2MG	N019955	002	Sep 06, 1995	Jan CAHN
		DESMOPRESSIN ACETATE						
AB		GLENMARK PHARMS LTD	0.1MG	A201831	001	May 28, 2015	May NEWA
AB			0.2MG	A201831	002	May 28, 2015	May NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET;ORAL-28

			BEKYREE						
	AB		LUPIN LTD	0.15MG,N/A;0.02MG,0.01MG	A202226	001	Aug 12, 2015	Jul	NEWA
			CYCLESSA						
>A>	AB	+	ASPEN GLOBAL INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025 MG,0.025MG	N021090	001	Dec 20, 2000	Aug	CAHN
>D>	AB	+	ORGANON USA INC	0.1MG,0.125MG,0.15MG;0.025MG,0.025 MG,0.025MG	N021090	001	Dec 20, 2000	Aug	CAHN
			ISIBLOOM						
	AB		SANDOZ INC	0.15MG;0.03MG	A202789	001	Aug 12, 2015	Jul	NEWA
			KARIVA						
	AB	+	BARR	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002	Apr	CTEC
			KIMIDESS						
	AB		VINTAGE PHARMS	0.15MG,N/A;0.02MG,0.01MG	A076681	001	Apr 30, 2015	Apr	NEWA

DESONIDE

CREAM;TOPICAL

			DESONIDE						
	AB		TEVA PHARMS	0.05%	A074027	001	Sep 28, 1992	May	CMFD

DESOXIMETASONE

CREAM;TOPICAL

			DESOXIMETASONE						
>A>	AB		ACTAVIS MID ATLANTIC	0.25%	A205082	001	Sep 04, 2015	Aug	NEWA
	AB		VERSAPHARM INC	0.25%	A203234	001	Jun 12, 2015	Jun	NEWA

OINTMENT;TOPICAL

			DESOXIMETASONE						
	AB		PERRIGO NEW YORK	0.25%	A077770	001	Apr 20, 2015	Apr	NEWA

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

			DESVENLAFAXINE SUCCINATE						
	AB		ALEMBIC PHARMS LTD	EQ 50MG BASE	A204003	001	Jun 29, 2015	Jun	NEWA
	AB			EQ 100MG BASE	A204003	002	Jun 29, 2015	Jun	NEWA
	AB		LUPIN LTD	EQ 50MG BASE	A204172	001	Jun 29, 2015	Jun	NEWA
	AB			EQ 100MG BASE	A204172	002	Jun 29, 2015	Jun	NEWA
	AB		MYLAN PHARMS INC	EQ 50MG BASE	A204095	001	Jun 29, 2015	Jun	NEWA
	AB			EQ 100MG BASE	A204095	002	Jun 29, 2015	Jun	NEWA
	AB		SANDOZ INC	EQ 50MG BASE	A204028	001	Jun 29, 2015	Jun	NEWA
	AB			EQ 100MG BASE	A204028	002	Jun 29, 2015	Jun	NEWA
			PRISTIQ						
	AB	+	WYETH PHARMS INC	EQ 50MG BASE	N021992	001	Feb 29, 2008	Jun	CFTG
	AB	+		EQ 100MG BASE	N021992	002	Feb 29, 2008	Jun	CFTG

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE;INJECTION

			DEXAMETHASONE SODIUM PHOSPHATE						
			@ EUROHLTH INTL SARL	EQ 4MG PHOSPHATE/ML	A084282	001		Mar	CAHN
	AP	+		EQ 10MG PHOSPHATE/ML	A087702	001	Sep 07, 1982	Feb	CAHN

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

			MAXITROL						
	AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N050065	002		Mar	CAHN

SUSPENSION/DROPS;OPHTHALMIC

			MAXITROL						
	AT	+	ALCON LABS INC	0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N050023	002		Mar	CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

			DEXMEDETOMIDINE HYDROCHLORIDE						
>A>	AP		SUN PHARM INDS INC	EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML)	A202126	001	Aug 20, 2015	Aug	NEWA
			PRECEDEX						
			HOSPIRA	EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML)	N021038	004	Nov 14, 2014	Jan	NEWA

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

DEXMETHYLPHENIDATE HYDROCHLORIDE

>A>	AB	MYLAN PHARMS INC	5MG	A204266	001	Aug 25, 2015	Aug	NEWA
>A>	AB		10MG	A204266	002	Aug 25, 2015	Aug	NEWA
>A>	AB		15MG	A204266	003	Aug 25, 2015	Aug	NEWA
>A>	AB		40MG	A204266	007	Aug 25, 2015	Aug	NEWA
	AB	WATSON LABS INC	5MG	A079108	001	Aug 05, 2015	Jul	NEWA
	AB		10MG	A079108	002	Aug 05, 2015	Jul	NEWA

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE; SODIUM GLUCONATE

INJECTABLE;INJECTION

PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER

		@ BAXTER HLTHCARE	5GM/100ML;30MG/100ML;37MG/100ML;368MG/100ML;526MG/100ML;502MG/100ML	N017451	001		Mar	DISC

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE;INJECTION

MD-76R

	AP	+ LIEBEL-FLARSHEIM	66%;10%	N019292	001	Sep 29, 1989	Feb	CAHN

SOLUTION;ORAL, RECTAL

MD-GASTROVIEW

	AA	LIEBEL-FLARSHEIM	66%;10%	A087388	001		Jan	CAHN

DICHLORPHENAMIDE

TABLET;ORAL

KEVEYIS

>A>		TARO	50MG	N011366	002	Aug 07, 2015	Aug	NEWA

DICLOFENAC SODIUM

GEL;TOPICAL

VOLTAREN

>A>		+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Aug	CAHN
>D>		+ NOVARTIS	1%	N022122	001	Oct 17, 2007	Aug	CAHN

SOLUTION;TOPICAL

DICLOFENAC SODIUM

	AT	IGI LABS INC	1.5%	A202769	001	Jul 08, 2015	Jun	NEWA
>A>	AT	LUPIN LTD	1.5%	A204132	001	Aug 20, 2015	Aug	NEWA

DIETHYLPROPION HYDROCHLORIDE

TABLET;ORAL

TENUATE

	AA	+ ACTAVIS LABS UT INC	25MG	N011722	002		Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

TENUATE DOSPAN

	AB	+ ACTAVIS LABS UT INC	75MG	N012546	001		Mar	CAHN

DIFLORASONE DIACETATE

OINTMENT;TOPICAL

DIFLORASONE DIACETATE

	AB	VERSAPHARM INC	0.05%	A206572	001	Jul 24, 2015	Jul	NEWA

DIFLUNISAL

TABLET;ORAL

DIFLUNISAL

	AB	HERITAGE PHARMA	500MG	A202845	001	Mar 08, 2012	Mar	CAHN

DIGOXIN

INJECTABLE;INJECTION

DIGOXIN

	AP	EUROHLTH INTL SARL	0.25MG/ML	A083391	001		Feb	CAHN

TABLET;ORAL

DIGOXIN

	AB	MYLAN PHARMS INC	0.125MG	A040282	001	Dec 23, 1999	Jan	CTEC
	AB		0.25MG	A040282	002	Dec 23, 1999	Jan	CTEC
	AB	SUN PHARM INDS INC	0.125MG	A076363	001	Jan 31, 2003	Feb	CMFD
	AB		0.25MG	A076363	002	Jan 31, 2003	Feb	CMFD

LANOXIN

		CONCORDIA PHARMS INC	0.0625MG	N020405	001	Sep 30, 1997	Apr	CAHN
	AB		0.125MG	N020405	002	Sep 30, 1997	Apr	CAHN

TABLET;ORAL
LANOXIN

			0.1875MG	N020405	003	Sep 30, 1997	Apr	CAHN
AB	+		0.25MG	N020405	004	Sep 30, 1997	Apr	CAHN
	@		0.375MG	N020405	005	Sep 30, 1997	Apr	CAHN
	@		0.5MG	N020405	006	Sep 30, 1997	Apr	CAHN

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
DILTIAZEM HYDROCHLORIDE

AB2	+	MYLAN	240MG	A075124	001	Mar 18, 1998	Feb	CRLD

TIAZAC

AB4		VALEANT PHARMS NORTH	120MG	N020401	001	Sep 11, 1995	Feb	CAHN
AB4			180MG	N020401	002	Sep 11, 1995	Feb	CAHN
AB4			240MG	N020401	003	Sep 11, 1995	Feb	CAHN
AB4			300MG	N020401	004	Sep 11, 1995	Feb	CAHN
AB4			360MG	N020401	005	Sep 11, 1995	Feb	CAHN
AB4	+		420MG	N020401	006	Oct 16, 1998	Feb	CAHN

INJECTABLE;INJECTION
DILTIAZEM HYDROCHLORIDE

AP		EUROHLTH INTL SARL	5MG/ML	A078538	001	Dec 17, 2008	Jun	CAHN

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DIPHENHYDRAMINE HYDROCHLORIDE

AP	+	EUROHLTH INTL SARL	50MG/ML	A080817	002		Jun	CAHN

DIPYRIDAMOLE

INJECTABLE;INJECTION
DIPYRIDAMOLE

AP		EUROHLTH INTL SARL	5MG/ML	A074521	001	Oct 18, 1996	Jun	CAHN

DISULFIRAM

TABLET;ORAL
DISULFIRAM

AB		MYLAN PHARMS INC	250MG	A203916	001	Mar 04, 2015	Feb	NEWA
AB			500MG	A203916	002	Mar 04, 2015	Feb	NEWA

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE;ORAL
DIVALPROEX SODIUM

AB		AMNEAL PHARMS	EQ 250MG VALPROIC ACID	A203730	001	May 29, 2015	May	NEWA
AB			EQ 500MG VALPROIC ACID	A203730	002	May 29, 2015	May	NEWA
	@	G AND W LABS INC	EQ 500MG VALPROIC ACID	A078700	001	Aug 03, 2009	Jul	CAHN

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION
DOBUTAMINE HYDROCHLORIDE

	@	IGI LABS INC	EQ 12.5MG BASE/ML	A074098	001	Feb 21, 1995	Mar	CAHN

DOCETAXEL

INJECTABLE;INJECTION
DOCETAXEL

>A> AP		TEVA PHARMS USA	20MG/ML (20MG/ML)	A203877	001	Sep 16, 2015	Aug	NEWA
>A> AP			80MG/4ML (20MG/ML)	A203877	002	Sep 16, 2015	Aug	NEWA

DONEPEZIL HYDROCHLORIDE

TABLET;ORAL
DONEPEZIL HYDROCHLORIDE

AB		HETERO LABS LTD V	5MG	A203034	001	Jan 30, 2015	Jan	NEWA
AB			10MG	A203034	002	Jan 30, 2015	Jan	NEWA
AB		SUN PHARM INDS LTD	5MG	A076786	001	Nov 26, 2010	Apr	CAHN
AB			10MG	A076786	002	Nov 26, 2010	Apr	CAHN
AB			23MG	A204293	001	Jun 05, 2015	May	NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL
NAMZARIC

		FOREST LABS LLC	10MG;14MG	N206439	001	Dec 23, 2014	Mar	CAHN
	+		10MG;28MG	N206439	002	Dec 23, 2014	Mar	CAHN

DOPAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOPAMINE HYDROCHLORIDE

	@ IGI LABS INC	40MG/ML	A070087	001	Oct 23, 1985	Mar	CAHN
	@	40MG/ML	N018656	001	Jun 28, 1983	Mar	CAHN
	@	80MG/ML	A070089	001	Oct 23, 1985	Mar	CAHN
	@	80MG/ML	A070090	001	Oct 23, 1985	Mar	CAHN
	@	80MG/ML	A070091	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070092	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070093	001	Oct 23, 1985	Mar	CAHN
	@	160MG/ML	A070094	001	Oct 23, 1985	Mar	CAHN

DOXAPRAM HYDROCHLORIDE

INJECTABLE;INJECTION

DOPRAM

AP	+ EUROHLTH INTL SARL	20MG/ML	N014879	001		Jun	CAHN

DOXEPIN HYDROCHLORIDE

CAPSULE;ORAL

DOXEPIN HYDROCHLORIDE

AB	+ MYLAN PHARMS INC	EQ 100MG BASE	A070791	005	May 13, 1986	Jan	CRLD
	+ PAR PHARM	EQ 150MG BASE	A071669	001	Nov 09, 1987	Jan	CRLD

CREAM;TOPICAL

ZONALON

	+ DELCOR ASSET CORP	5%	N020126	001	Apr 01, 1994	Mar	CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION

DOXERCALCIFEROL

AP	AKORN INC	4MCG/2ML (2MCG/ML)	A203929	001	May 07, 2015	Apr	NEWA

DOXYCYCLINE

CAPSULE;ORAL

DOXYCYCLINE

AB	NOVEL LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	May	NEWA
AB		EQ 75MG BASE	A204446	002	May 28, 2015	May	NEWA
AB		EQ 100MG BASE	A204446	003	May 28, 2015	May	NEWA
AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065053	001	Nov 22, 2000	Apr	CAHN
AB		EQ 75MG BASE	A065053	003	Sep 10, 2003	Apr	CAHN
AB		EQ 100MG BASE	A065053	002	Nov 22, 2000	Apr	CAHN

TABLET;ORAL

DOXYCYCLINE

AB	SUN PHARM INDS LTD	EQ 50MG BASE	A065356	001	May 31, 2006	Apr	CAHN
AB		EQ 75MG BASE	A065356	002	May 31, 2006	Apr	CAHN
AB		EQ 100MG BASE	A065356	003	May 31, 2006	Apr	CAHN

DOXYCYCLINE HYCLATE

INJECTABLE;INJECTION

DOXYCYCLINE

	@ EUROHLTH INTL SARL	EQ 100MG BASE/VIAL	A062450	001	Oct 27, 1983	Jun	CAHN
	@	EQ 200MG BASE/VIAL	A062450	002	Oct 27, 1983	Jun	CAHN

DROPERIDOL

INJECTABLE;INJECTION

DROPERIDOL

	@ IGI LABS INC	2.5MG/ML	A072019	001	Oct 19, 1988	Mar	CAHN
	@	2.5MG/ML	A072020	001	Oct 19, 1988	Mar	CAHN
	@	2.5MG/ML	A072021	001	Oct 19, 1988	Mar	CAHN

DROSPIRENONE; ETHINYL ESTRADIOL

TABLET;ORAL

DROSPIRENONE AND ETHINYL ESTRADIOL

>A> AB	GLENMARK PHARMS LTD	3MG;0.02MG	A204296	001	Aug 17, 2015	Aug	NEWA

DULOXETINE HYDROCHLORIDE

CAPSULE, DELAYED REL PELLETS;ORAL

DULOXETINE HYDROCHLORIDE

>A> AB	ALKEM LABS LTD	EQ 20MG BASE	A203197	001	Aug 26, 2015	Aug	NEWA
>A> AB		EQ 30MG BASE	A203197	002	Aug 26, 2015	Aug	NEWA
>A> AB		EQ 60MG BASE	A203197	003	Aug 26, 2015	Aug	NEWA

ECONAZOLE NITRATE

CREAM;TOPICAL

ECONAZOLE NITRATE

AB		FOUGERA PHARMS	1%	A076075	001	Nov 26, 2002	Mar CRLD
AB	+	PERRIGO NEW YORK	1%	A076479	001	Jun 23, 2004	Mar CRLD

EDOXABAN TOSYLATE

TABLET;ORAL

SAVAYSA

		DAIICHI SANKYO	EQ 15MG BASE	N206316	001	Jan 08, 2015	Jan NEWA
			EQ 30MG BASE	N206316	002	Jan 08, 2015	Jan NEWA
	+		EQ 60MG BASE	N206316	003	Jan 08, 2015	Jan NEWA

EDROPHONIUM CHLORIDE

INJECTABLE;INJECTION

ENLON

	+	MYLAN INSTITUTIONAL	10MG/ML	A088873	001	Aug 06, 1985	Mar CRLD

TENSILON

	@	IGI LABS INC	10MG/ML	N007959	001		Apr CAHN
	@	VALEANT PHARMS	10MG/ML	N007959	001		Mar DISC

TENSILON PRESERVATIVE FREE

	@	IGI LABS INC	10MG/ML	N007959	002		Apr CAHN
	@	VALEANT PHARMS	10MG/ML	N007959	002		Mar DISC

>A> ELTROMBOPAG OLAMINE

>A> FOR SUSPENSION;ORAL

>A> PROMACTA

>A>	+	NOVARTIS PHARMS CORP	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Aug NEWA

TABLET;ORAL

PROMACTA

		NOVARTIS PHARMS CORP	EQ 12.5MG ACID	N022291	004	Oct 20, 2011	Mar CAHN
			EQ 25MG ACID	N022291	001	Nov 20, 2008	Mar CAHN
			EQ 50MG ACID	N022291	002	Nov 20, 2008	May CRLD
	+		EQ 50MG ACID	N022291	002	Nov 20, 2008	Mar CAHN
	+		EQ 75MG ACID	N022291	003	Sep 08, 2009	May CRLD
			EQ 75MG ACID	N022291	003	Sep 08, 2009	Mar CAHN
	+		EQ 100MG ACID	N022291	005	Nov 16, 2012	May CRLD
			EQ 100MG ACID	N022291	005	Nov 16, 2012	Mar CAHN

ELUXADOLINE

TABLET;ORAL

VIBERZI

		FOREST TOSARA LTD	75MG	N206940	001	May 27, 2015	Jul CAHN
	+		100MG	N206940	002	May 27, 2015	Jul CAHN
		FURIEX PHARMS	75MG	N206940	001	May 27, 2015	May NEWA
	+		100MG	N206940	002	May 27, 2015	May NEWA

EMPAGLIFLOZIN; LINAGLIPTIN

TABLET;ORAL

GLYXAMBI

		BOEHRINGER INGELHEIM	10MG;5MG	N206073	001	Jan 30, 2015	Jan NEWA
	+		25MG;5MG	N206073	002	Jan 30, 2015	Jan NEWA

>A> EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE

>A> TABLET;ORAL

>A> SYNJARDY

>A>		BOEHRINGER INGELHEIM	5MG;500MG	N206111	001	Aug 26, 2015	Aug NEWA
>A>			5MG;1GM	N206111	002	Aug 26, 2015	Aug NEWA
>A>			12.5MG;500MG	N206111	003	Aug 26, 2015	Aug NEWA
>A>	+		12.5MG;1GM	N206111	004	Aug 26, 2015	Aug NEWA

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

AB		SANDOZ INC	2.5MG	A075496	001	Aug 22, 2000	Mar CMFD
AB			5MG	A075496	002	Aug 22, 2000	Mar CMFD
AB			10MG	A075459	001	Aug 22, 2000	Mar CMFD
AB			20MG	A075459	002	Aug 22, 2000	Mar CMFD
	@	SUN PHARM INDS LTD	2.5MG	A075556	001	Aug 22, 2000	Apr CAHN
	@		5MG	A075556	002	Aug 22, 2000	Apr CAHN
	@		10MG	A075556	003	Aug 22, 2000	Apr CAHN

TABLET;ORAL
ENALAPRIL MALEATE

		@	20MG	A075556	004	Aug 22, 2000	Apr	CAHN

VASOTEC

	AB		VALEANT PHARMS NORTH	2.5MG	N018998	005	Jul 26, 1988	Apr CAHN
	AB			5MG	N018998	001	Dec 24, 1985	Apr CAHN
	AB			10MG	N018998	002	Dec 24, 1985	Apr CAHN
	AB	+		20MG	N018998	003	Dec 24, 1985	Apr CAHN

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

	AB		G AND W LABS INC	5MG;12.5MG	A075727	001	Sep 18, 2001	Apr CAHN
	AB			10MG;25MG	A075727	002	Sep 18, 2001	Apr CAHN

ENTACAPONE

TABLET;ORAL
ENTACAPONE

	AB		AUROBINDO PHARMA LTD	200MG	A203437	001	Jun 19, 2015	Jun NEWA

ENTECAVIR

TABLET;ORAL
ENTECAVIR

>A>	AB		AUROBINDO PHARMA LTD	0.5MG	A206217	001	Aug 26, 2015	Aug NEWA
>A>	AB			1MG	A206217	002	Aug 26, 2015	Aug NEWA
>A>	AB		HETERO LABS LTD V	0.5MG	A205740	001	Aug 21, 2015	Aug NEWA
>A>	AB			1MG	A205740	002	Aug 21, 2015	Aug NEWA

EPINEPHRINE

INJECTABLE;INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS
ADRENALIN

		+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS
ADRENALIN

		+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN

EPROSARTAN MESYLATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL
TEVETEN HCT

		@	ABBVIE	600MG;12.5MG	N021268	001	Nov 01, 2001	Jun DISC
		@		600MG;25MG	N021268	002	Nov 01, 2001	Jun DISC

EPTIFIBATIDE

INJECTABLE;INJECTION
EPTIFIBATIDE

	AP		TEVA PHARMS USA	2MG/ML	A090854	001	Jun 12, 2015	Jun NEWA
	AP			75MG/100ML	A091555	001	Jun 05, 2015	May NEWA

INTEGRILIN

	AP	+	SCHERING	2MG/ML	N020718	001	May 18, 1998	Jun CTEC
	AP	+		75MG/100ML	N020718	002	May 18, 1998	May CFTG

ERGOCALCIFEROL

CAPSULE;ORAL
VITAMIN D

	AA		BANNER LIFE SCIENCES	50,000 IU	A080704	001		Jan CAHN

ERGOTAMINE TARTRATE

TABLET;SUBLINGUAL
ERGOSTAT

>D>		@	PARKE DAVIS	2MG	A088337	001	Jun 08, 1984	Aug CAHN
>A>		@	WATSON LABS INC	2MG	A088337	001	Jun 08, 1984	Aug CAHN

ERLOTINIB HYDROCHLORIDE

TABLET;ORAL
ERLOTINIB HYDROCHLORIDE

>A>	AB		TEVA PHARMS USA	EQ 100MG BASE	A091059	002	Aug 28, 2015	Aug NEWA
>A>	AB			EQ 150MG BASE	A091059	003	Aug 28, 2015	Aug NEWA

ERYTHROMYCIN ESTOLATE

SUSPENSION;ORAL

ERYTHROMYCIN ESTOLATE

	@ G AND W LABS INC	EQ 125MG BASE/5ML	A062169	001	Oct 17, 1990	Apr	CAHN
	@	EQ 250MG BASE/5ML	A062169	002	Oct 17, 1990	Apr	CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE;ORAL

ERYTHROMYCIN ETHYLSUCCINATE

	@ ANI PHARMS INC	EQ 200MG BASE/5ML	A062055	001		Jul	CAHN

ESCITALOPRAM OXALATE

SOLUTION;ORAL

ESCITALOPRAM OXALATE

AA	ANTRIM PHARMS LLC	EQ 5MG BASE/5ML	A203967	001	May 26, 2015	May	NEWA

TABLET;ORAL

ESCITALOPRAM OXALATE

AB	MYLAN PHARMS INC	EQ 5MG BASE	A077550	001	May 14, 2015	Apr	NEWA
AB		EQ 10MG BASE	A077550	002	May 14, 2015	Apr	NEWA
AB		EQ 20MG BASE	A077550	003	May 14, 2015	Apr	NEWA
>A> AB	PRINSTON INC	EQ 5MG BASE	A078032	001	Aug 28, 2015	Aug	NEWA
>A> AB		EQ 10MG BASE	A078032	002	Aug 28, 2015	Aug	NEWA
>A> AB		EQ 20MG BASE	A078032	003	Aug 28, 2015	Aug	NEWA

ESMOLOL HYDROCHLORIDE

INJECTABLE;INJECTION

ESMOLOL HYDROCHLORIDE

AP	AUROBINDO PHARMA LTD	10MG/ML	A205520	001	Jul 23, 2015	Jul	NEWA
AP	LUITPOLD	10MG/ML	A201126	001	Feb 20, 2015	Feb	NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL

ESOMEPRAZOLE MAGNESIUM

AB	IVAX SUB TEVA PHARMS	EQ 20MG BASE	A078003	001	Jan 26, 2015	Jan	NEWA
AB		EQ 40MG BASE	A078003	002	Jan 26, 2015	Jan	NEWA
AB	MYLAN LABS LTD	EQ 20MG BASE	A078936	001	Aug 02, 2015	Jul	NEWA
AB		EQ 40MG BASE	A078936	002	Aug 03, 2015	Jul	NEWA

NEXIUM

AB	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Jan	CFTG
AB +		EQ 40MG BASE	N021153	002	Feb 20, 2001	Jan	CFTG

ESOMEPRAZOLE STRONTIUM

CAPSULE, DELAYED RELEASE;ORAL

ESOMEPRAZOLE STRONTIUM

>D>	HANMI PHARM CO LTD	EQ 20MG BASE	N202342	001	Aug 06, 2013	Aug	CPOT
>A>		24.65MG	N202342	001	Aug 06, 2013	Aug	CPOT
>D> +		EQ 40MG BASE	N202342	002	Aug 06, 2013	Aug	CPOT
>A> +		49.3MG	N202342	002	Aug 06, 2013	Aug	CPOT

ESTRADIOL

FILM, EXTENDED RELEASE;TRANSDERMAL

ALORA

BX	ACTAVIS LABS UT INC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN

MINIVELLE

	NOVEN	0.025MG/24HR	N203752	005	Sep 23, 2014	Jan	NEWA

TABLET;VAGINAL

ESTRADIOL

	@ AMNEAL PHARMS	10MCG	A205256	001	May 29, 2015	May	DISC

ESZOPICLONE

TABLET;ORAL

ESZOPICLONE

AB	MACLEODS PHARMS LTD	1MG	A202929	001	Jan 30, 2015	Jan	NEWA
AB		2MG	A202929	002	Jan 30, 2015	Jan	NEWA
AB		3MG	A202929	003	Jan 30, 2015	Jan	NEWA

ETHACRYNATE SODIUM

INJECTABLE;INJECTION

EDECRIN

AP	+	ATON	EQ 50MG BASE/VIAL	N016093	001			Jul CFTG

ETHACRYNATE SODIUM

AP		PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015		Jul NEWA

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL

ETHAMBUTOL HYDROCHLORIDE

AB		VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999		Jan CMFD
AB			400MG	A075095	002	Nov 30, 1999		Jan CMFD

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

ASHLYNA

AB		GLENMARK GENERICS	0.03MG,0.01MG;0.15MG,N/A	A203163	001	Feb 23, 2015		Feb NEWA

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		GLENMARK GENERICS	0.02MG;0.09MG	A202791	001	Apr 09, 2015		Mar NEWA
AB		GLENMARK PHARMS LTD	0.03MG;0.15MG	A203164	001	Jun 12, 2015		Jun NEWA
AB	+	WATSON LABS	0.02MG;0.09MG	A079218	001	Jun 06, 2011		Mar CTEC

TABLET;ORAL-28

LEVORA 0.15/30-28

>D> AB		WATSON LABS	0.03MG;0.15MG	A073594	001	Dec 13, 1993		Aug CRLD
>A> AB	+		0.03MG;0.15MG	A073594	001	Dec 13, 1993		Aug CRLD

>D> NORDETTE-28

>D> AB	+	TEVA BRANDED PHARM	0.03MG;0.15MG	N018782	001	Jul 21, 1982		Aug DISC
>A>	@		0.03MG;0.15MG	N018782	001	Jul 21, 1982		Aug DISC

VIENVA

AB1		SANDOZ INC	0.02MG;0.1MG	A201088	001	May 21, 2015		May NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL

ORTHO EVRA

	@	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001		Feb DISC

XULANE

AB	+	MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014		Feb CRLD

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

	@	ACTAVIS LABS UT INC	0.035MG;0.5MG	N017566	001			Mar CAHN

NORINYL 1+35 21-DAY

AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	001			Feb CAHN

TRI-NORINYL 21-DAY

	@	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG, 0.5MG	N018977	001	Apr 13, 1984		Feb CAHN

TABLET;ORAL-28

BREVICON 28-DAY

AB		ACTAVIS LABS UT INC	0.035MG;0.5MG	N017743	001			Mar CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

AB		FAMY CARE LTD	0.035MG;0.4MG	A200897	001	May 11, 2015		Apr NEWA
AB	+	JAI PHARMA LTD	0.035MG;0.4MG	A200897	001	May 11, 2015		Jul CRLD
	+		0.05MG;1MG	A203006	001	Aug 05, 2013		Jul CTEC

NORINYL 1+35 28-DAY

AB		ACTAVIS LABS UT INC	0.035MG;1MG	N017565	002			Feb CAHN

OVCON-35

	@	WARNER CHILCOTT LLC	0.035MG;0.4MG	N017716	001			Jul DISC

TRI-NORINYL 28-DAY

AB	+	ACTAVIS LABS UT INC	0.035MG,0.035MG,0.035MG;0.5MG,1MG, 0.5MG	N018977	002	Apr 13, 1984		Feb CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

FEMHRT

AB		WARNER CHILCOTT LLC	0.0025MG;0.5MG	N021065	001	Jan 14, 2005		Mar CTEC

LARIN 24 FE

AB		NOVAST LABS LTD	0.02MG;1MG	A202994	001	Feb 18, 2015		Feb NEWA

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB	+	BARR LABS INC	0.005MG;1MG	A076221	001	Nov 06, 2009		Mar CTEC
AB		GLENMARK GENERICS	0.0025MG;0.5MG	A203038	001	Apr 02, 2015		Mar NEWA

		TABLET;ORAL							
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL							
	AB		0.005MG;1MG		A203038	002	Apr 02, 2015	Mar	NEWA
		NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE							
	AB	+ AMNEAL PHARMS	0.02MG;1MG		A078267	001	Sep 01, 2009	Jan	CRLD
		ETHINYL ESTRADIOL; NORGESTIMATE							
		TABLET;ORAL-28							
		NORGESTIMATE AND ETHINYL ESTRADIOL							
>A>	AB	JAI PHARMA LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG		A202132	001	Sep 09, 2015	Aug	NEWA
	AB	OC PHARMA	0.035MG;0.035MG;0.035MG;0.18MG;0.2 15MG;0.25MG		A200383	001	Apr 07, 2015	Mar	NEWA
	AB		0.035MG;0.25MG		A200384	001	Apr 07, 2015	Mar	NEWA
		TRI-LO-ESTARYLLA							
	AB	SANDOZ INC	0.025MG,0.025MG,0.025MG;0.18MG,0.2 15MG,0.25MG		A091232	001	Jun 29, 2015	Jun	NEWA
		ETHINYL ESTRADIOL; NORGESTREL							
		TABLET;ORAL-28							
		LOW-OGESTREL-28							
	AB	WATSON LABS	0.03MG;0.3MG		A075288	002	Jul 28, 1999	Feb	CMFD
		ETHOSUXIMIDE							
		CAPSULE;ORAL							
		ETHOSUXIMIDE							
	AB	BANNER LIFE SCIENCES	250MG		A040430	001	Oct 28, 2002	Jan	CAHN
		ETONOGESTREL							
		IMPLANT;IMPLANTATION							
		IMPLANON							
		@ ORGANON USA INC	68MG/IMPLANT		N021529	001	Jul 17, 2006	Jun	DISC
		EZETIMIBE							
		TABLET;ORAL							
		EZETIMIBE							
		@ GLENMARK PHARMS LTD	10MG		A078560	001	Jun 26, 2015	Jun	DISC
	AB		10MG		A078560	001	Jun 26, 2015	Jun	NEWA
		ZETIA							
		+ MSD INTL GMBH	10MG		N021445	001	Oct 25, 2002	Jun	CTEC
	AB	+	10MG		N021445	001	Oct 25, 2002	Jun	CFTG
		FAMOTIDINE							
		INJECTABLE;INJECTION							
		FAMOTIDINE							
	AP	+ EUROHLTH INTL SARL	10MG/ML		A075488	001	Apr 16, 2001	Jun	CAHN
		FAMOTIDINE PRESERVATIVE FREE							
	AP	+ EUROHLTH INTL SARL	10MG/ML		A075486	001	Apr 16, 2001	Jun	CAHN
		TABLET;ORAL							
		PEPCID							
	AB	VALEANT PHARMS NORTH	20MG		N019462	001	Oct 15, 1986	Feb	CAHN
	AB	+	40MG		N019462	002	Oct 15, 1986	Feb	CAHN
		FELODIPINE							
		TABLET, EXTENDED RELEASE;ORAL							
		FELODIPINE							
	AB	ORCHID HLTHCARE	2.5MG		A203032	001	May 21, 2015	May	NEWA
	AB		5MG		A203032	002	May 21, 2015	May	NEWA
	AB		10MG		A203032	003	May 21, 2015	May	NEWA
	AB	SUN PHARM INDS LTD	2.5MG		A091200	001	Dec 13, 2013	Apr	CAHN
	AB		5MG		A091200	002	Dec 13, 2013	Apr	CAHN
	AB		10MG		A091200	003	Dec 13, 2013	Apr	CAHN
		FENOFIBRATE							
		CAPSULE;ORAL							
		FENOFIBRATE							
	AB	SUN PHARM INDS LTD	43MG		A201748	001	Oct 31, 2014	Apr	CAHN
	AB		130MG		A201748	002	Oct 31, 2014	Apr	CAHN
		TABLET;ORAL							
		FENOFIBRATE							
>A>	AB	LUPIN LTD	54MG		A204019	001	Aug 17, 2015	Aug	NEWA
>A>	AB		160MG		A204019	002	Aug 17, 2015	Aug	NEWA

		TABLET;ORAL						
		FENOFIBRATE						
	AB	SUN PHARM INDS LTD	54MG	A076635	001	Oct 31, 2005	Apr	CAHN
			107MG	A076635	002	Oct 31, 2005	Apr	CAHN
	AB		160MG	A076635	003	Oct 31, 2005	Apr	CAHN
>D>	AB	VALEANT BARBADOS SRL	48MG	A090715	001	Apr 05, 2012	Aug	CAHN
>D>	AB		145MG	A090715	002	Apr 05, 2012	Aug	CAHN
>A>	AB	VALEANT PHARMS NORTH	48MG	A090715	001	Apr 05, 2012	Aug	CAHN
>A>	AB		145MG	A090715	002	Apr 05, 2012	Aug	CAHN
		FENOFIBRIC ACID						
		TABLET;ORAL						
		FIBRICOR						
		TRIBUTE PHARMS INTL	35MG	N022418	001	Aug 14, 2009	Jun	CAHN
	+		105MG	N022418	002	Aug 14, 2009	Jun	CAHN
		FENTANYL						
		FILM, EXTENDED RELEASE;TRANSDERMAL						
		FENTANYL-100						
	AB	ACTAVIS LABS UT INC	100MCG/HR	A076709	004	Aug 20, 2007	Mar	CAHN
		FENTANYL-12						
	AB	MALLINCKRODT INC	12.5MCG/HR	A077154	005	Jun 11, 2015	Jun	NEWA
		FENTANYL-25						
	AB	ACTAVIS LABS UT INC	25MCG/HR	A076709	001	Aug 20, 2007	Mar	CAHN
		FENTANYL-50						
	AB	ACTAVIS LABS UT INC	50MCG/HR	A076709	002	Aug 20, 2007	Mar	CAHN
		FENTANYL-75						
	AB	ACTAVIS LABS UT INC	75MCG/HR	A076709	003	Aug 20, 2007	Mar	CAHN
		FENTANYL CITRATE						
		FILM;BUCCAL						
		ONSOLIS						
		@ BIODELIVERY SCI INTL	EQ 0.2MG BASE	N022266	001	Jul 16, 2009	Mar	CAHN
		@	EQ 0.4MG BASE	N022266	002	Jul 16, 2009	Mar	CAHN
		@	EQ 0.6MG BASE	N022266	003	Jul 16, 2009	Mar	CAHN
		@	EQ 0.8MG BASE	N022266	004	Jul 16, 2009	Mar	CAHN
		@	EQ 1.2MG BASE	N022266	005	Jul 16, 2009	Mar	CAHN
		INJECTABLE;INJECTION						
		FENTANYL CITRATE PRESERVATIVE FREE						
	AP	+ EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	N019101	001	Jul 11, 1984	Feb	CAHN
		FENTANYL HYDROCHLORIDE						
		SYSTEM;IONTOPHORESIS, TRANSDERMAL						
		IONSYS						
		@ THE MEDICINES CO	10.8MCG	N021338	001	May 22, 2006	Apr	CAHN
		+	EQ 40MCG BASE/ACTIVATION	N021338	001	May 22, 2006	Jun	CMFD
		FERRIC CITRATE						
		TABLET;ORAL						
		AURYXIA						
		+ KERYX BIOPHARMS	EQ 210MG IRON	N205874	001	Sep 05, 2014	Jan	CTNA
		FERRIC PYROPHOSPHATE CITRATE						
		SOLUTION;IV (INFUSION)						
		TRIFERIC						
		+ ROCKWELL MEDICAL INC	27.2MG IRON/5ML (5.44MG IRON/ML)	N206317	001	Jan 23, 2015	Jan	NEWA
		FIDAXOMICIN						
		TABLET;ORAL						
		DIFICID						
>D>		+ CUBIST PHARMS	200MG	N201699	001	May 27, 2011	Aug	CAHN
>A>		+ CUBIST PHARMS LLC	200MG	N201699	001	May 27, 2011	Aug	CAHN
		FLECAINIDE ACETATE						
		TABLET;ORAL						
		FLECAINIDE ACETATE						
	AB	ANI PHARMS INC	50MG	A075882	001	Oct 28, 2002	Apr	CAHN
	AB		100MG	A075882	002	Oct 28, 2002	Apr	CAHN
	AB		150MG	A075882	003	Oct 28, 2002	Apr	CAHN
	AB	AUROBINDO PHARMA LTD	50MG	A202821	001	Jul 08, 2015	Jun	NEWA
	AB		100MG	A202821	002	Jul 08, 2015	Jun	NEWA
	AB		150MG	A202821	003	Jul 08, 2015	Jun	NEWA

TABLET;ORAL
FLECAINIDE ACETATE

AB	SUN PHARM INDS LTD	50MG	A076421	001	Mar 28, 2003	Apr	CAHN
AB		100MG	A076421	002	Mar 28, 2003	Apr	CAHN
AB		150MG	A076421	003	Mar 28, 2003	Apr	CAHN

>A> FLIBANSERIN
>A> TABLET;ORAL
>A> ADDYI

>A>	+ SPROUT PHARMS	100MG	N022526	001	Aug 18, 2015	Aug	NEWA

FLUCONAZOLE
FOR SUSPENSION;ORAL
FLUCONAZOLE

AB	SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Apr	CAHN
AB		200MG/5ML	A076332	002	Jul 29, 2004	Apr	CAHN

INJECTABLE;INJECTION
FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077988	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077988	002	May 26, 2010	Apr	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9%

AP	CLARIS PHARMASERVICE	200MG/100ML (2MG/ML)	A077947	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077947	002	May 26, 2010	Apr	CAHN

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	CLARIS PHARMASERVICE	100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr	NEWA
		100MG/50ML (2MG/ML)	A077909	003	Apr 20, 2015	Apr	CAHN
AP		200MG/100ML (2MG/ML)	A077909	001	May 26, 2010	Apr	CAHN
AP		400MG/200ML (2MG/ML)	A077909	002	May 26, 2010	Apr	CAHN

TABLET;ORAL
FLUCONAZOLE

AB	HARRIS PHARM	50MG	A078423	001	Mar 07, 2011	May	CMFD
AB		100MG	A078423	002	Mar 07, 2011	May	CMFD
AB		150MG	A078423	003	Mar 07, 2011	May	CMFD
AB		200MG	A078423	004	Mar 07, 2011	May	CMFD

FLUDEOXYGLUCOSE F-18
INJECTABLE;INTRAVENOUS
FLUDEOXYGLUCOSE F18

>A> AP	IBA MOLECULAR N AM	20-300mCi/ML	A203591	001	Aug 31, 2015	Aug	NEWA
AP	METHODIST HOSP RES	20-300mCi/ML	A203904	001	Apr 23, 2015	Apr	NEWA
>A> AP	MIPS CRF	20-300mCi/ML	A204472	001	Sep 11, 2015	Aug	NEWA
	PRECISION NUCLEAR	20-500mCi/ML	A204546	001	Apr 07, 2015	Mar	NEWA
>A>	QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Aug	NEWA
	SPECTRON MRC LLC	4-500mCi/ML	A203911	001	Apr 22, 2015	Apr	NEWA
AP	UNIV MICHIGAN	20-300mCi/ML	A204531	001	Jul 17, 2015	Jul	NEWA

FLUMAZENIL
INJECTABLE;INJECTION
FLUMAZENIL

	@ CLARIS PHARMASERVICE	0.5MG/5ML (0.1MG/ML)	A076755	002	Oct 12, 2004	Apr	CAHN
	@	1MG/10ML (0.1MG/ML)	A076755	001	Oct 12, 2004	Apr	CAHN
AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076787	002	Oct 12, 2004	Jun	CAHN
AP		1MG/10ML (0.1MG/ML)	A076787	001	Oct 12, 2004	Jun	CAHN

FLUOCINOLONE ACETONIDE
OIL;TOPICAL
FLUOCINOLONE ACETONIDE

AT	VERSAPHARM INC	0.01%	A091514	001	Jun 25, 2015	Jun	NEWA

SOLUTION;TOPICAL
FLUOCINOLONE ACETONIDE

>A> AT	GAVIS PHARMS LLC	0.01%	A206422	001	Sep 02, 2015	Aug	NEWA

FLUOCINONIDE
GEL;TOPICAL
FLUOCINONIDE

AB	G AND W LABS INC	0.05%	A072537	001	Feb 07, 1989	Apr	CAHN

FLUOROURACIL

CREAM;TOPICAL

CARAC

AB	+	VALEANT PHARMS NORTH	0.5%	N020985	001	Oct 27, 2000	Apr	CFTG
	+		0.5%	N020985	001	Oct 27, 2000	Feb	CAHN

FLUOROURACIL

AB		SPEAR PHARMS INC	0.5%	A203122	001	Apr 20, 2015	Apr	NEWA

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

	@	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Mar	DISC
	@		EQ 20MG BASE	A076287	002	May 20, 2008	Mar	DISC
	+	MYLAN	EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CRLD
			EQ 20MG BASE	A078045	002	Nov 17, 2008	Mar	CTEC
	@	SANDOZ	EQ 10MG BASE	A077469	001	Nov 17, 2008	Mar	DISC
	@		EQ 20MG BASE	A077469	002	Nov 17, 2008	Mar	DISC
AB1		SCIEGEN PHARMS INC	EQ 10MG BASE	A204597	001	Mar 16, 2015	Mar	NEWA
AB1			EQ 20MG BASE	A204597	002	Mar 16, 2015	Mar	NEWA
AB			EQ 40MG BASE	A204597	003	Mar 16, 2015	Mar	NEWA
AB		SUN PHARM INDS LTD	EQ 40MG BASE	A076990	001	Dec 13, 2004	Apr	CAHN

FLURANDRENOLIDE

OINTMENT;TOPICAL

CORDRAN

	+	AQUA PHARMS	0.05%	N012806	001		Jun	CRLD
			0.05%	N012806	001		May	CMFD

TAPE;TOPICAL

CORDRAN

	+	ACTAVIS LABS UT INC	0.004MG/SQ CM	N016455	001		Mar	CAHN

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER;INHALATION

BREO ELLIPTA

		GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Apr	NEWA

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE;ORAL

FLUVASTATIN SODIUM

>A> AB		MYLAN PHARMS INC	80MG	A202458	001	Sep 11, 2015	Aug	NEWA

LESCOL XL

>D>	+	NOVARTIS	80MG	N021192	001	Oct 06, 2000	Aug	CFTG
>A> AB	+		80MG	N021192	001	Oct 06, 2000	Aug	CFTG

FLUVOXAMINE MALEATE

TABLET;ORAL

FLUVOXAMINE MALEATE

AB		ANI PHARMS INC	25MG	A075897	001	Jan 25, 2001	Jul	CAHN
	@		25MG	A075898	001	Mar 12, 2001	Jul	CAHN
AB			50MG	A075897	002	Jan 25, 2001	Jul	CAHN
	@		50MG	A075898	002	Mar 12, 2001	Jul	CAHN
AB			100MG	A075897	003	Jan 25, 2001	Jul	CAHN
	@		100MG	A075898	003	Mar 12, 2001	Jul	CAHN

FOLIC ACID

TABLET;ORAL

FOLIC ACID

>A> AA		AIPING PHARM INC	1MG	A091145	001	Jul 12, 2013	Aug	CAHN
>D> AA		BICON PHARM	1MG	A091145	001	Jul 12, 2013	Aug	CAHN
AA		NUVO PHARM INC	1MG	A204418	001	Jul 28, 2015	Jul	NEWA

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET;ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB		SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Apr	CAHN
AB			20MG;12.5MG	A076739	002	Dec 17, 2004	Apr	CAHN

FUROSEMIDE

INJECTABLE;INJECTION

FUROSEMIDE

	@	IGI LABS INC	10MG/ML	A070095	001	Sep 09, 1985	Mar	CAHN
	@		10MG/ML	A070096	001	Sep 09, 1985	Mar	CAHN

GABAPENTIN

CAPSULE;ORAL

GABAPENTIN

AB		SUN PHARM INDS LTD	100MG	A076606	001	Oct 07, 2005	Apr	CAHN
AB			300MG	A076606	002	Oct 07, 2005	Apr	CAHN
AB			400MG	A076606	003	Oct 07, 2005	Apr	CAHN

TABLET;ORAL

GABAPENTIN

	@	HIKMA PHARMS	600MG	A078782	001	Jul 21, 2011	Jun	DISC
	@		800MG	A078782	002	Jul 21, 2011	Jun	DISC

GADOVERSETAMIDE

INJECTABLE;INJECTION

OPTIMARK

+		LIEBEL-FLARSHEIM	1654.5MG/5ML (330.9MG/ML)	N020937	001	Dec 08, 1999	Feb	CAHN
+			3309MG/10ML (330.9MG/ML)	N020937	002	Dec 08, 1999	Feb	CAHN
+			4963.5MG/15ML (330.9MG/ML)	N020937	003	Dec 08, 1999	Feb	CAHN
+			6618MG/20ML (330.9MG/ML)	N020937	004	Dec 08, 1999	Feb	CAHN
+			16.545GM/50ML (330.9MG/ML)	N020975	001	Dec 08, 1999	Feb	CAHN

OPTIMARK IN PLASTIC CONTAINER

+		LIEBEL-FLARSHEIM	3309MG/10ML (330.9MG/ML)	N020976	002	Dec 08, 1999	Feb	CAHN
+			4963.5MG/15ML (330.9MG/ML)	N020976	003	Dec 08, 1999	Feb	CAHN
+			6618MG/20ML (330.9MG/ML)	N020976	004	Dec 08, 1999	Feb	CAHN
+			9927MG/30ML (330.9MG/ML)	N020976	001	Dec 08, 1999	Feb	CAHN

GEFITINIB

TABLET;ORAL

IRESSA

+		ASTRAZENECA PHARMS	250MG	N206995	001	Jul 13, 2015	Jul	NEWA

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

>A>	AB		AUROBINDO PHARMA LTD	600MG	A202726	001	Sep 16, 2015	Aug	NEWA

GEMIFLOXACIN MESYLATE

TABLET;ORAL

FACTIVE

AB	+		LG LIFE SCIENCES	EQ 320MG BASE	N021158	001	Apr 04, 2003	Jun	CFTG

GEMIFLOXACIN MESYLATE

AB			ORCHID HLTHCARE	EQ 320MG BASE	A090466	001	Jun 15, 2015	Jun	NEWA

GLATIRAMER ACETATE

INJECTABLE;SUBCUTANEOUS

COPAXONE

AP	+		TEVA PHARMS USA	20MG/ML	N020622	002	Feb 12, 2002	Mar	CFTG

GLATOPA

AP			SANDOZ INC	20MG/ML	A090218	001	Apr 16, 2015	Mar	NEWA

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

	@	HIKMA PHARMS	1MG	A078952	001	Aug 01, 2013	Apr	DISC
	@		2MG	A078952	002	Aug 01, 2013	Apr	DISC
	@		4MG	A078952	003	Aug 01, 2013	Apr	DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDARYL

	@	SB PHARMCO	1MG;4MG	N021700	001	Nov 23, 2005	Jun	DISC
	@		2MG;4MG	N021700	002	Nov 23, 2005	Jun	DISC
	@		2MG;8MG	N021700	004	Mar 30, 2007	Jun	DISC
	@		4MG;4MG	N021700	003	Nov 23, 2005	Jun	DISC
	@		4MG;8MG	N021700	005	Mar 30, 2007	Jun	DISC

GLIPIZIDE

TABLET;ORAL

GLIPIZIDE

>A>	@ ANI PHARMS INC	5MG	A074387	001	Mar 04, 1996	Aug CAHN
>A>	@	10MG	A074387	002	Mar 04, 1996	Aug CAHN
>D>	@ TEVA	5MG	A074387	001	Mar 04, 1996	Aug CAHN
>D>	@	10MG	A074387	002	Mar 04, 1996	Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

GLIPIZIDE

AB	MYLAN PHARMS INC	2.5MG	A202298	001	May 19, 2015	May NEWA
AB		5MG	A202298	002	May 19, 2015	May NEWA
AB		10MG	A202298	003	May 19, 2015	May NEWA

GLUCAGON HYDROCHLORIDE

POWDER;INTRAMUSCULAR, INTRAVENOUS

GLUCAGON

+	FRESENIUS KABI USA	EQ 1MG BASE/VIAL	N201849	001	May 08, 2015	May NEWA

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

RAVICTI

+	HORIZON THERAPS INC	1.1GM/ML	N203284	001	Feb 01, 2013	May CAHN

GLYCOPYRROLATE

INJECTABLE;INJECTION

ROBINUL

AP +	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Jun CAHN

TABLET;ORAL

GLYCOPYRROLATE

AA	SUN PHARM INDS LTD	1MG	A040844	001	Aug 18, 2009	Apr CAHN
AA		2MG	A040844	002	Aug 18, 2009	Apr CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP	BANNER LIFE SCIENCES	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan CAHN
	@ CLARIS PHARMASERVICE	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078198	001	Jun 30, 2008	Apr CAHN
	@	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078198	002	Jun 30, 2008	Apr CAHN
AP	EUROHLTH INTL SARL	EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077177	001	Dec 31, 2007	Jun CAHN

GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE

AP	BANNER LIFE SCIENCES	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYCOFENIX

+	MIKART INC	200MG/5ML;2.5MG/5ML;30MG/5ML	N022279	001	May 14, 2015	May NEWA

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUANFACINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 1MG BASE	A202578	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A202578	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A202578	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A202578	004	Jun 02, 2015	May NEWA
AB	SANDOZ INC	EQ 1MG BASE	A202568	001	Jun 03, 2015	May NEWA
AB		EQ 2MG BASE	A202568	002	Jun 03, 2015	May NEWA
AB		EQ 3MG BASE	A202568	003	Jun 03, 2015	May NEWA
AB		EQ 4MG BASE	A202568	004	Jun 03, 2015	May NEWA
AB	TEVA PHARMS USA	EQ 1MG BASE	A201382	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A201382	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A201382	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A201382	004	Jun 02, 2015	May NEWA
AB	TWI PHARMS INC	EQ 1MG BASE	A201408	001	Jun 02, 2015	May NEWA
AB		EQ 2MG BASE	A201408	002	Jun 02, 2015	May NEWA
AB		EQ 3MG BASE	A201408	003	Jun 02, 2015	May NEWA
AB		EQ 4MG BASE	A201408	004	Jun 02, 2015	May NEWA

HALOPERIDOL

TABLET;ORAL

HALOPERIDOL

		@	CYCLE PHARMS LTD	0.5MG	A071128	001	Feb 17, 1987	May CAHN
		@		1MG	A071129	001	Feb 17, 1987	Jun CAHN
		@		5MG	A071131	001	Feb 17, 1987	Jun CAHN
		@		10MG	A071132	001	May 12, 1987	Jun CAHN
		@		20MG	A071133	001	May 12, 1987	May CAHN
		@	ROXANE	2MG	A071130	001	Feb 17, 1987	Jun CAHN

HALOPERIDOL LACTATE

CONCENTRATE;ORAL

HALOPERIDOL INTENSOL

		@	CYCLE PHARMS LTD	EQ 2MG BASE/ML	A072045	001	Apr 12, 1988	May CAHN

INJECTABLE;INJECTION

HALOPERIDOL

		@	CLARIS PHARMASERVICE	EQ 5MG BASE/ML	A076791	001	Aug 25, 2004	Apr CAHN
		@		EQ 5MG BASE/ML	A076828	001	Aug 25, 2004	May CAHN

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

>D>		@	BAXTER HLTHCARE CORP	1,000 UNITS/ML	N017007	001		Aug CAHN
>D>		@		2,500 UNITS/ML	N017007	007		Aug CAHN
>D>		@		5,000 UNITS/ML	N017007	002		Aug CAHN
>D>		@		5,000 UNITS/0.5ML	N017007	010		Aug CAHN
>D>		@		7,500 UNITS/ML	N017007	003		Aug CAHN
>D>		@		10,000 UNITS/ML	N017007	004		Aug CAHN
>D>		@		15,000 UNITS/ML	N017007	005		Aug CAHN
>D>		@		20,000 UNITS/ML	N017007	006		Aug CAHN
>A>		@	EUROHLTH INTL SARL	1,000 UNITS/ML	N017007	001		Aug CAHN
	AP	+		1,000 UNITS/ML	N017037	001		Jun CAHN
>A>		@		2,500 UNITS/ML	N017007	007		Aug CAHN
>A>		@		5,000 UNITS/ML	N017007	002		Aug CAHN
>A>		@		5,000 UNITS/0.5ML	N017007	010		Aug CAHN
	AP	+		5,000 UNITS/ML	N017037	002		Jun CAHN
		@		5,000 UNITS/0.5ML	N017037	013	Apr 07, 1986	Jun CAHN
>A>		@		7,500 UNITS/ML	N017007	003		Aug CAHN
>A>		@		10,000 UNITS/ML	N017007	004		Aug CAHN
	AP	+		10,000 UNITS/ML	N017037	003		Jun CAHN
>A>		@		15,000 UNITS/ML	N017007	005		Aug CAHN
>A>		@		20,000 UNITS/ML	N017007	006		Aug CAHN

HYDRALAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

HYDRALAZINE HYDROCHLORIDE

	AP	+	AKORN	20MG/ML	A040730	001	Apr 21, 2009	Feb CRLD
	AP		LUITPOLD	20MG/ML	A040136	001	Jun 30, 1997	Feb CRLD
	AP		X-GEN PHARMS INC	20MG/ML	A203110	001	Jun 29, 2015	Jun NEWA

HYDROCHLOROTHIAZIDE

CAPSULE;ORAL

HYDROCHLOROTHIAZIDE

>D>	AB		SUN PHARM INDS INC	12.5MG	A090651	001	Apr 07, 2014	Aug DISC
>A>		@		12.5MG	A090651	001	Apr 07, 2014	Aug DISC

MICROZIDE

	AB	+	ACTAVIS LABS UT INC	12.5MG	N020504	001	Dec 27, 1996	Feb CAHN

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET;ORAL

LISINOPRIL AND HYDROCHLOROTHIAZIDE

	AB		SUN PHARM INDS LTD	12.5MG;10MG	A076007	001	Jul 01, 2002	Apr CAHN
	AB			12.5MG;20MG	A076007	002	Jul 01, 2002	Apr CAHN
	AB			25MG;20MG	A076007	003	Jul 01, 2002	Apr CAHN

ZESTORETIC

	AB		ALVOGEN IPCO SARL	12.5MG;10MG	N019888	003	Nov 18, 1993	Feb CAHN
	AB	+		12.5MG;20MG	N019888	001	Sep 20, 1990	Feb CAHN
	AB	+		25MG;20MG	N019888	002	Jul 20, 1989	Feb CAHN

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE;ORAL

DUTOPROL

		CONCORDIA PHARMS INC	12.5MG;EQ 25MG TARTRATE	N021956	001	Aug 28, 2006	Jun	CAHN
			12.5MG;EQ 50MG TARTRATE	N021956	002	Aug 28, 2006	Jun	CAHN
	+		12.5MG;EQ 100MG TARTRATE	N021956	003	Aug 28, 2006	Jun	CAHN

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

		@ ANI PHARMS INC	25MG;40MG	A070704	001	Oct 01, 1986	Jul	CAHN
>A>	AB		25MG;40MG	A072042	001	Mar 14, 1988	Aug	CAHN
		@	25MG;80MG	A070705	001	Oct 01, 1986	Jul	CAHN
>A>	AB		25MG;80MG	A072043	001	Mar 14, 1988	Aug	CAHN
>D>	AB	PLIVA	25MG;40MG	A072042	001	Mar 14, 1988	Aug	CAHN
>D>	AB		25MG;80MG	A072043	001	Mar 14, 1988	Aug	CAHN

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

	AB	SUN PHARM INDS LTD	12.5MG;EQ 10MG BASE	A078211	001	Mar 04, 2009	Apr	CAHN
	AB		12.5MG;EQ 20MG BASE	A078211	002	Mar 04, 2009	Apr	CAHN
	AB		25MG;EQ 20MG BASE	A078211	003	Mar 04, 2009	Apr	CAHN

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A>		@ ANI PHARMS INC	25MG;37.5MG	A074970	001	Jan 06, 1998	Aug	CAHN
>D>		@ BARR	25MG;37.5MG	A074970	001	Jan 06, 1998	Aug	CAHN

TABLET;ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

>A>	AB	ANI PHARMS INC	50MG;75MG	A073467	001	Jan 31, 1996	Aug	CAHN
>D>	AB	PLIVA	50MG;75MG	A073467	001	Jan 31, 1996	Aug	CAHN

HYDROCODONE BITARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

ZOHYDRO ER

	+	FERRIMILL LTD	10MG	N202880	001	Oct 25, 2013	Apr	CAHN
			15MG	N202880	002	Oct 25, 2013	Apr	CAHN
			20MG	N202880	003	Oct 25, 2013	Apr	CAHN
			30MG	N202880	004	Oct 25, 2013	Apr	CAHN
			40MG	N202880	005	Oct 25, 2013	Apr	CAHN
			50MG	N202880	006	Oct 25, 2013	Apr	CAHN
	+	PERNIX IRELAND PAIN	10MG	N202880	001	Oct 25, 2013	Jun	CAHN
			15MG	N202880	002	Oct 25, 2013	Jun	CAHN
			20MG	N202880	003	Oct 25, 2013	Jun	CAHN
			30MG	N202880	004	Oct 25, 2013	Jun	CAHN
			40MG	N202880	005	Oct 25, 2013	Jun	CAHN
			50MG	N202880	006	Oct 25, 2013	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL

HYSINGLA

	+	PURDUE PHARMA LP	20MG	N206627	001	Nov 20, 2014	Mar	CRLD

HYDROCORTISONE

CREAM;TOPICAL

HYDROCORTISONE

	AT	RISING PHARMS INC	2.5%	A040879	001	Aug 20, 2010	Mar	CAHN

POWDER;FOR RX COMPOUNDING

HYDRO-RX

		@ X GEN PHARMS	100%	A085982	001		Apr	DISC

TABLET;ORAL

HYDROCORTISONE

	AB	HIKMA INTL PHARMS	5MG	A083365	002	Feb 23, 2015	Feb	NEWA
	AB		10MG	A083365	003	Feb 23, 2015	Feb	NEWA
	AB		20MG	A083365	001		Feb	CMFD

HYDROCORTISONE ACETATE

POWDER;FOR RX COMPOUNDING

HYDROCORTISONE ACETATE

	@	X GEN PHARMS	100%	A085981	001		Apr DISC

HYDROCORTISONE VALERATE

CREAM;TOPICAL

HYDROCORTISONE VALERATE

	@	G AND W LABS INC	0.2%	A074489	001	Aug 12, 1998	Apr CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS;OTIC

CORTISPORIN

AT	+	CITRON PHARMA LLC	1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML	N060613	001		Jun CMS2

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

HYDROMORPHONE HYDROCHLORIDE

AB		PADDOCK LLC	8MG	A204278	001	Apr 06, 2015	Mar NEWA
AB			12MG	A204278	002	Apr 06, 2015	Mar NEWA
AB			16MG	A204278	003	Apr 06, 2015	Mar NEWA

HYDROXOCOBALAMIN

INJECTABLE;INJECTION

CYANOKIT

	@	SERB SAS	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Apr CAHN
	+		5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Apr CAHN

HYDROXYCHLOROQUINE SULFATE

TABLET;ORAL

PLAQUENIL

AB	+	CONCORDIA PHARMS INC	200MG	N009768	001		Jun CAHN

HYDROXYPROGESTERONE CAPROATE

INJECTABLE;INJECTION

HYDROXYPROGESTERONE CAPROATE

	@	ACTAVIS LABS UT INC	125MG/ML	N017439	001		Mar CAHN
	@		250MG/ML	N017439	002		Mar CAHN
>A>	+	MCGUFF	250MG/ML	A200271	001	Aug 24, 2015	Aug NEWA

HYDROXYZINE HYDROCHLORIDE

TABLET;ORAL

HYDROXYZINE HYDROCHLORIDE

AB		ELITE LABS INC	10MG	A040600	001	Dec 28, 2004	Jun CAHN
AB			25MG	A040602	001	Dec 28, 2004	Jun CAHN
AB			50MG	A040604	001	Dec 28, 2004	Jun CAHN
AB		HERITAGE PHARMA	10MG	A204279	001	Aug 20, 2014	Mar CAHN
AB			25MG	A204279	002	Aug 20, 2014	Mar CAHN
AB			50MG	A204279	003	Aug 20, 2014	Mar CAHN
AB		MIKAH PHARMA	10MG	A040600	001	Dec 28, 2004	Mar CMFD
AB			25MG	A040602	001	Dec 28, 2004	Mar CMFD
AB			50MG	A040604	001	Dec 28, 2004	Mar CMFD
	@	MUTUAL PHARM	10MG	A089381	001	May 19, 1986	Jul DISC
	@		25MG	A089382	001	May 19, 1986	Jul DISC
	@		50MG	A089383	001	May 19, 1986	Jul DISC
	@	WATSON LABS	10MG	A088348	001	Sep 15, 1983	Jul DISC
	@		25MG	A088349	001	Sep 15, 1983	Jul DISC
	@		50MG	A088350	001	Sep 15, 1983	Jul DISC

HYDROXYZINE PAMOATE

CAPSULE;ORAL

HYDROXYZINE PAMOATE

AB		HERITAGE PHARMA	EQ 25MG HYDROCHLORIDE	A201507	001	Jun 03, 2013	Mar CAHN
AB			EQ 50MG HYDROCHLORIDE	A201507	002	Jun 03, 2013	Mar CAHN

IBANDRONATE SODIUM

INJECTABLE;INTRAVENOUS

IBANDRONATE SODIUM

>A>	AP	AUROBINDO PHARMA LTD	EQ 3MG BASE/3ML	A205332	001	Aug 19, 2015	Aug	NEWA

IBUPROFEN

TABLET;ORAL

IBUPROFEN

>A>	AB	GRANULES INDIA LTD	400MG	A091625	001	Sep 15, 2015	Aug	NEWA
>A>	AB		600MG	A091625	002	Sep 15, 2015	Aug	NEWA
>A>	AB		800MG	A091625	003	Sep 15, 2015	Aug	NEWA
	@	VINTAGE PHARMS	300MG	A071230	001	Oct 22, 1986	Jul	DISC
	@		400MG	A071231	001	Oct 22, 1986	Jul	DISC
	@		600MG	A071232	001	Oct 22, 1986	Jul	DISC
	@		800MG	A072004	001	Nov 18, 1987	Jul	DISC

ILOPERIDONE

TABLET;ORAL

FANAPT

	+	VANDA PHARMS INC	1MG	N022192	001	May 06, 2009	Jan	CAHN
			2MG	N022192	002	May 06, 2009	Jan	CAHN
			4MG	N022192	003	May 06, 2009	Jan	CAHN
			6MG	N022192	004	May 06, 2009	Jan	CAHN
			8MG	N022192	005	May 06, 2009	Jan	CAHN
			10MG	N022192	006	May 06, 2009	Jan	CAHN
			12MG	N022192	007	May 06, 2009	Jan	CAHN

IMIQUIMOD

CREAM;TOPICAL

IMIQUIMOD

AB		G AND W LABS INC	5%	A200481	001	Apr 18, 2011	Apr	CAHN

INDAPAMIDE

TABLET;ORAL

INDAPAMIDE

AB		ANI PHARMS INC	1.25MG	A074299	002	Apr 29, 1996	Jul	CAHN
	@		1.25MG	A074498	002	Feb 12, 1998	Jul	CAHN
AB			2.5MG	A074299	001	Jul 27, 1995	Jul	CAHN
	@		2.5MG	A074498	001	Oct 31, 1996	Jul	CAHN

INGENOL MEBUTATE

GEL;TOPICAL

PICATO

	+	LEO PHARMA AS	0.015%	N202833	001	Jan 23, 2012	May	CRLD

INSULIN GLARGINE RECOMBINANT

SOLUTION;SUBCUTANEOUS

TOUJEO SOLOSTAR

	+	SANOFI US SERVICES	300 UNITS/ML (300 UNITS/ML)	N206538	001	Feb 25, 2015	Feb	NEWA

INSULIN LISPRO RECOMBINANT

SOLUTION;SUBCUTANEOUS

HUMALOG KWIKPEN

	+	ELI LILLY AND CO	200 UNITS/ML	N205747	001	May 26, 2015	May	NEWA

INSULIN RECOMBINANT HUMAN

POWDER;INHALATION

AFREZZA

		SANOFI AVENTIS	12 UNITS/INH	N022472	003	Apr 17, 2015	Apr	NEWA

IOHEXOL

FOR SOLUTION;ORAL

ORALTAG

		INTERPHARMA PRAHA AS	9.7GM/BOT	N205383	001	Mar 26, 2015	Mar	NEWA

IOPAMIDOL

INJECTABLE;INJECTION

IOPAMIDOL-250

	@	FRESENIUS KABI USA	51%	A074679	001	Apr 02, 1997	Jan	DISC

		INJECTABLE;INJECTION						
		IOPAMIDOL-300						
		@ FRESENIUS KABI USA	61%	A074679	002	Apr 02, 1997	Jan	DISC
		IOPAMIDOL-370						
		@ FRESENIUS KABI USA	76%	A074679	003	Apr 02, 1997	Jan	DISC
		ISOVUE-200						
	+	BRACCO	41%	N018735	006	Jul 07, 1987	Feb	CTEC
		ISOVUE-250						
	+	BRACCO	51%	N018735	007	Jul 06, 1992	Feb	CTEC
	+		51%	N020327	002	Oct 12, 1994	Feb	CTEC
		ISOVUE-300						
	+	BRACCO	61%	N020327	003	Oct 12, 1994	Feb	CTEC
		ISOVUE-370						
	+	BRACCO	76%	N020327	004	Oct 12, 1994	Feb	CTEC
		SCANLUX-300						
>A>	AP	MYLAN INSTITUTIONAL	61%	A090394	001	Jun 18, 2010	Aug	CAHN
>D>	AP	SANOCHEMIA CORP USA	61%	A090394	001	Jun 18, 2010	Aug	CAHN
		SCANLUX-370						
>A>	AP	MYLAN INSTITUTIONAL	76%	A090394	002	Jun 18, 2010	Aug	CAHN
>D>	AP	SANOCHEMIA CORP USA	76%	A090394	002	Jun 18, 2010	Aug	CAHN
		IOTHALAMATE MEGLUMINE						
		INJECTABLE;INJECTION						
		CONRAY						
	+	LIEBEL-FLARSHEIM	60%	N013295	001		Feb	CAHN
		CONRAY 30						
	+	LIEBEL-FLARSHEIM	30%	N016983	001		Feb	CAHN
		CONRAY 43						
	+	LIEBEL-FLARSHEIM	43%	N013295	002		Feb	CAHN
		SOLUTION;INTRAVESICAL						
		CYSTO-CONRAY II						
		LIEBEL-FLARSHEIM	17.2%	N017057	002		Feb	CAHN
		IOVERSOL						
		INJECTABLE;INJECTION						
		OPTIRAY 160						
		@ LIEBEL-FLARSHEIM	34%	N019710	003	Dec 30, 1988	Feb	CAHN
		OPTIRAY 240						
	+	LIEBEL-FLARSHEIM	51%	N019710	002	Dec 30, 1988	Feb	CAHN
		@	51%	N020923	001	May 28, 1998	Feb	CAHN
		OPTIRAY 300						
	+	LIEBEL-FLARSHEIM	64%	N019710	004	Jan 22, 1992	Feb	CAHN
	+		64%	N020923	004	May 13, 1999	Feb	CAHN
		OPTIRAY 320						
	+	LIEBEL-FLARSHEIM	68%	N019710	001	Dec 30, 1988	Feb	CAHN
		@	68%	N020923	002	May 29, 1998	Feb	CAHN
		OPTIRAY 350						
	+	LIEBEL-FLARSHEIM	74%	N019710	005	Jan 22, 1992	Feb	CAHN
	+		74%	N020923	003	May 28, 1998	Feb	CAHN
		IOXAGLATE MEGLUMINE; IOXAGLATE SODIUM						
		INJECTABLE;INJECTION						
		HEXABRIX						
		@ GUERBET	39.3%;19.6%	N018905	002	Jul 26, 1985	May	DISC
		IRBESARTAN						
		TABLET;ORAL						
		IRBESARTAN						
	AB	JUBILANT GENERICS	75MG	A203534	001	Feb 23, 2015	Feb	NEWA
	AB		150MG	A203534	002	Feb 23, 2015	Feb	NEWA
	AB		300MG	A203534	003	Feb 23, 2015	Feb	NEWA
		IRON DEXTRAN						
		INJECTABLE;INJECTION						
		INFED						
	BP	+ ACTAVIS LABS UT INC	EQ 50MG IRON/ML	N017441	001		Mar	CAHN

ISAVUCONAZONIUM SULFATE

	CAPSULE;ORAL						
	CRESEMBA						
+	ASTELLAS	186MG	N207500	001	Mar 06, 2015	Mar	NEWA
	POWDER;IV (INFUSION)						
	CRESEMBA						
+	ASTELLAS	372MG	N207501	001	Mar 06, 2015	Mar	NEWA

ISOSORBIDE DINITRATE

	TABLET;ORAL						
	ISORDIL						
AB	VALEANT PHARMS NORTH	5MG	N012093	007	Jul 29, 1988	Feb	CAHN
+		40MG	N012093	001	Jul 29, 1988	Feb	CAHN

ISOTRETINOIN

	CAPSULE;ORAL						
	ABSORICA						
	RANBAXY	25MG	N021951	005	Aug 15, 2014	Feb	NEWA
		35MG	N021951	006	Aug 15, 2014	Feb	NEWA
	MYORISAN						
>A> AB	DOUGLAS PHARMS	30MG	A076485	004	Aug 25, 2015	Aug	NEWA
	SOTRET						
AB	SUN PHARM INDS LTD	10MG	A076041	001	Dec 24, 2002	Apr	CAHN
AB		20MG	A076041	002	Dec 24, 2002	Apr	CAHN
AB		30MG	A076503	001	Jun 20, 2003	Apr	CAHN
AB		40MG	A076041	003	Dec 24, 2002	Apr	CAHN
	ZENATANE						
AB	DR REDDYS LABS LTD	30MG	A202099	004	Feb 23, 2015	Feb	NEWA

ISRADIPINE

	CAPSULE;ORAL						
	ISRADIPINE						
AB	ELITE LABS INC	2.5MG	A077169	001	Apr 24, 2006	Mar	CAHN
AB		5MG	A077169	002	Apr 24, 2006	Mar	CAHN

IVABRADINE HYDROCHLORIDE

	TABLET;ORAL						
	CORLANOR						
	AMGEN INC	EQ 5MG BASE	N206143	001	Apr 15, 2015	Apr	NEWA
+		EQ 7.5MG BASE	N206143	002	Apr 15, 2015	Apr	NEWA

IVACAFTOR

	GRANULE;ORAL						
	KALYDECO						
	VERTEX PHARMS INC	50MG/PACKET	N207925	001	Mar 17, 2015	Mar	NEWA
+		75MG/PACKET	N207925	002	Mar 17, 2015	Mar	NEWA

IVACAFTOR; LUMACAFTOR

	TABLET;ORAL						
	ORKAMBI						
+	VERTEX PHARMS INC	125MG;200MG	N206038	001	Jul 02, 2015	Jul	NEWA

IXABEPILONE

	INJECTABLE;IV (INFUSION)						
	IXEMPRA KIT						
+	R-PHARM US LLC	15MG/VIAL	N022065	001	Oct 16, 2007	Jun	CAHN
+		45MG/VIAL	N022065	002	Oct 16, 2007	Jun	CAHN

KANAMYCIN SULFATE

	INJECTABLE;INJECTION						
	KANAMYCIN						
	@ EUROHLTH INTL SARL	EQ 75MG BASE/2ML	A062324	001		Jun	CAHN
	@	EQ 500MG BASE/2ML	A062324	002		Jun	CAHN
	@	EQ 1GM BASE/3ML	A062324	003		Jun	CAHN

KETOROLAC TROMETHAMINE

		INJECTABLE;INJECTION						
		KETOROLAC TROMETHAMINE						
		@ CLARIS PHARMASERVICE	15MG/ML	A	075631	002	Jun 29, 2001	Apr CAHN
		@	30MG/ML	A	075631	001	Jun 29, 2001	Apr CAHN
		@ EUROHLTH INTL SARL	15MG/ML	A	075772	001	Jul 21, 2004	Jun CAHN
		@	30MG/ML	A	075772	002	Jul 21, 2004	Jun CAHN
		SPRAY, METERED;NASAL						
		SPRIX						
	+	EGALET US INC	15.75MG/SPRAY	N	022382	001	May 14, 2010	Jan CAHN

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

		SOLUTION;IRRIGATION						
		OMIDRIA						
	+	OMEROS	EQ 4.24MG BASE/ML;EQ 12.4MG BASE/ML	N	205388	001	May 30, 2014	Feb CPOT

LABETALOL HYDROCHLORIDE

		INJECTABLE;INJECTION						
		LABETALOL HYDROCHLORIDE						
		@ CLARIS PHARMASERVICE	5MG/ML	A	076051	001	Jul 05, 2002	Apr CAHN
		TABLET;ORAL						
		LABETALOL HYDROCHLORIDE						
AB		MUTUAL PHARM	100MG	A	075215	001	Jul 29, 1999	Jan CMFD
AB			200MG	A	075215	002	Jul 29, 1999	Jan CMFD
AB			300MG	A	075215	003	Jul 29, 1999	Jan CMFD

LACTULOSE

		SOLUTION;ORAL, RECTAL						
		LACTULOSE						
AA		BIO-PHARM INC	10GM/15ML	A	203762	001	Mar 27, 2015	Mar NEWA

>D> LAMIVUDINE; RALTEGRAVIR POTASSIUM

>D>		TABLET;ORAL						
>D>		DUTREBIS						
>D>	+	MERCK SHARP DOHME	150MG;EQ 300MG BASE	N	206510	001	Feb 06, 2015	Aug DISC
>A>	@		150MG;EQ 300MG BASE	N	206510	001	Feb 06, 2015	Aug DISC
	+		150MG;EQ 300MG BASE	N	206510	001	Feb 06, 2015	Feb NEWA

LAMIVUDINE; ZIDOVUDINE

		TABLET;ORAL						
		LAMIVUDINE AND ZIDOVUDINE						
>A>	AB	HETERO LABS LTD III	150MG;300MG	A	079124	001	Sep 17, 2015	Aug NEWA
>D>	AB	STRIDES ARCOLAB LTD	150MG;300MG	A	079128	001	May 13, 2015	Aug CAHN
	AB		150MG;300MG	A	079128	001	May 13, 2015	Apr NEWA
>A>	AB	STRIDES PHARMA	150MG;300MG	A	079128	001	May 13, 2015	Aug CAHN

LAMOTRIGINE

		TABLET;ORAL						
		LAMOTRIGINE						
		@ HIKMA PHARMS	25MG	A	078134	001	Apr 19, 2011	May DISC
		@	100MG	A	078134	002	Apr 19, 2011	May DISC
		@	150MG	A	078134	003	Apr 19, 2011	May DISC
		@	200MG	A	078134	004	Apr 19, 2011	May DISC

LAPATINIB DITOSYLATE

		TABLET;ORAL						
		TYKERB						
	+	NOVARTIS PHARMS CORP	EQ 250MG BASE	N	022059	001	Mar 13, 2007	Mar CAHN

LENVATINIB MESYLATE

		CAPSULE;ORAL						
		LENVIMA						
		EISAI INC	EQ 4MG BASE	N	206947	001	Feb 13, 2015	Feb NEWA
	+		EQ 10MG BASE	N	206947	002	Feb 13, 2015	Feb NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)

LEVETIRACETAM

AP	FRESENIUS KABI USA	500MG/5ML (100MG/ML)	A090876	001	Aug 13, 2015	Jul	NEWA

SOLUTION;ORAL

LEVETIRACETAM

AA	PHARM ASSOC	100MG/ML	A201157	001	Jun 04, 2015	May	NEWA

TABLET;ORAL

SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Jul	NEWA
		500MG	N207958	002	Jul 31, 2015	Jul	NEWA
		750MG	N207958	003	Jul 31, 2015	Jul	NEWA
		1GM	N207958	004	Jul 31, 2015	Jul	NEWA

TABLET, EXTENDED RELEASE;ORAL

ELEPSIA XR

	SPARC	1GM	N204417	001	Mar 02, 2015	Mar	NEWA
		1.5GM	N204417	002	Mar 02, 2015	Mar	NEWA

LEVETIRACETAM

	APOTEX INC	1GM	A202958	001	Feb 25, 2015	Feb	NEWA
>A> AB	DEXCEL PHARMA	500MG	A202167	001	Sep 04, 2015	Aug	NEWA
>A> AB		750MG	A202167	002	Sep 04, 2015	Aug	NEWA
>A> AB	PHARMADAX INC	500MG	A201464	001	May 25, 2012	Aug	CAHN
>A> AB		750MG	A201464	002	May 25, 2012	Aug	CAHN
AB	PRINSTON INC	500MG	A203468	001	May 21, 2015	May	NEWA
AB		750MG	A203468	002	May 21, 2015	May	NEWA
>D> AB	VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Aug	CAHN
>D> AB		750MG	A201464	002	May 25, 2012	Aug	CAHN

LEVOCARNITINE

INJECTABLE;INJECTION

LEVOCARNITINE

	@ TEVA PHARMS USA	200MG/ML	A075881	001	Mar 29, 2001	Apr	DISC

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB	APOTEX INC	5MG	A203027	001	Feb 13, 2015	Feb	NEWA
AB	SUN PHARM INDS LTD	5MG	A201653	001	Jun 26, 2015	Jun	NEWA

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

AP	CLARIS PHARMASERVICE	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	CAHN
AP	HOSPIRA INC	EQ 500MG/20ML (EQ 25MG/ML)	A078577	001	Aug 12, 2015	Jul	NEWA
AP		EQ 750MG/30ML (EQ 25MG/ML)	A078577	002	Aug 12, 2015	Jul	NEWA

LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	CLARIS PHARMASERVICE	EQ 250MG/50ML (EQ 5MG/ML)	A091397	001	Aug 08, 2013	Apr	CAHN
AP		EQ 500MG/100ML (EQ 5MG/ML)	A091397	002	Aug 08, 2013	Apr	CAHN
AP		EQ 750MG/150ML (EQ 5MG/ML)	A091397	003	Aug 08, 2013	Apr	CAHN
>A> AP	HOSPIRA INC	EQ 250MG/50ML (EQ 5MG/ML)	A078579	001	Sep 03, 2015	Aug	NEWA
>A> AP		EQ 500MG/100ML (EQ 5MG/ML)	A078579	002	Sep 03, 2015	Aug	NEWA
>A> AP		EQ 750MG/150ML (EQ 5MG/ML)	A078579	003	Sep 03, 2015	Aug	NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

AT +	NEXUS PHARMS	0.5%	A077700	001	Dec 20, 2010	Jul	CRLD

QUIXIN

	@ SANTEN	0.5%	N021199	001	Aug 18, 2000	Jul	DISC

TABLET;ORAL

LEVOFLOXACIN

AB	JUBILANT GENERICS	250MG	A203613	001	Jun 19, 2015	Jun	NEWA
AB		500MG	A203613	002	Jun 19, 2015	Jun	NEWA

LEVOLEUCOVORIN CALCIUM

SOLUTION;IV (INFUSION)

LEVOLEUCOVORIN CALCIUM

	SANDOZ	EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Feb	NEWA
	SANDOZ INC	EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML)	A203563	001	Mar 09, 2015	Feb	NEWA
+		EQ 250MG BASE/25ML (EQ 10MG BASE/ML)	A203563	002	Mar 09, 2015	Mar	CRLD

LEVONORGESTREL

INTRAUTERINE DEVICE;INTRAUTERINE

LILETTA

	MEDICINES360	52MG	N206229	001	Feb 26, 2015	Feb	NEWA

LEVORPHANOL TARTRATE

TABLET;ORAL

LEVORPHANOL TARTRATE

+	SENTYNL THERAPS INC	2MG	A074278	001	Mar 31, 2000	Apr	CAHN

LIDOCAINE

OINTMENT;TOPICAL

LIDOCAINE

AT	AMNEAL PHARMS	5%	A206297	001	Aug 07, 2015	Jul	NEWA

PATCH;TOPICAL

LIDOCAINE

AB	ACTAVIS LABS UT INC	5%	A200675	001	Aug 23, 2012	Mar	CAHN
AB	MYLAN TECHNOLOGIES	5%	A202346	001	Aug 07, 2015	Jul	NEWA

LIDOCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

LIDOCAINE HYDROCHLORIDE

@	EUROHLTH INTL SARL	1%	A080407	001		Mar	CAHN
@		2%	A080407	002		Mar	CAHN
>A> AP	LUITPOLD	1%	A091564	001	Aug 14, 2015	Aug	NEWA

LIDOCAINE HYDROCHLORIDE PRESERVATIVE FREE

@	EUROHLTH INTL SARL	1%	A084625	001		Feb	CAHN
@		2%	A084625	002		Feb	CAHN

JELLY;TOPICAL

ANESTACON

@	BANNER LIFE SCIENCES	2%	A080429	001		Jan	CAHN

LIDOCAINE HYDROCHLORIDE

@	G AND W LABS INC	2%	A081318	001	Apr 29, 1993	Apr	CAHN

LIDOCAINE; PRILOCAINE

CREAM;TOPICAL

EMLA

AB +	ACTAVIS LABS UT INC	2.5%;2.5%	N019941	001	Dec 30, 1992	Feb	CAHN

LINACLOTIDE

CAPSULE;ORAL

LINZESS

	FOREST LABS LLC	145MCG	N202811	001	Aug 30, 2012	Mar	CAHN
+		290MCG	N202811	002	Aug 30, 2012	Mar	CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION

LINCOCIN

AP +	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N050317	001		May	CFTG

LINCOMYCIN

AP	X-GEN PHARMS INC	EQ 300MG BASE/ML	A201746	001	Jun 04, 2015	May	NEWA

LINEZOLID

FOR SUSPENSION;ORAL

LINEZOLID

AB	ROXANE	100MG/5ML	A200068	001	Jun 03, 2015	May	NEWA

ZYVOX

AB +	PHARMACIA AND UPJOHN	100MG/5ML	N021132	001	Apr 18, 2000	May	CFTG

SOLUTION;IV (INFUSION)

LINEZOLID

AP	HOSPIRA INC	600MG/300ML (2MG/ML)	A205442	001	Jul 07, 2015	Jun	NEWA
AP	SANDOZ INC	200MG/100ML (2MG/ML)	A200904	001	Jul 16, 2015	Jul	NEWA
AP		600MG/300ML (2MG/ML)	A200904	002	Jul 16, 2015	Jul	NEWA
AP	TEVA PHARMS	600MG/300ML (2MG/ML)	A200222	001	Jun 27, 2012	May	CDFR

LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

+	HOSPIRA INC	600MG/300ML (2MG/ML)	N206473	001	Jun 18, 2015	Jun	NEWA

ZYVOX

AP	PHARMACIA AND UPJOHN	200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	Jul	CTEC
		200MG/100ML (2MG/ML)	N021131	001	Apr 18, 2000	May	CDFR
		400MG/200ML (2MG/ML)	N021131	002	Apr 18, 2000	May	NEWA

	SOLUTION;IV (INFUSION)						
	ZYVOX						
AP	+	600MG/300ML (2MG/ML)	N021131	003	Apr 18, 2000	May	NEWA
	TABLET;ORAL						
	LINEZOLID						
AB	TEVA PHARMS USA	600MG	A078061	001	May 18, 2015	May	NEWA
	ZYVOX						
AB	+ PHARMACIA AND UPJOHN	600MG	N021130	002	Apr 18, 2000	May	CFTG
	LISINOPRIL						
	TABLET;ORAL						
	LISINOPRIL						
AB	SUN PHARM INDS LTD	2.5MG	A075944	001	Jul 01, 2002	Apr	CAHN
AB		5MG	A075944	002	Jul 01, 2002	Apr	CAHN
AB		10MG	A075944	003	Jul 01, 2002	Apr	CAHN
AB		20MG	A075944	004	Jul 01, 2002	Apr	CAHN
AB		30MG	A075944	006	Feb 11, 2003	Apr	CAHN
AB		40MG	A075944	005	Jul 01, 2002	Apr	CAHN
	ZESTRIL						
AB	ALVOGEN IPCO SARL	2.5MG	N019777	005	Apr 29, 1993	Feb	CAHN
AB		5MG	N019777	001	May 19, 1988	Feb	CAHN
AB		10MG	N019777	002	May 19, 1988	Feb	CAHN
AB		20MG	N019777	003	May 19, 1988	Feb	CAHN
AB		30MG	N019777	006	Jan 20, 1999	Feb	CAHN
AB	+	40MG	N019777	004	May 19, 1988	Feb	CAHN
	LITHIUM CARBONATE						
	TABLET, EXTENDED RELEASE;ORAL						
	LITHIUM CARBONATE						
AB	ALEMBIC PHARMS LTD	300MG	A204445	001	Jun 10, 2015	May	NEWA
	@ HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Feb	DISC
AB	UNIQUE PHARM LABS	300MG	A204779	001	Jul 27, 2015	Jul	NEWA
	LOMITAPIDE MESYLATE						
	CAPSULE;ORAL						
	JUXTAPID						
	AEGERION	EQ 30MG BASE	N203858	004	Apr 23, 2015	Apr	NEWA
		EQ 40MG BASE	N203858	005	Apr 23, 2015	Apr	NEWA
		EQ 60MG BASE	N203858	006	Apr 23, 2015	Apr	NEWA
	LOMUSTINE						
	CAPSULE;ORAL						
	GLEOSTINE						
	CORDEN PHARMA	5MG	N017588	004	Dec 19, 2014	Jan	NEWA
	LOPERAMIDE HYDROCHLORIDE						
	CAPSULE;ORAL						
	IMODIUM						
	@ J AND J CONSUMER INC	2MG	N017690	001		Jul	CAHN
AB	+	2MG	N017694	001		Jul	CAHN
	LOPINAVIR; RITONAVIR						
	CAPSULE;ORAL						
	KALETRA						
	@ ABBVIE	133.3MG;33.3MG	N021226	001	Sep 15, 2000	Jun	DISC
	LORAZEPAM						
	INJECTABLE;INJECTION						
	ATIVAN						
AP	+ EUROHLTH INTL SARL	2MG/ML	N018140	001		Jun	CAHN
AP	+	4MG/ML	N018140	002		Jun	CAHN
	TABLET;ORAL						
	LORAZEPAM						
AB	SUN PHARM INDS LTD	0.5MG	A076045	001	Aug 29, 2001	Apr	CAHN
AB		1MG	A076045	002	Aug 29, 2001	Apr	CAHN
AB		2MG	A076045	003	Aug 29, 2001	Apr	CAHN

LOSARTAN POTASSIUM

TABLET;ORAL

LOSARTAN POTASSIUM

AB	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Jul	NEWA
AB		50MG	A203835	002	Aug 12, 2015	Jul	NEWA
AB		100MG	A203835	003	Aug 12, 2015	Jul	NEWA
AB	WATSON LABS	25MG	A091129	001	Oct 06, 2010	Feb	CMFD
AB		50MG	A091129	002	Oct 06, 2010	Feb	CMFD
AB		100MG	A091129	003	Oct 06, 2010	Feb	CMFD

LOVASTATIN

TABLET, EXTENDED RELEASE;ORAL

ALTOPREV

@	COVIS PHARMA SARL	10MG	N021316	001	Jun 26, 2002	May	CAHN
		20MG	N021316	002	Jun 26, 2002	May	CAHN
		40MG	N021316	003	Jun 26, 2002	May	CAHN
+		60MG	N021316	004	Jun 26, 2002	May	CAHN

LOXAPINE HYDROCHLORIDE

CONCENTRATE;ORAL

LOXITANE C

@	ACTAVIS LABS UT INC	EQ 25MG BASE/ML	N017658	001		Mar	CAHN

INJECTABLE;INJECTION

LOXITANE IM

@	ACTAVIS LABS UT INC	EQ 50MG BASE/ML	N018039	001		Mar	CAHN

LOXAPINE SUCCINATE

CAPSULE;ORAL

LOXAPINE SUCCINATE

AB	ELITE LABS INC	EQ 5MG BASE	A076868	001	Aug 04, 2005	May	CAHN
AB		EQ 10MG BASE	A076868	002	Aug 04, 2005	May	CAHN
AB		EQ 25MG BASE	A076868	003	Aug 04, 2005	May	CAHN
AB		EQ 50MG BASE	A076868	004	Aug 04, 2005	May	CAHN

LOXITANE

@	ACTAVIS LABS UT INC	EQ 5MG BASE	N017525	001		Mar	CAHN
@		EQ 10MG BASE	N017525	002		Mar	CAHN
@		EQ 25MG BASE	N017525	003		Mar	CAHN
@		EQ 50MG BASE	N017525	004		Mar	CAHN

TABLET;ORAL

LOXITANE

@	ACTAVIS LABS UT INC	EQ 10MG BASE	N017525	006		Mar	CAHN
@		EQ 25MG BASE	N017525	007		Mar	CAHN
@		EQ 50MG BASE	N017525	008		Mar	CAHN

LUCINACTANT

SUSPENSION;INTRATRACHEAL

SURFAXIN

@	DISCOVERY LABS	8.5ML	N021746	001	Mar 06, 2012	May	DISC

MAGNESIUM ACETATE TETRAHYDRATE; POTASSIUM ACETATE; SODIUM CHLORIDE

INJECTABLE;INJECTION

PLASMA-LYTE 56 IN PLASTIC CONTAINER

@	BAXTER HLTHCARE	32MG/100ML;128MG/100ML;234MG/100ML	N019047	001	Jun 15, 1984	Mar	DISC

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

AP	EXELA PHARMA SCS LLC	5GM/10ML (500MG/ML)	A206039	001	Dec 18, 2014	Apr	CDFR
AP +	FRESENIUS KABI USA	5GM/10ML (500MG/ML)	N019316	001	Sep 08, 1986	Apr	CPOT
AP +	HOSPIRA	5GM/10ML (500MG/ML)	A075151	001	Apr 25, 2000	Apr	CDFR
	HOSPIRA INC	10GM/20ML (500MG/ML)	A202411	001	May 14, 2015	Apr	NEWA

MAGNESIUM SULFATE

SOLUTION;INTRAMUSCULAR, INTRAVENOUS

MAGNESIUM SULFATE

+	FRESENIUS KABI USA	1GM/2ML (500MG/ML)	N019316	002	Sep 08, 1986	Apr	NEWA

MAGNESIUM SULFATE; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; POTASSIUM SULFATE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE

SOLUTION;ORAL

>D>		SUCLEAR						
>D>	+	BRAINTREE LABS	1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM	N203595	001	Jan 18, 2013	Aug DISC	
>A>	@		1.6GM/BOT,3.13GM/BOT,17.5GM/BOT,N/A,N/A,N/A,N/A;N/A,N/A,N/A,210GM,0.74GM,2.86GM,5.6GM	N203595	001	Jan 18, 2013	Aug DISC	

MANNITOL

INJECTABLE;INJECTION

MANNITOL 25%

	@	IGI LABS INC	12.5GM/50ML	A089239	001	May 06, 1987	Mar CAHN	
	@		12.5GM/50ML	A089240	001	May 06, 1987	Mar CAHN	

MECLIZINE HYDROCHLORIDE

TABLET;ORAL

MECLIZINE HYDROCHLORIDE

>A>	@	ANI PHARMS INC	12.5MG	A084975	001		Aug CAHN	
>A>	@		25MG	A084657	001		Aug CAHN	
>D>	@	IVAX SUB TEVA PHARMS	12.5MG	A084975	001		Aug CAHN	
>D>	@		25MG	A084657	001		Aug CAHN	
	@	VINTAGE PHARMS	12.5MG	A040179	001	Jan 30, 1997	Jun DISC	
	@		25MG	A040179	002	Jan 30, 1997	Jun DISC	

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

NAMENDA XR

		FOREST LABS LLC	7MG	N022525	001	Jun 21, 2010	Mar CAHN	
			14MG	N022525	002	Jun 21, 2010	Mar CAHN	
			21MG	N022525	003	Jun 21, 2010	Mar CAHN	
	+		28MG	N022525	004	Jun 21, 2010	Mar CAHN	

SOLUTION;ORAL

NAMENDA

	+	FOREST LABS LLC	2MG/ML	N021627	001	Apr 18, 2005	Mar CAHN	

TABLET;ORAL

MEMANTINE

AB		SUN PHARMA GLOBAL	5MG	A090058	001	May 05, 2010	Mar CMFD	
AB			10MG	A090058	002	May 05, 2010	Mar CMFD	

MEMANTINE HYDROCHLORIDE

AB		AMNEAL PHARMS	5MG	A090041	001	Apr 10, 2015	Mar NEWA	
AB			10MG	A090041	002	Apr 10, 2015	Mar NEWA	
AB		DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jun CMFD	
AB			10MG	A090048	002	Apr 14, 2010	Jun CMFD	
AB		LUPIN LTD	5MG	A090051	001	Apr 10, 2015	Mar NEWA	
AB			10MG	A090051	002	Apr 10, 2015	Mar NEWA	
AB		MYLAN PHARMS INC	5MG	A079225	001	Jan 30, 2015	Jun CMFD	
	@		5MG	A079225	001	Jan 30, 2015	Mar DISC	
AB			5MG	A079225	001	Jan 30, 2015	Jan NEWA	
AB			10MG	A079225	002	Jan 30, 2015	Jun CMFD	
	@		10MG	A079225	002	Jan 30, 2015	Mar DISC	
AB			10MG	A079225	002	Jan 30, 2015	Jan NEWA	
AB		TEVA PHARMS	5MG	A090052	001	Oct 25, 2011	May CMFD	
AB			10MG	A090052	002	Oct 25, 2011	May CMFD	
AB		UPSHER SMITH	5MG	A090043	001	Jul 31, 2015	Jul NEWA	
AB			10MG	A090043	002	Jul 31, 2015	Jul NEWA	
>A> AB		WOCKHARDT LTD	5MG	A090073	001	Sep 04, 2015	Aug NEWA	
>A> AB			10MG	A090073	002	Sep 04, 2015	Aug NEWA	

NAMENDA

AB		FOREST LABS LLC	5MG	N021487	001	Oct 16, 2003	Mar CAHN	
AB	+		10MG	N021487	002	Oct 16, 2003	Mar CAHN	

MENOTROPINS (FSH;LH)

INJECTABLE;INTRAMUSCULAR, SUBCUTANEOUS

REPRONEX

	@	FERRING	75 IU/VIAL;75 IU/VIAL	N021047	001	Aug 27, 1999	May DISC	

MEPERIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERIDINE HYDROCHLORIDE

AP	EUROHLTH INTL SARL	25MG/ML	A080445	001			Feb CAHN
AP		50MG/ML	A080445	002			Feb CAHN
AP		75MG/ML	A080445	003			Feb CAHN
AP		100MG/ML	A080445	004			Feb CAHN
	@ IGI LABS INC	25MG/ML	A089781	001	Mar 31, 1989		May CAHN
	@	50MG/ML	A089782	001	Mar 31, 1989		Mar CAHN
	@	50MG/ML	A089783	001	Mar 31, 1989		Mar CAHN
	@	50MG/ML	A089784	001	Mar 31, 1989		Mar CAHN
	@	75MG/ML	A089785	001	Mar 31, 1989		Mar CAHN
	@	100MG/ML	A089786	001	Mar 31, 1989		Mar CAHN
	@	100MG/ML	A089787	001	Mar 31, 1989		Mar CAHN
	@	100MG/ML	A089788	001	Mar 31, 1989		Mar CAHN

MEPERIDINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

MEPERGAN

	@ EUROHLTH INTL SARL	25MG/ML;25MG/ML	N011730	001			Jun CAHN

MEROPENEM

POWDER;IV (INFUSION)

MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER

	B BRAUN MEDICAL INC	500MG/VIAL	N202106	001	Apr 30, 2015		Apr NEWA
		1GM/VIAL	N202106	002	Apr 30, 2015		Apr NEWA

MESALAMINE

CAPSULE, EXTENDED RELEASE;ORAL

APRISO

+	VALEANT PHARMS INTL	375MG	N022301	001	Oct 31, 2008		Jul CAHN

ENEMA;RECTAL

MESALAMINE

>A> AB	G AND W LABS INC	4GM/60ML	A076841	001	Sep 30, 2004		Aug CAHN
>D> AB	TEVA	4GM/60ML	A076841	001	Sep 30, 2004		Aug CAHN

SUPPOSITORY;RECTAL

CANASA

>D>	@ FOREST LABS INC	500MG	N021252	001	Jan 05, 2001		Aug CAHN
>D> +		1GM	N021252	002	Nov 05, 2004		Aug CAHN
>A>	@ FOREST LABS LLC	500MG	N021252	001	Jan 05, 2001		Aug CAHN
>A> +		1GM	N021252	002	Nov 05, 2004		Aug CAHN

MESTRANOL; NORETHINDRONE

TABLET;ORAL-20

NORINYL

	@ ACTAVIS LABS UT INC	0.1MG;2MG	N013625	004			Mar CAHN

TABLET;ORAL-21

NORINYL 1+50 21-DAY

	@ ACTAVIS LABS UT INC	0.05MG;1MG	N013625	002			Mar CAHN

TABLET;ORAL-28

NORINYL 1+50 28-DAY

+	ACTAVIS LABS UT INC	0.05MG;1MG	N016659	001			Mar CAHN

METAPROTERENOL SULFATE

SOLUTION;INHALATION

METAPROTERENOL SULFATE

	@ MYLAN SPECLT	0.4%	A071786	001	Aug 05, 1988		Apr DISC
	@	0.6%	A070804	001	Aug 17, 1987		Apr DISC
	@ WOCKHARDT	0.4%	A075586	001	May 30, 2002		Apr DISC
	@	0.6%	A075586	002	May 30, 2002		Apr DISC

SYRUP;ORAL

METAPROTERENOL SULFATE

	@ G AND W LABS INC	10MG/5ML	A072761	001	Feb 27, 1992		Apr CAHN
	@	10MG/5ML	A073034	001	Aug 30, 1991		Apr CAHN

METAXALONE

TABLET;ORAL

METAXALONE

		COREPHARMA	400MG	A040486	001	Feb 27, 2015	Feb NEWA
			640MG	N022503	001	Jun 01, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE

SOLUTION;ORAL

RIOMET

	+	SUN PHARM INDS LTD	500MG/5ML	N021591	001	Sep 11, 2003	Apr CAHN

METFORMIN HYDROCHLORIDE; REPAGLINIDE

TABLET;ORAL

PRANDIMET

AB		NOVO NORDISK INC	500MG;1MG	N022386	001	Jun 23, 2008	Jun CFTG
AB	+		500MG;2MG	N022386	002	Jun 23, 2008	Jun CFTG

REPAGLINIDE AND METFORMIN HYDROCHLORIDE

AB		LUPIN LTD	500MG;1MG	A200624	001	Jul 15, 2015	Jun NEWA
AB			500MG;2MG	A200624	002	Jul 15, 2015	Jun NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

AVANDAMET

	@	SB PHARMCO	500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	May DISC
	@		500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	May DISC
	@		1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	May DISC
	@		1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	May DISC

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

		TEVA	500MG;EQ 2MG BASE	A077337	001	May 07, 2014	May CTEC
			500MG;EQ 4MG BASE	A077337	002	May 07, 2014	May CTEC
	+		1GM;EQ 4MG BASE	A077337	004	May 07, 2014	May CRLD
			1GM;EQ 2MG BASE	A077337	003	May 07, 2014	May CTEC

METHADONE HYDROCHLORIDE

TABLET;ORAL

METHADONE HYDROCHLORIDE

>A> AA		AUROLIFE PHARMA LLC	5MG	A203502	001	Aug 31, 2015	Aug NEWA
>A> AA			10MG	A203502	002	Aug 31, 2015	Aug NEWA
>A> AA		COREPHARMA	5MG	A090065	001	Aug 18, 2015	Aug NEWA
>A> AA			10MG	A090065	002	Aug 18, 2015	Aug NEWA

METHIMAZOLE

TABLET;ORAL

METHIMAZOLE

AB		HERITAGE PHARMA	5MG	A040734	001	Dec 14, 2007	Mar CAHN
AB			10MG	A040734	002	Dec 14, 2007	Mar CAHN

METHOCARBAMOL

SOLUTION;IM-IV

ROBAXIN

AP	+	EUROHLTH INTL SARL	1GM/10ML (100MG/ML)	N011790	001		Jun CAHN

METHOTREXATE SODIUM

INJECTABLE;INJECTION

METHOTREXATE PRESERVATIVE FREE

AP		FRESENIUS KABI USA	EQ 25MG BASE/ML	A040265	001	Feb 26, 1999	May CMFD

TABLET;ORAL

METHOTREXATE SODIUM

AB		ORION CORP ORION	EQ 2.5MG BASE	A201749	001	May 21, 2015	May NEWA

METHOXSALEN

CAPSULE;ORAL

METHOXSALEN

AB		ACTAVIS INC	10MG	A202603	001	Jun 09, 2015	May NEWA

METHYLPHENIDATE HYDROCHLORIDE

		CAPSULE, EXTENDED RELEASE;ORAL						
		APTENSIO XR						
		RHODES PHARMS	10MG	N205831	001	Apr 17, 2015	Apr	NEWA
			15MG	N205831	002	Apr 17, 2015	Apr	NEWA
			20MG	N205831	003	Apr 17, 2015	Apr	NEWA
			30MG	N205831	004	Apr 17, 2015	Apr	NEWA
			40MG	N205831	005	Apr 17, 2015	Apr	NEWA
			50MG	N205831	006	Apr 17, 2015	Apr	NEWA
	+		60MG	N205831	007	Apr 17, 2015	Apr	NEWA
		RITALIN LA						
	AB1	NOVARTIS	40MG	N021284	003	Jun 05, 2002	Feb	CRLD
	+		60MG	N021284	005	Oct 27, 2014	Feb	CRLD
		SOLUTION;ORAL						
		METHYLPHENIDATE HYDROCHLORIDE						
>A>	AA	NOVEL LABS INC	5MG/5ML	A204602	001	Aug 14, 2015	Aug	NEWA
>A>	AA		10MG/5ML	A204602	002	Aug 14, 2015	Aug	NEWA
		TABLET, CHEWABLE;ORAL						
		METHYLIN						
	AB	MALLINCKRODT	2.5MG	N021475	001	Apr 15, 2003	Feb	CFTG
	AB		5MG	N021475	002	Apr 15, 2003	Feb	CFTG
	AB	+	10MG	N021475	003	Apr 15, 2003	Feb	CFTG
		METHYLPHENIDATE HYDROCHLORIDE						
	AB	NOVEL LABS INC	2.5MG	A204115	001	Feb 25, 2015	Feb	NEWA
	AB		5MG	A204115	002	Feb 25, 2015	Feb	NEWA
	AB		10MG	A204115	003	Feb 25, 2015	Feb	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		METHYLIN ER						
	AB	MALLINCKRODT INC	10MG	A075629	001	May 09, 2000	May	CTEC
		METHYLPHENIDATE HYDROCHLORIDE						
	AB	ABHAI	10MG	A207488	001	Jun 09, 2015	May	NEWA
	AB		20MG	A207488	002	Jun 09, 2015	May	NEWA

METOPROLOL TARTRATE

		INJECTABLE;INJECTION						
		METOPROLOL TARTRATE						
	AP	CLARIS PHARMASERVICE	1MG/ML	A078950	001	Apr 29, 2013	Apr	CAHN
		TABLET;ORAL						
		METOPROLOL TARTRATE						
		MYLAN	37.5MG	A076704	004	Mar 18, 2015	Mar	NEWA
			75MG	A076704	005	Mar 18, 2015	Mar	NEWA

METRONIDAZOLE

		CREAM;TOPICAL						
		NORITATE						
	+	VALEANT PHARMS NORTH	1%	N020743	001	Sep 26, 1997	Feb	CAHN
		GEL;VAGINAL						
		METRONIDAZOLE						
	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CAHN
		NUVESSA						
	+	ACTAVIS LABS UT INC	1.3%	N205223	001	Mar 24, 2014	Feb	CTNA
		INJECTABLE;INJECTION						
		METRONIDAZOLE						
>A>		@ EUROHLTH INTL SARL	500MG/100ML	N018907	001	Mar 30, 1984	Aug	CAHN
>D>		@ HIKMA MAPLE	500MG/100ML	N018907	001	Mar 30, 1984	Aug	CAHN
		METRONIDAZOLE IN PLASTIC CONTAINER						
	AP	CLARIS PHARMASERVICE	500MG/100ML	A078084	001	Mar 31, 2008	Apr	CAHN
		TABLET;ORAL						
		METRONIDAZOLE						
	AB	AUROBINDO PHARMA LTD	250MG	A203974	001	May 29, 2015	May	NEWA
	AB		500MG	A203974	002	May 29, 2015	May	NEWA

MICONAZOLE

		TABLET;BUCCAL						
		ORAVIG						
	+	DARA BIOSCIENCES	50MG	N022404	001	Apr 16, 2010	Apr	CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE;INJECTION

MIDAZOLAM HYDROCHLORIDE

	@	CLARIS PHARMASERVICE	EQ 1MG BASE/ML	A	075637	001	Oct 31, 2000	Apr CAHN
	@		EQ 5MG BASE/ML	A	075637	002	Oct 31, 2000	Apr CAHN
AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A	075243	001	Jun 20, 2000	Jun CAHN
AP			EQ 5MG BASE/ML	A	075243	002	Jun 20, 2000	Jun CAHN
	@	IGI LABS INC	EQ 5MG BASE/ML	A	075263	001	Jun 26, 2000	Apr CAHN
	@	WOCKHARDT	EQ 1MG BASE/ML	A	078141	001	May 30, 2008	Mar DISC
	@		EQ 1MG BASE/ML	A	078511	001	Nov 10, 2008	Mar DISC
	@		EQ 5MG BASE/ML	A	078141	002	May 30, 2008	Mar DISC
	@		EQ 5MG BASE/ML	A	078511	002	Nov 10, 2008	Mar DISC

SYRUP;ORAL

MIDAZOLAM HYDROCHLORIDE

AA		SUN PHARM INDS LTD	EQ 2MG BASE/ML	A	076058	001	Mar 15, 2002	Apr CAHN

MIGLITOL

TABLET;ORAL

GLYSET

AB		PHARMACIA AND UPJOHN	25MG	N	020682	001	Dec 18, 1996	Mar CTEC
AA			25MG	N	020682	001	Dec 18, 1996	Feb CFTG
AB			50MG	N	020682	002	Dec 18, 1996	Mar CTEC
AA			50MG	N	020682	002	Dec 18, 1996	Feb CFTG
AB	+		100MG	N	020682	003	Dec 18, 1996	Mar CTEC
AA	+		100MG	N	020682	003	Dec 18, 1996	Feb CFTG

MIGLITOL

AB		ORIENT PHARMA CO LTD	25MG	A	203965	001	Feb 24, 2015	Mar CTEC
AA			25MG	A	203965	001	Feb 24, 2015	Feb NEWA
AB			50MG	A	203965	002	Feb 24, 2015	Mar CTEC
AA			50MG	A	203965	002	Feb 24, 2015	Feb NEWA
AB			100MG	A	203965	003	Feb 24, 2015	Mar CTEC
AA			100MG	A	203965	003	Feb 24, 2015	Feb NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION

MILRINONE LACTATE

AP		BEDFORD	EQ 1MG BASE/ML	A	075660	001	May 28, 2002	Jan CRLD
AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A	075530	001	May 28, 2002	Jun CAHN
AP	+	HIKMA FARMACEUTICA	EQ 1MG BASE/ML	A	077966	001	Dec 03, 2010	Jan CRLD

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 50MG BASE	A	065062	001	Nov 30, 2000	Apr CAHN
AB			EQ 75MG BASE	A	065062	002	Nov 30, 2000	Apr CAHN
AB			EQ 100MG BASE	A	065062	003	Nov 30, 2000	Apr CAHN
AB		TORRENT PHARMA INC	EQ 50MG BASE	A	065062	001	Nov 30, 2000	Jun CAHN
AB			EQ 75MG BASE	A	065062	002	Nov 30, 2000	Jun CAHN
AB			EQ 100MG BASE	A	065062	003	Nov 30, 2000	Jun CAHN

CAPSULE, EXTENDED RELEASE;ORAL

XIMINO

	@	SUN PHARM INDS LTD	EQ 45MG BASE	N	201922	001	Jul 11, 2012	Apr CAHN
	@		EQ 67.5MG BASE	N	201922	002	Jul 11, 2012	Apr CAHN
	@		EQ 90MG BASE	N	201922	003	Jul 11, 2012	Apr CAHN
	@		EQ 112.5MG BASE	N	201922	004	Jul 11, 2012	Apr CAHN
	@		EQ 135MG BASE	N	201922	005	Jul 11, 2012	Apr CAHN

TABLET;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 50MG BASE	A	065156	001	Jan 06, 2004	Apr CAHN
AB			EQ 75MG BASE	A	065156	002	Jan 06, 2004	Apr CAHN
AB			EQ 100MG BASE	A	065156	003	Jan 06, 2004	Apr CAHN
AB		TORRENT PHARMA INC	EQ 50MG BASE	A	065156	001	Jan 06, 2004	Jun CAHN
AB			EQ 75MG BASE	A	065156	002	Jan 06, 2004	Jun CAHN
AB			EQ 100MG BASE	A	065156	003	Jan 06, 2004	Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 45MG BASE	A	091118	001	Sep 25, 2014	Apr CAHN
AB			EQ 80MG BASE	A	091118	004	Sep 25, 2014	Apr CAHN
AB			EQ 90MG BASE	A	091118	005	Sep 25, 2014	Apr CAHN
AB			EQ 105MG BASE	A	091118	006	Sep 25, 2014	Apr CAHN
AB			EQ 135MG BASE	A	091118	008	Sep 25, 2014	Apr CAHN

MIVACURIUM CHLORIDE

SOLUTION;INTRAVENOUS

MIVACRON

		ABBVIE	EQ 10MG BASE/5ML (EQ 2MG BASE/ML)	N020098	004	Jan 22, 1992	Jan NEWA
	+		EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	N020098	005	Jan 22, 1992	Jan NEWA

MOLINDONE HYDROCHLORIDE

TABLET;ORAL

MOLINDONE HYDROCHLORIDE

		COREPHARMA	5MG	A090453	001	Mar 20, 2015	Mar NEWA
			10MG	A090453	002	Mar 20, 2015	Mar NEWA
	+		25MG	A090453	003	Mar 20, 2015	Mar NEWA

MONTELUKAST SODIUM

GRANULE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	EQ 4MG BASE/PACKET	A203438	001	Jul 31, 2015	Jul NEWA

TABLET;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	EQ 10MG BASE	A203432	001	Jul 31, 2015	Jul NEWA
>A> AB		AMNEAL PHARMS	EQ 10MG BASE	A204604	001	Sep 04, 2015	Aug NEWA
AB		KREMERS URBAN PHARMS	EQ 10MG BASE	A201522	001	Aug 03, 2012	Mar CAHN

TABLET, CHEWABLE;ORAL

MONTELUKAST SODIUM

AB		AJANTA PHARMA LTD	EQ 4MG BASE	A203328	001	Jul 31, 2015	Jul NEWA
AB			EQ 5MG BASE	A203328	002	Jul 31, 2015	Jul NEWA
AB		HETERO LABS LTD V	EQ 4MG BASE	A204093	001	May 22, 2015	May NEWA
AB			EQ 5MG BASE	A204093	002	May 22, 2015	May NEWA
AB		JUBILANT GENERICS	EQ 4MG BASE	A203795	001	Feb 27, 2015	Feb NEWA
AB			EQ 5MG BASE	A203795	002	Feb 27, 2015	Feb NEWA
AB		KREMERS URBAN PHARMS	EQ 4MG BASE	A200405	001	Aug 03, 2012	Mar CAHN
AB			EQ 5MG BASE	A200405	002	Aug 03, 2012	Mar CAHN
AB		MACLEODS PHARMS LTD	EQ 4MG BASE	A203582	001	Mar 12, 2015	Feb NEWA
AB			EQ 5MG BASE	A203582	002	Mar 12, 2015	Feb NEWA

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

AB1	+	ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Mar CAHN
AB1			20MG	N020616	001	Jul 03, 1996	Mar CAHN
AB1			30MG	N020616	004	Mar 09, 2001	Mar CAHN
AB1			40MG	N020616	009	Jul 09, 2012	May CTEC
			40MG	N020616	009	Jul 09, 2012	Mar CAHN
AB1			50MG	N020616	002	Jul 03, 1996	Mar CAHN
AB1			60MG	N020616	005	Mar 09, 2001	Mar CAHN
AB1			70MG	N020616	010	Jul 09, 2012	May CTEC
			70MG	N020616	010	Jul 09, 2012	Mar CAHN
AB1			80MG	N020616	006	Oct 27, 2006	Mar CAHN
AB1	+		100MG	N020616	003	Jul 03, 1996	Mar CAHN
			130MG	N020616	011	Jul 09, 2012	Mar CAHN
			150MG	N020616	012	Jul 09, 2012	Mar CAHN
AB1	+		200MG	N020616	007	Feb 27, 2007	Mar CAHN

MORPHINE SULFATE

AB1		TEVA PHARMS USA	40MG	A202718	007	Jun 03, 2015	May NEWA
AB1			70MG	A202718	008	Jun 03, 2015	May NEWA

INJECTABLE;INJECTION

DURAMORPH PF

AP	+	EUROHLTH INTL SARL	0.5MG/ML	N018565	001	Sep 18, 1984	Jun CAHN
AP	+		1MG/ML	N018565	002	Sep 18, 1984	Jun CAHN

INFUMORPH

	+	EUROHLTH INTL SARL	10MG/ML	N018565	003	Jul 19, 1991	Jun CAHN
	+		25MG/ML	N018565	004	Jul 19, 1991	Jun CAHN

MORPHINE SULFATE

AP		EUROHLTH INTL SARL	4MG/ML	A205758	001	May 21, 2015	May NEWA
AP			8MG/ML	A205758	002	May 21, 2015	May NEWA
AP			10MG/ML	A205758	003	May 21, 2015	May NEWA
AP	+	HOSPIRA INC	4MG/ML	N202515	002	Nov 14, 2011	May CFTG
AP	+		8MG/ML	N202515	003	Nov 14, 2011	May CFTG
AP	+		10MG/ML	N202515	004	Nov 14, 2011	May CFTG

		SOLUTION;ORAL						
		MORPHINE SULFATE						
	AA	TRIS PHARMA INC	10MG/5ML	A203518	001	May 12, 2015	May	NEWA
	AA		100MG/5ML	A203518	002	May 12, 2015	May	NEWA
		TABLET, EXTENDED RELEASE;ORAL						
		MORPHINE SULFATE						
	AB	ACTAVIS ELIZABETH	15MG	A203849	001	Apr 06, 2015	Mar	NEWA
	AB		30MG	A203849	002	Apr 06, 2015	Mar	NEWA
	AB		60MG	A203849	003	Apr 06, 2015	Mar	NEWA
	AB		100MG	A203849	004	Apr 06, 2015	Mar	NEWA
	AB		200MG	A203849	005	Apr 06, 2015	Mar	NEWA
	AB	SUN PHARM INDS LTD	15MG	A078761	001	May 11, 2012	Apr	CAHN
	AB		30MG	A078761	002	May 11, 2012	Apr	CAHN
	AB		60MG	A078761	003	May 11, 2012	Apr	CAHN
	AB		100MG	A078761	004	May 11, 2012	Apr	CAHN
	AB		200MG	A078761	005	May 11, 2012	Apr	CAHN
		MOXIFLOXACIN HYDROCHLORIDE						
		SOLUTION;IV (INFUSION)						
		MOXIFLOXACIN HYDROCHLORIDE						
	+	FRESENIUS KABI USA	EQ 400MG BASE/250ML (EQ 1.6MG BASE/ML)	N205572	001	Apr 03, 2015	Apr	NEWA
		SOLUTION/DROPS;OPHTHALMIC						
		MOXEZA						
	AT2 +	ALCON PHARMS LTD	EQ 0.5% BASE	N022428	001	Nov 19, 2010	May	CFTG
		MOXIFLOXACIN HYDROCHLORIDE						
	AT1	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	May	CTEC
	AT2		EQ 0.5% BASE	A204079	001	May 28, 2015	May	NEWA
	AT1	WATSON LABS INC	EQ 0.5% BASE	A202525	001	Mar 06, 2015	May	CTEC
	AT		EQ 0.5% BASE	A202525	001	Mar 06, 2015	Feb	NEWA
		VIGAMOX						
	AT1 +	ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	May	CTEC
		TABLET;ORAL						
		MOXIFLOXACIN HYDROCHLORIDE						
>A>	AB	MYLAN PHARMS INC	EQ 400MG BASE	A204635	001	Aug 31, 2015	Aug	NEWA
		NADOLOL						
		TABLET;ORAL						
		NADOLOL						
>A>	AB	ORION CORP ORION	40MG	A201893	001	Sep 16, 2015	Aug	NEWA
>A>	AB		80MG	A201893	002	Sep 16, 2015	Aug	NEWA
		NALBUPHINE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		NALBUPHINE HYDROCHLORIDE						
	@	IGI LABS INC	10MG/ML	A072070	001	Apr 10, 1989	Mar	CAHN
	@		10MG/ML	A072071	001	Apr 10, 1989	Mar	CAHN
	@		10MG/ML	A072072	001	Apr 10, 1989	Mar	CAHN
	@		20MG/ML	A072073	001	Apr 10, 1989	Mar	CAHN
	@		20MG/ML	A072074	001	Apr 10, 1989	Mar	CAHN
	@		20MG/ML	A072075	001	Apr 10, 1989	Mar	CAHN
		NALMEFENE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		REVEX						
	@	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML	N020459	001	Apr 17, 1995	Jun	CAHN
	@		EQ 1MG BASE/ML	N020459	002	Apr 17, 1995	Jun	CAHN
		NALOXONE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		NALOXONE						
	@	EUROHLTH INTL SARL	0.4MG/ML	A070299	001	Sep 24, 1986	Mar	CAHN
		NALOXONE HYDROCHLORIDE						
	@	IGI LABS INC	0.02MG/ML	A072082	001	Apr 11, 1989	Mar	CAHN
	@		0.02MG/ML	A072083	001	Apr 11, 1989	Mar	CAHN
	@		0.02MG/ML	A072084	001	Apr 11, 1989	Mar	CAHN
	@		0.02MG/ML	A072085	001	Apr 11, 1989	Mar	CAHN
	@		0.4MG/ML	A072086	001	Apr 11, 1989	Mar	CAHN
	@		0.4MG/ML	A072087	001	Apr 11, 1989	Mar	CAHN
	@		0.4MG/ML	A072088	001	Apr 11, 1989	Mar	CAHN
	@		0.4MG/ML	A072089	001	Apr 11, 1989	Mar	CAHN
	@		0.4MG/ML	A072090	001	Apr 11, 1989	Mar	CAHN

	INJECTABLE;INJECTION						
	NALOXONE HYDROCHLORIDE						
	@	1MG/ML	A072091	001	Apr 11, 1989		Mar CAHN
	@	1MG/ML	A072092	001	Apr 11, 1989		Mar CAHN
	@	1MG/ML	A072093	001	Apr 11, 1989		Mar CAHN
	NARCAN						
>A>	@ ADAPT	0.02MG/ML	N016636	002			Aug CAHN
>A>	@	0.4MG/ML	N016636	001			Aug CAHN
>A>	@	1MG/ML	N016636	003	Jun 14, 1982		Aug CAHN
>D>	@ ENDO PHARMS	0.02MG/ML	N016636	002			Aug CAHN
>D>	@	0.4MG/ML	N016636	001			Aug CAHN
>D>	@	1MG/ML	N016636	003	Jun 14, 1982		Aug CAHN
	NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE						
	TABLET;ORAL						
	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE						
AB	SUN PHARM INDS LTD	EQ 0.5MG BASE;EQ 50MG BASE	A075523	001	Mar 17, 2000		Apr CAHN
	NAPROXEN						
	SUSPENSION;ORAL						
	NAPROSYN						
AB	+ PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987		Apr CAHN
	NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE						
	TABLET;ORAL						
	TREXIMET						
	PERNIX IRELAND LTD	60MG;EQ 10MG BASE	N021926	002	May 14, 2015		Jun NEWA
	NEBIVOLOL HYDROCHLORIDE						
	TABLET;ORAL						
	NEBIVOLOL HYDROCHLORIDE						
	@ ALKEM LABS LTD	EQ 2.5MG BASE	A203741	001	Jun 24, 2015		Jun DISC
		EQ 2.5MG BASE	A203741	001	Jun 24, 2015		Jun NEWA
	@	EQ 5MG BASE	A203741	002	Jun 24, 2015		Jun DISC
		EQ 5MG BASE	A203741	002	Jun 24, 2015		Jun NEWA
	@	EQ 10MG BASE	A203741	003	Jun 24, 2015		Jun DISC
		EQ 10MG BASE	A203741	003	Jun 24, 2015		Jun NEWA
	@	EQ 20MG BASE	A203741	004	Jun 24, 2015		Jun DISC
		EQ 20MG BASE	A203741	004	Jun 24, 2015		Jun NEWA
	@ AMERIGEN PHARMS LTD	EQ 2.5MG BASE	A203659	001	Apr 16, 2015		Apr DISC
AB		EQ 2.5MG BASE	A203659	001	Apr 16, 2015		Mar NEWA
	@	EQ 5MG BASE	A203659	002	Apr 16, 2015		Apr DISC
AB		EQ 5MG BASE	A203659	002	Apr 16, 2015		Mar NEWA
	@	EQ 10MG BASE	A203659	003	Apr 16, 2015		Apr DISC
AB		EQ 10MG BASE	A203659	003	Apr 16, 2015		Mar NEWA
	@	EQ 20MG BASE	A203659	004	Apr 16, 2015		Apr DISC
AB		EQ 20MG BASE	A203659	004	Apr 16, 2015		Mar NEWA
	@ INDCHEMIE HEALTH	EQ 2.5MG BASE	A203828	001	Jul 29, 2015		Jul DISC
		EQ 2.5MG BASE	A203828	001	Jul 29, 2015		Jul NEWA
	@	EQ 5MG BASE	A203828	002	Jul 29, 2015		Jul DISC
		EQ 5MG BASE	A203828	002	Jul 29, 2015		Jul NEWA
	@	EQ 10MG BASE	A203828	003	Jul 29, 2015		Jul DISC
		EQ 10MG BASE	A203828	003	Jul 29, 2015		Jul NEWA
	@	EQ 20MG BASE	A203828	004	Jul 29, 2015		Jul DISC
		EQ 20MG BASE	A203828	004	Jul 29, 2015		Jul NEWA
	NEFAZODONE HYDROCHLORIDE						
	TABLET;ORAL						
	NEFAZODONE HYDROCHLORIDE						
	@ IDT AUSTRALIA LTD	50MG	A076072	001	Sep 16, 2003		Apr CAHN
	@	100MG	A076072	002	Sep 16, 2003		Apr CAHN
	@	150MG	A076072	003	Sep 16, 2003		Apr CAHN
	@	200MG	A076072	004	Sep 16, 2003		Apr CAHN
	@	250MG	A076072	005	Sep 16, 2003		Apr CAHN
AB	SUN PHARM INDS LTD	50MG	A076409	001	Sep 16, 2003		Apr CAHN
AB		100MG	A076409	002	Sep 16, 2003		Apr CAHN
AB		150MG	A076409	003	Sep 16, 2003		Apr CAHN
AB		200MG	A076409	004	Sep 16, 2003		Apr CAHN
AB		250MG	A076409	005	Sep 16, 2003		Apr CAHN

NELARABINE

INJECTABLE;IV (INFUSION)

ARRANON

	+	NOVARTIS PHARMS CORP	250MG/50ML (5MG/ML)	N021877	001	Oct 28, 2005	Mar	CAHN

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS

NEOSTIGMINE METHYLSULFATE

		FRESENIUS KABI USA	5MG/10ML (0.5MG/ML)	N203629	001	Jan 08, 2015	Jan	NEWA
			10MG/10ML (1MG/ML)	N203629	002	Jan 08, 2015	Jan	NEWA

NEVIRAPINE

TABLET, EXTENDED RELEASE;ORAL

NEVIRAPINE

AB		ALVOGEN PINE BROOK	400MG	A204621	001	Jul 10, 2015	Jun	NEWA

NIACIN

TABLET, EXTENDED RELEASE;ORAL

NIACIN

AB		AMNEAL PHARMS	500MG	A203578	001	Jul 24, 2015	Jul	NEWA
AB			1GM	A203578	002	Jul 24, 2015	Jul	NEWA

NIFEDIPINE

CAPSULE;ORAL

NIFEDIPINE

AB		HERITAGE PHARMA	10MG	A202644	001	Apr 25, 2013	Mar	CAHN
AB			20MG	A202644	002	Apr 25, 2013	Mar	CAHN

TABLET, EXTENDED RELEASE;ORAL

NIFEDIPINE

>D> AB2		VALEANT INTL	30MG	A075289	002	Feb 06, 2001	Aug	CAHN
>D> AB2			60MG	A075289	001	Sep 27, 2000	Aug	CAHN
>A> AB2		VALEANT PHARMS NORTH	30MG	A075289	002	Feb 06, 2001	Aug	CAHN
>A> AB2			60MG	A075289	001	Sep 27, 2000	Aug	CAHN

NILUTAMIDE

TABLET;ORAL

NILANDRON

	@	CONCORDIA PHARMS INC	50MG	N020169	001	Sep 19, 1996	Apr	CAHN
	+		150MG	N020169	002	Apr 30, 1999	Apr	CAHN

NIMODIPINE

CAPSULE;ORAL

NIMODIPINE

AB	+	BANNER LIFE SCIENCES	30MG	A076740	001	Jan 17, 2008	Jan	CAHN
AB		SOFGEN PHARMS	30MG	A201832	001	Jul 24, 2015	Jul	NEWA

NINTEDANIB ESYLATE

CAPSULE;ORAL

OFEV

		BOEHRINGER INGELHEIM	EQ 100MG BASE	N205832	001	Oct 15, 2014	Mar	CAIN
	+		EQ 150MG BASE	N205832	002	Oct 15, 2014	Mar	CAIN

NITRIC OXIDE

GAS;INHALATION

INOMAX

	@	INO	100PPM	N020845	002	Dec 23, 1999	Jun	DISC

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

MACRODANTIN

AB		ALVOGEN INC	25MG	N016620	003		Jun	CTEC

NITROFURANTOIN

AB		ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Jun	NEWA
AB			50MG	A091095	002	Jun 18, 2015	Jun	NEWA
AB			100MG	A091095	003	Jun 18, 2015	Jun	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE;ORAL

NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS)

AB	WATSON LABS INC	75MG;25MG	A202250	001	Jul 08, 2015	Jun	NEWA

NORETHINDRONE

TABLET;ORAL-28

NOR-QD

AB1	+ ACTAVIS LABS UT INC	0.35MG	N017060	001		Mar	CAHN

NORGESTREL

TABLET;ORAL

OVRETTE

	@ LABORATOIRE HRA	0.075MG	N017031	001		Jun	CAHN

NYSTATIN

CREAM;TOPICAL

NYSTATIN

AT	G AND W LABS INC	100,000 UNITS/GM	A061966	001		Jun	CMFD

SUSPENSION;ORAL

NYSTATIN

AA	G AND W LABS INC	100,000 UNITS/ML	A062349	001	Jul 14, 1982	Apr	CAHN
	@	100,000 UNITS/ML	A062776	001	Dec 17, 1987	Apr	CAHN

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062367	001	May 28, 1985	Mar	CMFD

OINTMENT;TOPICAL

MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 09, 1987	Mar	CMFD

OFLOXACIN

TABLET;ORAL

OFLOXACIN

AB	LARKEN LABS	400MG	A076093	003	Sep 02, 2003	Jul	CMFD

OLANZAPINE

TABLET;ORAL

OLANZAPINE

AB	IVAX PHARMS INC	20MG	A077301	001	Apr 29, 2015	Apr	NEWA

TABLET, ORALLY DISINTEGRATING;ORAL

OLANZAPINE

AB	MACLEODS PHARMS LTD	5MG	A203044	001	Feb 20, 2015	Feb	NEWA
AB		10MG	A203044	002	Feb 20, 2015	Feb	NEWA
AB		15MG	A203044	003	Feb 20, 2015	Feb	NEWA
AB		20MG	A203044	004	Feb 20, 2015	Feb	NEWA
AB	ORCHID HLTHCARE	5MG	A202937	001	Mar 02, 2015	Feb	NEWA
AB		10MG	A202937	002	Mar 02, 2015	Feb	NEWA
AB		15MG	A202937	003	Mar 02, 2015	Feb	NEWA
AB		20MG	A202937	004	Mar 02, 2015	Feb	NEWA

OLAPARIB

CAPSULE;ORAL

LYNPARZA

	ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Jan	CTNA

OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE

SPRAY, METERED;INHALATION

STIOLTO RESPIMAT

	+ BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH;EQ 0.0025MG BASE/INH	N206756	001	May 21, 2015	May	NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OLOPATADINE HYDROCHLORIDE

AT	BARR LABS INC	EQ 0.2% BASE	A090848	001	Jul 13, 2015	Jun	NEWA

PATADAY

AT	+ ALCON PHARMS LTD	EQ 0.2% BASE	N021545	001	Dec 22, 2004	Jun	CFTG

		SOLUTION/DROPS;OPHTHALMIC						
		PAZEO						
	+	ALCON RES LTD	EQ 0.7% BASE	N206276	001	Jan 30, 2015	Jan NEWA	
		OMBITASVIR; PARITAPREVIR; RITONAVIR						
		TABLET;ORAL						
		TECHNIVIE						
>D>	+	ABBVIE INC	12.5MG;75MG;50MG	N207931	001	Jul 25, 2015	Aug CMS1	
>A>	+		12.5MG;75MG;50MG	N207931	001	Jul 24, 2015	Aug CMS1	
	+		12.5MG;75MG;50MG	N207931	001	Jul 25, 2015	Jul NEWA	
		OMEPRAZOLE						
		CAPSULE, DELAYED REL PELLETS;ORAL						
		OMEPRAZOLE						
>A>	AB	AUROBINDO PHARMA USA	10MG	A203270	001	Aug 19, 2015	Aug NEWA	
>A>	AB		20MG	A203270	002	Aug 19, 2015	Aug NEWA	
>A>	AB		40MG	A203270	003	Aug 19, 2015	Aug NEWA	
>A>	AB	LUPIN LTD	40MG	A202384	001	Aug 25, 2015	Aug NEWA	
		ONDANSETRON						
		TABLET, ORALLY DISINTEGRATING;ORAL						
		ONDANSETRON						
	AB	SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Apr CAHN	
	AB		8MG	A078602	002	Feb 24, 2011	Apr CAHN	
		ZOFRAN ODT						
	AB	NOVARTIS PHARMS CORP	4MG	N020781	001	Jan 27, 1999	Mar CAHN	
	AB	+	8MG	N020781	002	Jan 27, 1999	Mar CAHN	
		ONDANSETRON HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		ONDANSETRON HYDROCHLORIDE						
	AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206846	001	Jul 13, 2015	Jun NEWA	
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078288	001	Feb 22, 2013	Apr CAHN	
	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077365	001	Dec 26, 2006	Jun CAHN	
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
	AP	CLARIS PHARMASERVICE	EQ 2MG BASE/ML	A078287	001	Feb 22, 2013	Apr CAHN	
	AP	EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077541	001	Dec 26, 2006	Jun CAHN	
		@ TARO PHARMS IRELAND	EQ 2MG BASE/ML	A078014	001	Mar 21, 2008	Jan DISC	
		ZOFRAN						
	AP	+ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	001	Jan 04, 1991	Mar CAHN	
		ZOFRAN PRESERVATIVE FREE						
	AP	+ NOVARTIS PHARMS CORP	EQ 2MG BASE/ML	N020007	003	Dec 10, 1993	Mar CAHN	
		SOLUTION;ORAL						
		ZOFRAN						
	AA	+ NOVARTIS PHARMS CORP	EQ 4MG BASE/5ML	N020605	001	Jan 24, 1997	Mar CAHN	
		TABLET;ORAL						
		ZOFRAN						
	AB	NOVARTIS PHARMS CORP	EQ 4MG BASE	N020103	001	Dec 31, 1992	Mar CAHN	
	AB		EQ 8MG BASE	N020103	002	Dec 31, 1992	Mar CAHN	
	AB	+	EQ 24MG BASE	N020103	003	Aug 27, 1999	Mar CAHN	
		ORPHENADRINE CITRATE						
		INJECTABLE;INJECTION						
		NORFLEX						
		@ IGI LABS INC	30MG/ML	N013055	001		Apr CAHN	
		@ MEDICIS	30MG/ML	N013055	001		Mar DISC	
		ORPHENADRINE CITRATE						
	AP	+ AKORN	30MG/ML	A040484	001	May 24, 2006	Mar CRLD	
		OXACILLIN SODIUM						
		CAPSULE;ORAL						
		OXACILLIN SODIUM						
>A>		@ ANI PHARMS INC	EQ 250MG BASE	A062222	001		Aug CAHN	
>A>		@	EQ 500MG BASE	A062222	002		Aug CAHN	
>D>		@ TEVA	EQ 250MG BASE	A062222	001		Aug CAHN	
>D>		@	EQ 500MG BASE	A062222	002		Aug CAHN	

OXANDROLONE

TABLET;ORAL

OXANDRIN

>D>	AB		CREALTA PHARMS LLC	2.5MG	N013718	001		Aug CAHN
>D>	AB	+		10MG	N013718	002	Nov 05, 2001	Aug CAHN
>A>	AB		GEMINI LABS LLC	2.5MG	N013718	001		Aug CAHN
>A>	AB	+		10MG	N013718	002	Nov 05, 2001	Aug CAHN

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

	AB		SUN PHARM INDS LTD	300MG/5ML	A078734	001	Jun 26, 2009	Apr CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL

	AB	+	ACTAVIS LABS UT INC	3.9MG/24HR	N021351	002	Feb 26, 2003	Mar CAHN

GEL, METERED;TRANSDERMAL

GELNIQUE 3%

		+	ACTAVIS LABS UT INC	3%	N202513	001	Dec 07, 2011	Mar CAHN

OXYBUTYNIN CHLORIDE

GEL;TRANSDERMAL

GELNIQUE

		+	ACTAVIS LABS UT INC	10%(100MG/PACKET)	N022204	001	Jan 27, 2009	Mar CAHN

OXYCODONE HYDROCHLORIDE

CAPSULE;ORAL

OXYCODONE HYDROCHLORIDE

>A>	AB		AVANTHI INC	5MG	A202773	001	Aug 17, 2015	Aug NEWA
>A>	AB		NOVEL LABS INC	5MG	A204752	001	Aug 24, 2015	Aug NEWA

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

	AA		ANI PHARMS INC	5MG/5ML	A204979	001	Jun 01, 2015	May NEWA
	AA		NOVEL LABS INC	100MG/5ML	A204603	001	Apr 29, 2015	Apr NEWA
	AA		WOCKHARDT BIO AG	5MG/5ML	A206456	001	Jun 16, 2015	Jun NEWA

TABLET;ORAL

OXAYDO

			ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	Mar CTNA
				7.5MG	N202080	002	Jun 17, 2011	Mar CTNA
			EGALET LTD	5MG	N202080	001	Jun 17, 2011	May CAHN
				7.5MG	N202080	002	Jun 17, 2011	May CAHN
			EGALET US INC	5MG	N202080	001	Jun 17, 2011	Jul CAHN
				7.5MG	N202080	002	Jun 17, 2011	Jul CAHN

OXYCODONE HYDROCHLORIDE

	AB		ACTAVIS ELIZABETH	5MG	A076636	003	Apr 07, 2015	Mar NEWA
	AB		VINTAGE PHARMS	10MG	A077712	004	Apr 13, 2015	Mar NEWA
	AB			20MG	A077712	005	Apr 13, 2015	Mar NEWA

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OXYMORPHONE HYDROCHLORIDE

	AB		SUN PHARM INDS LTD	5MG	A203506	001	Apr 24, 2015	Apr NEWA
	AB			7.5MG	A203506	002	Apr 24, 2015	Apr NEWA
	AB			10MG	A203506	003	Apr 24, 2015	Apr NEWA
	AB			15MG	A203506	004	Apr 24, 2015	Apr NEWA
	AB			20MG	A203506	005	Apr 24, 2015	Apr NEWA
	AB			30MG	A203506	006	Apr 24, 2015	Apr NEWA
	AB			40MG	A203506	007	Apr 24, 2015	Apr NEWA

OXYTOCIN

INJECTABLE;INJECTION

OXYTOCIN

	AP	+	EUROHLTH INTL SARL	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		Feb CAHN
	AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	Feb CAHN

PALBOCICLIB

CAPSULE;ORAL

IBRANCE

	PFIZER INC	75MG	N207103	001	Feb 03, 2015	Feb	NEWA
		100MG	N207103	002	Feb 03, 2015	Feb	NEWA
+		125MG	N207103	003	Feb 03, 2015	Feb	NEWA

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL

INVEGA

AB	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Jul	CFTG
AB		3MG	N021999	001	Dec 19, 2006	Jul	CFTG
AB	+	6MG	N021999	002	Dec 19, 2006	Jul	CFTG
AB		9MG	N021999	003	Dec 19, 2006	Jul	CFTG

PALIPERIDONE

AB	ACTAVIS LABS FL INC	1.5MG	A202645	001	Aug 03, 2015	Jul	NEWA
AB		3MG	A202645	002	Aug 03, 2015	Jul	NEWA
AB		6MG	A202645	003	Aug 03, 2015	Jul	NEWA
AB		9MG	A202645	004	Aug 03, 2015	Jul	NEWA

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

INVEGA TRINZA

	JANSSEN PHARMS	273MG/0.875ML (273MG/0.875ML)	N207946	001	May 18, 2015	May	NEWA
		410MG/1.315ML (311.79MG/ML)	N207946	002	May 18, 2015	May	NEWA
		546MG/1.75ML (312MG/ML)	N207946	003	May 18, 2015	May	NEWA
+		819MG/2.625ML (312MG/ML)	N207946	004	May 18, 2015	May	NEWA

PANCURONIUM BROMIDE

INJECTABLE;INJECTION

PANCURONIUM BROMIDE

@	IGI LABS INC	1MG/ML	A072210	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072211	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072212	001	Mar 31, 1988	Mar	CAHN
@		2MG/ML	A072213	001	Mar 31, 1988	Mar	CAHN

PANOBINOSTAT

CAPSULE;ORAL

FARYDAK

	NOVARTIS PHARMS CORP	10MG	N205353	001	Feb 23, 2015	Feb	NEWA
		15MG	N205353	002	Feb 23, 2015	Feb	NEWA
+		20MG	N205353	003	Feb 23, 2015	Feb	NEWA

PANOBINOSTAT LACTATE

CAPSULE;ORAL

FARYDAK

	NOVARTIS PHARMS CORP	EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar	CAIN
		EQ 10MG BASE	N205353	001	Feb 23, 2015	Mar	CPOT
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CAIN
		EQ 15MG BASE	N205353	002	Feb 23, 2015	Mar	CPOT
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CAIN
+		EQ 20MG BASE	N205353	003	Feb 23, 2015	Mar	CPOT

PANTOPRAZOLE SODIUM

INJECTABLE;IV (INFUSION)

PANTOPRAZOLE SODIUM

AP	SANDOZ INC	EQ 40MG BASE/VIAL	A090296	001	Jul 14, 2015	Jun	NEWA

TABLET, DELAYED RELEASE;ORAL

PANTOPRAZOLE SODIUM

AB	KREMERS URBAN PHARMS	EQ 20MG BASE	A078281	001	Jan 20, 2011	Mar	CAHN
AB		EQ 40MG BASE	A078281	002	Jan 20, 2011	Mar	CAHN
AB	SUN PHARM INDS LTD	EQ 20MG BASE	A200794	001	May 02, 2012	Apr	CAHN
AB		EQ 40MG BASE	A200794	002	May 02, 2012	Apr	CAHN

PARICALCITOL

CAPSULE;ORAL

PARICALCITOL

AB	BANNER LIFE SCIENCES	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL

VOTRIENT

	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N022465	001	Oct 19, 2009	Mar	CAHN
>D>			EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug	DISC
>A>	@		EQ 400MG BASE	N022465	002	Oct 19, 2009	Aug	DISC
			EQ 400MG BASE	N022465	002	Oct 19, 2009	Mar	CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB		VALEANT PHARMS	400MG	A075028	001	Jul 20, 1998	Feb	CAHN

PHENDIMETRAZINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL

BONTRIL

	@	VALEANT	105MG	A088021	001	Sep 21, 1982	Jan	DISC

PHENDIMETRAZINE TARTRATE

	+	SANDOZ	105MG	N018074	001		Jan	CTEC

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE;ORAL

DIBENZYLINE

AB	+	CONCORDIA PHARMS INC	10MG	N008708	001		Jun	CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA		MIKAH PHARMA LLC	37.5MG	A040228	001	Jun 19, 1997	Jun	CMFD

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

		AKORN INC	2.5%	N207926	001	Jan 15, 2015	Jan	NEWA
			10%	N207926	002	Jan 15, 2015	Jan	NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH VC PLAIN

AA	+	G AND W LABS INC	5MG/5ML;6.25MG/5ML	A088761	001	Nov 08, 1984	Jul	CAHN

PHENYTOIN SODIUM

CAPSULE;ORAL

EXTENDED PHENYTOIN SODIUM

	@	WOCKHARDT	30MG EXTENDED	A040759	001	Dec 18, 2007	Jun	DISC
	@	WOCKHARDT USA	100MG EXTENDED	A040732	001	Jan 30, 2008	Jun	DISC

PHENYTOIN SODIUM

AB		AUROBINDO PHARMA LTD	100MG EXTENDED	A204309	001	Jun 10, 2015	May	NEWA

INJECTABLE;INJECTION

PHENYTOIN SODIUM

AP	+	EUROHLTH INTL SARL	50MG/ML	A084307	001		Feb	CAHN

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

	@	IGI LABS INC	1MG/0.5ML	N012223	002		Apr	CAHN
	@		10MG/ML	N012223	001		Apr	CAHN

PILOCARPINE HYDROCHLORIDE

GEL;OPHTHALMIC

PILOPINE HS

>D>	+	ALCON	4%	N018796	001	Oct 01, 1984	Aug	DISC
>A>	@		4%	N018796	001	Oct 01, 1984	Aug	DISC

TABLET;ORAL

PILOCARPINE HYDROCHLORIDE

AB		ELAN PHARMA INTL LTD	5MG	A076746	001	Nov 16, 2004	Mar	CAHN

PINDOLOL

TABLET;ORAL

PINDOLOL

	@ G AND W LABS INC	5MG	A073661	001	Oct 31, 1993	Apr	CAHN
	@	5MG	A073687	001	Feb 26, 1993	Apr	CAHN
	@	5MG	A074123	001	Apr 17, 1997	Apr	CAHN
	@	10MG	A073661	002	Oct 31, 1993	Apr	CAHN
	@	10MG	A073687	002	Feb 26, 1993	Apr	CAHN
	@	10MG	A074123	002	Apr 17, 1997	Apr	CAHN

PIRBUTEROL ACETATE

AEROSOL, METERED;INHALATION

MAXAIR

	@ MEDICIS	EQ 0.2MG BASE/INH	N020014	001	Nov 30, 1992	Jan	DISC

PIRFENIDONE

CAPSULE;ORAL

ESBRIET

	+ GENENTECH INC	267MG	N022535	001	Oct 15, 2014	Feb	CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	MYLAN PHARMS INC	10MG	A074116	001	Jun 15, 1993	May	CAHN
AB		20MG	A074118	001	Jun 15, 1993	May	CAHN

PODOFILOX

GEL;TOPICAL

CONDYLOX

	+ ACTAVIS LABS UT INC	0.5%	N020529	001	Mar 13, 1997	Feb	CAHN

SOLUTION;TOPICAL

CONDYLOX

AT	+ ACTAVIS LABS UT INC	0.5%	N019795	001	Dec 13, 1990	Jan	CAHN

PODOFILOX

AT	BAUSCH AND LOMB INC	0.5%	A090184	001	Jul 21, 2010	May	CAHN

POLYMYXIN B SULFATE; TRIMETHOPRIM SULFATE

SOLUTION/DROPS;OPHTHALMIC

TRIMETHOPRIM SULFATE AND POLYMYXIN B SULFATE

AT	ALCON RES LTD	10,000 UNITS/ML;EQ 1MG BASE/ML	A064211	001	Apr 13, 1998	Jan	CAHN

PONATINIB HYDROCHLORIDE

TABLET;ORAL

ICLUSIG

	ARIAD	EQ 30MG BASE	N203469	003	Apr 23, 2015	Apr	NEWA

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

KLOR-CON

AB	UPSHER SMITH	8MEQ	A203106	001	Jul 10, 2015	Jun	NEWA
AB		10MEQ	A203106	002	Jul 10, 2015	Jun	NEWA

>A> FOR SOLUTION;ORAL

>A> POTASSIUM CHLORIDE

>A>	PHARMA RES SOFTWARE	20MEQ	N208019	001	Aug 19, 2015	Aug	NEWA

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CHLORIDE

AB1	ADARE PHARMS INC	20MEQ	A076368	001	Aug 18, 2004	Jul	CAHN
AB2	MYLAN PHARMS INC	8MEQ	A204662	001	Aug 21, 2014	Feb	CPOT
AB2		10MEQ	A204662	002	Aug 21, 2014	Feb	CPOT

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

>A> AB	GLENMARK GENERICS	0.75MG	A090781	006	Sep 11, 2015	Aug	NEWA

TABLET, EXTENDED RELEASE;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	DR REDDYS LABS LTD	0.375MG	A203354	001	Aug 07, 2015	Jul	NEWA
AB		0.75MG	A203354	002	Aug 07, 2015	Jul	NEWA
AB		1.5MG	A203354	003	Aug 07, 2015	Jul	NEWA
AB		3MG	A203354	004	Aug 07, 2015	Jul	NEWA

		TABLET, EXTENDED RELEASE;ORAL						
		PRAMIPEXOLE DIHYDROCHLORIDE						
	AB		4.5MG	A203354	005	Aug 07, 2015	Jul	NEWA
		PREDNICARBATE						
		OINTMENT;TOPICAL						
		DERMATOP						
	AB	+ VALEANT PHARMS NORTH	0.1%	N019568	001	Sep 23, 1991	Apr	CAHN
		PREDNISONE						
		TABLET;ORAL						
		PREDNISONE						
>D>	AB	HIKMA PHARMS	1MG	A040890	001	Nov 01, 2010	Aug	DISC
>A>		@	1MG	A040890	001	Nov 01, 2010	Aug	DISC
		PREGABALIN						
		CAPSULE;ORAL						
		LYRICA						
		PF PRISM CV	25MG	N021446	001	Dec 30, 2004	Apr	CTEC
			50MG	N021446	002	Dec 30, 2004	Apr	CTEC
			75MG	N021446	003	Dec 30, 2004	Apr	CTEC
			100MG	N021446	004	Dec 30, 2004	Apr	CTEC
			150MG	N021446	005	Dec 30, 2004	Apr	CTEC
			200MG	N021446	006	Dec 30, 2004	Apr	CTEC
			225MG	N021446	007	Dec 30, 2004	Apr	CTEC
		+	300MG	N021446	008	Dec 30, 2004	Apr	CTEC
		PROCAINAMIDE HYDROCHLORIDE						
		CAPSULE;ORAL						
		PROCAINAMIDE HYDROCHLORIDE						
		@ IDT AUSTRALIA LTD	250MG	A089219	001	Jul 01, 1986	Jun	CAHN
		@	500MG	A089221	001	Jul 01, 1986	Jun	CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		PROCAINAMIDE HYDROCHLORIDE						
		@ IDT AUSTRALIA LTD	250MG	A089369	001	Aug 14, 1987	Jun	CAHN
		@	500MG	A089370	001	Jan 09, 1987	Jun	CAHN
		@	750MG	A089371	001	Aug 14, 1987	Jun	CAHN
		PROCHLORPERAZINE EDISYLATE						
		INJECTABLE;INJECTION						
		PROCHLORPERAZINE EDISYLATE						
	AP	+ EUROHLTH INTL SARL	EQ 5MG BASE/ML	A089903	001	Aug 29, 1989	Feb	CAHN
		PROGESTERONE						
		CAPSULE;ORAL						
		PROGESTERONE						
	AB	BANNER LIFE SCIENCES	100MG	A200900	001	Aug 16, 2013	Jan	CAHN
	AB		200MG	A200900	002	Aug 16, 2013	Jan	CAHN
		GEL;VAGINAL						
		CRINONE						
		ACTAVIS LABS UT INC	4%	N020701	001	Jul 31, 1997	Feb	CAHN
		+	8%	N020701	002	Jul 31, 1997	Feb	CAHN
		INJECTABLE;INJECTION						
		PROGESTERONE						
	AO	+ ACTAVIS LABS UT INC	50MG/ML	N017362	002		Mar	CAHN
		PROMETHAZINE HYDROCHLORIDE						
		INJECTABLE;INJECTION						
		PROMETHAZINE HYDROCHLORIDE						
	AP	+ EUROHLTH INTL SARL	25MG/ML	A083312	001		Jun	CAHN
	AP	+	50MG/ML	A083312	002		Jun	CAHN
		SUPPOSITORY;RECTAL						
		PHENERGAN						
		@ DELCOR ASSET CORP	12.5MG	N010926	002		Apr	CAHN
		@	25MG	N010926	001		Apr	CAHN
		TABLET;ORAL						
		PROMETHAZINE HYDROCHLORIDE						
	AB	HERITAGE PHARMA	12.5MG	A040673	001	Mar 05, 2008	Mar	CAHN
	AB		25MG	A040673	002	Mar 05, 2008	Mar	CAHN
	AB		50MG	A040673	003	Mar 05, 2008	Mar	CAHN

PROPAFENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

PROPAFENONE HYDROCHLORIDE

>A>	AB		WATSON LABS INC	225MG	A202688	001	Aug 24, 2015	Aug NEWA
>A>	AB			325MG	A202688	002	Aug 24, 2015	Aug NEWA
>A>	AB			425MG	A202688	003	Aug 24, 2015	Aug NEWA

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

>A>		@	ANI PHARMS INC	30MG	A040512	002	Jul 20, 2005	Aug CAHN
>A>		@		60MG	A040512	001	Oct 08, 2003	Aug CAHN
>D>		@	BARR	30MG	A040512	002	Jul 20, 2005	Aug CAHN
>D>		@		60MG	A040512	001	Oct 08, 2003	Aug CAHN
	AB		ZYDUS PHARMS USA INC	60MG	A205650	001	Jun 22, 2015	Jun NEWA

TABLET, EXTENDED RELEASE;ORAL

MESTINON

	AB	+	VALEANT PHARMS LLC	180MG	N011665	001		Jun CFTG

PYRIDOSTIGMINE BROMIDE

	AB		ALVOGEN INC	180MG	A204737	001	Jun 26, 2015	Jun NEWA
>A>	AB		IMPAX LABS INC	180MG	A203184	001	Sep 15, 2015	Aug NEWA

PYRIMETHAMINE

TABLET;ORAL

DARAPRIM

>D>		+	AMEDRA PHARMS	25MG	N008578	001		Aug CAHN
>A>		+	TURING PHARMS AG	25MG	N008578	001		Aug CAHN

QUAZEPAM

TABLET;ORAL

DORAL

		@	SCIECURE PHARMA INC	15MG	N018708	001	Dec 27, 1985	Jun DISC

QUETIAPINE FUMARATE

TABLET;ORAL

SEROQUEL

	AB	+	ASTRAZENECA PHARMS	EQ 25MG BASE	N020639	001	Sep 26, 1997	May CAHN
	AB			EQ 50MG BASE	N020639	007	Oct 04, 2005	May CAHN
	AB			EQ 100MG BASE	N020639	002	Sep 26, 1997	May CAHN
		@		EQ 150MG BASE	N020639	004	Dec 20, 1998	May CAHN
	AB			EQ 200MG BASE	N020639	003	Sep 26, 1997	May CAHN
	AB	+		EQ 300MG BASE	N020639	005	Jul 26, 2000	May CAHN
	AB			EQ 400MG BASE	N020639	006	Oct 04, 2005	May CAHN

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

	AB		SUN PHARM INDS LTD	EQ 5MG BASE	A076607	001	Dec 15, 2004	Apr CAHN
	AB			EQ 10MG BASE	A076607	002	Dec 15, 2004	Apr CAHN
	AB			EQ 20MG BASE	A076607	003	Dec 15, 2004	Apr CAHN
	AB			EQ 40MG BASE	A076607	004	Dec 15, 2004	Apr CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE GLUCONATE

		@	CYCLE PHARMS LTD	324MG	A088431	001	Jan 06, 1984	Jun CAHN

QUINIDINE SULFATE

TABLET;ORAL

QUINIDINE SULFATE

		@	CYCLE PHARMS LTD	200MG	A083640	001		Jun CAHN
		@		300MG	A085632	001		Jun CAHN

TABLET, EXTENDED RELEASE;ORAL

QUINIDINE SULFATE

		+	G AND W LABS INC	300MG	A040045	001	Jun 30, 1994	Apr CAHN

QUININE SULFATE

CAPSULE;ORAL

QUININE SULFATE

AB	AMNEAL PHARMS	324MG	A203729	001	Jul 15, 2015	Jun	NEWA
AB	LUPIN LTD	324MG	A203112	001	Apr 24, 2015	Apr	NEWA
AB	RICONPHARMA LLC	324MG	A204372	001	Jul 22, 2015	Jul	NEWA

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

RABEPRAZOLE SODIUM

AB	AMNEAL PHARMS	20MG	A204179	001	Jul 31, 2015	Jul	NEWA

RALOXIFENE HYDROCHLORIDE

TABLET;ORAL

RALOXIFENE HYDROCHLORIDE

>A> AB	AUROBINDO PHARMA LTD	60MG	A204310	001	Aug 28, 2015	Aug	NEWA
AB	WATSON LABS INC	60MG	A200825	001	Jan 21, 2015	Jan	NEWA

RAMELTEON

TABLET;ORAL

RAMELTEON

>A> AB	ACTAVIS LABS FL INC	8MG	A091610	001	Aug 19, 2015	Aug	NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE;INJECTION

ZANTAC

AP	+ CONCORDIA PHARMS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jun	CAHN

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

	@ SUN PHARM INDS LTD	EQ 150MG BASE	A075439	001	Apr 19, 2000	Apr	CAHN
	@	EQ 300MG BASE	A075439	002	Apr 19, 2000	Apr	CAHN

REPAGLINIDE

TABLET;ORAL

REPAGLINIDE

AB	STANDARD CHEM PHARM	0.5MG	A091517	001	Apr 24, 2015	Apr	NEWA
AB		1MG	A091517	002	Apr 24, 2015	Apr	NEWA
AB		2MG	A091517	003	Apr 24, 2015	Apr	NEWA

RIBAVIRIN

CAPSULE;ORAL

REBETOL

	@ MERCK SHARP DOHME	200MG	N020903	001	Jun 03, 1998	Jun	DISC

RISEDRONATE SODIUM

TABLET, DELAYED RELEASE;ORAL

ATELVIA

AB	+ WARNER CHILCOTT LLC	35MG	N022560	001	Oct 08, 2010	May	CFTG

RISEDRONATE SODIUM

AB	TEVA PHARMS USA	35MG	A203217	001	May 18, 2015	May	NEWA

RISPERIDONE

TABLET, ORALLY DISINTEGRATING;ORAL

RISPERIDONE

AB	SUN PHARM INDS LTD	0.5MG	A077542	001	Aug 06, 2010	Apr	CAHN
AB		1MG	A077542	002	Aug 06, 2010	Apr	CAHN
AB		2MG	A077542	003	Aug 06, 2010	Apr	CAHN
AB		3MG	A078474	001	Aug 06, 2010	Apr	CAHN
AB		4MG	A078474	002	Aug 06, 2010	Apr	CAHN

RIVAROXABAN

TABLET;ORAL

XARELTO

	JANSSEN PHARMS	10MG	N022406	001	Jul 01, 2011	Apr	CRLD

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

EXELON

>D>		NOVARTIS	4.6MG/24HR	N022083	001	Jul 06, 2007	Aug	CFTG
>A>	AB		4.6MG/24HR	N022083	001	Jul 06, 2007	Aug	CFTG
>D>	+		9.5MG/24HR	N022083	002	Jul 06, 2007	Aug	CFTG
>A>	AB +		9.5MG/24HR	N022083	002	Jul 06, 2007	Aug	CFTG
>D>			13.3MG/24HR	N022083	005	Aug 31, 2012	Aug	CFTG
>A>	AB		13.3MG/24HR	N022083	005	Aug 31, 2012	Aug	CFTG

RIVASTIGMINE

>A>	AB	ALVOGEN INC	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug	NEWA
>A>	AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Aug	NEWA
>A>	AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Aug	NEWA
>A>	AB	ALVOGEN PINE BROOK	4.6MG/24HR	A204403	001	Sep 03, 2015	Aug	CAHN
>A>	AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Aug	CAHN
>A>	AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Aug	CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL

RIVASTIGMINE TARTRATE

	AB	ORCHID HLTHCARE	EQ 1.5MG BASE	A090879	001	Jun 10, 2015	May	NEWA
	AB		EQ 3MG BASE	A090879	002	Jun 10, 2015	May	NEWA
	AB		EQ 4.5MG BASE	A090879	003	Jun 10, 2015	May	NEWA
	AB		EQ 6MG BASE	A090879	004	Jun 10, 2015	May	NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION

ROCURONIUM BROMIDE

>A>	AP	SAGENT PHARMS	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug	CAHN
>A>	AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug	CAHN
>D>	AP	SAGENT STRIDES	50MG/5ML (10MG/ML)	A091458	001	Jul 28, 2010	Aug	CAHN
>D>	AP		100MG/10ML (10MG/ML)	A091458	002	Jul 28, 2010	Aug	CAHN

ROFLUMILAST

TABLET;ORAL

DALIRESP

	+	ASTRAZENECA PHARMS	500MCG	N022522	001	Feb 28, 2011	Mar	CAHN

ROPINIROLE HYDROCHLORIDE

TABLET;ORAL

ROPINIROLE HYDROCHLORIDE

	AB	G AND W LABS INC	EQ 0.25MG BASE	A077460	001	May 05, 2008	Apr	CAHN
	AB		EQ 0.5MG BASE	A077460	002	May 05, 2008	Apr	CAHN
	AB		EQ 1MG BASE	A077460	003	May 05, 2008	Apr	CAHN
	AB		EQ 2MG BASE	A077460	004	May 05, 2008	Apr	CAHN
	AB		EQ 3MG BASE	A077460	005	May 05, 2008	Apr	CAHN
	AB		EQ 4MG BASE	A077460	006	May 05, 2008	Apr	CAHN
	AB		EQ 5MG BASE	A077460	007	May 19, 2008	Apr	CAHN

SACUBITRIL; VALSARTAN

TABLET;ORAL

ENTRESTO

		NOVARTIS PHARMS CORP	24MG;26MG	N207620	001	Jul 07, 2015	Jul	NEWA
			49MG;51MG	N207620	002	Jul 07, 2015	Jul	NEWA
	+		97MG;103MG	N207620	003	Jul 07, 2015	Jul	NEWA

SCOPOLAMINE

FILM, EXTENDED RELEASE;TRANSDERMAL

SCOPOLAMINE

	AB	PERRIGO PHARMS CO	1MG/72HR	A078830	001	Jan 30, 2015	Mar	CAHN
	AB	PERRIGO R AND D	1MG/72HR	A078830	001	Jan 30, 2015	Jan	NEWA

TRANSDERM SCOP

	AB +	NOVARTIS	1MG/72HR	N017874	001		Jan	CFTG

SELEGILINE HYDROCHLORIDE

TABLET;ORAL

SELEGILINE HYDROCHLORIDE

	@	G AND W LABS INC	5MG	A074537	001	Aug 02, 1996	Apr	CAHN
	@		5MG	A074744	001	Jan 27, 1997	Apr	CAHN
	@		5MG	A074756	001	Nov 25, 1998	Apr	CAHN

SERTRALINE HYDROCHLORIDE

TABLET;ORAL

SERTRALINE HYDROCHLORIDE

	@	HIKMA PHARMS	EQ 25MG BASE	A077864	001	Aug 10, 2009	May	DISC
	@		EQ 50MG BASE	A077864	002	Aug 10, 2009	May	DISC
	@		EQ 100MG BASE	A077864	003	Aug 10, 2009	May	DISC
AB		SUN PHARM INDS LTD	EQ 25MG BASE	A077977	001	Feb 06, 2007	Apr	CAHN
AB			EQ 50MG BASE	A077977	002	Feb 06, 2007	Apr	CAHN
AB			EQ 100MG BASE	A077977	003	Feb 06, 2007	Apr	CAHN
			EQ 150MG BASE	A077977	004	Feb 06, 2007	Apr	CAHN
			EQ 200MG BASE	A077977	005	Feb 06, 2007	Apr	CAHN

SILDENAFIL CITRATE

SOLUTION;INTRAVENOUS

REVATIO

AP	+	PFIZER	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	N022473	001	Nov 18, 2009	Mar	CFTG

SILDENAFIL CITRATE

AP		AUROBINDO PHARMA LTD	EQ 10MG BASE/12.5ML (EQ 0.8MG BASE/ML)	A203988	001	Apr 01, 2015	Mar	NEWA

SILODOSIN

CAPSULE;ORAL

RAPAFLO

	+	ACTAVIS LABS UT INC	4MG	N022206	001	Oct 08, 2008	Mar	CAHN
			8MG	N022206	002	Oct 08, 2008	Mar	CAHN

SIMVASTATIN

TABLET;ORAL

SIMVASTATIN

AB		SUN PHARM INDS LTD	5MG	A076285	001	Dec 20, 2006	Apr	CAHN
AB			10MG	A076285	002	Dec 20, 2006	Apr	CAHN
AB			20MG	A076285	003	Dec 20, 2006	Apr	CAHN
AB			40MG	A076285	004	Dec 20, 2006	Apr	CAHN
AB			80MG	A076285	005	Jun 23, 2006	Apr	CAHN

SODIUM CHLORIDE

INJECTABLE;INJECTION

SODIUM CHLORIDE 0.9%

AP		EUROHLTH INTL SARL	9MG/ML	A201850	001	Jan 20, 2012	Feb	CAHN

SODIUM CHLORIDE 0.9%

		EUROHLTH INTL SARL	9MG/ML	A201833	001	Sep 24, 2013	Feb	CAHN

SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	+	LIEBEL-FLARSHEIM	45MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb	CAHN
			112.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb	CAHN
	+		405MG/50ML (9MG/ML)	N021569	001	Jul 27, 2006	Feb	CPOT
			1012.5MG/125ML (9MG/ML)	N021569	002	Jul 27, 2006	Feb	CPOT

SODIUM FERRIC GLUCONATE COMPLEX

INJECTABLE;INJECTION

SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE

AB		EUROHLTH INTL SARL	62.5MG/5ML	A078215	001	Mar 31, 2011	Jun	CAHN

SODIUM FLUORIDE F-18

INJECTABLE;INTRAVENOUS

SODIUM FLUORIDE F-18

AP		CARDINAL HEALTH 414	10-200mCi/ML	A203780	001	Jul 30, 2015	Jul	NEWA
AP		HOT SHOTS NM LLC	10-200mCi/ML	A204530	001	Jul 29, 2015	Jul	NEWA
>A> AP		IBA MOLECULAR N AM	10-200mCi/ML	A203592	001	Aug 18, 2015	Aug	NEWA
AP		MIPS CRF	10-200mCi/ML	A204517	001	Jul 21, 2015	Jul	NEWA
AP		PRECISION NUCLEAR	10-200mCi/ML	A204542	001	Feb 27, 2015	Feb	NEWA
AP		SPECTRON MRC LLC	10-200mCi/ML	A203912	001	Apr 22, 2015	Apr	NEWA
AP		UNIV UTAH CYCLOTRON	10-200mCi/ML	A204497	001	Apr 20, 2015	Apr	NEWA

SODIUM IODIDE I-123

CAPSULE;ORAL

SODIUM IODIDE I 123

AA	+	CARDINAL HEALTH 418	100uCi	N018671	001	May 27, 1982	Apr	CAHN
AA	+		200uCi	N018671	002	May 27, 1982	Apr	CAHN
	@		400uCi	N018671	003	May 27, 1982	Apr	CAHN

SODIUM POLYSTYRENE SULFONATE

		POWDER;ORAL, RECTAL						
		KALEXATE						
		KVK TECH	15GM/BOT	A040905	002	Apr 03, 2015	Mar	NEWA
		KAYEXALATE						
AA	+	CONCORDIA PHARMS INC	453.6GM/BOT	N011287	001		Apr	CAHN

SODIUM TETRADECYL SULFATE

		INJECTABLE;INJECTION						
		SOTRADECOL						
	+	MYLAN INSTITUTIONAL	20MG/2ML (10MG/ML)	A040541	001	Nov 12, 2004	Jul	CRLD

SOMATROPIN RECOMBINANT

		INJECTABLE;INJECTION						
		NORDITROPIN FLEXPRO						
		NOVO NORDISK INC	30MG/3ML	N021148	011	Jan 23, 2015	Jan	NEWA
		NORDITROPIN NORDIFLEX						
		@ NOVO NORDISK INC	30MG/3ML	N021148	007	Mar 10, 2009	Jul	DISC
			30MG/3ML	N021148	007	Mar 10, 2009	Mar	CMFD
		@	30MG/3ML	N021148	007	Mar 10, 2009	Jan	DISC
		NUTROPIN						
		@ GENENTECH	5MG/VIAL	N020168	001	Nov 17, 1993	Jun	DISC
		@	10MG/VIAL	N020168	002	Nov 17, 1993	Jun	DISC
BX	+		10MG/VIAL	N020168	002	Nov 17, 1993	Mar	CTEC
		NUTROPIN AQ						
		@ GENENTECH	10MG/2ML (5MG/ML)	N020522	001	Dec 29, 1995	Jun	DISC
		NUTROPIN AQ NUSPIN						
	+	GENENTECH	5MG/2ML (2.5MG/ML)	N020522	003	Jan 03, 2008	Jun	CTNA
	+		10MG/2ML (5MG/ML)	N020522	005	Jan 03, 2008	Jun	NEWA
	+		20MG/2ML (10MG/ML)	N020522	004	Jan 03, 2008	Jun	CTNA
		NUTROPIN AQ PEN						
	+	GENENTECH	20MG/2ML (10MG/ML)	N020522	006	Jan 03, 2008	Jun	NEWA
		ZOMACTON						
BX	+	FERRING	5MG/VIAL	N019774	002	Jan 04, 2002	Mar	CTNA
BX			10MG/VIAL	N019774	003	Mar 07, 2012	Apr	CRLD
BX	+		10MG/VIAL	N019774	003	Mar 07, 2012	Mar	NEWA

SONIDEGIB PHOSPHATE

		CAPSULE;ORAL						
		ODOMZO						
	+	NOVARTIS PHARMS CORP	EQ 200MG BASE	N205266	001	Jul 24, 2015	Jul	NEWA

SOTALOL HYDROCHLORIDE

		SOLUTION;INTRAVENOUS						
		SOTALOL HYDROCHLORIDE						
	+	ALTATHERA PHARMS LLC	150MG/10ML (15MG/ML)	N022306	001	Jul 02, 2009	Apr	CAHN
		TABLET;ORAL						
		BETAPACE						
AB1		COVIS PHARMA SARL	80MG	N019865	001	Oct 30, 1992	Mar	CAHN
AB1			120MG	N019865	005	Apr 20, 1994	Mar	CAHN
AB1	+		160MG	N019865	002	Oct 30, 1992	Mar	CAHN
AB1			240MG	N019865	003	Oct 30, 1992	Mar	CAHN
	@		320MG	N019865	004	Oct 30, 1992	Mar	CAHN

STERILE WATER FOR INJECTION

		LIQUID;N/A						
		STERILE WATER FOR INJECTION						
>A>	AP	EUROHLTH INTL SARL	100%	A206369	001	Sep 02, 2015	Aug	NEWA

SUCCINYLCHOLINE CHLORIDE

		INJECTABLE;INJECTION						
		QUELICIN PRESERVATIVE FREE						
		@ HOSPIRA	100MG/ML	N008845	004		Jun	DISC

SUCRALFATE

		TABLET;ORAL						
		SUCRALFATE						
AB		MYLAN PHARMS INC	1GM	A074415	001	Jun 08, 1998	May	CAHN

SUFENTANIL CITRATE

INJECTABLE;INJECTION

SUFENTANIL CITRATE

AP	EUROHLTH INTL SARL	EQ 0.05MG BASE/ML	A074413	001	Dec 15, 1995	Jun	CAHN

SULFACETAMIDE SODIUM

LOTION;TOPICAL

KLARON

AB	+ VALEANT PHARMS NORTH	10%	N019931	001	Dec 23, 1996	Mar	CAHN

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM

AT	AKORN	10%	A040215	001	May 25, 1999	Mar	CMFD

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION;ORAL

SULFAMETHOXAZOLE AND TRIMETHOPRIM

	@ ANI PHARMS INC	200MG/5ML;40MG/5ML	A070028	001	Jun 02, 1987	Jul	CAHN

SULFANILAMIDE

CREAM;VAGINAL

SULFANILAMIDE

	@ G AND W LABS INC	15%	A088718	001	Sep 19, 1985	Apr	CAHN

SULINDAC

TABLET;ORAL

SULINDAC

>A>	@ ANI PHARMS INC	150MG	A072972	001	Feb 28, 1992	Aug	CAHN
>A>	@	200MG	A072973	001	Feb 28, 1992	Aug	CAHN
>D>	@ TEVA	150MG	A072972	001	Feb 28, 1992	Aug	CAHN
>D>	@	200MG	A072973	001	Feb 28, 1992	Aug	CAHN

SUMATRIPTAN SUCCINATE

TABLET;ORAL

SUMATRIPTAN SUCCINATE

AB	SUN PHARM INDS LTD	EQ 25MG BASE	A076554	001	Aug 10, 2009	Apr	CAHN
AB		EQ 50MG BASE	A076554	002	Aug 10, 2009	Apr	CAHN
AB		EQ 100MG BASE	A076572	001	Feb 09, 2009	Apr	CAHN

TACROLIMUS

TABLET, EXTENDED RELEASE;ORAL

ENVARSUS XR

	VELOXIS PHARMS INC	EQ 0.75MG BASE	N206406	001	Jul 10, 2015	Jul	NEWA
		EQ 1MG BASE	N206406	002	Jul 10, 2015	Jul	NEWA
+		EQ 4MG BASE	N206406	003	Jul 10, 2015	Jul	NEWA

TAPENTADOL HYDROCHLORIDE

SOLUTION;ORAL

NUCYNTA

+	DEPOMED INC	EQ 20MG BASE/ML	N203794	001	Oct 15, 2012	May	CAHN

TABLET;ORAL

NUCYNTA

	DEPOMED INC	EQ 50MG BASE	N022304	001	Nov 20, 2008	May	CAHN
		EQ 75MG BASE	N022304	002	Nov 20, 2008	May	CAHN
+		EQ 100MG BASE	N022304	003	Nov 20, 2008	May	CAHN

TABLET, EXTENDED RELEASE;ORAL

NUCYNTA ER

	DEPOMED INC	EQ 50MG BASE	N200533	001	Aug 25, 2011	May	CAHN
		EQ 100MG BASE	N200533	002	Aug 25, 2011	May	CAHN
		EQ 150MG BASE	N200533	003	Aug 25, 2011	May	CAHN
		EQ 200MG BASE	N200533	004	Aug 25, 2011	May	CAHN
+		EQ 250MG BASE	N200533	005	Aug 25, 2011	May	CAHN

TELAPREVIR

TABLET;ORAL

INCIVEK

	@ VERTEX PHARMS	375MG	N201917	001	May 23, 2011	Jan	DISC

TELMISARTAN

TABLET;ORAL

TELMISARTAN

>A>	AB	AMNEAL PHARMS	20MG	A204415	001	Sep 08, 2015	Aug	NEWA
>A>	AB		40MG	A204415	002	Sep 08, 2015	Aug	NEWA
>A>	AB		80MG	A204415	003	Sep 08, 2015	Aug	NEWA
>A>	AB	AUROBINDO PHARMA LTD	20MG	A206511	001	Sep 03, 2015	Aug	NEWA
>A>	AB		40MG	A206511	002	Sep 03, 2015	Aug	NEWA
>A>	AB		80MG	A206511	003	Sep 03, 2015	Aug	NEWA

TEMAZEPAM

CAPSULE;ORAL

TEMAZEPAM

	AB	VINTAGE PHARMS	7.5MG	A201781	001	Jun 04, 2015	May	NEWA
	AB		15MG	A201781	002	Jun 04, 2015	May	NEWA
	AB		22.5MG	A201781	003	Jun 04, 2015	May	NEWA
	AB		30MG	A201781	004	Jun 04, 2015	May	NEWA

TEMOZOLOMIDE

CAPSULE;ORAL

TEMOZOLOMIDE

	AB	AMNEAL PHARMS	5MG	A203691	001	May 08, 2015	Apr	NEWA
	AB		20MG	A203691	002	May 08, 2015	Apr	NEWA
	AB		100MG	A203691	003	May 08, 2015	Apr	NEWA
	AB		140MG	A203691	004	May 08, 2015	Apr	NEWA
	AB		180MG	A203691	005	May 08, 2015	Apr	NEWA
	AB		250MG	A203691	006	May 08, 2015	Apr	NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

	AB	TEVA PHARMS USA	300MG	A091612	001	Mar 18, 2015	Mar	NEWA

VIREAD

	AB +	GILEAD SCIENCES INC	300MG	N021356	001	Oct 26, 2001	Mar	CFTG

TERBINAFINE

GEL;TOPICAL

LAMISIL

>A>		@ GLAXOSMITHKLINE CONS	1%	N020846	001	Apr 29, 1998	Aug	CAHN
>D>		@ NOVARTIS	1%	N020846	001	Apr 29, 1998	Aug	CAHN

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL

>A>		@ GLAXOSMITHKLINE CONS	1%	N020749	001	Oct 17, 1997	Aug	CAHN
>D>		@ NOVARTIS	1%	N020749	001	Oct 17, 1997	Aug	CAHN

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

		@ WOCKHARDT	EQ 250MG BASE	A078229	001	Jul 02, 2007	Feb	DISC

TESTOSTERONE

GEL;TRANSDERMAL

ANDROGEL

	AB1	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jan	CTEC
	AB1 +		50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jan	CTEC

TESTIM

	AB2 +	AUXILIUM PHARMS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Jan	CTEC

TESTOSTERONE

		@ ACTAVIS LABS UT INC	1% (2.5GM/PACKET)	A076737	001	Jan 27, 2006	Mar	CAHN
		@	1% (5GM/PACKET)	A076737	002	Jan 27, 2006	Mar	CAHN
	AB1		25MG/2.5GM PACKET	A076737	001	Jan 27, 2006	Jul	CMFD
	AB1		50MG/5GM PACKET	A076737	002	Jan 27, 2006	Jul	CMFD
	BX	ANI PHARMS INC	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	May	CAHN
	BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	May	CAHN
>D>		@ PAR PHARM	1% (2.5GM/PACKET)	A076744	001	May 23, 2007	Aug	CMFD
>D>		@	1% (5GM/PACKET)	A076744	002	May 23, 2007	Aug	CMFD
>A>	AB1		25MG/2.5GM PACKET	A076744	001	May 23, 2007	Aug	CMFD
>A>	AB1		50MG/5GM PACKET	A076744	002	May 23, 2007	Aug	CMFD
	AB1	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jan	CTEC
	AB1		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jan	CTEC

		GEL;TRANSDERMAL						
		VOGELXO						
	AB2	UPSHER SMITH	50MG/5GM PACKET	N204399	002	Jun 04, 2014	Jan CTEC
		GEL, METERED;TRANSDERMAL						
		ANDROGEL						
	AB +	ABBVIE	1.62% (20.25MG/1.25GM ACTUATION)	N022309	001	Apr 29, 2011	Jul CFTG
		FORTESTA						
	AB +	ENDO PHARMS	10MG/0.5GM ACTUATION	N021463	001	Dec 29, 2010	Jul CFTG
		TESTOSTERONE						
	AB	ACTAVIS LABS UT INC	10MG/0.5GM ACTUATION	A204571	001	Aug 05, 2015	Jul NEWA
>A>	AB		12.5MG/1.25GM ACTUATION	A076737	003	Mar 09, 2015	Aug NEWA
	AB	PERRIGO ISRAEL	1.62% (20.25MG/1.25GM ACTUATION)	A204268	001	Aug 04, 2015	Jul NEWA
		TETRABENAZINE						
		TABLET;ORAL						
>A>		TETRABENAZINE						
>A>	AB	SUN PHARMA GLOBAL	12.5MG	A206129	001	Aug 17, 2015	Aug NEWA
>A>	AB		25MG	A206129	002	Aug 17, 2015	Aug NEWA
		XENAZINE						
>D>		VALEANT PHARMS NORTH	12.5MG	N021894	001	Aug 15, 2008	Aug CFTG
>A>	AB		12.5MG	N021894	001	Aug 15, 2008	Aug CFTG
			12.5MG	N021894	001	Aug 15, 2008	Feb CAHN
>D>	+		25MG	N021894	002	Aug 15, 2008	Aug CFTG
>A>	AB +		25MG	N021894	002	Aug 15, 2008	Aug CFTG
	+		25MG	N021894	002	Aug 15, 2008	Feb CAHN
		TETRACYCLINE HYDROCHLORIDE						
		CAPSULE;ORAL						
		ACHROMYCIN V						
	AB +	HERITAGE PHARMS INC	500MG	N050278	001		Apr CRLD
		TETRACYCLINE HYDROCHLORIDE						
		@ IVAX SUB TEVA PHARMS	250MG	A060704	001		Apr DISC
		@	500MG	A060704	002		Apr DISC
		THEOPHYLLINE						
		TABLET;ORAL						
		THEOLAIR						
		@ MEDICIS	125MG	A086399	001		Mar DISC
		@	250MG	A086399	002		Mar DISC
		TABLET, EXTENDED RELEASE;ORAL						
		THEOPHYLLINE						
	AB	MYLAN PHARMS INC	400MG	A040595	001	Apr 21, 2006	May CAHN
	AB +		600MG	A040560	002	Apr 21, 2006	May CAHN
		THIOTEPA						
		INJECTABLE;INJECTION						
		THIOTEPA						
	+	EUROHLTH INTL SARL	15MG/VIAL	A075547	001	Apr 02, 2001	May CRLD
		TIGECYCLINE						
		INJECTABLE;IV (INFUSION)						
		TIGECYCLINE						
	AP	SANDOZ INC	50MG/VIAL	A091620	001	May 27, 2015	May NEWA
		TYGACIL						
	AP +	PF PRISM CV	50MG/VIAL	N021821	001	Jun 15, 2005	May CFTG
		TIMOLOL MALEATE						
		SOLUTION/DROPS;OPHTHALMIC						
		ISTALOL						
	AT2 +	BAUSCH AND LOMB	EQ 0.5% BASE	N021516	001	Jun 04, 2004	Apr CFTG
		TIMOLOL MALEATE						
	AT1	AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	Apr CTEC
	AT1		EQ 0.5% BASE	A074516	001	Mar 25, 1997	Apr CTEC
	AT1	ALCON RES LTD	EQ 0.5% BASE	A074262	001	Apr 28, 1995	Apr CTEC
	AT2	APOTEX INC	EQ 0.5% BASE	A204936	001	Apr 17, 2015	Apr NEWA
	AT1	BAUSCH AND LOMB	EQ 0.5% BASE	A074776	001	Mar 25, 1997	Apr CTEC
	AT1	FDC LTD	EQ 0.5% BASE	A077259	002	Apr 30, 2008	Apr CTEC
	AT1	HI TECH PHARMA	EQ 0.5% BASE	A075163	001	Sep 10, 2002	Apr CTEC
	AT1	PACIFIC PHARMA	EQ 0.5% BASE	A074747	001	Mar 25, 1997	Apr CTEC
	AT1	WOCKHARDT	EQ 0.5% BASE	A078771	002	Sep 28, 2009	Apr CTEC

SOLUTION/DROPS;OPHTHALMIC
TIMOPTIC

AT1	+	ATON	EQ 0.5% BASE	N018086	002			Apr CTEC

TINIDAZOLE

TABLET;ORAL
TINIDAZOLE

AB		EDENBRIDGE PHARMS	250MG	A203808	001	Aug 04, 2015	Jul	NEWA
AB			500MG	A203808	002	Aug 04, 2015	Jul	NEWA

TOBRAMYCIN

SOLUTION;INHALATION
KITABIS PAK

AN		PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Feb	CTEC

TOBRAMYCIN

AN		AMNEAL PHARMS	300MG/5ML	A205501	001	Jul 13, 2015	Jun	NEWA

SOLUTION/DROPS;OPHTHALMIC
TOBREX

AT	+	ALCON LABS INC	0.3%	N050541	001			Mar CAHN

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION
TOBRAMYCIN SULFATE

	@	IGI LABS INC	EQ 10MG BASE/ML	A063119	001	Oct 31, 1994	Mar	CAHN
	@		EQ 40MG BASE/ML	A063120	001	Oct 31, 1994	Mar	CAHN
	@		EQ 40MG BASE/ML	A063121	001	Oct 31, 1994	Mar	CAHN
	@		EQ 40MG BASE/ML	A063122	001	Oct 31, 1994	Mar	CAHN

TOBRAMYCIN SULFATE (PHARMACY BULK)

	+	FRESENIUS KABI USA	EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul	CTEC
AP	+		EQ 40MG BASE/ML	A065120	001	Nov 29, 2002	Jul	CRLD
	@	HOSPIRA	EQ 40MG BASE/ML	A063116	001	May 18, 1992	Jul	DISC
AP			EQ 40MG BASE/ML	A063116	001	May 18, 1992	Jul	CTNA

TOLAZAMIDE

TABLET;ORAL
TOLAZAMIDE

	@	G AND W LABS INC	100MG	N018894	001	Nov 02, 1984	Apr	CAHN
	@		250MG	N018894	002	Nov 02, 1984	Apr	CAHN
	@		500MG	N018894	003	Nov 02, 1984	Apr	CAHN

TOLCAPONE

TABLET;ORAL
TASMAR

AB	+	VALEANT PHARMS LLC	100MG	N020697	001	Jan 29, 1998	Mar	CFTG

TOLCAPONE

AB		PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	Mar	NEWA

TOLMETIN SODIUM

TABLET;ORAL
TOLMETIN SODIUM

	@	G AND W LABS INC	EQ 600MG BASE	A074399	001	Mar 28, 1996	May	CAHN
	@		EQ 600MG BASE	A074729	001	Feb 27, 1997	Apr	CAHN

TOLTERODINE TARTRATE

CAPSULE, EXTENDED RELEASE;ORAL
TOLTERODINE TARTRATE

AB		TORRENT PHARMS LTD	2MG	A203016	001	Aug 11, 2015	Jul	NEWA
AB			4MG	A203016	002	Aug 11, 2015	Jul	NEWA

TABLET;ORAL
TOLTERODINE TARTRATE

AB		IVAX SUB TEVA PHARMS	1MG	A077006	001	Feb 23, 2015	Feb	NEWA
AB			2MG	A077006	002	Feb 23, 2015	Feb	NEWA
>A> AB		MACLEODS PHARMS LTD	1MG	A203409	001	Aug 31, 2015	Aug	NEWA
>A> AB			2MG	A203409	002	Aug 31, 2015	Aug	NEWA

TOPIRAMATE

TABLET;ORAL
TOPIRAMATE

AB		SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Apr	CAHN
AB			100MG	A076327	002	Mar 27, 2009	Apr	CAHN
AB			200MG	A076327	003	Mar 27, 2009	Apr	CAHN
	@	WOCKHARDT USA	25MG	A090353	001	Sep 01, 2010	Apr	DISC

		TABLET;ORAL						
		TOPIRAMATE						
		@	50MG	A090353	002	Sep 01, 2010	Apr	DISC
		@	100MG	A090353	003	Sep 01, 2010	Apr	DISC
		@	200MG	A090353	004	Sep 01, 2010	Apr	DISC
		TOPIRAMATE						
		@ HIKMA PHARMS	25MG	A091185	001	Nov 25, 2013	May	DISC
		@	50MG	A091185	002	Nov 25, 2013	May	DISC
		@	100MG	A091185	003	Nov 25, 2013	May	DISC
		@	200MG	A091185	004	Nov 25, 2013	May	DISC
	TOPOTECAN HYDROCHLORIDE							
		CAPSULE;ORAL						
		HYCAMTIN						
		NOVARTIS PHARMS CORP	EQ 0.25MG BASE	N020981	001	Oct 11, 2007	Mar	CAHN
	+		EQ 1MG BASE	N020981	002	Oct 11, 2007	Mar	CAHN
		INJECTABLE;INJECTION						
		HYCAMTIN						
AP	+	NOVARTIS PHARMS CORP	EQ 4MG BASE/VIAL	N020671	001	May 28, 1996	Mar	CAHN
		TOPOTECAN HYDROCHLORIDE						
AP		CHEM WERTH INC	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	May	CAHN
	TORSEMIDE							
		INJECTABLE;INJECTION						
		TORSEMIDE						
		@ EUROHLTH INTL SARL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Jan	DISC
		@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Jan	DISC
		@ LUITPOLD	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Jan	DISC
		@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Jan	DISC
	TRAMETINIB DIMETHYL SULFOXIDE							
		TABLET;ORAL						
		MEKINIST						
		NOVARTIS PHARMS CORP	EQ 0.5MG NON-SOLVATED PARENT	N204114	001	May 29, 2013	Mar	CAHN
			EQ 1MG NON-SOLVATED PARENT	N204114	002	May 29, 2013	Mar	CAHN
	+		EQ 2MG NON-SOLVATED PARENT	N204114	003	May 29, 2013	Mar	CAHN
	TRANEXAMIC ACID							
		INJECTABLE;INJECTION						
		TRANEXAMIC ACID						
AP		FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Apr	CMFD
	TRANYLCYPROMINE SULFATE							
		TABLET;ORAL						
		PARNATE						
AB	+	CONCORDIA PHARMS INC	EQ 10MG BASE	N012342	003	Aug 16, 1985	Jun	CAHN
	TRAVOPROST							
		SOLUTION/DROPS;OPHTHALMIC						
		IZBA						
		@ ALCON LABS INC	0.003%	N204822	001	May 15, 2014	Jul	DISC
		TRAVATAN Z						
AT	+	ALCON PHARMS LTD	0.004%	N021994	001	Sep 21, 2006	Jun	CTEC
		TRAVOPROST						
AT		APOTEX INC	0.004%	A203431	001	Jul 10, 2015	Jun	NEWA
	TRAZODONE HYDROCHLORIDE							
		TABLET;ORAL						
		DESYREL						
		@ PRAGMA PHARMS LLC	50MG	N018207	001		May	CAHN
		@	100MG	N018207	002		May	CAHN
		@	150MG	N018207	003	Mar 25, 1985	May	CAHN
		@	300MG	N018207	004	Nov 07, 1988	May	CAHN
		TABLET, EXTENDED RELEASE;ORAL						
		OLEPTRO						
		@ ANGELINI PHARMA	150MG	N022411	001	Feb 02, 2010	Mar	DISC
		@	300MG	N022411	002	Feb 02, 2010	Mar	DISC

TRETINOIN

CREAM;TOPICAL

RENOVA

	+	VALEANT PHARMS NORTH	0.02%	N021108	001	Aug 31, 2000	Apr CAHN
AB2	+		0.05%	N019963	001	Dec 29, 1995	Apr CAHN

RETIN-A

AB	+	VALEANT PHARMS NORTH	0.1%	N017340	001		Apr CAHN

GEL;TOPICAL

ATRALIN

AB	+	DOW PHARM	0.05%	N022070	001	Jul 26, 2007	Jul CTEC

TRETINOIN

AB		SPEAR PHARMS INC	0.05%	A207955	001	Aug 13, 2015	Jul NEWA

TRIAMCINOLONE ACETONIDE

CREAM;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		G AND W LABS	0.025%	A089797	001	May 31, 1991	Apr CMFD
AT			0.1%	A089798	001	May 31, 1991	Apr CMFD

TRIDERM

AT		CROWN LABS	0.025%	A088042	002	Mar 25, 2015	Mar NEWA
AT			0.5%	A088042	003	Mar 25, 2015	Mar NEWA

LOTION;TOPICAL

TRIAMCINOLONE ACETONIDE

AT		G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Mar CMFD

OINTMENT;TOPICAL

KENALOG

AT		DELCOR ASSET CORP	0.025%	N011600	003		Mar CMFD
AT			0.1%	N011600	001		Mar CMFD

TRIAMCINOLONE ACETONIDE

>D>		@ G AND W LABS	0.025%	A089795	001	Dec 23, 1988	Aug CMFD
>A> AT			0.025%	A089795	001	Dec 23, 1988	Aug CMFD
>D>		@	0.1%	A089796	001	Dec 23, 1988	Aug CMFD
>A> AT			0.1%	A089796	001	Dec 23, 1988	Aug CMFD

SPRAY;TOPICAL

KENALOG

>D> AT	+	RANBAXY	0.147MG/GM	N012104	001		Aug CAHN
AT	+		0.147MG/GM	N012104	001		Mar CFTG
>A> AT	+	SUN PHARM INDS LTD	0.147MG/GM	N012104	001		Aug CAHN

TRIAMCINOLONE ACETONIDE

AT		PERRIGO UK FINCO	0.147MG/GM	A205782	001	Apr 13, 2015	Mar NEWA

TRIAMTERENE

CAPSULE;ORAL

DYRENIUM

		CONCORDIA PHARMS INC	50MG	N013174	001		Apr CAHN
	+		100MG	N013174	002		Apr CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

SURMONTIL

AB	+	ODYSSEY PHARMS	EQ 50MG BASE	N016792	002		Jun CRLD
AB			EQ 100MG BASE	N016792	003	Sep 15, 1982	Jun CRLD

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)

CREAM;VAGINAL

VAGILIA

		@ G AND W LABS INC	3.7%;2.86%;3.42%	A088821	001	Nov 09, 1987	Jul CAHN

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

TRELSTAR

	+	ACTAVIS LABS UT INC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Jan CAHN
	+		EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Jan CAHN
	+		EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Jan CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

SANCTURA XR

	@ ALLERGAN	60MG	N022103	001	Aug 03, 2007	May	DISC

TROSPIUM CHLORIDE

AB	ACTAVIS LABS FL INC	60MG	A091289	001	Oct 12, 2012	Jun	CRLD
AB +		60MG	A091289	001	Oct 12, 2012	May	CRLD
AB	SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	NEWA

TABLET;ORAL

SANCTURA

	@ ALLERGAN	20MG	N021595	001	May 28, 2004	May	DISC

TROSPIUM CHLORIDE

AB	GLENMARK GENERICS	20MG	A091575	001	Aug 13, 2010	Jun	CRLD
AB +		20MG	A091575	001	Aug 13, 2010	May	CRLD

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

+	R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	May	CAHN
+	SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Jan	CAHN

URSODIOL

CAPSULE;ORAL

ACTIGALL

	@ ACTAVIS LABS UT INC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
AB +		300MG	N019594	002	Dec 31, 1987	Mar	CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB	HETERO LABS LTD V	EQ 500MG BASE	A203047	001	Apr 08, 2015	Mar	NEWA
AB		EQ 1GM BASE	A203047	002	Apr 08, 2015	Mar	NEWA
AB	SUN PHARM INDS LTD	EQ 500MG BASE	A076588	001	Jan 31, 2007	Apr	CAHN
AB		EQ 1GM BASE	A076588	002	Jan 31, 2007	Apr	CAHN

VALPROIC ACID

CAPSULE;ORAL

VALPROIC ACID

AB	BANNER LIFE SCIENCES	250MG	A073484	001	Jun 29, 1993	Jan	CAHN

CAPSULE, DELAYED RELEASE;ORAL

STAVZOR

	@ BANNER LIFE SCIENCES	125MG	N022152	001	Jul 29, 2008	Jan	CAHN
	@	250MG	N022152	002	Jul 29, 2008	Jan	CAHN
	@	500MG	N022152	003	Jul 29, 2008	Jan	CAHN

VALSARTAN

TABLET;ORAL

VALSARTAN

AB	PRINSTON INC	40MG	A204821	001	Jun 09, 2015	May	NEWA
AB		80MG	A204821	002	Jun 09, 2015	May	NEWA
AB		160MG	A204821	003	Jun 09, 2015	May	NEWA
AB		320MG	A204821	004	Jun 09, 2015	May	NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE;ORAL

VANCOMYCIN HYDROCHLORIDE

AB	LUPIN LTD	EQ 125MG BASE	A090439	001	Jan 28, 2015	Jan	NEWA
AB		EQ 250MG BASE	A090439	002	Jan 28, 2015	Jan	NEWA

INJECTABLE;INJECTION

VANCOLED

	@ EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A062682	001	Jul 22, 1986	Jun	CAHN
	@	EQ 1GM BASE/VIAL	A062682	002	Mar 30, 1988	Jun	CAHN
	@	EQ 2GM BASE/VIAL	A062682	003	May 11, 1988	Jun	CAHN
	@	EQ 5GM BASE/VIAL	A062682	004	May 11, 1988	Jun	CAHN
	@	EQ 10GM BASE/VIAL	A062682	005	May 11, 1988	Jun	CAHN

VANCOMYCIN HYDROCHLORIDE

>A> AP	XELLIA PHARMS APS	EQ 500MG BASE/VIAL	A091377	001	Sep 09, 2015	Aug	NEWA
>A> AP		EQ 1GM BASE/VIAL	A091377	002	Sep 09, 2015	Aug	NEWA

VARDENAFIL HYDROCHLORIDE

TABLET, ORALLY DISINTEGRATING;ORAL

STAXYN

AB	+	BAYER HLTHCARE	10MG	N200179	001	Jun 17, 2010	Apr CFTG

VARDENAFIL HYDROCHLORIDE

AB		WATSON LABS INC	10MG	A203689	001	Apr 22, 2015	Apr NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		VALEANT PHARMS NORTH	EQ 37.5MG BASE	A090071	001	Apr 15, 2011	Feb CAHN
AB			EQ 75MG BASE	A090071	002	Apr 15, 2011	Feb CAHN
AB			EQ 150MG BASE	A090071	003	Apr 15, 2011	Feb CAHN

TABLET;ORAL

VENLAFAXINE HYDROCHLORIDE

AB		YAOPHARMA CO LTD	EQ 25MG BASE	A202036	001	May 28, 2015	May NEWA
AB			EQ 37.5MG BASE	A202036	002	May 28, 2015	May NEWA
AB			EQ 50MG BASE	A202036	003	May 28, 2015	May NEWA
AB			EQ 75MG BASE	A202036	004	May 28, 2015	May NEWA
AB			EQ 100MG BASE	A202036	005	May 28, 2015	May NEWA

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

VERELAN

AB		RECRO GAINESVILLE	120MG	N019614	001	May 29, 1990	Apr CAHN
AB			180MG	N019614	003	Jan 09, 1992	Apr CAHN
AB			240MG	N019614	002	May 29, 1990	Apr CAHN
	+		360MG	N019614	004	May 10, 1996	Apr CAHN

VERELAN PM

AB		RECRO GAINESVILLE	100MG	N020943	001	Nov 25, 1998	Apr CAHN
AB			200MG	N020943	002	Nov 25, 1998	Apr CAHN
AB	+		300MG	N020943	003	Nov 25, 1998	Apr CAHN

INJECTABLE;INJECTION

CALAN

>A>		@ EXELA PHARMA SCS LLC	2.5MG/ML	N018925	001	Mar 30, 1984	Aug CAHN
>D>		@ GD SEARLE LLC	2.5MG/ML	N018925	001	Mar 30, 1984	Aug CAHN

ISOPTIN

		@ MT ADAMS	2.5MG/ML	N018485	001		Apr CAHN

TABLET;ORAL

ISOPTIN

		@ MT ADAMS	40MG	N018593	003	Nov 23, 1987	Apr CAHN
		@	80MG	N018593	001	Mar 08, 1982	Apr CAHN
		@	120MG	N018593	002	Mar 08, 1982	Apr CAHN

VERTEPORFIN

INJECTABLE;INJECTION

VISUDYNE

	+	VALEANT LUXEMBOURG	15MG/VIAL	N021119	001	Apr 12, 2000	Mar CAHN

VILAZODONE HYDROCHLORIDE

TABLET;ORAL

VIIBRYD

	+	FOREST LABS LLC	10MG	N022567	001	Jan 21, 2011	Mar CAHN
			20MG	N022567	002	Jan 21, 2011	Mar CAHN
			40MG	N022567	003	Jan 21, 2011	Mar CAHN

VORICONAZOLE

TABLET;ORAL

VORICONAZOLE

>A>	AB	GLENMARK PHARMS LTD	50MG	A203503	001	Sep 02, 2015	Aug NEWA
>A>	AB		200MG	A203503	002	Sep 02, 2015	Aug NEWA

ZAFIRLUKAST

TABLET;ORAL

ACCOLATE

AB		PAR PHARM INC	10MG	N020547	003	Sep 17, 1999	Feb CAHN
AB	+		20MG	N020547	001	Sep 26, 1996	Feb CAHN

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)

ZOLEDRONIC ACID

AP	FRESENIUS KABI USA	EQ 4MG BASE/5ML	A091516	001	Apr 23, 2015	Apr	NEWA
AP	HOSPIRA INC	EQ 4MG BASE/5ML	A090621	001	Mar 19, 2015	Mar	NEWA
AP	MYLAN LABS LTD	EQ 4MG BASE/5ML	A202650	001	Mar 04, 2013	Jul	CAHN
AP	USV NORTH AMERICA	EQ 4MG BASE/5ML	A202923	001	Sep 04, 2014	Mar	CPOT

ZOLPIDEM TARTRATE

TABLET;ORAL

ZOLPIDEM TARTRATE

	@ HIKMA	5MG	A078129	001	Apr 30, 2008	Mar	DISC
	@	10MG	A078129	002	Apr 30, 2008	Mar	DISC
AB	SUN PHARM INDS LTD	5MG	A078055	001	Apr 23, 2007	Apr	CAHN
AB		10MG	A078055	002	Apr 23, 2007	Apr	CAHN

TABLET;SUBLINGUAL

INTERMEZZO

AB	PURDUE PHARMA	1.75MG	N022328	001	Nov 23, 2011	May	CFTG
AB	+	3.5MG	N022328	002	Nov 23, 2011	May	CFTG

ZOLPIDEM TARTRATE

AB	NOVEL LABS INC	1.75MG	A204299	001	Jun 03, 2015	May	NEWA
AB		3.5MG	A204299	002	Jun 03, 2015	May	NEWA

ZONISAMIDE

CAPSULE;ORAL

ZONISAMIDE

AB	BANNER LIFE SCIENCES	25MG	A077813	001	Aug 16, 2006	Jan	CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan	CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan	CAHN

ACETAMINOPHEN

SUPPOSITORY;RECTAL

TYLENOL

>A>	@	J AND J CONSUMER INC	120MG	N017756	002			Aug CAHN
>A>	@		650MG	N017756	001			Aug CAHN
>D>	@	MCNEIL CONS	120MG	N017756	002			Aug CAHN
>D>	@		650MG	N017756	001			Aug CAHN

TABLET, EXTENDED RELEASE;ORAL

ACETAMINOPHEN

		SUN PHARM INDS LTD	650MG	A078569	001	Dec 14, 2011		Apr CAHN
	@		650MG	A090205	001	Nov 18, 2009		Apr CAHN

TYLENOL

>A>	+	J AND J CONSUMER INC	650MG	N019872	001	Jun 08, 1994		Aug CAHN
>A>	+		650MG	N019872	002	Jan 11, 2001		Aug CAHN
>D>	+	MCNEIL CONS	650MG	N019872	001	Jun 08, 1994		Aug CAHN
>D>	+		650MG	N019872	002	Jan 11, 2001		Aug CAHN

AVOBENZONE; OCTINOXATE; OXYBENZONE

LOTION;TOPICAL

SHADE UVAGUARD

	+	BAYER HEALTHCARE LLC	3%;7.5%;3%	N020045	001	Dec 07, 1992		Mar CAHN

BUDESONIDE

SPRAY, METERED;NASAL

RHINOCORT ALLERGY

	+	ASTRAZENECA PHARMS	0.032MG/SPRAY	N020746	003	Mar 23, 2015		Mar NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL

LOTRIMIN ULTRA

	+	BAYER HEALTHCARE LLC	1%	N021307	001	Dec 07, 2001		Mar CAHN

CALCIUM CARBONATE; FAMOTIDINE; MAGNESIUM HYDROXIDE

TABLET, CHEWABLE;ORAL

PEPCID COMPLETE

>A>	+	J AND J CONSUMER INC	800MG;10MG;165MG	N020958	001	Oct 16, 2000		Aug CAHN
>D>	+	MCNEIL CONS	800MG;10MG;165MG	N020958	001	Oct 16, 2000		Aug CAHN

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

		BANNER LIFE SCIENCES	5MG	N022429	001	Jul 23, 2009		Jan CAHN
	+		10MG	N022429	004	Jul 23, 2009		Jan CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

		BANNER LIFE SCIENCES	5MG	N022429	003	Jul 23, 2009		Jan CAHN
	+		10MG	N022429	002	Jul 23, 2009		Jan CAHN

SYRUP;ORAL

CHILDREN'S ZYRTEC ALLERGY

>A>	+	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007		Aug CAHN
>D>	+	MCNEIL CONSUMER	5MG/5ML	N022155	002	Nov 16, 2007		Aug CAHN

CHILDREN'S ZYRTEC HIVES RELIEF

>A>	+	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007		Aug CAHN
>D>	+	MCNEIL CONSUMER	5MG/5ML	N022155	001	Nov 16, 2007		Aug CAHN

TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

		AUROBINDO PHARMA LTD	5MG	A090760	001	Aug 05, 2015		Jul NEWA
			10MG	A090760	003	Aug 05, 2015		Jul NEWA
		SUN PHARM INDS LTD	5MG	A077498	001	Dec 27, 2007		Apr CAHN
			10MG	A077498	002	Dec 27, 2007		Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES

		SUN PHARM INDS LTD	5MG	A077498	003	Dec 27, 2007		Apr CAHN
			10MG	A077498	004	Dec 27, 2007		Apr CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

		AUROBINDO PHARMA LTD	5MG	A090760	002	Aug 05, 2015		Jul NEWA
			10MG	A090760	004	Aug 05, 2015		Jul NEWA

ZYRTEC ALLERGY

>A>		J AND J CONSUMER INC	5MG	N019835	003	Nov 16, 2007		Aug CAHN
>A>	+		10MG	N019835	004	Nov 16, 2007		Aug CAHN
>D>		MCNEIL CONSUMER	5MG	N019835	003	Nov 16, 2007		Aug CAHN

		TABLET;ORAL						
		ZYRTEC ALLERGY						
>D>	+		10MG	N019835	004	Nov 16, 2007	Aug	CAHN
		ZYRTEC HIVES RELIEF						
>A>		J AND J CONSUMER INC	5MG	N019835	005	Nov 16, 2007	Aug	CAHN
>A>	+		10MG	N019835	006	Nov 16, 2007	Aug	CAHN
>D>		MCNEIL CONSUMER	5MG	N019835	005	Nov 16, 2007	Aug	CAHN
>D>	+		10MG	N019835	006	Nov 16, 2007	Aug	CAHN
		TABLET, CHEWABLE;ORAL						
		CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY						
		JUBILANT GENERICS	5MG	A091116	001	Feb 19, 2015	Feb	NEWA
			10MG	A091116	002	Feb 19, 2015	Feb	NEWA
		SANDOZ	5MG	A078692	001	Feb 14, 2008	Feb	CTNA
	+		10MG	A078692	002	Feb 14, 2008	Feb	CTNA
		CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF						
		JUBILANT GENERICS	5MG	A091116	003	Feb 19, 2015	Feb	NEWA
			10MG	A091116	004	Feb 19, 2015	Feb	NEWA
		CHILDREN'S ZYRTEC ALLERGY						
>A>		@ J AND J CONSUMER INC	5MG	N021621	003	Nov 16, 2007	Aug	CAHN
>A>		@	10MG	N021621	004	Nov 16, 2007	Aug	CAHN
>D>		@ MCNEIL CONS	5MG	N021621	003	Nov 16, 2007	Aug	CAHN
>D>		@	10MG	N021621	004	Nov 16, 2007	Aug	CAHN
		CHILDREN'S ZYRTEC HIVES RELIEF						
>A>		@ J AND J CONSUMER INC	5MG	N021621	005	Nov 16, 2007	Aug	CAHN
>A>		@	10MG	N021621	006	Nov 16, 2007	Aug	CAHN
>D>		@ MCNEIL CONS	5MG	N021621	005	Nov 16, 2007	Aug	CAHN
>D>		@	10MG	N021621	006	Nov 16, 2007	Aug	CAHN
		TABLET, ORALLY DISINTEGRATING;ORAL						
>A>		CETIRIZINE HYDROCHLORIDE ALLERGY						
>A>		PAR PHARM INC	10MG	A205490	001	Sep 02, 2015	Aug	NEWA
		ZYRTEC ALLERGY						
>A>	+	J AND J CONSUMER INC	10MG	N022578	001	Sep 03, 2010	Aug	CAHN
>D>	+	MCNEIL CONSUMER	10MG	N022578	001	Sep 03, 2010	Aug	CAHN
		CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE						
		TABLET, EXTENDED RELEASE;ORAL						
		ZYRTEC-D 12 HOUR						
>A>	+	J AND J CONSUMER INC	5MG;120MG	N021150	002	Nov 09, 2007	Aug	CAHN
>D>	+	MCNEIL	5MG;120MG	N021150	002	Nov 09, 2007	Aug	CAHN
		CHLORPHENIRAMINE MALEATE						
		TABLET, EXTENDED RELEASE;ORAL						
		CHLOR-TRIMETON						
		@ BAYER HEALTHCARE LLC	8MG	N007638	001		Mar	CAHN
	+		12MG	N007638	002		Mar	CAHN
		CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE						
		TABLET, EXTENDED RELEASE;ORAL						
		CHLOR-TRIMETON						
	+	BAYER HEALTHCARE LLC	8MG;120MG	N018397	001		Mar	CAHN
		CLEMASTINE FUMARATE						
		TABLET;ORAL						
		CLEMASTINE FUMARATE						
		@ ANI PHARMS INC	1.34MG	A073282	002	Dec 03, 1992	Jul	CAHN
		CLOTRIMAZOLE						
		CREAM;VAGINAL						
		GYNE-LOTRIMIN						
	+	BAYER HEALTHCARE LLC	1%	N018052	002	Nov 30, 1990	Mar	CAHN
		GYNE-LOTRIMIN 3						
	+	BAYER HEALTHCARE LLC	2%	N020574	001	Nov 24, 1998	Mar	CAHN
		CREAM, TABLET;TOPICAL, VAGINAL						
		GYNE-LOTRIMIN COMBINATION PACK						
	+	BAYER HEALTHCARE LLC	1%,100MG	N020289	002	Apr 26, 1993	Mar	CAHN
		TABLET;VAGINAL						
		GYNE-LOTRIMIN						
	+	BAYER HEALTHCARE LLC	100MG	N017717	002	Nov 30, 1990	Mar	CAHN

DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE

>A>	ACTAVIS LABS FL INC	30MG;600MG	A091070	001	Aug 31, 2015	Aug NEWA
>A>		60MG;1.2GM	A091070	002	Aug 31, 2015	Aug NEWA

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BANNER LIFE SCIENCES	25MG;EQ 200MG FREE ACID AND POTASSIUM SALT	A090397	001	Nov 22, 2010	Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr CAHN
	20MG	A090283	002	Nov 17, 2009	Apr CAHN

PEPCID AC

J AND J CONSUMER INC	10MG	N020325	001	Apr 28, 1995	Jul CAHN
+	20MG	N020325	002	Sep 23, 2003	Jul CAHN

PEPCID AC

>A>	J AND J CONSUMER INC	10MG	N020902	001	Aug 05, 1999	Aug CAHN
>D>	MCNEIL CONS	10MG	N020902	001	Aug 05, 1999	Aug CAHN

TABLET, CHEWABLE;ORAL

PEPCID AC

>A>	@ J AND J CONSUMER INC	10MG	N020801	001	Sep 24, 1998	Aug CAHN
>A>	+	20MG	N020801	002	Dec 17, 2007	Aug CAHN
>D>	@ MCNEIL CONS	10MG	N020801	001	Sep 24, 1998	Aug CAHN
>D>	+	20MG	N020801	002	Dec 17, 2007	Aug CAHN

FEXOFENADINE HYDROCHLORIDE

TABLET;ORAL

FEXOFENADINE HYDROCHLORIDE ALLERGY

>A>	SCIEGEN PHARMS INC	60MG	A204507	002	Sep 16, 2015	Aug NEWA
>A>		180MG	A204507	003	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE HIVES

>A>	SCIEGEN PHARMS INC	60MG	A204507	004	Sep 16, 2015	Aug NEWA
>A>		180MG	A204507	005	Sep 16, 2015	Aug NEWA

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

SUN PHARMA GLOBAL	60MG;120MG	A090818	001	Jan 29, 2015	Jan NEWA

GUAIFENESIN

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN

>A>	ACTAVIS LABS FL INC	1.2GM	A091009	002	Sep 03, 2015	Aug NEWA

GUAIFENESIN; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

ACTAVIS LABS FL INC	600MG;60MG	A091071	001	May 27, 2015	May NEWA
	1.2GM;120MG	A091071	002	May 27, 2015	May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BANNER LIFE SCIENCES	EQ 200MG FREE ACID AND POTASSIUM SALT	A078682	001	Mar 24, 2009	Jan CAHN

MIDOL LIQUID GELS

+	BANNER LIFE SCIENCES	200MG	N021472	001	Oct 18, 2002	Jan CAHN

SUSPENSION;ORAL

CHILDREN'S MOTRIN

>A>	+	J AND J CONSUMER INC	100MG/5ML	N020516	001	Jun 16, 1995	Aug CAHN
>D>	+	MCNEIL	100MG/5ML	N020516	001	Jun 16, 1995	Aug CAHN

SUSPENSION/DROPS;ORAL

CHILDREN'S MOTRIN

>A>	+	J AND J CONSUMER INC	40MG/ML	N020603	001	Jun 10, 1996	Aug CAHN
>D>	+	MCNEIL CONS	40MG/ML	N020603	001	Jun 10, 1996	Aug CAHN

		TABLET;ORAL						
		IBUPROFEN						
>A>		@ ANI PHARMS INC	200MG	A072901	001	Dec 19, 1991	Aug	CAHN
>A>		@	200MG	A072903	001	Dec 19, 1991	Aug	CAHN
>D>		@ IVAX SUB TEVA PHARMS	200MG	A072901	001	Dec 19, 1991	Aug	CAHN
>D>		@	200MG	A072903	001	Dec 19, 1991	Aug	CAHN
		JUNIOR STRENGTH MOTRIN						
>A>		J AND J CONSUMER INC	100MG	N020602	001	Jun 10, 1996	Aug	CAHN
>D>		MCNEIL CONS	100MG	N020602	001	Jun 10, 1996	Aug	CAHN
		MOTRIN IB						
>A>	+	J AND J CONSUMER INC	200MG	N019012	003	Dec 17, 1990	Aug	CAHN
>D>	+	MCNEIL	200MG	N019012	003	Dec 17, 1990	Aug	CAHN
		MOTRIN MIGRAINE PAIN						
>A>	+	J AND J CONSUMER INC	200MG	N019012	004	Feb 25, 2000	Aug	CAHN
>D>	+	MCNEIL	200MG	N019012	004	Feb 25, 2000	Aug	CAHN
		NUPRIN						
>A>		@ J AND J CONSUMER INC	200MG	N019012	001	May 18, 1984	Aug	CAHN
>A>		@	200MG	N019012	002	Jul 29, 1987	Aug	CAHN
>D>		@ MCNEIL	200MG	N019012	001	May 18, 1984	Aug	CAHN
>D>		@	200MG	N019012	002	Jul 29, 1987	Aug	CAHN
		TABLET, CHEWABLE;ORAL						
		CHILDREN'S MOTRIN						
>A>		J AND J CONSUMER INC	50MG	N020601	001	Nov 15, 1996	Aug	CAHN
>D>		MCNEIL CONS	50MG	N020601	001	Nov 15, 1996	Aug	CAHN
		JUNIOR STRENGTH MOTRIN						
>A>	+	J AND J CONSUMER INC	100MG	N020601	003	Nov 15, 1996	Aug	CAHN
>D>	+	MCNEIL CONS	100MG	N020601	003	Nov 15, 1996	Aug	CAHN
		IBUPROFEN SODIUM						
		TABLET;ORAL						
		IBUPROFEN SODIUM						
		PERRIGO R AND D	EQ 200MG BASE	A206581	001	Aug 03, 2015	Jul	NEWA
		IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE						
		SUSPENSION;ORAL						
		CHILDREN'S MOTRIN COLD						
>A>	+	J AND J CONSUMER INC	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000	Aug	CAHN
>D>	+	MCNEIL CONS	100MG/5ML;15MG/5ML	N021128	001	Aug 01, 2000	Aug	CAHN
		TABLET;ORAL						
		SINE-AID IB						
>A>		J AND J CONSUMER INC	200MG;30MG	N019899	001	Dec 31, 1992	Aug	CAHN
>D>		MCNEIL CONS	200MG;30MG	N019899	001	Dec 31, 1992	Aug	CAHN
		KETOTIFEN FUMARATE						
		SOLUTION/DROPS;OPHTHALMIC						
		ALAWAY						
		BAUSCH AND LOMB	EQ 0.035% BASE	N021996	002	Feb 11, 2015	Feb	NEWA
		LEVONORGESTREL						
		TABLET;ORAL						
		LEVONORGESTREL						
		LOTUS PHARM CO LTD	1.5MG	A202246	001	Jun 05, 2015	May	NEWA
		OC PHARMA	1.5MG	A202380	001	May 29, 2015	May	NEWA
		LOPERAMIDE HYDROCHLORIDE						
		CAPSULE;ORAL						
		LOPERAMIDE HYDROCHLORIDE						
		BANNER LIFE SCIENCES	1MG	N021855	001	Aug 04, 2005	Jan	CAHN
	+		2MG	N021855	002	Aug 04, 2005	Jan	CAHN
		SOLUTION;ORAL						
		IMODIUM A-D						
>A>	+	J AND J CONSUMER INC	1MG/5ML	N019487	001	Mar 01, 1988	Aug	CAHN
>D>	+	MCNEIL CONS	1MG/5ML	N019487	001	Mar 01, 1988	Aug	CAHN
		SUSPENSION;ORAL						
		IMODIUM A-D						
>A>	+	J AND J CONSUMER INC	1MG/7.5ML	N019487	002	Jul 08, 2004	Aug	CAHN
>D>	+	MCNEIL CONS	1MG/7.5ML	N019487	002	Jul 08, 2004	Aug	CAHN
		TABLET;ORAL						
		IMODIUM A-D						
>A>	+	J AND J CONSUMER INC	2MG	N019860	001	Nov 22, 1989	Aug	CAHN
>D>	+	MCNEIL CONS	2MG	N019860	001	Nov 22, 1989	Aug	CAHN

TABLET, CHEWABLE;ORAL
IMODIUM A-D EZ CHEWS

>A>	+	J AND J CONSUMER INC	2MG	N020448	001	Jul 24, 1997	Aug	CAHN
>D>	+	MCNEIL	2MG	N020448	001	Jul 24, 1997	Aug	CAHN

LOPERAMIDE HYDROCHLORIDE; SIMETHICONE

TABLET;ORAL
IMODIUM MULTI-SYMPTOM RELIEF

>A>	+	J AND J CONSUMER INC	2MG;125MG	N021140	001	Nov 30, 2000	Aug	CAHN
>D>	+	MCNEIL CONS	2MG;125MG	N021140	001	Nov 30, 2000	Aug	CAHN
		LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE						
		SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	Apr	CAHN

TABLET, CHEWABLE;ORAL
IMODIUM MULTI-SYMPTOM RELIEF

>A>	+	J AND J CONSUMER INC	2MG;125MG	N020606	001	Jun 26, 1996	Aug	CAHN
>D>	+	MCNEIL	2MG;125MG	N020606	001	Jun 26, 1996	Aug	CAHN

LORATADINE

CAPSULE;ORAL
CLARITIN

	+	BAYER HEALTHCARE LLC	10MG	N021952	001	Jun 16, 2008	Mar	CAHN

SYRUP;ORAL
CLARITIN

	+	BAYER HEALTHCARE LLC	1MG/ML	N020641	002	Nov 27, 2002	Mar	CAHN
		CLARITIN HIVES RELIEF						
	@	BAYER HEALTHCARE LLC	1MG/ML	N020641	003	Nov 19, 2003	Mar	CAHN
		LORATADINE						
		TARO	1MG/ML	A201865	001	Jul 31, 2015	Jul	NEWA

TABLET;ORAL
LORATADINE

		SUN PHARM INDS LTD	10MG	A076134	001	Aug 18, 2003	Apr	CAHN

TABLET, CHEWABLE;ORAL
CHILDREN'S CLARITIN

	+	BAYER HEALTHCARE LLC	5MG	N021891	001	Aug 23, 2006	Mar	CAHN

TABLET, ORALLY DISINTEGRATING;ORAL
CLARITIN REDITABS

	+	BAYER HEALTHCARE LLC	5MG	N021993	001	Dec 12, 2006	Mar	CAHN
		LORATADINE REDIDOSE						
		SUN PHARM INDS LTD	10MG	A077153	001	Apr 11, 2007	Apr	CAHN

LORATADINE; PSEUDOEPHEDRINE SULFATE

TABLET, EXTENDED RELEASE;ORAL
CLARITIN-D

	+	BAYER HEALTHCARE LLC	5MG;120MG	N019670	002	Nov 27, 2002	Mar	CAHN
		CLARITIN-D 24 HOUR						
	+	BAYER HEALTHCARE LLC	10MG;240MG	N020470	002	Nov 27, 2002	Mar	CAHN
		LORATADINE AND PSEUDOEPHEDRINE SULFATE						
		SUN PHARM INDS LTD	10MG;240MG	A076557	001	Sep 22, 2004	Apr	CAHN

NAPROXEN SODIUM

CAPSULE;ORAL
NAPROXEN SODIUM

	+	BANNER LIFE SCIENCES	EQ 200MG BASE	N021920	001	Feb 17, 2006	Jan	CAHN
		CATALENT	EQ 200MG BASE	A202807	001	Feb 13, 2015	Feb	NEWA
		OHM LABS INC	EQ 200MG BASE	A202807	001	Feb 13, 2015	Jun	CAHN

TABLET;ORAL
NAPROXEN SODIUM

		SUN PHARM INDS LTD	EQ 200MG BASE	A091183	001	May 20, 2011	Apr	CAHN

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL
NICOTINE POLACRILEX

	@	IVAX SUB TEVA PHARMS	EQ 2MG BASE	A076880	001	Feb 18, 2009	Mar	DISC
	@		EQ 4MG BASE	A077850	001	Feb 18, 2009	Mar	DISC

OMEPRAZOLE MAGNESIUM

TABLET, DELAYED RELEASE;ORAL
OMEPRAZOLE MAGNESIUM

		PERRIGO R AND D	EQ 20MG BASE	A204152	001	Jul 30, 2015	Jul	NEWA

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID OTC

+	BAYER HEALTHCARE LLC	20MG;1.1GM	N022281	001	Dec 01, 2009	Mar	CAHN

FOR SUSPENSION;ORAL

ZEGERID OTC

+	BAYER HEALTHCARE LLC	20MG/PACKET;1.68GM/PACKET	N022283	001	Jun 17, 2013	Mar	CAHN

OXYMETAZOLINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

OCUCLEAR

	BAYER HEALTHCARE LLC	0.025%	N018471	001	May 30, 1986	Mar	CAHN

POLYETHYLENE GLYCOL 3350

FOR SOLUTION;ORAL

MIRALAX

+	BAYER HEALTHCARE LLC	17GM/SCOOPFUL	N022015	001	Oct 06, 2006	Mar	CAHN

POLYETHYLENE GLYCOL 3350

	RARITAN PHARMS INC	17GM/SCOOPFUL	A202071	001	Dec 28, 2012	Jan	CAHN

PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

PSEUDOEPHEDRINE HYDROCHLORIDE

	SUN PHARM INDS LTD	120MG	A077442	001	Sep 28, 2005	Apr	CAHN

SUDAFED 24 HOUR

>A>	+ J AND J CONSUMER INC	240MG	N020021	002	Dec 15, 1992	Aug	CAHN
>D>	+ MCNEIL CONS	240MG	N020021	002	Dec 15, 1992	Aug	CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

@	SUN PHARM INDS LTD	EQ 75MG BASE	A075132	001	Jan 14, 2000	Apr	CAHN
@	WOCKHARDT	EQ 75MG BASE	A078884	001	Jul 31, 2008	Jan	DISC

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 8 AUGUST 2015

NO AUGUST 2015 APPROVALS

ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

http://www.fda.gov/orphan/designat/list.htm

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO AUGUST 2015 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ABACAVIR SULFATE - ZIAGEN							
N 020977	001					D-147	Mar 23, 2018
ABACAVIR SULFATE - ZIAGEN							
N 020978	001					D-147	Mar 23, 2018
ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ							
N 205551	001	6417191	Mar 28, 2016	DP U-1572			
		6417191*PED	Sep 28, 2016				
ABACAVIR SULFATE; LAMIVUDINE - EPZICOM							
N 021652	001	6417191	Mar 28, 2016	DP U-257			
		6417191*PED	Sep 28, 2016				
ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR							
N 204031	001	8980319	Dec 21, 2030	DP			
		8992975	May 16, 2032	DP			
		9050335	May 16, 2032	DP			
ACLIDINIUM BROMIDE - TUDORZA PRESSAIR							
N 202450	001	9056100	Jul 07, 2020	DP U-1263			
ACYCLOVIR; HYDROCORTISONE - XERESE							
N 022436	001	7223387	Jul 24, 2021	DP U-1006			
		7223387	Jul 24, 2021	DP U-1484			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO							
N 022320	001	8936800	Dec 23, 2022	DP U-1078			
ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE							
N 207917	001	8445543	Jul 12, 2027	U-1078		NP	Jul 15, 2018
		8703820	Mar 12, 2023	U-1078			
		8729127	Mar 12, 2023	U-1078			
		8785420	Dec 23, 2022	U-1078			
		8909305	Dec 23, 2022	U-1078			
		8936800	Dec 23, 2022	DP U-1078			
ALBUTEROL SULFATE - PROAIR RESPICLICK							
N 205636	001	6446627	Dec 18, 2017	DP		NP	Mar 12, 2018
		6701917	Jun 23, 2021	DP			
		6718972	Jun 23, 2021	DP			
		6748947	Jun 23, 2021	DP			
		6871646	Jun 23, 2021	DP			
		7540282	May 06, 2023	DP			
		8006690	Jun 23, 2021	DP			
		8651103	Mar 26, 2028	DP			
ALBUTEROL SULFATE; IPRATROPIUM BROMIDE - COMBIVENT RESPIMAT							
N 021747	001 >A>	8733341	Dec 16, 2029	DP			
	>A>	9027967	Mar 31, 2027	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	001	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	002	8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426	003	8637079	Jun 04, 2029	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 004		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 005		8637079	Jun 04, 2029	DP			
ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI							
N 022426 006		8637079	Jun 04, 2029	DP			
ALVIMOPAN - ENTEREG							
N 021775 001		8946262	Feb 12, 2030	U-1655			
AMOXICILLIN - MOXATAG							
N 050813 001		8778924	Dec 08, 2026	DS DP U-897			
APIXABAN - ELIQUIS							
N 202155 001	>A>	6967208	Feb 03, 2023	DS DP U-1167			
	>A>	6967208	Feb 03, 2023	DS DP U-1200			
	>A>	6967208	Feb 03, 2023	DS DP U-1301			
	>A>	6967208	Feb 03, 2023	DS DP U-1302			
	>A>	6967208	Feb 03, 2023	DS DP U-1323			
	>A>	6967208	Feb 03, 2023	DS DP U-1501			
	>A>	6967208	Feb 03, 2023	DS DP U-1502			
	>A>	6967208	Feb 03, 2023	DS DP U-1729			
	>A>	6967208	Feb 03, 2023	DS DP U-1730			
APIXABAN - ELIQUIS							
N 202155 002		6413980	Dec 22, 2019	DS DP U-1200			
		6413980	Dec 22, 2019	DS DP U-1301			
		6413980	Dec 22, 2019	DS DP U-1302			
		6967208	Feb 03, 2023	DS DP U-1200			
		6967208	Feb 03, 2023	DS DP U-1301			
		6967208	Feb 03, 2023	DS DP U-1302			
		6967208	Feb 03, 2023	DS DP U-1323			
APREMILAST - OTEZLA							
N 205437 001		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
APREMILAST - OTEZLA							
N 205437 002		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
APREMILAST - OTEZLA							
N 205437 003		9018243	Mar 19, 2023	U-1505			
		9018243	Mar 19, 2023	U-1595			
APREPITANT - EMEND							
N 021549 001						>A> NPP	Aug 28, 2018
APREPITANT - EMEND							
N 021549 002						>A> NPP	Aug 28, 2018
APREPITANT - EMEND							
N 021549 003						>A> NPP	Aug 28, 2018
ARIPIPRAZOLE - ABILIFY							
N 021436 001	>A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436 002	>A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY							
N 021436 003	>A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436 004	>A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436 005	>A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021436 006	>A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021713 001		5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
		5006528	Oct 20, 2014	DS DP U-761			
		5006528*PED	Apr 20, 2015				
		6977257	Apr 24, 2022	DP			
		6977257*PED	Oct 24, 2022				
ARIPIPRAZOLE - ABILIFY							
N 021729 002	>A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021729 003	>A>	9089567	Jan 28, 2022	U-543		ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021729 004						ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021729 005						ODE	Dec 12, 2021
ARIPIPRAZOLE - ABILIFY							
N 021866 001		5006528	Oct 20, 2014	DS DP U-543		ODE	Dec 12, 2021
		5006528	Oct 20, 2014	DS DP U-763			
		5006528*PED	Apr 20, 2015				
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 001		5006528	Oct 20, 2014	DS DP U-543			
		5006528	Oct 20, 2014	DS DP U-1632			
		5006528*PED	Apr 20, 2015				
		8030313	Oct 19, 2024	U-543			
		8030313	Oct 19, 2024	U-1632			
		8338427	Mar 15, 2025	DP U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8399469	Jun 29, 2025	DS			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
	>A>	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 002		5006528	Oct 20, 2014	DS DP U-543			
		5006528	Oct 20, 2014	DS DP U-1632			
		5006528*PED	Apr 20, 2015				
		8030313	Oct 19, 2024	U-543			
		8030313	Oct 19, 2024	U-1632			
		8338427	Mar 15, 2025	DP U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8399469	Jun 29, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 002		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
	>A>	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 003		5006528	Oct 20, 2014	DS DP U-543			
		5006528	Oct 20, 2014	DS DP U-1632			
		5006528*PED	Apr 20, 2015				
		8030313	Oct 19, 2024	U-543			
		8030313	Oct 19, 2024	U-1632			
		8338427	Mar 15, 2025	DP U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8399469	Jun 29, 2025	DS			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
	>A>	9089567	Jan 28, 2022	U-543			
ARIPIPRAZOLE - ABILIFY MAINTENA KIT							
N 202971 004		5006528	Oct 20, 2014	DS DP U-543			
		5006528	Oct 20, 2014	DS DP U-1632			
		5006528*PED	Apr 20, 2015				
		8030313	Oct 19, 2024	U-543			
		8030313	Oct 19, 2024	U-1632			
		8338427	Mar 15, 2025	DP U-543			
		8338427	Mar 15, 2025	DP U-1633			
		8338428	Aug 06, 2023	DP U-543			
		8338428	Aug 06, 2023	DP U-1633			
		8399469	Jun 29, 2025	DS			
		8759351	Aug 06, 2023	DP U-1530			
		8759351	Aug 06, 2023	DP U-1633			
		8993761	Sep 25, 2022	DS			
	>A>	9089567	Jan 28, 2022	U-543			
ASENAPINE MALEATE - SAPHRIS							
N 022117 001		5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
		5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
		7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
		7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASENAPINE MALEATE - SAPHRIS							
N 022117 002		5763476	Jun 09, 2020	DP U-326		M-158	Mar 17, 2018
		5763476*PED	Dec 09, 2020			NPP	Mar 17, 2018
		7741358	Apr 06, 2026	DS DP U-1064		PED	Sep 17, 2018
		7741358*PED	Oct 06, 2026			PED	Sep 17, 2018
		8022228	Apr 06, 2026	DS DP			
		8022228*PED	Oct 06, 2026				
ASPIRIN - ASPIRIN							
N 203697 001	>A>	9101637	Mar 23, 2022	U-1731			
	>A>	9101637	Mar 23, 2022	U-1732			
	>A>	9101637	Mar 23, 2022	U-1733			
ATAZANAVIR SULFATE - REYATAZ							
N 021567 001		5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ATAZANAVIR SULFATE - REYATAZ							
N 021567	002	5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567	003	5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 021567	004	5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
ATAZANAVIR SULFATE - REYATAZ							
N 206352	001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
		5849911*PED	Dec 20, 2017			PED	Dec 02, 2017
		6087383	Dec 21, 2018	DS DP			
ATAZANAVIR SULFATE; COBICISTAT - EVOTAZ							
N 206353	001	5849911	Jun 20, 2017	DS DP U-167			
		5849911*PED	Dec 20, 2017				
		6087383	Dec 21, 2018	DS DP			
		6087383*PED	Jun 21, 2019				
		8148374	Sep 03, 2029	DS DP U-1279			
AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ							
N 206494	001	7112592	Feb 24, 2022	DS DP U-282			
		7612087	Nov 12, 2026	DP			
		8178554	Jul 24, 2021	DS DP U-282			
		8471025	Aug 12, 2031	DS			
		8835455	Oct 08, 2030	DP			
		8969566	Jun 15, 2032	DS			
AZELAIC ACID - FINACEA							
N 207071	001	>A> 6730288	Sep 08, 2019	DP		NP	Jul 29, 2018
		>A> 7700076	Sep 18, 2027	DP			
		>A> 8435498	Mar 01, 2024	U-1727			
		>A> 8722021	Oct 24, 2023	DP			
		>A> 8900554	Oct 24, 2023	DP			
AZELASTINE HYDROCHLORIDE - ASTEPRO							
N 022203	001					NPP	Feb 20, 2018
						NPP	Feb 20, 2018
AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA							
N 202236	001	8163723	Aug 29, 2023	U-77		NPP	Feb 20, 2018
		8163723	Aug 29, 2023	U-81			
		8163723	Aug 29, 2023	U-644			
		8163723	Aug 29, 2023	U-707			
		8163723	Aug 29, 2023	U-1667			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	001	9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL - EDARBI							
N 200796	002	9066936	Mar 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331 001		9066936	Mar 26, 2028	DP			
AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR							
N 202331 002		9066936	Mar 26, 2028	DP			
BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA							
N 050819 001		8895070	Jun 03, 2029	U-124			
BESIFLOXACIN HYDROCHLORIDE - BESIVANCE							
N 022308 001		8937062	Nov 13, 2029	U-80			
BIMATOPROST - LUMIGAN							
N 022184 001		8933120	Mar 16, 2025	DP			
		8933127	Mar 16, 2025	DP			
BIMATOPROST - LATISSE							
N 022369 001		7351404	May 25, 2024	U-939	Y		
		7388029	Jan 21, 2022	U-938	Y		
		8541466	Jan 31, 2021	U-1217			
		8986715	Jan 15, 2023	U-1217			
BORTEZOMIB - VELCADE							
N 021602 001	>A>	5780454	May 03, 2017	DS DP		>A> D-141	Oct 08, 2017
	>A>	5780454*PED	Nov 03, 2017			>A> D-142	Oct 08, 2017
	>A>	6713446	Jan 25, 2022	DS DP		>A> I-695	Oct 08, 2017
	>A>	6713446*PED	Jul 25, 2022			>A> M-139	Aug 08, 2017
	>A>	6958319	Jan 25, 2022	DS DP		>A> ODE	Oct 08, 2021
	>A>	6958319*PED	Jul 25, 2022			>A> PED	Feb 08, 2018
						>A> PED	Apr 08, 2018
						>A> PED	Apr 08, 2018
						>A> PED	Apr 08, 2018
						>A> PED	Apr 08, 2022
BREXPIPRAZOLE - REXULTI							
N 205422 001		7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422 002		7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422 003		7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422 004		7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422 005		7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
BREXPIPRAZOLE - REXULTI							
N 205422 006		7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
BREXPIPRAZOLE - REXULTI							
N 205422	006	7888362	Feb 23, 2027	DS		NCE	Jul 10, 2020
		8349840	Apr 12, 2026	DP U-1529			
		8618109	Apr 12, 2026	U-543			
BRIMONIDINE TARTRATE; BRINZOLAMIDE - SIMBRINZA							
N 204251	001	9044484	Oct 30, 2030	DP			
BROMOCRIPTINE MESYLATE - CYCLOSET							
N 020866	001	8877708	Jun 07, 2030	DP U-1706			
BUDESONIDE - UCERIS							
N 203634	001 >A>	9132093	Sep 07, 2031	DP			
BUDESONIDE - UCERIS							
N 205613	001	5914122	Dec 19, 2015	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	001	8470361	May 22, 2030	DP U-1425		>A> I-713	Aug 10, 2018
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	002	8470361	May 22, 2030	DP U-1425		>A> I-713	Aug 10, 2018
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	003	8470361	May 22, 2030	DP U-1425		>A> I-713	Aug 10, 2018
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	004	8470361	May 22, 2030	DP U-1425		>A> I-713	Aug 10, 2018
		8940330	Sep 18, 2032	DP			
BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV							
N 204242	005	8454996	Sep 24, 2019	U-1421		>A> I-713	Aug 10, 2018
		8470361	May 22, 2030	DP U-1425			
		8658198	Dec 03, 2027	DP U-1494			
		8940330	Sep 18, 2032	DP			
BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE							
N 200063	001	8916195	Feb 02, 2030	U-1639			
	>A>	9107837	Jun 04, 2027	U-1639			
CALCIUM ACETATE - PHOSLO GELCAPS							
N 021160	003	6875445	Jul 30, 2021	DP			
CALCIUM ACETATE - PHOSLYRA							
N 022581	001 >A>	9089528	Jul 20, 2027	U-1469			
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM BK 4/2.5 IN PLASTIC CONTAINER							
N 207026	001					ODE	Jan 13, 2022
CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE - PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER							
N 207026	002					ODE	Jan 13, 2022
CANGRELOR - KENGREAL							
N 204958	001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
		6130208	Jun 29, 2018	DP U-1715			
		8680052	Mar 09, 2033	U-1715			
		8759316	May 13, 2029	U-1715			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CANGRELOR - KENGREAL						
N 204958 001	6114313	Dec 11, 2017	DP U-1715		NCE	Jun 22, 2020
	6130208	Jun 29, 2018	DP U-1715			
	8680052	Mar 09, 2033	U-1715			
	8759316	May 13, 2029	U-1715			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 001	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 002	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 003	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			
CARBIDOPA; LEVODOPA - RYTARY						
N 203312 004	7094427	May 29, 2022	DP U-1645		NDF	Jan 07, 2018
	8377474	Dec 26, 2028	DP U-219			
	8377474	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-219			
	8454998	Dec 26, 2028	DP U-1645			
	8454998	Dec 26, 2028	DP U-1646			
	8454998	Dec 26, 2028	DP U-1647			
	8454998	Dec 26, 2028	DP U-1649			
	8557283	Dec 26, 2028	DP U-219			
	8557283	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1645			
	9089607	Dec 26, 2028	DP U-1720			
	9089608	Dec 26, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CARBIDOPA; LEVODOPA - DUOPA						
N 203952 001					NP	Jan 09, 2018
					ODE	Jan 09, 2022
CARFILZOMIB - KYPROLIS						
N 202714 001					I-712	Jul 24, 2018
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 001	6417175	Apr 11, 2022	DS DP U-1676			
CEFTAROLINE FOSAMIL - TEFLARO						
N 200327 002	6417175	Apr 11, 2022	DS DP U-1676			
CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA						
N 206829 001	8968753	Mar 14, 2034	U-1672			
	8968753	Mar 14, 2034	U-1673			
CELECOXIB - CELECOXIB						
A 076898 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 076898 003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 076898 004					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 078857 004					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 200562 002					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 200562 003					PC	Jun 02, 2015
CELECOXIB - CELECOXIB						
A 200562 004					PC	Jun 02, 2015
CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE - CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE						
N 206323 001	6248363	Nov 23, 2019	DP U-1716			
	6383471	Apr 06, 2019	DP U-1716			
	9066942	Jan 03, 2032	U-1716			
CHLORPHENIRAMINE POLISTIREX; CODEINE POLISTIREX - TUZISTRA XR						
N 207768 001	8062667	Mar 29, 2029	DP			
	8790700	Mar 15, 2027	DP			
CHOLIC ACID - CHOLBAM						
N 205750 001					ODE	Mar 17, 2022
CHOLIC ACID - CHOLBAM						
N 205750 002					ODE	Mar 17, 2022

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CICLESONIDE - ALVESCO						
N 021658 002	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - ALVESCO						
N 021658 003	8371292	Feb 01, 2028	U-1355			
CICLESONIDE - OMNARIS						
N 022004 001	8371292	Feb 01, 2028	U-1356			
CICLESONIDE - ZETONNA						
N 202129 001	8371292	Feb 01, 2028	U-1357			
CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE						
A 090898 001					PC	Jul 01, 2015
CLOBETASOL PROPIONATE - OLUX E						
N 022013 001	8962000	Aug 31, 2025	DP U-1410			
COBICISTAT; DARUNAVIR ETHANOLATE - PREZCOBIX						
N 205395 001	5843946	Dec 01, 2015	DP U-1660			
	5843946*PED	Jun 01, 2016				
	7470506	Jun 23, 2019	U-1660			
	7470506*PED	Dec 23, 2019				
	7700645	Dec 26, 2026	DS DP			
	7700645*PED	Jun 26, 2027				
	8148374	Sep 03, 2029	DS DP U-1660			
	8518987	Feb 16, 2024	DS DP			
	8518987*PED	Aug 16, 2024				
	8597876	Jun 23, 2019	U-1660			
	8597876*PED	Dec 23, 2019				
	RE42889	Oct 19, 2016	DP			
	RE42889*PED	Apr 19, 2017				
	RE43596	May 09, 2017	DS DP			
	RE43596*PED	Nov 09, 2017				
	RE43802	Oct 19, 2016	U-1660			
	RE43802*PED	Apr 19, 2017				
COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD						
N 203100 001	8981103	Oct 26, 2026	DS DP		I-704	Dec 17, 2017
COLCHICINE - MITIGARE						
N 204820 001	8927607	Aug 22, 2033	U-1020			
CRIZOTINIB - XALKORI						
N 202570 001	7230098	Aug 26, 2025	DS			
CRIZOTINIB - XALKORI						
N 202570 002	7230098	Aug 26, 2025	DS			
CROFELEMER - FULYZAQ						
N 202292 001	8962680	Oct 31, 2031	U-1319			
CYANOCOBALAMIN - NASCOBAL						
N 021642 001	7229636	Aug 01, 2024	DP U-817			
	7879349	Aug 01, 2024	DP U-1152			
	8003353	Aug 01, 2024	U-817			
	8940714	Feb 26, 2024	U-1152			
CYSTEAMINE BITARTRATE - PROCYSBI						
N 203389 001					>A> NPP	Aug 14, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
CYSTEAMINE BITARTRATE - PROCYSBI							
N 203389	002					>A> NPP	Aug 14, 2018
DABRAFENIB MESYLATE - TAFINLAR							
N 202806	001	8703781	Oct 15, 2030	DS DP U-1713			
DABRAFENIB MESYLATE - TAFINLAR							
N 202806	002	8703781	Oct 15, 2030	DS DP U-1713			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	001	>A> 8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
		>A> 8629171	Jun 13, 2031	DS DP U-1724			
		>A> 8642025	Aug 11, 2027	DS DP U-1724			
		>A> 8642025	Aug 11, 2027	DS DP U-1725			
		>A> 8900566	Aug 08, 2027	U-1724			
		>A> 8900566	Aug 08, 2027	U-1725			
DACLATASVIR DIHYDROCHLORIDE - DAKLINZA							
N 206843	002	>A> 8329159	Apr 13, 2028	DS		NCE	Jul 24, 2020
		>A> 8629171	Jun 13, 2031	DS DP U-1724			
		>A> 8642025	Aug 11, 2027	DS DP U-1724			
		>A> 8642025	Aug 11, 2027	DS DP U-1725			
		>A> 8900566	Aug 08, 2027	U-1724			
		>A> 8900566	Aug 08, 2027	U-1725			
DANTROLENE SODIUM - RYANODEX							
N 205579	001					ODE	Jul 22, 2021
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA							
N 202293	001					M-157	Mar 11, 2018
DAPAGLIFLOZIN PROPANEDIOL - FARXIGA							
N 202293	002					M-157	Mar 11, 2018
DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)							
N 206619	001	6037157	Jun 26, 2016	U-1635			
		6703403	Jun 26, 2016	U-1635			
		7148359	Jul 19, 2019	DP			
		7364752	Nov 10, 2020	DP			
		8188104	May 17, 2029	DS DP U-1636			
		8268349	Aug 25, 2024	DP			
		8399015	Aug 25, 2024	DP			
		8420596	Apr 10, 2031	DS DP			
		8466159	Sep 04, 2032	U-1637			
		8492386	Sep 04, 2032	U-1637			
		8501238	Sep 17, 2028	DS DP U-1636			
		8642538	Sep 10, 2029	DS DP U-1638			
		8680106	Sep 04, 2032	U-1637			
		8685984	Sep 04, 2032	U-1637			
		8686026	Jun 09, 2031	DP			
		8691938	Apr 13, 2032	DS DP			
		9006387	Jun 10, 2030	U-1687			
		9044480	Apr 10, 2031	U-1638			
DEFERASIROX - EXJADE							
N 021882	001					ODE	Jan 23, 2020
DEFERASIROX - EXJADE							
N 021882	002					ODE	Jan 23, 2020
DEFERASIROX - EXJADE							
N 021882	003					ODE	Jan 23, 2020

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEFERASIROX - JADENU						
N 206910 001	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
DEFERASIROX - JADENU						
N 206910 002	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
DEFERASIROX - JADENU						
N 206910 003	6465504	Apr 05, 2019	DS DP			
	6596750	Jun 24, 2017	DS U-735			
DEOXYCHOLIC ACID - KYBELLA						
N 206333 001	7622130	Dec 10, 2027	U-1690			
	7754230	Dec 10, 2027	U-1690			
	8101593	Mar 02, 2030	DP			
	8242294	May 16, 2028	DS			
	8298556	Aug 03, 2025	U-1690			
	8367649	Mar 02, 2030	DP			
	8461140	Feb 21, 2028	DP			
	8546367	Feb 21, 2028	DP U-1690			
	8653058	Mar 02, 2030	DP			
	8846066	Feb 08, 2025	U-1690			
	8883770	Feb 21, 2028	DP			
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE						
A 200653 001					PC	May 16, 2015
DESMOPRESSIN ACETATE - DESMOPRESSIN ACETATE						
A 200653 002					PC	May 16, 2015
DESONIDE - VERDESO						
N 021978 001	8962000	Aug 31, 2025	DP U-1412			
DESVENLAFAXINE SUCCINATE - PRISTIQ						
N 021992 003	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
	8269040	Jul 05, 2027	DS			
DEXAMETHASONE - OZURDEX						
N 022315 001	8043628	Oct 20, 2020	U-1205			
	8088407	Oct 20, 2020	U-1205			
	9012437	Oct 20, 2020	U-1205			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 001	9011926	Feb 24, 2026	DP			
DEXLANSOPRAZOLE - DEXILANT						
N 022287 002	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8784885*PED	Apr 15, 2024				
	9011926	Feb 24, 2026	DP			
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX						
N 021038 004	6716867	Mar 31, 2019	U-1472			
	6716867*PED	Oct 01, 2019				
	8242158	Jan 04, 2032	DP			
	8242158*PED	Jul 04, 2032				
	8338470	Jan 04, 2032	DP			
	8338470*PED	Jul 04, 2032				
	8455527	Jan 04, 2032	U-421			
	8455527*PED	Jul 04, 2032				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX							
N 021038	004	8648106	Jan 04, 2032	DP			
		8648106*PED	Jul 04, 2032				
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE							
A 078908	002					PC	Aug 01, 2015
DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE							
A 078908	003					PC	Dec 19, 2015
DICLOFENAC - ZORVOLEX							
N 204592	001	8999387	Apr 23, 2030	U-55			
		9017721	Apr 23, 2030	DP			
DICLOFENAC - ZORVOLEX							
N 204592	002	8999387	Apr 23, 2030	U-55			
		9017721	Apr 23, 2030	DP			
DICLOFENAC POTASSIUM - CAMBIA							
N 022165	001	8927604	Jun 16, 2026	U-436			
DICLOFENAC SODIUM - DYLOJECT							
N 022396	001	6407079	Jun 18, 2019	DP			
		8946292	Mar 22, 2027	U-1659			
DICLOFENAC SODIUM - PENNSAID							
N 204623	001	9066913	Oct 17, 2027	DP U-1488			
		9101591	Oct 17, 2027	DP U-1488			
	>A>	9132110	Oct 17, 2027	U-1488			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	001	5061703	Apr 11, 2015	U-1641			
		5061703*PED	Oct 11, 2015				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	002	5061703	Apr 11, 2015	U-1641			
		5061703*PED	Oct 11, 2015				
		8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC							
N 206439	002	5061703	Apr 11, 2015	U-1641			
		5061703*PED	Oct 11, 2015				
		8039009	Mar 24, 2029	U-1641			
		8039009*PED	Sep 24, 2029				
		8058291	Dec 05, 2029	U-1641			
		8168209	Nov 22, 2025	DP			
		8168209*PED	May 22, 2026				
		8173708	Nov 22, 2025	U-1641			
		8173708*PED	May 22, 2026				
		8283379	Nov 22, 2025	U-1641			
		8283379*PED	May 22, 2026				
		8293794	Nov 22, 2025	DP			
		8329752	Nov 22, 2025	DP			
		8329752*PED	May 22, 2026				
		8338485	Nov 22, 2025	DP			
		8338486	Nov 22, 2025	U-1641			
		8362085	Nov 22, 2025	U-1641			
		8362085*PED	May 22, 2026				
		8580858	Nov 22, 2025	U-1641			
		8598233	Nov 22, 2025	DP			
		8598233*PED	May 22, 2026				
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036	001	>A> 9107898	May 01, 2028	DP U-620			
DOXEPIN HYDROCHLORIDE - SILENOR							
N 022036	002	>A> 9107898	May 01, 2028	DP U-620			
DOXYCYCLINE HYCLATE - DOXTERIC							
N 050795	006	6958161	Dec 15, 2022	DP U-918			
		8715724	Feb 03, 2028	DP			
DRONEDARONE HYDROCHLORIDE - MULTAQ							
N 022425	001	>A> 9107900	Apr 16, 2029	U-1726			
		>A> 9107900	Apr 16, 2029	U-1728			
DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE							
A 090694	003					PC	Jan 11, 2016
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	001	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	002	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EDOXABAN TOSYLATE - SAVAYSA							
N 206316	003	7365205	Jun 12, 2023	DS		NCE	Jan 08, 2020
EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA							
N 021937	001	9018192	Jun 13, 2026	U-750			
		9018192	Jun 13, 2026	U-1170			
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	001	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
		>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
		>A> 6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
		>A> 6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
		>A> 6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
		>A> 7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
		>A> 7160870	Nov 20, 2022	DS DP U-1306			
		>A> 7160870	Nov 20, 2022	DS DP U-1575			
		>A> 7160870	Nov 20, 2022	DS DP U-1714			
		>A> 7160870*PED	May 20, 2023				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	001	>A> 7332481	May 24, 2021	U-930			
		>A> 7332481	May 24, 2021	U-1306			
		>A> 7332481	May 24, 2021	U-1575			
		>A> 7332481	May 24, 2021	U-1714			
		>A> 7332481*PED	Nov 24, 2021				
		>A> 7452874	May 24, 2021	DS DP U-1714			
		>A> 7452874*PED	Nov 24, 2021				
		>A> 7473686	May 24, 2021	DS DP U-930			
		>A> 7473686	May 24, 2021	DS DP U-1306			
		>A> 7473686	May 24, 2021	DS DP U-1575			
		>A> 7473686	May 24, 2021	DS DP U-1714			
		>A> 7473686*PED	Nov 24, 2021				
		>A> 7547719	Jul 13, 2025	DS DP U-930			
		>A> 7547719	Jul 13, 2025	DS DP U-1306			
		>A> 7547719	Jul 13, 2025	DS DP U-1575			
		>A> 7547719	Jul 13, 2025	DS DP U-1714			
		>A> 7547719*PED	Jan 13, 2026				
		>A> 7790704	May 24, 2021	U-930			
		>A> 7790704	May 24, 2021	U-1306			
		>A> 7790704	May 24, 2021	U-1575			
		>A> 7790704	May 24, 2021	U-1714			
		>A> 7790704*PED	Nov 24, 2021				
		>A> 7795293	May 21, 2023	U-930			
		>A> 7795293	May 21, 2023	U-1306			
		>A> 7795293	May 21, 2023	U-1575			
		>A> 7795293	May 21, 2023	U-1714			
		>A> 7795293*PED	Nov 21, 2023				
		>A> 8052993	Aug 01, 2027	DP U-930			
		>A> 8052993	Aug 01, 2027	DP U-1306			
		>A> 8052993	Aug 01, 2027	DP U-1575			
		>A> 8052993	Aug 01, 2027	DP U-1714			
		>A> 8052993*PED	Feb 01, 2028				
		>A> 8052994	Aug 01, 2027	DP U-1714			
		>A> 8052994*PED	Feb 01, 2028				
		>A> 8062665	Aug 01, 2027	DP U-1714			
		>A> 8062665*PED	Feb 01, 2028				
		>A> 8071129	Aug 01, 2027	DP U-1714			
		>A> 8071129*PED	Feb 01, 2028				
		>A> 8828430	Aug 01, 2027	DP U-1306			
		>A> 8828430	Aug 01, 2027	DP U-1619			
		>A> 8828430	Aug 01, 2027	DP U-1714			
		>A> 8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	002	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
		>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
		>A> 6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
		>A> 6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
		>A> 6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
		>A> 7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
		>A> 7160870	Nov 20, 2022	DS DP U-1306			
		>A> 7160870	Nov 20, 2022	DS DP U-1575			
		>A> 7160870	Nov 20, 2022	DS DP U-1714			
		>A> 7160870*PED	May 20, 2023				
		>A> 7332481	May 24, 2021	U-930			
		>A> 7332481	May 24, 2021	U-1306			
		>A> 7332481	May 24, 2021	U-1575			
		>A> 7332481	May 24, 2021	U-1714			
		>A> 7332481*PED	Nov 24, 2021				
		>A> 7452874	May 24, 2021	DS DP U-1714			
		>A> 7452874*PED	Nov 24, 2021				
		>A> 7473686	May 24, 2021	DS DP U-930			
		>A> 7473686	May 24, 2021	DS DP U-1306			
		>A> 7473686	May 24, 2021	DS DP U-1575			
		>A> 7473686	May 24, 2021	DS DP U-1714			
		>A> 7473686*PED	Nov 24, 2021				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 002	>A>	7547719	Jul 13, 2025	DS DP U-930			
	>A>	7547719	Jul 13, 2025	DS DP U-1306			
	>A>	7547719	Jul 13, 2025	DS DP U-1575			
	>A>	7547719	Jul 13, 2025	DS DP U-1714			
	>A>	7547719*PED	Jan 13, 2026				
	>A>	7790704	May 24, 2021	U-930			
	>A>	7790704	May 24, 2021	U-1306			
	>A>	7790704	May 24, 2021	U-1575			
	>A>	7790704	May 24, 2021	U-1714			
	>A>	7790704*PED	Nov 24, 2021				
	>A>	7795293	May 21, 2023	U-930			
	>A>	7795293	May 21, 2023	U-1306			
	>A>	7795293	May 21, 2023	U-1575			
	>A>	7795293	May 21, 2023	U-1714			
	>A>	7795293*PED	Nov 21, 2023				
	>A>	8052993	Aug 01, 2027	DP U-1714			
	>A>	8052993*PED	Feb 01, 2028				
	>A>	8052994	Aug 01, 2027	DP U-930			
	>A>	8052994	Aug 01, 2027	DP U-1306			
	>A>	8052994	Aug 01, 2027	DP U-1575			
	>A>	8052994	Aug 01, 2027	DP U-1714			
	>A>	8052994*PED	Feb 01, 2028				
	>A>	8062665	Aug 01, 2027	DP U-1714			
	>A>	8062665*PED	Feb 01, 2028				
	>A>	8071129	Aug 01, 2027	DP U-1714			
	>A>	8071129*PED	Feb 01, 2028				
	>A>	8828430	Aug 01, 2027	DP U-1306			
	>A>	8828430	Aug 01, 2027	DP U-1619			
	>A>	8828430	Aug 01, 2027	DP U-1714			
	>A>	8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291 003	>A>	6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
	>A>	6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
	>A>	6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
	>A>	6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
	>A>	7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
	>A>	7160870	Nov 20, 2022	DS DP U-1306			
	>A>	7160870	Nov 20, 2022	DS DP U-1575			
	>A>	7160870	Nov 20, 2022	DS DP U-1714			
	>A>	7160870*PED	May 20, 2023				
	>A>	7332481	May 24, 2021	U-930			
	>A>	7332481	May 24, 2021	U-1306			
	>A>	7332481	May 24, 2021	U-1575			
	>A>	7332481	May 24, 2021	U-1714			
	>A>	7332481*PED	Nov 24, 2021				
	>A>	7452874	May 24, 2021	DS DP U-1714			
	>A>	7452874*PED	Nov 24, 2021				
	>A>	7473686	May 24, 2021	DS DP U-930			
	>A>	7473686	May 24, 2021	DS DP U-1306			
	>A>	7473686	May 24, 2021	DS DP U-1575			
	>A>	7473686	May 24, 2021	DS DP U-1714			
	>A>	7473686*PED	Nov 24, 2021				
	>A>	7547719	Jul 13, 2025	DS DP U-930			
	>A>	7547719	Jul 13, 2025	DS DP U-1306			
	>A>	7547719	Jul 13, 2025	DS DP U-1575			
	>A>	7547719	Jul 13, 2025	DS DP U-1714			
	>A>	7547719*PED	Jan 13, 2026				
	>A>	7790704	May 24, 2021	U-930			
	>A>	7790704	May 24, 2021	U-1306			
	>A>	7790704	May 24, 2021	U-1575			
	>A>	7790704	May 24, 2021	U-1714			
	>A>	7790704*PED	Nov 24, 2021				
	>A>	7795293	May 21, 2023	U-930			
	>A>	7795293	May 21, 2023	U-1306			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	003	>A> 7795293	May 21, 2023	U-1575			
		>A> 7795293	May 21, 2023	U-1714			
		>A> 7795293*PED	Nov 21, 2023				
		>A> 8052993	Aug 01, 2027	DP U-1714			
		>A> 8052993*PED	Feb 01, 2028				
		>A> 8052994	Aug 01, 2027	DP U-1714			
		>A> 8052994*PED	Feb 01, 2028				
		>A> 8062665	Aug 01, 2027	DP U-714			
		>A> 8062665	Aug 01, 2027	DP U-930			
		>A> 8062665	Aug 01, 2027	DP U-1306			
		>A> 8062665	Aug 01, 2027	DP U-1575			
		>A> 8062665*PED	Feb 01, 2028				
		>A> 8071129	Aug 01, 2027	DP U-1714			
		>A> 8071129*PED	Feb 01, 2028				
		>A> 8828430	Aug 01, 2027	DP U-1306			
		>A> 8828430	Aug 01, 2027	DP U-1619			
		>A> 8828430	Aug 01, 2027	DP U-1714			
		>A> 8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	004	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
		>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
		>A> 6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
		>A> 6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
		>A> 6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
		>A> 7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
		>A> 7160870	Nov 20, 2022	DS DP U-1306			
		>A> 7160870	Nov 20, 2022	DS DP U-1575			
		>A> 7160870	Nov 20, 2022	DS DP U-1714			
		>A> 7160870*PED	May 20, 2023				
		>A> 7332481	May 24, 2021	U-930			
		>A> 7332481	May 24, 2021	U-1306			
		>A> 7332481	May 24, 2021	U-1575			
		>A> 7332481	May 24, 2021	U-1714			
		>A> 7332481*PED	Nov 24, 2021				
		>A> 7452874	May 24, 2021	DS DP U-1714			
		>A> 7452874*PED	Nov 24, 2021				
		>A> 7473686	May 24, 2021	DS DP U-930			
		>A> 7473686	May 24, 2021	DS DP U-1306			
		>A> 7473686	May 24, 2021	DS DP U-1575			
		>A> 7473686	May 24, 2021	DS DP U-1714			
		>A> 7473686*PED	Nov 24, 2021				
		>A> 7547719	Jul 13, 2025	DS DP U-930			
		>A> 7547719	Jul 13, 2025	DS DP U-1306			
		>A> 7547719	Jul 13, 2025	DS DP U-1575			
		>A> 7547719	Jul 13, 2025	DS DP U-1714			
		>A> 7547719*PED	Jan 13, 2026				
		>A> 7790704	May 24, 2021	U-930			
		>A> 7790704	May 24, 2021	U-1306			
		>A> 7790704	May 24, 2021	U-1575			
		>A> 7790704	May 24, 2021	U-1714			
		>A> 7790704*PED	Nov 24, 2021				
		>A> 7795293	May 21, 2023	U-930			
		>A> 7795293	May 21, 2023	U-1306			
		>A> 7795293	May 21, 2023	U-1575			
		>A> 7795293	May 21, 2023	U-1714			
		>A> 7795293*PED	Nov 21, 2023				
		>A> 8052993	Aug 01, 2027	DP U-1714			
		>A> 8052993*PED	Feb 01, 2028				
		>A> 8052994	Aug 01, 2027	DP U-1714			
		>A> 8052994*PED	Feb 01, 2028				
		>A> 8062665	Aug 01, 2027	DP U-1714			
		>A> 8062665*PED	Feb 01, 2028				
		>A> 8071129	Aug 01, 2027	DP U-930			
		>A> 8071129	Aug 01, 2027	DP U-1306			
		>A> 8071129	Aug 01, 2027	DP U-1575			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	004	>A> 8071129	Aug 01, 2027	DP U-1714			
		>A> 8071129*PED	Feb 01, 2028				
		>A> 8828430	Aug 01, 2027	DP U-1306			
		>A> 8828430	Aug 01, 2027	DP U-1619			
		>A> 8828430	Aug 01, 2027	DP U-1714			
		>A> 8828430*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA							
N 022291	005	>A> 6280959	Oct 30, 2018	DS DP U-930		>A> D-149	Jun 11, 2018
		>A> 6280959	Oct 30, 2018	DS DP U-1306		>A> I-711	Jun 11, 2018
		>A> 6280959	Oct 30, 2018	DS DP U-1575		>A> ODE	Aug 26, 2021
		>A> 6280959	Oct 30, 2018	DS DP U-1714		>A> PED	Dec 11, 2018
		>A> 6280959*PED	Apr 30, 2019			>A> PED	Dec 11, 2018
		>A> 7160870	Nov 20, 2022	DS DP U-930		>A> PED	Feb 26, 2022
		>A> 7160870	Nov 20, 2022	DS DP U-1306			
		>A> 7160870	Nov 20, 2022	DS DP U-1575			
		>A> 7160870	Nov 20, 2022	DS DP U-1714			
		>A> 7160870*PED	May 20, 2023				
		>A> 7332481	May 24, 2021	U-930			
		>A> 7332481	May 24, 2021	U-1306			
		>A> 7332481	May 24, 2021	U-1575			
		>A> 7332481	May 24, 2021	U-1714			
		>A> 7332481*PED	Nov 24, 2021				
		>A> 7452874	May 24, 2021	DS DP U-1714			
		>A> 7452874*PED	Nov 24, 2021				
		>A> 7473686	May 24, 2021	DS DP U-930			
		>A> 7473686	May 24, 2021	DS DP U-1306			
		>A> 7473686	May 24, 2021	DS DP U-1575			
		>A> 7473686	May 24, 2021	DS DP U-1714			
		>A> 7473686*PED	Nov 24, 2021				
		>A> 7547719	Jul 13, 2025	DS DP U-930			
		>A> 7547719	Jul 13, 2025	DS DP U-1306			
		>A> 7547719	Jul 13, 2025	DS DP U-1575			
		>A> 7547719*PED	Jan 13, 2026				
		>A> 7790704	May 24, 2021	U-930			
		>A> 7790704	May 24, 2021	U-1306			
		>A> 7790704	May 24, 2021	U-1575			
		>A> 7790704*PED	Nov 24, 2021				
		>A> 7795293	May 21, 2023	U-930			
		>A> 7795293	May 21, 2023	U-1306			
		>A> 7795293	May 21, 2023	U-1575			
		>A> 7795293*PED	Nov 21, 2023				
		>A> 8052995	Aug 01, 2027	DP U-1306			
		>A> 8052995	Aug 01, 2027	DP U-1575			
		>A> 8052995*PED	Feb 01, 2028				
ELTROMBOPAG OLAMINE - PROMACTA							
N 207027	001					>A> D-149	Jun 11, 2018
						>A> I-711	Jun 11, 2018
						>A> ODE	Nov 20, 2015
						>A> PED	Dec 11, 2018
						>A> PED	Dec 11, 2018
ELUXADOLINE - VIBERZI							
N 206940	001	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
		7786158	Mar 14, 2025	DS			
		8344011	Mar 14, 2025	U-1709			
		8609709	Mar 14, 2025	DS			
		8691860	Jul 07, 2028	DS U-1709			
ELUXADOLINE - VIBERZI							
N 206940	002	7741356	Mar 25, 2028	DS DP		NCE	May 27, 2020
		7786158	Mar 14, 2025	DS			
		8344011	Mar 14, 2025	U-1709			
		8609709	Mar 14, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ELUXADOLINE - VIBERZI						
N 206940 002	8691860	Jul 07, 2028	DS U-1709			
ELVITEGRAVIR - VITEKTA						
N 203093 001	8981103	Oct 26, 2026	DS DP			
ELVITEGRAVIR - VITEKTA						
N 203093 002	8981103	Oct 26, 2026	DS DP			
EMPAGLIFLOZIN - JARDIANCE						
N 204629 001					M-160	Jun 26, 2018
					M-161	Jun 26, 2018
EMPAGLIFLOZIN - JARDIANCE						
N 204629 002					M-160	Jun 26, 2018
					M-161	Jun 26, 2018
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 001	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2027	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI						
N 206073 002	6303661	Apr 24, 2017	U-1651		NC	Jan 30, 2018
	6890898	Feb 02, 2019	U-1652		NCE	May 02, 2016
	7078381	Feb 02, 2019	U-1651		NCE	Aug 01, 2019
	7407955	Aug 12, 2023	DS DP			
	7459428	Feb 02, 2019	U-1651			
	7579449	Nov 05, 2025	DS			
	7713938	Apr 15, 2027	DS DP			
	8119648	Aug 12, 2023	U-1651			
	8178541	Aug 12, 2023	DP U-1653			
	8178541	Aug 12, 2023	DP U-1654			
	8551957	Oct 19, 2029	DP U-1651			
	8673927	May 04, 2024	DP U-1652			
	8846695	Jun 04, 2030	U-1652			
	8883805	Nov 26, 2025	DP			
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 001					>A> NCE	Aug 01, 2019
					>A> NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 002					>A> NCE	Aug 01, 2019
					>A> NP	Aug 26, 2018
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY						
N 206111 003					>A> NCE	Aug 01, 2019
					>A> NP	Aug 26, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY							
N 206111	004					>A> NCE	Aug 01, 2019
						>A> NP	Aug 26, 2018
EPINEPHRINE - AUVI-Q							
N 201739	001	8920377	Nov 23, 2024	DP			
		8926594	Mar 31, 2026	DP			
		9056170	Nov 23, 2024	DP			
EPINEPHRINE - AUVI-Q							
N 201739	002	8920377	Nov 23, 2024	DP			
		8926594	Mar 31, 2026	DP			
		9056170	Nov 23, 2024	DP			
EPINEPHRINE - ADRENALIN							
N 204640	001	>A> 9119876	Mar 13, 2035	DP			
ERIBULIN MESYLATE - HALAVEN							
N 201532	001	6214865	Jul 20, 2023	DS			
ERLOTINIB HYDROCHLORIDE - TARCEVA							
N 021743	001	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
		5747498*PED	May 08, 2019			PED	Nov 14, 2016
		6900221	Nov 09, 2020	DS DP U-659			
		6900221	Nov 09, 2020	DS DP U-875			
		6900221	Nov 09, 2020	DS DP U-1046			
		6900221	Nov 09, 2020	DS DP U-1403			
		6900221*PED	May 09, 2021				
		7087613	Nov 09, 2020	U-659			
		7087613	Nov 09, 2020	U-1045			
		7087613	Nov 09, 2020	U-1403			
		7087613*PED	May 09, 2021				
		RE41065	Nov 08, 2018	DS DP			
		RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA							
N 021743	002	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
		5747498*PED	May 08, 2019			PED	Nov 14, 2016
		6900221	Nov 09, 2020	DS DP U-659			
		6900221	Nov 09, 2020	DS DP U-875			
		6900221	Nov 09, 2020	DS DP U-1046			
		6900221	Nov 09, 2020	DS DP U-1403			
		6900221*PED	May 09, 2021				
		7087613	Nov 09, 2020	U-659			
		7087613	Nov 09, 2020	U-1045			
		7087613	Nov 09, 2020	U-1403			
		7087613*PED	May 09, 2021				
		RE41065	Nov 08, 2018	DS DP			
		RE41065*PED	May 08, 2019				
ERLOTINIB HYDROCHLORIDE - TARCEVA							
N 021743	003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
		5747498*PED	May 08, 2019			PED	Nov 14, 2016
		6900221	Nov 09, 2020	DS DP U-659			
		6900221	Nov 09, 2020	DS DP U-875			
		6900221	Nov 09, 2020	DS DP U-1046			
		6900221	Nov 09, 2020	DS DP U-1403			
		6900221*PED	May 09, 2021				
		7087613	Nov 09, 2020	U-659			
		7087613	Nov 09, 2020	U-1045			
		7087613	Nov 09, 2020	U-1403			
		7087613*PED	May 09, 2021				
		RE41065	Nov 08, 2018	DS DP			
		RE41065*PED	May 08, 2019				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ERLOTINIB HYDROCHLORIDE - TARCEVA							
N 021743	003	5747498	Nov 08, 2018	DS DP U-659		I-671	May 14, 2016
		5747498*PED	May 08, 2019			PED	Nov 14, 2016
		6900221	Nov 09, 2020	DS DP U-659			
		6900221	Nov 09, 2020	DS DP U-875			
		6900221	Nov 09, 2020	DS DP U-1046			
		6900221	Nov 09, 2020	DS DP U-1403			
		6900221*PED	May 09, 2021				
		7087613	Nov 09, 2020	U-659			
		7087613	Nov 09, 2020	U-1045			
		7087613	Nov 09, 2020	U-1403			
		7087613*PED	May 09, 2021				
		RE41065	Nov 08, 2018	DS DP			
		RE41065*PED	May 08, 2019				
ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR							
N 204655	001	5690960	Nov 25, 2014	DP U-1509			
		5690960*PED	May 25, 2015				
		5714504	Feb 03, 2015	DP U-1509			
		5714504*PED	Aug 03, 2015				
		5877192*PED	Nov 27, 2014				
		5900424	May 04, 2016	DS U-1509			
		5900424*PED	Nov 04, 2016				
		6369085	May 25, 2018	DS DP U-1509			
		6369085*PED	Nov 25, 2018				
		6428810	Nov 03, 2019	DP U-1509			
		6428810*PED	May 03, 2020				
		6875872*PED	Nov 27, 2014				
		7411070	May 25, 2018	DS			
		7411070*PED	Nov 25, 2018				
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	001	8945621	Oct 17, 2031	U-1661			
ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO							
N 022511	002	8945621	Oct 17, 2031	U-1661			
ESTRADIOL - MINIVELLE							
N 203752	005	6841716	Apr 27, 2020	DP			
		8231906	Jul 04, 2030	DS DP			
EVEROLIMUS - AFINITOR							
N 022334	001	8410131	Nov 01, 2025	DS DP U-1368			
		8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR							
N 022334	002	8410131	Nov 01, 2025	DS DP U-1368			
		8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR							
N 022334	003	8410131	Nov 01, 2025	DS DP U-1368			
		8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
EVEROLIMUS - AFINITOR							
N 022334	004	8410131	Nov 01, 2025	DS DP U-1368			
		8410131*PED	May 01, 2026				
		9006224	Jul 01, 2028	U-1681			
FEBUXOSTAT - ULORIC							
N 021856	001 >A>	9107912	Sep 08, 2031	U-1346			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FEBUXOSTAT - ULORIC								
N 021856 002	>A>	9107912	Sep 08, 2031		U-1346			
FENTANYL CITRATE - LAZANDA								
N 022569 001		9078814	Jan 08, 2024		DP			
FENTANYL CITRATE - LAZANDA								
N 022569 002		9078814	Jan 08, 2024		DP			
FENTANYL HYDROCHLORIDE - IONSYS								
N 021338 001		6169920	Jan 02, 2018		DP U-736			
		6181963	Nov 02, 2019		DP			
		8301238	Sep 30, 2031		DP			
		8428708	May 21, 2032		U-736			
		8428709	Jun 11, 2032		DP U-736			
		8781571	Mar 31, 2032		DP U-736			
		9095706	Jan 17, 2033		DP			
FERRIC CITRATE - AURYXIA								
N 205874 001		8901349	Feb 18, 2024		U-1577			
		9050316	Feb 18, 2024		U-1577			
FERRIC PYROPHOSPHATE CITRATE - TRIFERIC								
N 206317 001		6689275	Dec 31, 2016		U-1656			
		6779468	Dec 31, 2016		U-1656			
		7816404	Apr 17, 2029		DP U-1656			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA ALLERGY								
N 201373 001		8933097	Aug 16, 2032		DP			
FEXOFENADINE HYDROCHLORIDE - CHILDREN'S ALLEGRA HIVES								
N 201373 002		8933097	Aug 16, 2032		DP			
FINAFLOXACIN - XTORO								
N 206307 001		6133260	Apr 12, 2017	DS	DP			
		6432948	Apr 12, 2017	DS	DP			
		8536167	Aug 08, 2031		U-1679			
	>A>	9119859	Jul 02, 2030		U-1679			
FLIBANSERIN - ADDYI								
N 022526 001	>A>	7151103	May 09, 2023		U-1734		>A> NCE	Aug 18, 2020
	>A>	7420057	Aug 01, 2022	DS	DP			
	>A>	8227471	May 09, 2023		U-1734			
FLUTEMETAMOL F-18 - VIZAMYL								
N 203137 001		8916131	Sep 16, 2028		DP			
FLUTEMETAMOL F-18 - VIZAMYL								
N 203137 002		8916131	Sep 16, 2028		DP			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275 001		6537983	Aug 03, 2021		DP U-1401		I-708	Apr 30, 2018
		6537983	Aug 03, 2021		DP U-1691			
		6759398	Aug 03, 2021		DP U-1401			
		6759398	Aug 03, 2021		DP U-1691			
		7101866	Aug 03, 2021	DS	DP U-1401			
		7101866	Aug 03, 2021	DS	DP U-1691			
		7439393	Sep 11, 2022	DS	DP U-1401			
		7439393	Sep 11, 2022	DS	DP U-1691			
		8511304	Jun 14, 2027		DP U-1424			
		8511304	Jun 14, 2027		DP U-1691			
		RE44874	Mar 23, 2023	DS	DP U-1548			
		RE44874	Mar 23, 2023	DS	DP U-1691			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE		PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	001	6537983	Aug 03, 2021		DP U-1401		I-708	Apr 30, 2018
		6537983	Aug 03, 2021		DP U-1691			
		6759398	Aug 03, 2021		DP U-1401			
		6759398	Aug 03, 2021		DP U-1691			
		7101866	Aug 03, 2021	DS	DP U-1401			
		7101866	Aug 03, 2021	DS	DP U-1691			
		7439393	Sep 11, 2022	DS	DP U-1401			
		7439393	Sep 11, 2022	DS	DP U-1691			
		8511304	Jun 14, 2027		DP U-1424			
		8511304	Jun 14, 2027		DP U-1691			
		RE44874	Mar 23, 2023	DS	DP U-1548			
		RE44874	Mar 23, 2023	DS	DP U-1691			
FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA								
N 204275	002	5873360	Feb 23, 2016		DP		NP	Apr 30, 2018
		6537983	Aug 03, 2021		DP U-1691			
		6759398	Aug 03, 2021		DP U-1691			
		7101866	Aug 03, 2021	DS	DP U-1691			
		7439393	Sep 11, 2022	DS	DP U-1691			
		7629335	Aug 03, 2021		DP			
		7776895	Sep 11, 2022		DP			
		8113199	Oct 23, 2027		DP			
		8161968	Feb 05, 2028		DP			
		8511304	Jun 14, 2027		DP U-1691			
		8534281	Aug 10, 2029		DP			
		8746242	Oct 11, 2030		DP			
		RE44874	Mar 23, 2023	DS	DP U-1691			
FLUTICASONE PROPIONATE - CUTIVATE								
N 021152	001						NPP	Jan 16, 2018
GADOXETATE DISODIUM - EOVIST								
N 022090	001						M-155	Mar 27, 2018
GADOXETATE DISODIUM - EOVIST								
N 022090	002						M-155	Mar 27, 2018
GEFITINIB - IRESSA								
N 206995	001	5770599	May 05, 2017	DS	DP U-1403		NP	Jul 13, 2018
							>A> ODE	Jul 13, 2022
GLATIRAMER ACETATE - COPAXONE								
N 020622	003	8969302	Aug 19, 2030		U-441			
GLYCEROL PHENYLBUTYRATE - RAVICTI								
N 203284	001	>A> 9095559	Mar 09, 2032		U-1383			
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE								
A 200881	001						PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE								
A 200881	002						PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE								
A 200881	003						PC	May 30, 2015
GUANFACINE HYDROCHLORIDE - GUANFACINE HYDROCHLORIDE								
A 200881	004						PC	May 30, 2015

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 001					M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 002					M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 003					M-154	Mar 18, 2018
GUANFACINE HYDROCHLORIDE - INTUNIV						
N 022037 004					M-154	Mar 18, 2018
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 001	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 002	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 003	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 004	9023401	Oct 30, 2021	DP			
	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 005	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 006	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
HYDROCODONE BITARTRATE - HYSINGLA						
N 206627 007	9056052	Oct 30, 2021	DP			
	9060940	Oct 30, 2021	U-1556			
	9084816	Aug 24, 2027	DP			
	9095614	Aug 24, 2027	U-1556			
	9095615	Aug 24, 2027	DP			
IBRUTINIB - IMBRUVICA						
N 205552 001	8497277	Dec 28, 2026	U-1456		I-702	Jan 29, 2018
	8497277	Dec 28, 2026	U-1491		ODE	Jan 29, 2022
	8497277	Dec 28, 2026	U-1650			
	8957079	Dec 28, 2026	DS DP			
	8999999	Jun 03, 2031	U-1683			
	8999999	Jun 03, 2031	U-1684			
IBUPROFEN - CALDOLOR						
N 022348 002	8871810	Sep 30, 2029	U-1599			
	9012508	Sep 14, 2030	U-981			
ICATIBANT ACETATE - FIRAZYR						
N 022150 001	5648333	Jul 15, 2019	DS DP U-1187			
IDELALISIB - ZYDELIG						
N 205858 001	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
IDELALISIB - ZYDELIG						
N 205858 002	8138195	Apr 24, 2021	DS DP U-1549			
	8865730	Mar 05, 2033	DS DP U-1615			
	8980901	May 12, 2025	U-1678			
	RE44599	Jul 21, 2025	U-1558			
	RE44599	Jul 21, 2025	U-1615			
ILOPERIDONE - FANAPT						
N 022192 001	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT						
N 022192 002	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT						
N 022192 003	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			
	9074254	Dec 28, 2031	U-1674			
	9074255	Dec 17, 2030	U-1674			
	9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT						
N 022192 004	8652776	Aug 31, 2030	U-1685			
	8999638	Oct 28, 2030	U-1674			
	9072742	Jan 16, 2031	U-1674			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ILOPERIDONE - FANAPT							
N 022192 004		9074254	Dec 28, 2031	U-1674			
		9074255	Dec 17, 2030	U-1674			
		9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT							
N 022192 005		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
		9072742	Jan 16, 2031	U-1674			
		9074254	Dec 28, 2031	U-1674			
		9074255	Dec 17, 2030	U-1674			
		9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT							
N 022192 006		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
		9072742	Jan 16, 2031	U-1674			
		9074254	Dec 28, 2031	U-1674			
		9074255	Dec 17, 2030	U-1674			
		9074256	Feb 10, 2031	U-1674			
ILOPERIDONE - FANAPT							
N 022192 007		8652776	Aug 31, 2030	U-1685			
		8999638	Oct 28, 2030	U-1674			
		9072742	Jan 16, 2031	U-1674			
		9074254	Dec 28, 2031	U-1674			
		9074255	Dec 17, 2030	U-1674			
		9074256	Feb 10, 2031	U-1674			
INDACATEROL MALEATE - ARCAPTA NEOHALER							
N 022383 001		8658673	Jun 02, 2020	DS DP U-1168			
INDOMETHACIN - TIVORBEX							
N 204768 001		8992982	Apr 23, 2030	DP			
		9089471	Apr 23, 2030	U-55			
INDOMETHACIN - TIVORBEX							
N 204768 002		8992982	Apr 23, 2030	DP			
		9089471	Apr 23, 2030	U-55			
INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH							
N 020986 005		8920383	Jul 17, 2026	DP			
	>A>	9108002	Jan 20, 2026	DP			
	>A>	9132239	Feb 01, 2032	DP			
INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH							
N 021536 005		8920383	Jul 17, 2026	DP			
	>A>	9108002	Jan 20, 2026	DP			
	>A>	9132239	Feb 01, 2032	DP			
INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR							
N 021081 002		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR							
N 206538 001		7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
		7918833*PED	Mar 23, 2028				
		8512297	Sep 15, 2024	DP			
		8556864	Mar 03, 2024	DP			
		8603044	Mar 02, 2024	DP			
		8679069	Apr 12, 2025	DP			
		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR							
N 206538	001	7918833	Sep 23, 2027	DP		NP	Feb 25, 2018
		7918833*PED	Mar 23, 2028				
		8512297	Sep 15, 2024	DP			
		8556864	Mar 03, 2024	DP			
		8603044	Mar 02, 2024	DP			
		8679069	Apr 12, 2025	DP			
		8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR							
N 021629	003	8992486	Jun 05, 2024	DP			
		9011391	Mar 26, 2024	DP			
INSULIN LISPRO RECOMBINANT - HUMALOG KWIKPEN							
N 205747	001	6034054	Jun 11, 2018	DP U-1707			
		6034054	Jun 11, 2018	DP U-1708			
		6551992	Jun 11, 2018	DP U-1707			
		6551992	Jun 11, 2018	DP U-1708			
		7291132	Aug 09, 2024	DP			
INSULIN RECOMBINANT HUMAN - AFREZZA							
N 022472	001	>A> 8912193	Jun 12, 2029	DP U-1538			
INSULIN RECOMBINANT HUMAN - AFREZZA							
N 022472	002	>A> 7943572	Aug 10, 2026	U-1539			
		>A> 8424518	Oct 17, 2031	DP			
		>A> 8623817	Sep 18, 2029	U-1537			
		>A> 8912193	Jun 12, 2029	DP U-1538			
INSULIN RECOMBINANT HUMAN - AFREZZA							
N 022472	003	6444226	Jun 29, 2020	DP U-1534		NP	Jun 27, 2017
		6652885	Jun 29, 2020	U-1535			
		7305986	Jan 16, 2023	DP			
		7464706	Mar 02, 2023	DP			
		7648960	Jun 29, 2020	U-1535			
		7943178	Jun 29, 2020	DP U-1535			
		7943572	Aug 10, 2026	U-1539			
		8119593	Aug 11, 2029	U-1537			
		8146588	Apr 24, 2023	DP			
		8156936	Jan 16, 2023	DP			
		8215300	Nov 24, 2022	DP			
		8258095	Aug 11, 2029	U-1537			
		8389470	Jun 29, 2020	DP U-1697			
		8394414	May 15, 2015	DP U-1533			
		8424518	Oct 17, 2031	DP			
		8485180	Mar 25, 2030	DP			
		8499757	Feb 19, 2032	DP			
		8551528	Jun 11, 2030	DP			
		8623817	Sep 18, 2029	U-1537			
		8636001	Jul 12, 2032	DP			
		8729019	Jun 06, 2028	DP			
		8734845	Jun 11, 2030	DP			
		8778403	Jun 11, 2030	DP U-1538			
		8889099	Jun 29, 2020	DP U-1621			
		>A> 8912193	Jun 12, 2029	DP U-1538			
IPRATROPIUM BROMIDE - ATROVENT HFA							
N 021527	001	8474447	Jan 17, 2030	DP			
ISAVUCONAZONIUM SULFATE - CRESEMBA							
N 207500	001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
		7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
						GAIN	Mar 06, 2025
						GAIN	Mar 06, 2027

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207500 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISAVUCONAZONIUM SULFATE - CRESEMBA						
N 207501 001	6812238	Oct 31, 2020	DS		NCE	Mar 06, 2020
	7459561	Oct 31, 2020	DS		ODE	Mar 06, 2022
					GAIN	Mar 06, 2025
					GAIN	Mar 06, 2027
ISOTRETINOIN - ABSORICA						
N 021951 001	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 002	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 003	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 004	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 005	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
ISOTRETINOIN - ABSORICA						
N 021951 006	7435427	Sep 21, 2021	DP			
	8367102	Sep 21, 2021	U-1347			
	8952064	Sep 21, 2021	DP			
	9078925	Sep 21, 2021	DP			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 001	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVABRADINE HYDROCHLORIDE - CORLANOR						
N 206143 002	7361649	Apr 17, 2026	DS DP U-1694		NCE	Apr 15, 2020
	7361650	Apr 14, 2026	DS DP U-1694			
	7867996	Feb 22, 2026	DS DP U-1694			
	7879842	Feb 22, 2026	DS DP U-1694			
IVACAFTOR - KALYDECO						
N 203188 001	8354427	Jul 06, 2026	U-1311		I-705	Dec 30, 2017
IVACAFTOR - KALYDECO						
N 207925 001	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
IVACAFTOR - KALYDECO						
N 207925 002	7495103	May 20, 2027	DS DP			
	8324242	Apr 18, 2027	U-1311			
	8354427	Jul 06, 2026	U-1311			
	8410274	Dec 28, 2026	DP			
	8754224	Dec 28, 2026	DS DP			
	8883206	Feb 27, 2033	DP			
IVACAFTOR; LUMACAFTOR - ORKAMBI						
N 206038 001	7495103	May 20, 2027	DS DP		NCE	Jul 02, 2020
	8324242	Apr 18, 2027	U-1311		ODE	Jul 02, 2022
	8410274	Dec 28, 2026	DP			
	8507534	Sep 20, 2030	DS DP			
	8653103	Dec 04, 2028	DP			
	8716338	Nov 08, 2026	DP U-1718			
	8741933	Nov 08, 2026	U-1717			
	8754224	Dec 28, 2026	DS DP			
	8846718	Dec 04, 2028	U-1717			
	8993600	Dec 11, 2030	DP			
IVERMECTIN - SOOLANTRA						
N 206255 001	5952372	Sep 18, 2018	U-1631			
	6133310	Apr 26, 2019	U-1631			
	7550440	Apr 22, 2024	DP U-1631			
	8080530	Apr 22, 2024	DP U-1631			
	8093219	Apr 22, 2024	DP U-1631			
	8415311	Apr 22, 2024	DP U-1631			
	8470788	Apr 22, 2024	DP U-1631			
	8815816	Apr 22, 2024	DP U-1631			
	9089587	Mar 13, 2034	U-1631			
KETOROLAC TROMETHAMINE - ACULAR LS						
N 021528 001	8946281	May 28, 2024	U-1662			
KETOROLAC TROMETHAMINE - ACUVAIL						
N 022427 001	8992952	Aug 05, 2024	DP			
KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIDRIA						
N 205388 001	9066856	Oct 23, 2033	DP			
LAMIVUDINE - LAMIVUDINE						
A 203564 001					PC	Sep 01, 2015
LAMIVUDINE - EPIVIR						
N 020564 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
LAMIVUDINE - EPIVIR						
N 020564 003	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	5905082*PED	Nov 18, 2016				
LAMIVUDINE - EPIVIR						
N 020596 001	5905082	May 18, 2016	DS DP		D-147	Mar 23, 2018
	6004968	Mar 20, 2018	DP U-248			
	6004968*PED	Sep 20, 2018				
LAMIVUDINE; RALTEGRAVIR POTASSIUM - DUTREBIS						
N 206510 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-1663			
	7435734	Oct 21, 2022	U-1663			
	7754731	Mar 11, 2029	DS DP U-1663			
	7820660	Apr 25, 2023	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAMOTRIGINE - LAMOTRIGINE						
A 200828 001					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 002					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 003					PC	Sep 28, 2015
LAMOTRIGINE - LAMOTRIGINE						
A 200828 004					PC	Sep 28, 2015
LAMOTRIGINE - LAMICTAL						
N 020241 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 005					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL						
N 020241 006					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL CD						
N 020764 004					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 001					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 002					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 003					M-159	May 18, 2018
LAMOTRIGINE - LAMICTAL ODT						
N 022251 004					M-159	May 18, 2018
LANTHANUM CARBONATE - FOSRENOL						
N 204734 001	8980327	Dec 01, 2030	DP			
LANTHANUM CARBONATE - FOSRENOL						
N 204734 002	8980327	Dec 01, 2030	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LAPATINIB DITOSYLATE - TYKERB							
N 022059 001		8821927	Sep 18, 2029	DS DP			
LEDIPASVIR; SOFOSBUVIR - HARVONI							
N 205834 001		9085573	Mar 21, 2028	DS DP U-1470			
LENALIDOMIDE - REVLIMID							
N 021880 001		9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A>	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A>	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 002		9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A>	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A>	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 003		9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A>	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A>	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 004		9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A>	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A>	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 005		9056120	Apr 11, 2023	U-1215		I-706	Feb 17, 2018
	>A>	9101621	May 15, 2023	U-1216		ODE	Feb 17, 2022
	>A>	9101622	May 15, 2023	U-1216			
LENALIDOMIDE - REVLIMID							
N 021880 006		5635517	Oct 04, 2019	DS U-1211		I-706	Feb 17, 2018
		9056120	Apr 11, 2023	U-1215		ODE	Feb 17, 2022
	>A>	9101621	May 15, 2023	U-1216			
	>A>	9101622	May 15, 2023	U-1216			
LENVATINIB MESYLATE - LENVIMA							
N 206947 001		7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
		9006256	Jul 27, 2027	U-1695			
LENVATINIB MESYLATE - LENVIMA							
N 206947 002		7253286	Oct 19, 2021	DS DP		NCE	Feb 13, 2020
		7612208	Sep 19, 2026	DS DP		ODE	Feb 13, 2022
		9006256	Jul 27, 2027	U-1695			
LEUPROLIDE ACETATE - LUPRON DEPOT							
N 020517 003		7429559	Jan 13, 2019	DP			
		8815801	Jun 28, 2022	DP			
		8921326	Feb 05, 2031	DP U-1666			
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837 001						M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837 002						M-151	Jan 22, 2018
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837 003						M-151	Jan 22, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LEVALBUTEROL HYDROCHLORIDE - XOPENEX							
N 020837	004					M-151	Jan 22, 2018
LEVALBUTEROL TARTRATE - XOPENEX HFA							
N 021730	001					M-156	Mar 12, 2018
LEVETIRACETAM - ELEPSIA XR							
N 204417	001	8163306	Sep 03, 2027	DP			
		8425938	Feb 22, 2026	DP			
		8431156	Oct 31, 2027	DP			
		8470367	Jun 30, 2024	DP			
		8535717	Feb 22, 2026	DP			
LEVETIRACETAM - ELEPSIA XR							
N 204417	002	8163306	Sep 03, 2027	DP			
		8425938	Feb 22, 2026	DP			
		8431156	Oct 31, 2027	DP			
		8470367	Jun 30, 2024	DP			
		8535717	Feb 22, 2026	DP			
LEVETIRACETAM - SPRITAM							
N 207958	001	>A> 6471992	Feb 20, 2018	DP			
LEVETIRACETAM - SPRITAM							
N 207958	002	>A> 6471992	Feb 20, 2018	DP			
LEVETIRACETAM - SPRITAM							
N 207958	003	>A> 6471992	Feb 20, 2018	DP			
LEVETIRACETAM - SPRITAM							
N 207958	004	>A> 6471992	Feb 20, 2018	DP			
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM							
A 203563	001					PC	Oct 20, 2015
LEVOLEUCOVORIN CALCIUM - LEVOLEUCOVORIN CALCIUM							
A 203563	002					PC	Oct 20, 2015
LEVONORGESTREL - LILETTA							
N 206229	001					NP	Feb 26, 2018
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM							
N 202231	001	9006289	Oct 03, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM							
N 202231	002	9006289	Oct 03, 2032	DP			
LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM							
N 202231	003	9006289	Oct 03, 2032	DP			
LINACLOTIDE - LINZESS							
N 202811	001	8933030	Feb 17, 2031	DP			
LINACLOTIDE - LINZESS							
N 202811	002	8933030	Feb 17, 2031	DP			
LINAGLIPTIN - TRADJENTA							
N 201280	001	8673927	May 04, 2027	U-1503			
		8853156	Mar 05, 2031	U-1642			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 001	8673927	May 04, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 002	8673927	May 04, 2027	U-1503			
LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO						
N 201281 003	8673927	May 04, 2027	U-1503			
LINEZOLID - LINEZOLID						
A 078061 001					PC	Dec 19, 2015
LINEZOLID - LINEZOLID						
A 200222 001					PC	Jul 04, 2015
LINEZOLID - ZYVOX						
N 021131 002	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
LINEZOLID - ZYVOX						
N 021131 003	6559305	Jan 29, 2021	DS			
	6559305*PED	Jul 29, 2021				
LIRAGLUTIDE RECOMBINANT - VICTOZA						
N 022341 001	8846618	Jun 27, 2022	DP			
LIRAGLUTIDE RECOMBINANT - SAXENDA						
N 206321 001	6268343	Aug 22, 2022	DS DP U-1255			
	6458924	Aug 22, 2017	DS DP U-1255			
	6899699	Jan 01, 2022	DP			
	7235627	Aug 22, 2017	DS DP			
	7686786	Aug 03, 2026	DP			
	8114833	Aug 13, 2025	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8846618	Jun 27, 2022	DP			
	8920383	Jul 17, 2026	DP			
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 001					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 002					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 003					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 004					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 005					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 006					I-703	Jan 30, 2018
LISDEXAMFETAMINE DIMESYLATE - VYVANSE						
N 021977 007					I-703	Jan 30, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 001	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 002	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 003	5712279	Feb 21, 2016	DS U-1317			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 004	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 005	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LOMITAPIDE MESYLATE - JUXTAPID						
N 203858 006	5712279	Feb 21, 2016	DS U-1317		NCE	Dec 21, 2017
	6492365	Dec 10, 2019	U-1318		ODE	Dec 21, 2019
	7932268	Aug 19, 2027	U-1316			
	8618135	Mar 07, 2025	U-1316			
LORATADINE - CLARITIN						
N 020641 002	6132758	Jun 01, 2018	DP			
LORCASERIN HYDROCHLORIDE - BELVIQ						
N 022529 001	8946207	Jun 16, 2024	DP			
	8980881	Dec 20, 2025	U-1252			
	8980881	Dec 20, 2025	U-1253			
	8980881	Dec 20, 2025	U-1254			
	8980881	Dec 20, 2025	U-1255			
	8999970	Feb 07, 2033	U-1688			
	8999970	Feb 07, 2033	U-1689			
	8999970	Feb 07, 2033	U-1692			
LOXAPINE - ADASUVE						
N 022549 001	8955512	Oct 26, 2021	DP			
	8991387	May 21, 2024	DP			
LULICONAZOLE - LUZU						
N 204153 001	8980931	Apr 28, 2034	DP			
	9012484	Sep 06, 2033	DS DP U-540			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 001	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 002	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 003	RE45573	Jun 23, 2025	DS			
LURASIDONE HYDROCHLORIDE - LATUDA						
N 200603 004	RE45573	Jun 23, 2025	DS			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
LURASIDONE HYDROCHLORIDE - LATUDA							
N 200603 005		RE45573	Jun 23, 2025	DS			
MEGESTROL ACETATE - MEGACE ES							
N 021778 001		9040088	Apr 22, 2024			U-755	
	>A>	9101540	Apr 22, 2024	DP		U-755	
	>A>	9101549	Apr 22, 2024			U-755	
	>A>	9107827	Apr 22, 2024			U-755	
MESALAMINE - APRISO							
N 022301 001		8940328	Apr 20, 2018	DP			
		8956647	Apr 20, 2018	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET							
N 021842 001	>A>	9101660	Jan 22, 2027	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET							
N 021842 002	>A>	9101660	Jan 22, 2027	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024 001		9060941	Sep 19, 2023	DP			
METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR							
N 022024 002		9060941	Sep 19, 2023	DP			
METHOTREXATE - OTREXUP							
N 204824 001		8945063	Mar 19, 2030	DP		U-1442	
METHOTREXATE - OTREXUP							
N 204824 002		8945063	Mar 19, 2030	DP		U-1442	
METHOTREXATE - OTREXUP							
N 204824 003		8945063	Mar 19, 2030	DP		U-1442	
METHOTREXATE - OTREXUP							
N 204824 004		8945063	Mar 19, 2030	DP		U-1442	
METHOTREXATE - OTREXUP							
N 204824 005		8945063	Mar 19, 2030	DP		U-1442	
METHYLPHENIDATE - DAYTRANA							
N 021514 001		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 002		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 003		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE - DAYTRANA							
N 021514 004		9034370	Oct 07, 2025	DP			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 001		9000038	Jul 31, 2017			U-666	
		9000038	Jul 31, 2017			U-1693	
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP		U-666	

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 002		9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 003		9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - CONCERTA							
N 021121 004		9000038	Jul 31, 2017	U-666			
		9000038	Jul 31, 2017	U-1693			
		9000038*PED	Jan 31, 2018				
		9029416	Jul 31, 2017	DP U-666			
METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR							
N 202100 001		8956649	Feb 15, 2031	DP U-1665			
		9040083	Feb 15, 2031	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 001		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
	>A>	8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 002		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
	>A>	8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 003		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
	>A>	8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 004		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
	>A>	8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 005		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
	>A>	8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 006		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
	>A>	8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METHYLPHENIDATE HYDROCHLORIDE - APTENSIO XR							
N 205831 007		6419960	Dec 16, 2019	DP		NP	Apr 17, 2018
		7083808	Dec 16, 2019	DP			
		7247318	Dec 16, 2019	DP			
		7438930	Dec 16, 2019	DP			
	>A>	8580310	Dec 16, 2019	DP			
		9066869	Dec 16, 2019	DP			
METRONIDAZOLE - NUVESSA							
N 205223 001		7893097	Feb 19, 2028	DP			
		8658678	Jun 27, 2028	U-1682			
		8877792	Feb 02, 2028	DP			
		8946276	Jun 28, 2032	U-1664			
MIFEPRISTONE - KORLYM							
N 202107 001		8921348	Aug 27, 2028	U-1643			
MINOCYCLINE HYDROCHLORIDE - MINOCIN							
N 050444 001		9084802	May 12, 2031	U-282			
MINOCYCLINE HYDROCHLORIDE - ARESTIN							
N 050781 001		7699609	Mar 29, 2022	DP			
MINOXIDIL - WOMEN'S ROGAINE							
N 021812 002		6946120	Apr 20, 2019	DP U-702			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 001		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 002		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 003		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 004		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE - MORPHINE SULFATE							
N 204223 005		9072781	Mar 12, 2034	DP			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 001		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 002		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 003		8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321 004		8623418	Nov 07, 2029	U-1640			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321	005	8623418	Nov 07, 2029	U-1640			
MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA							
N 022321	006	8623418	Nov 07, 2029	U-1640			
MOXIFLOXACIN HYDROCHLORIDE - MOXEZA							
N 022428	001	>A> 9114168	May 29, 2029	DP			
NALOXEGOL OXALATE - MOVANTIK							
N 204760	001	7056500	Jun 29, 2024	DP U-1185			
		9012469	Apr 02, 2032	DS DP			
NALOXEGOL OXALATE - MOVANTIK							
N 204760	002	7056500	Jun 29, 2024	DP U-1185			
		9012469	Apr 02, 2032	DS DP			
NALOXONE HYDROCHLORIDE - EVZIO							
N 205787	001	8926594	Mar 31, 2026	DP			
		8939943	Feb 28, 2031	DP			
		9022022	Feb 28, 2031	DP			
		9056170	Nov 23, 2024	DP			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	001	8969369	May 10, 2022	DP U-1556			
		9056051	May 10, 2022	DP U-1556			
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	002	8969369	May 10, 2022	DP U-1556			
		9056051	May 10, 2022	DP U-1556			
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP U-1556			
NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ							
N 205777	003	8969369	May 10, 2022	DP U-1556			
		9056051	May 10, 2022	DP U-1556			
		9073933	Mar 30, 2025	DS			
		9084729	May 10, 2022	DP U-1556			
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET							
N 021926	001	6060499	Aug 14, 2017	DP U-867			
		6060499*PED	Feb 14, 2018				
		6586458	Aug 14, 2017	DP U-867			
		6586458*PED	Feb 14, 2018				
		7332183	Oct 02, 2025	DP U-867			
		7332183*PED	Apr 02, 2026				
		8022095	Aug 14, 2017	DP U-867			
		8022095*PED	Feb 14, 2018				
NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE - TREXIMET							
N 021926	002	5872145	Aug 14, 2017	DP U-1719		NP	May 14, 2018
		5872145*PED	Feb 14, 2018			PED	Nov 14, 2018
		6060499	Aug 14, 2017	DP U-1719			
		6060499*PED	Feb 14, 2018				
		6586458	Aug 14, 2017	DP U-1719			
		6586458*PED	Feb 14, 2018				
		7332183	Oct 02, 2025	DP U-1719			
		7332183*PED	Apr 02, 2026				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE		PATENT CODES		PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
NEPAFENAC - ILEVRO										
N 203491	001		8921337	Mar 31, 2032		DP				
NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO										
N 205718	001		8951969	Nov 18, 2030		DP				
NICOTINE - NICODERM CQ										
N 020165	004		8999379	Feb 13, 2020			U-1686			
NICOTINE - NICODERM CQ										
N 020165	005		8999379	Feb 13, 2020			U-1686			
NICOTINE - NICODERM CQ										
N 020165	006		8999379	Feb 13, 2020			U-1686			
NICOTINE POLACRILEX - NICORETTE										
N 022360	001		8940772	Apr 30, 2029		DP				
NICOTINE POLACRILEX - NICORETTE										
N 022360	002		8940772	Apr 30, 2029		DP				
NINTEDANIB ESYLATE - OFEV										
N 205832	001		7989474	Apr 06, 2024			U-1677			
NINTEDANIB ESYLATE - OFEV										
N 205832	002		7989474	Apr 06, 2024			U-1677			
OLAPARIB - LYNPARZA										
N 206162	001		7151102	Apr 29, 2022	DS	DP			ODE	Dec 19, 2021
			7449464	Oct 11, 2024	DS	DP				
			7981889	Oct 11, 2024	DS	DP				
			8143241	Aug 12, 2027			U-1634			
			8247416	Sep 24, 2028	DS					
			8859562	Aug 04, 2031			U-1634			
			8912187	Mar 12, 2024			U-1634			
OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT										
N 203108	001	>A>	8733341	Dec 16, 2029		DP				
		>A>	9027967	Mar 31, 2027		DP				
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT										
N 206756	001		5964416	Oct 04, 2016		DP			NC	May 21, 2018
			6149054	Dec 19, 2016		DP			NCE	Jul 31, 2019
			6176442	Oct 04, 2016		DP				
			6453795	Dec 05, 2016		DP				
			6726124	Oct 04, 2016		DP				
			6846413	Aug 28, 2018		DP				
			6977042	Aug 28, 2018		DP				
			6988496	Feb 23, 2020		DP				
			7056916	Dec 07, 2023	DS	DP				
			7104470	Oct 04, 2016		DP				
			7220742	May 12, 2025	DS	DP	U-1703			
			7246615	May 31, 2016		DP				
			7284474	Aug 26, 2024		DP				
			7396341	Oct 10, 2026		DP				
			7491719	Nov 10, 2023	DS	DP				
			7727984	Nov 10, 2023	DS					
			7786111	Nov 10, 2023		DP				
			7802568	Feb 26, 2019		DP				
			7837235	Mar 13, 2028		DP				
			7896264	May 26, 2025		DP				
			7988001	Aug 04, 2021		DP				
			8034809	May 12, 2025			U-1702			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO			PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT								
N 206756	001		8044046	Nov 10, 2023	U-1702			
			8733341	Dec 16, 2029	DP			
			9027967	Mar 31, 2027	DP			
			RE39820	Jan 30, 2018	DS DP U-1702			
OLOPATADINE HYDROCHLORIDE - PAZEO								
N 206276	001		8791154	May 19, 2032	DP U-1680		NP	Jan 30, 2018
							PED	Jul 30, 2018
OMBITASVIR; PARITAPREVIR; RITONAVIR - TECHNIVIE								
N 207931	001		6037157	Jun 26, 2016	U-1635		NCE	Dec 19, 2019
			6037157*PED	Dec 26, 2016			NP	Jul 24, 2018
			6703403	Jun 26, 2016	U-1635			
			6703403*PED	Dec 26, 2016				
			7148359	Jul 19, 2019	DP			
			7148359*PED	Jan 19, 2020				
			7364752	Nov 10, 2020	DP			
			7364752*PED	May 10, 2021				
			8268349	Aug 25, 2024	DP			
			8268349*PED	Feb 25, 2025				
			8399015	Aug 25, 2024	DP			
			8399015*PED	Feb 25, 2025				
			8420596	Apr 10, 2031	DS DP			
			8420596*PED	Oct 10, 2031				
			8642538	Sep 10, 2029	DS DP U-1638			
			8686026	Jun 09, 2031	DP			
			8691938	Apr 13, 2032	DS DP			
			9006387	Jun 10, 2030	U-1687			
			9044480	Apr 10, 2031	U-1638			
OMEGA-3-CARBOXYLIC ACIDS - EPANOVA								
N 205060	001		9012501	Feb 07, 2025	DP U-1511			
			9050308	Jan 04, 2033	U-1511			
			9050309	Jan 04, 2033	DS			
OMEPRAZOLE - OMEPRAZOLE								
N 022032	001		9023391	Aug 16, 2025	DP			
ONDANSETRON - ZUPLENZ								
N 022524	001	>A>	9095577	Jul 13, 2030	DP			
ONDANSETRON - ZUPLENZ								
N 022524	002	>A>	9095577	Jul 13, 2030	DP			
OSPEMIFENE - OSPHENA								
N 203505	001		8642079	Jul 09, 2028	DP			
OXCARBAZEPINE - OXTELLAR XR								
N 202810	001	>A>	9119791	Apr 13, 2027	U-1298			
OXCARBAZEPINE - OXTELLAR XR								
N 202810	002	>A>	9119791	Apr 13, 2027	U-1298			
OXCARBAZEPINE - OXTELLAR XR								
N 202810	003	>A>	9119791	Apr 13, 2027	U-1298			
OXYBUTYNIN CHLORIDE - GELNIQUE								
N 022204	001		8920392	Mar 26, 2031	U-1644			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	001	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	002	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	003	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	004	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	005	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	006	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
OXYCODONE HYDROCHLORIDE - OXYCONTIN							
N 022272	007	9060976	Aug 06, 2022	DP		M-153	Apr 16, 2016
		9073933	Mar 30, 2025	DS		>A> NPP	Aug 13, 2018
PACLITAXEL - ABRAXANE							
N 021660	001	>A> 9101543	Feb 21, 2026	U-1434			
PALBOCICLIB - IBRANCE							
N 207103	001	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1658			
PALBOCICLIB - IBRANCE							
N 207103	002	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1658			
PALBOCICLIB - IBRANCE							
N 207103	003	6936612	Jan 22, 2023	DS DP		NCE	Feb 03, 2020
		7208489	Jan 16, 2023	DS DP			
		7456168	Jan 16, 2023	U-1658			
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	001	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
		6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	002	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
		6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	003	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
		6077843*PED	Nov 12, 2017				
PALIPERIDONE PALMITATE - INVEGA TRINZA							
N 207946	004	6077843	May 12, 2017	DP U-543		NP	May 18, 2018
		6077843*PED	Nov 12, 2017				

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
>A>	9125905	Jan 30, 2024	DP			
PALONOSETRON HYDROCHLORIDE - ALOXI						
N 021372 002 >A>	9125905	Jan 30, 2024	DP			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 001	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 002	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PANOBINOSTAT LACTATE - FARYDAK						
N 205353 003	6552065	Aug 31, 2021	DS DP		NCE	Feb 23, 2020
	6833384	Sep 30, 2021	DS DP U-1669		ODE	Feb 23, 2022
	7067551	Aug 31, 2021	U-1669			
	7989494	Jan 17, 2028	DS DP			
	8883842	Jun 13, 2028	U-1669			
PAROXETINE MESYLATE - BRISDELLE						
N 204516 001	8946251	Aug 04, 2026	DS DP U-904			
PERAMPANEL - FYCOMPA						
N 202834 001					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 002					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 003					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 004					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 005					I-710	Jun 19, 2018
PERAMPANEL - FYCOMPA						
N 202834 006					I-710	Jun 19, 2018
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 001	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 002	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA						
N 022580 003	9011905	Jun 09, 2028	DP			
	9011906	Jun 09, 2028	U-1262			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA							
N 022580 004		9011905	Jun 09, 2028	DP			
		9011906	Jun 09, 2028	U-1262			
PIRFENIDONE - ESBRIET							
N 022535 001		7696236	Dec 18, 2027	U-1601			
POMALIDOMIDE - POMALYST							
N 204026 001		5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST							
N 204026 002		5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST							
N 204026 003		5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
POMALIDOMIDE - POMALYST							
N 204026 004		5653517	Jul 24, 2016	U-1359		I-707	Apr 23, 2018
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469 001		9029533	Dec 22, 2026	U-836			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469 002		9029533	Dec 22, 2026	U-836			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
PONATINIB HYDROCHLORIDE - ICLUSIG							
N 203469 003		9029533	Dec 22, 2026	U-836			
		9029533	Dec 22, 2026	U-1283			
		9029533	Dec 22, 2026	U-1699			
		9029533	Dec 22, 2026	U-1700			
		9029533	Dec 22, 2026	U-1701			
POSACONAZOLE - NOXAFIL							
N 205596 001		9023790	Jul 04, 2031	DP U-1698			
PREDNISONE - RAYOS							
N 202020 001		9040085	Apr 23, 2024	U-1362			
PREDNISONE - RAYOS							
N 202020 002		9040085	Apr 23, 2024	U-1362			
PREDNISONE - RAYOS							
N 202020 003		9040085	Apr 23, 2024	U-1362			
REGADENOSON - LEXISCAN							
N 022161 001		9045519	Jun 22, 2019	DP			
	>A>	9085601	Feb 02, 2027	DP			
REGORAFENIB - STIVARGA							
N 203085 001		8637553	Feb 16, 2031	DS DP			
		8680124	Jun 02, 2030	U-1506			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
RIFAXIMIN - XIFAXAN							
N 022554	001	6861053	Aug 11, 2019	U-1707		I-709	May 27, 2018
		6861053	Aug 11, 2019	U-1708			
		7452857	Aug 11, 2019	U-1707			
		7452857	Aug 11, 2019	U-1708			
		7605240	Aug 11, 2019	U-1707			
		7605240	Aug 11, 2019	U-1708			
		7718608	Aug 11, 2019	U-1707			
		7718608	Aug 11, 2019	U-1708			
		7915275	Feb 23, 2025	U-1707			
		7915275	Feb 23, 2025	U-1708			
		7935799	Aug 11, 2019	U-1707			
		7935799	Aug 11, 2019	U-1708			
		8193196	Sep 02, 2027	DS DP U-1707			
		8193196	Sep 02, 2027	DS DP U-1708			
		8309569	Jul 18, 2029	U-1707			
		8309569	Jul 18, 2029	U-1708			
		8741904	Feb 27, 2026	DS U-1526			
		8741904	Feb 27, 2026	DS U-1707			
		8741904	Feb 27, 2026	DS U-1708			
		8946252	Jul 24, 2029	U-1481			
		8969398	Oct 02, 2029	U-1481			
RILPIVIRINE HYDROCHLORIDE - EDURANT							
N 202022	001				>A>	NPP	Aug 26, 2018
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132	001					PC	Nov 28, 2015
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132	002					PC	Nov 28, 2015
RISEDRONATE SODIUM - RISEDRONATE SODIUM							
A 077132	003					PC	Nov 28, 2015
RIVASTIGMINE - RIVASTIGMINE							
A 204403	003				>A>	PC	Feb 29, 2016
ROFLUMILAST - DALIRESP							
N 022522	001	>A> 5712298	Jan 27, 2020	DS DP U-1115			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	001	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	002	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	003	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	004	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			
RUXOLITINIB PHOSPHATE - JAKAFI							
N 202192	005	9079912	Dec 12, 2026	U-1573			
		9079912	Dec 12, 2026	U-1721			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620 001		7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	>A>	8101659	Jan 14, 2023	DP			
	>A>	8404744	Jan 14, 2023	DP			
	>A>	8796331	Jan 14, 2023	U-1723			
	>A>	8877938	May 27, 2027	DS DP			
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620 002		7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	>A>	8101659	Jan 14, 2023	DP			
	>A>	8404744	Jan 14, 2023	DP			
	>A>	8796331	Jan 14, 2023	U-1723			
	>A>	8877938	May 27, 2027	DS DP			
SACUBITRIL; VALSARTAN - ENTRESTO							
N 207620 003		7468390	Nov 27, 2023	DP		NCE	Jul 07, 2020
	>A>	8101659	Jan 14, 2023	DP			
	>A>	8404744	Jan 14, 2023	DP			
	>A>	8796331	Jan 14, 2023	U-1723			
	>A>	8877938	May 27, 2027	DS DP			
SIMEPREVIR SODIUM - OLYSIO							
N 205123 001		9040562	Jul 28, 2026	DS DP U-1467			
SIROLIMUS - RAPAMUNE							
N 021083 001						ODE	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110 001						ODE	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110 002						ODE	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110 003						ODE	May 28, 2022
SIROLIMUS - RAPAMUNE							
N 021110 004						ODE	May 28, 2022
SODIUM OXYBATE - XYREM							
N 021196 001		8952062	Dec 22, 2019	U-1101			
		8952062	Dec 22, 2019	U-1102			
		9050302	Mar 15, 2033	U-1532			
SOFOSBUVIR - SOVALDI							
N 204671 001		9085573	Mar 21, 2028	DS DP U-1470			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 008		8920383	Jul 17, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 009		8920383	Jul 17, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 010		8920383	Jul 17, 2026	DP			
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 011		5849700	Dec 15, 2015	U-1041			
		5849704	Dec 15, 2015	DS DP U-1041			
		6899699	Jan 02, 2022	DP			
		7686786	Aug 03, 2026	DP			
		8672898	Jan 02, 2022	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO							
N 021148 011		8684969	Oct 20, 2025	DP			
		8841252	Dec 26, 2017	DP			
		8920383	Jul 17, 2026	DP			
SONIDEGIB PHOSPHATE - ODOMZO							
N 205266 001	>A>	8063043	Sep 15, 2029	DS DP		NCE	Jul 24, 2020
	>A>	8178563	Feb 06, 2029	DS U-1722			
SORAFENIB TOSYLATE - NEXAVAR							
N 021923 001		8124630	Jan 12, 2020	U-1459			
		8841330	Jan 12, 2020	U-1696			
SPINOSAD - NATROBA							
N 022408 001		6063771	Jul 25, 2023	DP U-1670		M-152	Nov 30, 2017
SUMATRIPTAN SUCCINATE - ZECUITY							
N 202278 001		8983594	Nov 19, 2030	DP U-1328			
TACROLIMUS - ENVARSUS XR							
N 206406 001	>A>	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
TACROLIMUS - ENVARSUS XR							
N 206406 002	>A>	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
TACROLIMUS - ENVARSUS XR							
N 206406 003	>A>	7994214	Aug 30, 2024	DP		ODE	Jul 10, 2022
TASIMELTEON - HETLIOZ							
N 205677 001		9060995	Jan 25, 2033	U-1710			
TEDUGLUTIDE RECOMBINANT - GATTEX KIT							
N 203441 001		5789379	Apr 14, 2016	DS DP U-1320			
		9060992	Nov 01, 2025	U-1320			
TESTOSTERONE - ANDROGEL							
N 021015 001	>A>	9125816	Aug 30, 2020	U-490			
TESTOSTERONE - ANDROGEL							
N 021015 002	>A>	9125816	Aug 30, 2020	U-490			
TESTOSTERONE - ANDROGEL							
N 021015 003	>A>	9125816	Aug 30, 2020	U-490			
TESTOSTERONE - ANDROGEL							
N 022309 001	>A>	9125816	Aug 30, 2020	U-1103			
TESTOSTERONE - ANDROGEL							
N 022309 002	>A>	9125816	Aug 30, 2020	U-1103			
TESTOSTERONE - ANDROGEL							
N 022309 003	>A>	9125816	Aug 30, 2020	U-1103			
TESTOSTERONE - AXIRON							
N 022504 001		8435944	Sep 27, 2027	U-1390			
		8993520	Jun 02, 2026	U-1390			
TIGECYCLINE - TYGACIL							
N 021821 001		8975242	Oct 24, 2028	DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO		PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT							
N 021936 001	>A>	8733341	Dec 16, 2029	DP			
	>A>	9027967	Mar 31, 2027	DP			
TOPIRAMATE - TROKENDI XR							
N 201635 001		8992989	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - TROKENDI XR							
N 201635 002		8992989	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - TROKENDI XR							
N 201635 003		8992989	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - TROKENDI XR							
N 201635 004		8992989	Nov 16, 2027	DP		U-1675	
TOPIRAMATE - QUDEXY XR							
N 205122 001		9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 002		9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 003		9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 004		9101545	Mar 19, 2033	DP			
TOPIRAMATE - QUDEXY XR							
N 205122 005		9101545	Mar 19, 2033	DP			
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 001		8703781	Oct 15, 2030	DS DP		U-1712	
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 002		8703781	Oct 15, 2030	DS DP		U-1712	
TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST							
N 204114 003		8703781	Oct 15, 2030	DS DP		U-1712	
TRANEXAMIC ACID - LYSTEDA							
N 022430 001		8957113	Mar 04, 2025	DP		U-1182	
		9060939	Mar 04, 2025	DP			
TRAVOPROST - IZBA							
N 204822 001	>A>	8178582	Oct 10, 2029	DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207 001		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207 002		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207 003		8133893	Mar 13, 2029	DS DP			
TRAZODONE HYDROCHLORIDE - DESYREL							
N 018207 004		8133893	Mar 13, 2029	DS DP			

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 001	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 002	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 003	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
TREPROSTINIL DIOLAMINE - ORENITRAM						
N 203496 004	7417070	Jul 30, 2026	DS			
	9050311	May 24, 2024	DS DP			
TRETINOIN - RETIN-A-MICRO						
N 020475 003	5955109	Sep 21, 2016	DP U-134			
ULIPRISTAL ACETATE - ELLA						
N 022474 001	8962603	Jun 12, 2030	U-1657			
UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA						
N 203975 001	8511304	Jun 14, 2027	DP U-1476			
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 021304 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VALGANCICLOVIR HYDROCHLORIDE - VALCYTE						
N 022257 001					D-148	Apr 23, 2018
					NPP	Apr 23, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 001					D-146	Mar 16, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 002					D-146	Mar 16, 2018
VILAZODONE HYDROCHLORIDE - VIIBRYD						
N 022567 003					D-146	Mar 16, 2018
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 001	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 002	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 003	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
VORTIOXETINE HYDROBROMIDE - BRINTELLIX						
N 204447 004	8722684	Jun 30, 2031	DS DP			
	8969355	Jun 15, 2027	U-1668			
ZOLMITRIPTAN - ZOMIG						
N 021450 003					>A> NPP	Jun 12, 2018

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 08 - August 2015

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE(S)	EXCLUSIVITY EXPIRATION DATE
ZOLMITRIPTAN - ZOMIG						
N 021450 004					>A> NPP	Jun 12, 2018

Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 35th Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm

The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm